var images_info;if (!images_info) images_info =[]; images_info["109"]={"109001":{"type":"graphic_diagnosticimage","displayName":"Gouty arthritis","title":"Gouty arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gouty arthritis</div><div class=\"cntnt\"><img style=\"width:404px; height:563px;\" src=\"images/RHEUM/109001_Gouty_arthritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph of the hand demonstrating features consistent with gout. There are juxta-articular punched-out erosions and intraosseous cystic lesions, most prominent at the index proximal interphalangeal (PIP) joint and distal ulna. There is cartilage loss at the little finger PIP joint and soft tissue swelling due to a subcutaneous tophus at the index finger PIP joint. Vascular calcification of forearm vessels is also evident.</div><div class=\"graphic_reference\">Image courtesy of&nbsp;Dr. Ian Gaywood, Consultant Rheumatologist, Nottingham University Hospitals NHS Trust.</div><div id=\"graphicVersion\">Graphic 109001 Version 1.0</div></div></div>"},"109002":{"type":"graphic_diagnosticimage","displayName":"OA and CPPD","title":"Osteoarthritis and CPPD","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Osteoarthritis and CPPD</div><div class=\"cntnt\"><img style=\"width:561px; height:756px;\" src=\"images/RHEUM/109002_OA_and_CPPD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph of the hand demonstrating features&nbsp;of osteoarthritis (OA) and calcium pyrophosphate deposition (CPPD). There is cartilage loss, osteophytosis, and bony remodeling at all finger distal interphalangeal (DIP) joints and radial deviation of middle, ring, and little finger DIP joints; joint space narrowing, osteophytosis, and cysts at the second metacarpophalangeal (MCP) joint; and thumb-base OA (mainly narrowing and sclerosis of first carpometacarpal [CMC]&nbsp;and scapho-trapezioid joints). There is also scapho-lunate dissociation (which is reported to associate with CPPD) and chondrocalcinosis in the triangular cartilage.</div><div class=\"graphic_reference\">Courtesy of Michael Doherty, MD, and Abhishek Abhishek, MD.</div><div id=\"graphicVersion\">Graphic 109002 Version 2.0</div></div></div>"},"109003":{"type":"graphic_diagnosticimage","displayName":"Erosive hand OA","title":"Erosive hand osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Erosive hand osteoarthritis</div><div class=\"cntnt\"><img style=\"width:532px; height:756px;\" src=\"images/RHEUM/109003_Erosive_hand_OA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph of the hand demonstrating features consistent with erosive osteoarthritis (OA)&nbsp;of the hand.&nbsp;There is a&nbsp;central subchondral erosion and pseudo-widening at the proximal interphalangeal (PIP) joint of the fourth finger, and bony proliferation at the diaphysis. The distal interphalangeal (DIP) joint of the fifth finger has a central erosion. The DIPs of the fifth and&nbsp;index fingers also show subluxation, disorganization, and radial deviation. There is marked narrowing and subluxation of the first carpometacarpal (CMC)&nbsp;joint, which is sometimes a key feature of erosive hand OA.</div><div class=\"graphic_reference\">Courtesy of Michael Doherty, MD, and Abhishek Abhishek, MD.</div><div id=\"graphicVersion\">Graphic 109003 Version 2.0</div></div></div>"},"109004":{"type":"graphic_movie","displayName":"Severe mitral stenosis on 3D TEE","title":"3D TEE showing severe mitral stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">3D TEE showing severe mitral stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/109004_Sevrmitrlstens3DTEEvid.mp4\" style=\"width:720px;height:512px\"></div><img style=\"width:663px; height:501px;\" src=\"images/ANEST/109004_Sevrmitrlstens3DTEEimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TEE 3D movie clip of a stenotic mitral valve depicting extensive calcification of both the anterior and posterior leaflets with a central stenotic opening.</div><div class=\"graphic_footnotes\">3D: three-dimensional; TEE: transesophageal echocardiography.</div><div id=\"graphicVersion\">Graphic 109004 Version 2.0</div></div></div>"},"109005":{"type":"graphic_movie","displayName":"Severe AR on TEE color Doppler","title":"Severe AR on TEE color Doppler","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Severe AR on TEE color Doppler</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/109005_SevereARTEEDopplervid.mp4\" style=\"width:704px;height:512px\"></div><img style=\"width:677px; height:454px;\" src=\"images/ANEST/109005_SevereARTEEDopplerimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transesophageal echocardiography long-axis view showing severe aortic regurgitant flow traversing the aortic valve into the left ventricular outflow tract.</div><div class=\"graphic_footnotes\">AR: aortic regurgitation; TEE: transesophageal echocardiography.</div><div id=\"graphicVersion\">Graphic 109005 Version 2.0</div></div></div>"},"109014":{"type":"graphic_diagnosticimage","displayName":"Extensive barotrauma","title":"Extensive barotrauma on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Extensive barotrauma on computed tomography</div><div class=\"cntnt\"><img style=\"width:512px; height:512px;\" src=\"images/PULM/109014_Extensive_barotrauma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomographic image of a ventilated patient with extensive barotrauma. Small bilateral pneumothoraces, extensive pneumomediastinum, and subcutaneous air are seen.</div><div id=\"graphicVersion\">Graphic 109014 Version 1.0</div></div></div>"},"109015":{"type":"graphic_diagnosticimage","displayName":"Anterior pneumomediastinum","title":"Anterior pneumomediastinum on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Anterior pneumomediastinum on computed tomography</div><div class=\"cntnt\"><img style=\"width:512px; height:512px;\" src=\"images/PULM/109015_Anterior_pneumomediastinum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomographic image of a ventilated patient with severe acute respiratory distress syndrome showing extensive anterior pneumomediastinum and a small amount of subcutaneous air in the left hemithorax.</div><div id=\"graphicVersion\">Graphic 109015 Version 1.0</div></div></div>"},"109016":{"type":"graphic_diagnosticimage","displayName":"Subcutaneous air","title":"Subcutaneous air on chest radiography","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Subcutaneous air on chest radiography</div><div class=\"cntnt\"><img style=\"width:756px; height:718px;\" src=\"images/PULM/109016_Subcutaneous_air.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain chest radiography of a ventilated patient with acute respiratory distress syndrome showing subcutaneous air in the left hemithorax and bilaterally in the neck.</div><div id=\"graphicVersion\">Graphic 109016 Version 1.0</div></div></div>"},"109017":{"type":"graphic_diagnosticimage","displayName":"Barotrauma","title":"Ventilator-induced barotrauma from unilateral lung disease","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Ventilator-induced barotrauma from unilateral lung disease</div><div class=\"cntnt\"><img style=\"width:764px; height:258px;\" src=\"images/PULM/109017_Barotrauma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative axial computed tomographic images of ventilated patient with right-sided pneumonia showing extensive pneumomediastinum and a small amount of subcutaneous air in the anterior chest wall.</div><div id=\"graphicVersion\">Graphic 109017 Version 1.0</div></div></div>"},"109018":{"type":"graphic_diagnosticimage","displayName":"Distended jugular sacs in the fetal neck","title":"Distended jugular sacs in the fetal neck","html":"<div class=\"graphic\"><div style=\"width: 767px\" class=\"figure\"><div class=\"ttl\">Distended jugular sacs in the fetal neck</div><div class=\"cntnt\"><img style=\"width:747px; height:566px;\" src=\"images/OBGYN/109018_Dstnd_jugular_sacs_ftl_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">â€‹Coronal view demonstrating distended jugular sacs bilaterally (arrows) in the fetal neck.</div><div id=\"graphicVersion\">Graphic 109018 Version 1.0</div></div></div>"},"109019":{"type":"graphic_diagnosticimage","displayName":"Enlarged first-trimester nuchal translucency","title":"Enlarged first-trimester nuchal translucency","html":"<div class=\"graphic\"><div style=\"width: 667px\" class=\"figure\"><div class=\"ttl\">Enlarged first-trimester nuchal translucency</div><div class=\"cntnt\"><img style=\"width:647px; height:448px;\" src=\"images/OBGYN/109019_Enlarged_first_trim_nuchal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enlarged nuchal translucency measuring over 3 mm in a 12-week fetus with the nonfused amnion (arrows) clearly separate from the fetal skin.</div><div class=\"graphic_footnotes\">NT: nuchal translucency.</div><div id=\"graphicVersion\">Graphic 109019 Version 1.0</div></div></div>"},"109020":{"type":"graphic_diagnosticimage","displayName":"3D US enlarged first-trimester nuchal translucency","title":"Three-dimensional ultrasound image of increased nuchal translucency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Three-dimensional ultrasound image of increased nuchal translucency</div><div class=\"cntnt\"><img style=\"width:360px; height:459px;\" src=\"images/OBGYN/109020_3D_US_enlrgd_frst_tri_nuchl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional image of an increased nuchal translucency (arrow).</div><div id=\"graphicVersion\">Graphic 109020 Version 1.0</div></div></div>"},"109021":{"type":"graphic_diagnosticimage","displayName":"First-trimester cystic hygroma","title":"First-trimester cystic hygroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">First-trimester cystic hygroma</div><div class=\"cntnt\"><img style=\"width:389px; height:394px;\" src=\"images/OBGYN/109021_First_trmstr_cystic_hygroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial view of a first-trimester cystic hygroma located posteriorly with multiple septations (arrows).</div><div id=\"graphicVersion\">Graphic 109021 Version 1.0</div></div></div>"},"109022":{"type":"graphic_diagnosticimage","displayName":"3D US first-trimester cystic hygroma","title":"Three-dimensional ultrasound image of cystic hygroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Three-dimensional ultrasound image of cystic hygroma</div><div class=\"cntnt\"><img style=\"width:356px; height:270px;\" src=\"images/OBGYN/109022_3D_US_frst_tri_cystc_hygrma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional image of a first-trimester fetus with a cystic hygroma (arrows).</div><div id=\"graphicVersion\">Graphic 109022 Version 1.0</div></div></div>"},"109023":{"type":"graphic_diagnosticimage","displayName":"Cystic hygroma with hydrops","title":"Cystic hygroma with hydrops","html":"<div class=\"graphic\"><div style=\"width: 760px\" class=\"figure\"><div class=\"ttl\">Cystic hygroma with hydrops</div><div class=\"cntnt\"><img style=\"width:740px; height:501px;\" src=\"images/OBGYN/109023_Cystic_hygroma_hydrops.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cystic hygroma extending the entire length of the fetus with associated generalized subcutaneous fluid and hydrops (arrows).</div><div class=\"graphic_footnotes\">CRL: crown-rump length; GA: gestational age.</div><div id=\"graphicVersion\">Graphic 109023 Version 1.0</div></div></div>"},"109025":{"type":"graphic_table","displayName":"Substance Use Brief Screen (SUBS)","title":"Substance Use Brief Screen (SUBS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Substance Use Brief Screen (SUBS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" colspan=\"4\"><strong>Instructions:</strong> Please check one box for each question</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\" style=\"border-bottom-width: 3px;\">In the past 12 months, how many days did you have or use&hellip;</td> <td class=\"subtitle1\">Three or more days</td> <td class=\"subtitle1\">One or two days</td> <td class=\"subtitle1\">Never</td> </tr> <tr> <td class=\"indent1\"><strong>Tobacco</strong>?</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"indent1\"><strong>Four&nbsp;or more alcoholic drinks</strong>* in a day, including wine or beer?</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"indent1\">Any <strong>illegal drug</strong>, including marijuana?</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"indent1\">Any <strong>prescription medications</strong><sup>&#182;</sup> \"recreationally\"<sup>&#916;</sup>?</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Consider a \"drink\" to be <strong>a can or bottle of beer</strong> (12 ounces), a <strong>glass of wine</strong> (5 ounces), a <strong>wine cooler</strong> (12 ounces), or a <strong>shot of hard liquor</strong> like gin, vodka, or whiskey (1.5 ounces).<br />&para; Prescription medications are those that are prescribed to you <strong>or</strong> to someone else.<br />&Delta; \"Recreationally\" means taking medications <strong>just for the feeling or experience</strong> they cause, <strong>to get high</strong>, or taking them <strong>more often</strong> or at <strong>higher doses</strong> than prescribed.</div><div class=\"graphic_reference\">Reproduced from: McNeely J, Strauss SM, Saitz R, et al. A brief patient self-administered substance use screening tool for primary care: Two-site validation study of the Substance Use Brief Screen (SUBS). Am J Med 2015; 128:784. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109025 Version 1.0</div></div></div>"},"109026":{"type":"graphic_table","displayName":"Liposomal irinotecan and 5-FU for metastatic pancreatic cancer","title":"Liposomal irinotecan and fluorouracil chemotherapy for metastatic pancreatic cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Liposomal irinotecan and fluorouracil chemotherapy for metastatic pancreatic cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 14 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Liposomal irinotecan</strong></td> <td>70* mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL 5 percent dextrose in water (D5W)<sup>&#916;</sup> or normal saline (NS) and administer over 90 minutes.</td> <td>Day 1</td> </tr> <tr> <td><strong>Leucovorin</strong><sup>&#9674;</sup></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Mix with 250 mL NS or D5W and administer over 30 minutes.</td> <td>Day 1</td> </tr> <tr> <td><strong>Fluorouracil (5-FU)</strong></td> <td>2400 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 to 1000 mL NS or D5W and administer over 46 hours. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.</td> <td>Day 1</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> MODERATE. Administration of a corticosteroid and antiemetic is recommended 30 minutes prior to liposomal irinotecan<sup>[2]</sup>. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Administration of a corticosteroid is recommended 30 minutes prior to liposomal irinotecan.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with granulocyte colony stimulating factors is not recommended for all patients (estimated risk of febrile neutropenia is approximately 3 percent<sup>[1]</sup>). However, given the 27 percent rate of grade 3 or 4 neutropenia in the NAPOLI trial and the black box warning about potentially fatal neutropenic sepsis<sup>[2]</sup>, primary prophylaxis should be considered on an individual basis, particularly for high-risk patients such as those with preexisting neutropenia, advanced disease, poor performance status, or patients age 65 years or older. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for liver or renal dysfunction:</strong> A lower starting dose of fluorouracil may be needed for patients with liver impairment<sup>[3]</sup>. There are no recommended dose adjustments available for liposomal irinotecan for patients with severe renal impairment or in patients with a total bilirubin above the upper limit of normal<sup>[2]</sup>. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Obtain CBC with differential and platelet count on days 1 and 8 of each treatment cycle and more frequently if clinically indicated.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess electrolytes and liver and renal function prior to each treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Diarrhea:</strong> Liposomal irinotecan is associated with early and late diarrhea, both of which may be severe (13 percent). For patients who develop abdominal cramps and/or diarrhea within 24 hours of treatment, administer atropine (0.25 to 1 mg subcutaneously or IV push) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea. Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. <strong>NOTE:</strong> Severe diarrhea, mucositis, and/or myelosuppression after the first dose of 5-FU and/or liposomal irinotecan should prompt evaluation for dihydropyrimidine dehydrogenase deficiency (for 5-FU) and UGT1A1*28 allele polymorphism (for liposomal irinotecan). Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>&#8226; <strong>Cardiopulmonary toxicity:</strong> Liposomal irinotecan can cause severe and fatal interstitial lung disease. Withhold the drug in patients with new or progressive dyspnea, cough, or fever, pending diagnostic evaluation, and permanently discontinue if interstitial lung disease is confirmed.</p> Cardiotoxicity observed with 5-FU includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Withhold therapy if the absolute neutrophil count is &#60;1500/microL, if the platelet count is &#60;100,000/microL, or if neutropenic fever occurs. Reduce the liposomal irinotecan dose for grade 3 to 4 neutropenia, thrombocytopenia, or neutropenic fever following recovery in subsequent cycles<sup>[2]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Diarrhea:</strong> Withhold treatment for grade 2 or worse diarrhea until resolution of diarrhea for at least 24 hours off antidiarrheal medications<sup>[2]</sup>. Following recovery to less than or equal to grade 1, resume liposomal irinotecan at a reduced dose. Withhold fluorouracil for grade 2 or worse diarrhea and restart at a lower dose after complete resolution. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Other toxicity:</strong> For any grade 3 or 4 adverse reactions due to liposomal irinotecan, reduce the dose upon recovery to less than or equal to grade 1. Liposomal irinotecan should be discontinued for any anaphylactic reactions<sup>[2]</sup>.</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated for all drugs.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count.<br />* The recommended starting dose of liposomal irinotecan in patients known to be homozygous for the UGT1A1*28 allele is 50 mg/m<SUP>2</SUP>. Increase the dose to 70 mg/m<SUP>2</SUP> as tolerated in subsequent cycles.<br />Î” Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibilities.<br /><FONT class=lozenge>â—Š</FONT> Leucovorin dose is given for d,l-racemic mixture<SUP>[4]</SUP>. Use half the dose for LEVOleucovorin (l-leucovorin).<br /></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Wang-Gillam A, et al. Lancet 2016; 387:545.</LI>&#xD;&#xA;<LI>Onivyde-(Irinotecan HCL injection). United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 30, 2016).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 30, 2016).</LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 30, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 109026 Version 3.0</div></div></div>"},"109027":{"type":"graphic_table","displayName":"SOAPP tool","title":"Screener and Opioid Assessment for Patients with Pain (SOAPP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screener and Opioid Assessment for Patients with Pain (SOAPP)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"5\" width=\"10%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"6\">The following are some questions given to all patients at the Pain Management Center who are on or being considered for opioids for their pain. Please answer each question as honestly as possible. This information is for our records and will remain confidential. Your answers alone will not determine your treatment. Thank you.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"6\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\">Never</td> <td class=\"subtitle1\">Seldom</td> <td class=\"subtitle1\">Sometimes</td> <td class=\"subtitle1\">Often</td> <td class=\"subtitle1\">Very often</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> <td class=\"subtitle2\">3</td> <td class=\"subtitle2\">4</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\"> <li>How often do you have mood swings? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"2\"> <li>How often do you smoke a cigarette within an hour after you wake up? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"3\"> <li>How often have any of your family members, including parents and grandparents, had a problem with alcohol or drugs? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"4\"> <li>How often have any of your close friends had a problem with alcohol or drugs? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"5\"> <li>How often have others suggested that you have a drug or alcohol problem? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"6\"> <li>How often have you attended an AA or NA meeting? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"7\"> <li>How often have you taken medication other than the way that it was prescribed? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"8\"> <li>How often have you been treated for an alcohol or drug problem? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"9\"> <li>How often have your medications been lost or stolen? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"10\"> <li>How often have others expressed concern over your use of medication? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"11\"> <li>How often have you felt a craving for medication? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"12\"> <li>How often have you been asked to give a urine screen for substance abuse? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"13\"> <li>How often have you used illegal drugs (eg, marijuana, cocaine, etc) in the past five years? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"14\"> <li>How often, in your lifetime, have you had legal problems or been arrested? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr> <td colspan=\"6\"><em>Please include any additional information you wish about the above answers.<br /> Thank you.</em> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AA: Alcoholics Anonymous; NA: Narcotics Anonymous.</div><div class=\"graphic_reference\">Â©2016 Inflexxion, Inc. Permission granted solely for use in published format by individual practitioners in clinical practice. No other uses or alterations are authorized or permitted by copyright holder. Permissions questions: <A href=\"mailto:PainEDU@inflexxion.com\" target=_blank>PainEDU@inflexxion.com</A>. An online version of this tool is included in <A spellcheck=true href=\"https://www.paincas.com/Welcome/Welcome\" target=_blank>PainCAS</A>. The SOAPPÂ® was developed with a grant from the National Institutes of Health and an educational grant from Endo Pharmaceuticals. Reproduced with permission. Copyright Â© 2016 Inflexxion, Inc., Newton MA. All rights reserved. <A href=\"http://www.inflexxion.com/\" target=_blank>www.Inflexxion.com</A>.</div><div id=\"graphicVersion\">Graphic 109027 Version 3.0</div></div></div>"},"109028":{"type":"graphic_table","displayName":"Differential diagnosis of meningioma","title":"Differential diagnosis of meningioma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of meningioma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Neoplastic</td> <td class=\"subtitle1\">Clinical and imaging clues</td> </tr> <tr> <td> <ul> <li>Solitary fibrous tumor/hemangiopericytoma </li> </ul> </td> <td> <ul> <li>Homogeneously enhancing dural-based tumors;&nbsp;usually indistinguishable from meningioma by imaging </li> </ul> </td> </tr> <tr> <td> <ul> <li>Lymphoma </li> </ul> </td> <td> <ul> <li>Lack of hyperostosis; low apparent diffusion coefficient </li> </ul> </td> </tr> <tr> <td> <ul> <li>Plasmacytoma </li> </ul> </td> <td> <ul> <li>Abnormal SPEP, UPEP; anemia; renal insufficiency </li> </ul> </td> </tr> <tr> <td> <ul> <li>Metastatic carcinoma </li> </ul> </td> <td> <ul> <li>Edema; adjacent skull metastasis; known breast, prostate, or lung cancer </li> </ul> </td> </tr> <tr> <td> <ul> <li>Melanocytic neoplasms </li> </ul> </td> <td> <ul> <li>Posterior fossa or spinal cord location </li> </ul> </td> </tr> <tr> <td> <ul> <li>Gliosarcoma </li> </ul> </td> <td> <ul> <li>Heterogenous enhancement, local invasion </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Leiomyosarcoma </li> </ul> </td> <td> <ul> <li>Rare, primarily seen in HIV-positive patients </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\">Non-neoplastic</td> <td class=\"subtitle1\">Clinical clues</td> </tr> <tr> <td> <ul> <li>Sarcoidosis </li> </ul> </td> <td> <ul> <li>Uncommon manifestation of neurosarcoidosis; systemic disease may or may not be present </li> </ul> </td> </tr> <tr> <td> <ul> <li>Granulomatosis with polyangiitis </li> </ul> </td> <td> <ul> <li>Constitutional symptoms, renal insufficiency </li> </ul> </td> </tr> <tr> <td> <ul> <li>Histiocytic disorders (eg, Langerhans cell histiocytosis, Erdheim-Chester disease) </li> </ul> </td> <td> <ul> <li>Bone&nbsp;lesions, multiorgan involvement, diabetes insipidus </li> </ul> </td> </tr> <tr> <td> <ul> <li>IgG4-related disease </li> </ul> </td> <td> <ul> <li>Orbital location; multiple tumors; elevated serum IgG4 </li> </ul> </td> </tr> <tr> <td> <ul> <li>Rosai-Dorfman disease </li> </ul> </td> <td> <ul> <li>Massive painless cervical lymphadenopathy and fever </li> </ul> </td> </tr> <tr> <td> <ul> <li>Tuberculosis </li> </ul> </td> <td> <ul> <li>Endemic regions; immunocompromise; chronic cough and constitutional symptoms </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SPEP: serum protein electrophoresis; UPEP: urinary protein electrophoresis; HIV: human immunodeficiency virus; IgG4: immunoglobulin G4.</div><div id=\"graphicVersion\">Graphic 109028 Version 3.0</div></div></div>"},"109029":{"type":"graphic_table","displayName":"Neuroimaging features of meningioma","title":"Neuroimaging featuresÂ of meningioma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuroimaging features&nbsp;of meningioma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Typical</td> <td class=\"subtitle1\">Atypical</td> </tr> <tr> <td> <ul> <li>Smooth contour </li> <li>Homogeneous enhancement </li> <li>Dural tail </li> <li>Calcification</li> </ul> </td> <td> <ul> <li>Large or disproportionate amount of associated edema </li> <li>Intratumoral cystic change </li> <li>Extensive bone involvement </li> <li>Brain or leptomeningeal invasion </li> <li>Low apparent diffusion coefficient </li> <li>Elevated cerebral blood volume </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 109029 Version 2.0</div></div></div>"},"109030":{"type":"graphic_table","displayName":"Pharmacokinetics alirocumab and evolocumab","title":"Pharmacokinetics and pharmacodynamics of alirocumab and evolocumab ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetics and pharmacodynamics of alirocumab and evolocumab </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"2\" width=\"42%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Alirocumab</td> <td class=\"subtitle1\">Evolocumab</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Pharmacokinetics</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Absorption</td> <td>Median Tmax: <ul class=\"decimal_heading\"> <li>Three to seven days </li> </ul> </td> <td>Median Tmax: <ul class=\"decimal_heading\"> <li>Three to four days </li> </ul> </td> </tr> <tr> <td>Estimated absolute bioavailability: <ul class=\"decimal_heading\"> <li>85% </li> </ul> </td> <td>Estimated absolute bioavailability: <ul class=\"decimal_heading\"> <li>72% </li> </ul> </td> </tr> <tr> <td>Cmax: <ul class=\"decimal_heading\"> <li>1.54 &#177; 1.02 ng/mL following 150 mg dose </li> </ul> </td> <td>Cmax: <ul class=\"decimal_heading\"> <li>18.6 &#177; 7.3 ug/mL following 140 mg dose </li> <li>59.0 &#177; 17.2 ug/mL following 420 mg dose </li> </ul> </td> </tr> <tr> <td>AUC: <ul class=\"decimal_heading\"> <li>129 &#177; 35.7 mg &#8226; day/L following 75 mg dose </li> </ul> </td> <td>AUC: <ul class=\"decimal_heading\"> <li>188 &#177; 98.6 day &#8226; ug/mL following 140 mg dose </li> <li>924 &#177; 346 day &#8226; ug/mL following 420 mg dose </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Distribution</td> <td>0.04 to 0.05 L/kg</td> <td>3.3 (0.5)* L</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Metabolism and elimination</td> <td>Specific metabolism studies were not conducted, because the antibodies are proteins. The antibodies are expected to degrade to small peptides and individual amino acids.</td> <td>Specific metabolism studies were not conducted, because the antibodies are proteins. The antibodies are expected to degrade to small peptides and individual amino acids.</td> </tr> <tr> <td>At low concentrations, the elimination is predominately through saturable binding to target (PCSK9), while at higher concentrations the elimination is largely through a non-saturable proteolytic pathway.</td> <td>At low concentrations, the elimination is predominately through saturable binding to target (PCSK9), while at higher concentrations the elimination is largely through a non-saturable proteolytic pathway.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Effective half-life of 17 to 20 days.</p> When co-administered with&nbsp;a statin, the half-life is 12&nbsp;days.&nbsp;</td> <td>Effective half-life of 11 to 17 days.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Pharmacodynamics</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">&nbsp;</td> <td>Following a single subcutaneous administration of 75 or 150 mg, maximal suppression of free PCSK9 occurred within four to eight hours.</td> <td> <ul> <li>Following single subcutaneous administration of 140 mg or 420 mg, maximum suppression of circulating unbound PCSK9 occurred by four hours. </li> <li>A mean nadir in LDL-C lowering response occurs by 14 and 21 days following 140 or 420 mg dos, respectively. </li> <li>Subcutaneous regimens of 140 mg every two weeks and 420 mg once monthly were equivalent in average LDL-C lowering. </li> <li>LDL-C lowering efficacy was sustained with continued use, in measurements made over 112 weeks. </li> </ul> </td> </tr> <tr> <td>Unbound PCSK9 concentrations returned toward baseline when antibody concentrations decreased below the limit of quantitation.</td> <td> <ul> <li>Unbound PCSK9 concentrations returned toward baseline when antibody concentrations decreased below the limit of quantitation. </li> <li>No rebound in PCSK9 or LDL-C above baseline was observed during the washout of evolocumab. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Standard deviation<br />AUC: exposure as measured by the area under the concentration x time curve; Cmax: maximum plasma concentration; PCSK9: proprotein convertase subtilisin/kexin type 9; Tmax: time to maximum plasma concentration. </div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Chung JE. Clinical pharmacology review PRALUENT (Alirocumab). U.S. Food and Drug Administration 2014.</LI>&#xD;&#xA;<LI>Suryanarayana Sista JE. Clinical phramacology review REPATHA (Evolocumab). U.S. Food and Drug Administration 2014.</LI>&#xD;&#xA;<LI>Evolocumab injection. US Food &amp; Drug Administration (FDA) approved product information. Revised July, 2016. Available on-line at http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm </LI>&#xD;&#xA;<LI>Alirocumab injection. US Food &amp; Drug Administration (FDA) approved product information. Revised October, 2015. Available on-line at http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm </LI>&#xD;&#xA;<LI>Evolocumab (Repatha) Summary of Product Characteristics; European Medicines Agency. Revised March 3, 2017. Available on-line at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003766/WC500191398.pdf </LI>&#xD;&#xA;<LI>Alirocumab (Praluent) Summary of Product Characteristics; European Medicines Agency. Revised November 18, 2016. Available on-line at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003882/WC500194521.pdf</LI></OL></div><div id=\"graphicVersion\">Graphic 109030 Version 2.0</div></div></div>"},"109032":{"type":"graphic_figure","displayName":"Log-linear genetically and pharmacologically mediate lower LDL-C","title":"Log-linear effect of genetically and pharmacologically mediated lower LDL-C","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">Log-linear effect of genetically and pharmacologically mediated lower LDL-C</div><div class=\"cntnt\"><img style=\"width:760px; height:1148px;\" src=\"images/CARD/109032_Lg-lnr_gene_pharma_lwr_LDLC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Boxes represent proportional CHD risk reduction (1 â€“ OR) for each exposure allele plotted against the absolute magnitude of lower LDL-C associated with that allele (top line), or the proportional CHD risk reduction (1 â€“ RR) for each trial plotted against the mean absolute difference in LDL-C between treatment arms at one-year follow-up for that trial (bottom line). Vertical lines represent one SE above and below point estimate of proportional risk reduction. SNPs and trials are plotted in order of increasing absolute magnitude of exposure to lower LDL-C. The lines (which are forced to pass through the origin) represent the increase in proportional risk reduction of CHD per unit exposure to lower LDL-C.<br />(Panel B) Boxes represent the OR for the association between the exposure allele (defined as the allele associated with lower LDL-C) and risk of CHD for each polymorphism or genetic LDL-C score. Bars represent 95% CI. Effect estimates and standard errors are adjusted for a standard decrement of 10 mg/dL (0.25 mmol/L) lower LDL-C using the usual ratio of effect estimates method.</div><div class=\"graphic_footnotes\">CHD: coronary heart disease; CI: confidence interval; LDL-C: low-density lipoprotein cholesterol; OR: odds ratio; RR: relative risk; SE: standard error.</div><div class=\"graphic_reference\">From: Ference BA. Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps. Curr Opin Lipidol 2015; 26:566. DOI: <a href=\"http://journals.lww.com/co-lipidology/pages/articleviewer.aspx?year=2015&amp;issue=12000&amp;article=00012&amp;type=abstract\" target=\"_blank\">10.1097/MOL.0000000000000247</a>. Copyright &copy; 2015. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 109032 Version 2.0</div></div></div>"},"109033":{"type":"graphic_figure","displayName":"Effect of PCSK9 antibody on free PCSK9 concentration","title":"Effect of PCSK9 antibody on free PCSK9 concentration","html":"<div class=\"graphic\"><div style=\"width: 768px\" class=\"figure\"><div class=\"ttl\">Effect of PCSK9 antibody on free PCSK9 concentration</div><div class=\"cntnt\"><img style=\"width:748px; height:376px;\" src=\"images/CARD/109033_PCSK9_antbdy_PCSK9_cncntrtn.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Stein EA, Raal FJ. New therapies for reducing low-density lipoprotein cholesterol. Endocrinol Metab Clin North Am 2014; 43:1007. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109033 Version 1.0</div></div></div>"},"109034":{"type":"graphic_figure","displayName":"PCSK9 pathway and effect of PCSK9 antibody on LDL-R","title":"PCSK9 pathway and effect of PCSK9 antibody on LDL-R","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">PCSK9 pathway and effect of PCSK9 antibody on LDL-R</div><div class=\"cntnt\"><img style=\"width:766px; height:492px;\" src=\"images/CARD/109034_Effect_PCSK9_antbdy_LDL-R.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LDL-R: low density lipoprotein cholesterol receptor.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery. Mullard A. Cholesterol-lowering blockbuster candidates speed into Phase III trials. Nat Rev Drug Discov 2012; 11:817. Copyright Â© 2012. <A href=\"http://www.nature.com/nrd\" target=_blank>www.nature.com/nrd</A>.</div><div id=\"graphicVersion\">Graphic 109034 Version 1.0</div></div></div>"},"109035":{"type":"graphic_figure","displayName":"Photo Amblyomma americanum","title":"Photograph of <em>Amblyomma americanum</em>, the lone star tick","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Photograph of <em>Amblyomma americanum</em>, the lone star tick</div><div class=\"cntnt\"><img style=\"width:535px; height:697px;\" src=\"images/ID/109035_Amblyomma_americanum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Heartland virus has been found in the lone star tick.</div><div class=\"graphic_reference\">Reproduced from: Pastula DM, Turabelidze G, Yates KF, et al. Notes from the field: Heartland virus disease - United States, 2012-2013. MMWR Morb Mortal Wkly Rep 2014; 63;270.</div><div id=\"graphicVersion\">Graphic 109035 Version 1.0</div></div></div>"},"109036":{"type":"graphic_figure","displayName":"Geographic distribution of Amblyomma americanum","title":"Geographic distribution of <em>Amblyomma americanum</em>","html":"<div class=\"graphic\"><div style=\"width: 759px\" class=\"figure\"><div class=\"ttl\">Geographic distribution of <em>Amblyomma americanum</em></div><div class=\"cntnt\"><img style=\"width:739px; height:449px;\" src=\"images/ID/109036_Geogr_distrb_Amblyomma_amer.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Geographic distribution of ticks that bite humans. Available at: <a href=\"http://www.cdc.gov/ticks/geographic_distribution.html\" target=\"_blank\">http://www.cdc.gov/ticks/geographic_distribution.html</a> (Accessed on July 14, 2016).</div><div id=\"graphicVersion\">Graphic 109036 Version 1.0</div></div></div>"},"109037":{"type":"graphic_figure","displayName":"Incidence of hepatitis A","title":"Incidence of hepatitis A, by year â€“ United States, 1980 to 2014","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Incidence of hepatitis A, by year â€“ United States, 1980 to 2014</div><div class=\"cntnt\"><img style=\"width:710px; height:424px;\" src=\"images/ID/109037_Incidence_of_hepatitis_A.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Hepatitis A Questions and Answers for Health Professionals. Available at: <A spellcheck=true href=\"http://www.cdc.gov/hepatitis/hav/havfaq.htm#general\" target=_blank>http://www.cdc.gov/hepatitis/hav/havfaq.htm#general</A> (Accessed on July 14, 2016).</div><div id=\"graphicVersion\">Graphic 109037 Version 1.0</div></div></div>"},"109040":{"type":"graphic_diagnosticimage","displayName":"Cuboid fracture AP radiograph","title":"Cuboid fracture AP radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cuboid fracture AP radiograph</div><div class=\"cntnt\"><img style=\"width:418px; height:756px;\" src=\"images/SM/109040_Cuboid_fracture_AP_radio_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior-posterior (AP) view of the foot depicting a mid cuboid fracture, minimally displaced (arrow) with mild associated soft tissue swelling.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD, and Shane Larson, MD.</div><div id=\"graphicVersion\">Graphic 109040 Version 1.0</div></div></div>"},"109041":{"type":"graphic_diagnosticimage","displayName":"Cuboid fracture oblique plain radiograph","title":"Cuboid fracture oblique plain radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cuboid fracture oblique plain radiograph</div><div class=\"cntnt\"><img style=\"width:442px; height:756px;\" src=\"images/SM/109041_Cuboid_fracture_oblique_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This oblique view of the foot&nbsp;reveals a mid-cuboid fracture with minimal displacement (arrow).</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD, and Shane Larson, MD.</div><div id=\"graphicVersion\">Graphic 109041 Version 1.0</div></div></div>"},"109042":{"type":"graphic_diagnosticimage","displayName":"CT dorsal cuboid fracture","title":"CT dorsal cuboid fracture","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">CT dorsal cuboid fracture</div><div class=\"cntnt\"><img style=\"width:512px; height:512px;\" src=\"images/SM/109042_CT_dorsal_cuboid_fractur_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;sagittal CT image of the&nbsp;left foot&nbsp;shows a minimally displaced, mildly comminuted fracture involving the dorsal aspect of the cuboid bone with overlying soft tissue swelling (region below arrow).&nbsp;</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD, and Shane Larson, MD.</div><div id=\"graphicVersion\">Graphic 109042 Version 1.0</div></div></div>"},"109044":{"type":"graphic_diagnosticimage","displayName":"CT 3D reconstruction cuboid fracture","title":"CT 3D reconstruction of a cuboid fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT 3D reconstruction of a cuboid fracture</div><div class=\"cntnt\"><img style=\"width:378px; height:306px;\" src=\"images/SM/109044_CT_3D_cuboid_fracture_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image above&nbsp;shows a three-dimensional (3D) reconstruction of a CT scan&nbsp;of the&nbsp;left foot. The image is in an anterolateral orientation&nbsp;and shows an&nbsp;isolated cuboid fracture that is&nbsp;minimally displaced (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD, and Shane Larson, MD.</div><div id=\"graphicVersion\">Graphic 109044 Version 1.0</div></div></div>"},"109045":{"type":"graphic_diagnosticimage","displayName":"MRI axillary view cuboid fracture","title":"MRI axillary view cuboid fracture","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">MRI axillary view cuboid fracture</div><div class=\"cntnt\"><img style=\"width:512px; height:512px;\" src=\"images/SM/109045_MRI_axillary_cuboid_frac_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows a&nbsp;T2 weighted fat suppression (FS) sequence, axillary&nbsp;view of the left foot depicting a healing, occult, nondisplaced cuboid fracture (arrow) with increased signal.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD, and Shane Larson, MD.</div><div id=\"graphicVersion\">Graphic 109045 Version 1.0</div></div></div>"},"109046":{"type":"graphic_diagnosticimage","displayName":"MRI sagittal view cuboid fracture","title":"MRI sagittal view cuboid fracture","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">MRI sagittal view cuboid fracture</div><div class=\"cntnt\"><img style=\"width:512px; height:512px;\" src=\"images/SM/109046_MRI_sagittal_cuboid_frac_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image&nbsp;shows a&nbsp;T2 weighted fat suppression (FS) sequence, sagittal&nbsp;view of the left foot depicting a minimally displaced mid-cuboid fracture (arrow) with increased signal.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD, and Shane Larson, MD.</div><div id=\"graphicVersion\">Graphic 109046 Version 1.0</div></div></div>"},"109065":{"type":"graphic_picture","displayName":"Collagenoma histology","title":"Histologic features of collagenoma in Buschke-Ollendorff syndrome","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Histologic features of collagenoma in Buschke-Ollendorff syndrome</div><div class=\"cntnt\"><img style=\"width:756px; height:540px;\" src=\"images/DERM/109065_Collagenoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power examination reveals a subtle dermal nodule containing widened collagen bundles. The epidermis is normal.</div><div class=\"graphic_reference\">Courtesy of Viktor Kokta, MD.</div><div id=\"graphicVersion\">Graphic 109065 Version 1.0</div></div></div>"},"109067":{"type":"graphic_picture","displayName":"Elastoma histopathology","title":"Histopathologic features of elastoma in Buschke-Ollendorff syndrome","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of elastoma in Buschke-Ollendorff syndrome</div><div class=\"cntnt\"><img style=\"width:756px; height:541px;\" src=\"images/DERM/109067_Elastoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Elastoma. Higher power reveals thickened and distorted elastic fibers (stained in red) within widened collagen bundles. Hematoxylin phloxine saffron stain; original magnification x320.</div><div class=\"graphic_reference\">Reproduced from: McCuaig CC, Vera C, Kokta V, et al. Connective tissue nevi in children: Institutional experience and review. J Am Acad Dermatol 2012; 67:890. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109067 Version 2.0</div></div></div>"},"109069":{"type":"graphic_picture","displayName":"Connective tissue nevus buttock","title":"Connective tissue nevus in Buschke-Ollendorff syndrome","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Connective tissue nevus in Buschke-Ollendorff syndrome</div><div class=\"cntnt\"><img style=\"width:756px; height:540px;\" src=\"images/DERM/109069_Connective_tissue_nevus_but.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grouped flesh-colored plaques on the right buttock of a patient with Buschke-Ollendorff syndrome.</div><div class=\"graphic_reference\">Courtesy of Catherine McCuaig, MD.</div><div id=\"graphicVersion\">Graphic 109069 Version 2.0</div></div></div>"},"109070":{"type":"graphic_picture","displayName":"Connective tissue nevus retroauricular","title":"Connective tissue nevus in Buschke-Ollendorff syndrome","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Connective tissue nevus in Buschke-Ollendorff syndrome</div><div class=\"cntnt\"><img style=\"width:540px; height:756px;\" src=\"images/DERM/109070_Conn_tiss_nevus_retroaurclr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Connective tissue nevus presenting as a flesh-colored plaque in the retroauricular area in a patient with Buschke-Ollendorff syndrome.</div><div class=\"graphic_reference\">Courtesy of Catherine McCuaig, MD.</div><div id=\"graphicVersion\">Graphic 109070 Version 1.0</div></div></div>"},"109072":{"type":"graphic_picture","displayName":"Buschke-Ollendorff syndrome bone","title":"Osteopoikilosis in Buschke-Ollendorff syndrome","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Osteopoikilosis in Buschke-Ollendorff syndrome</div><div class=\"cntnt\"><img style=\"width:756px; height:540px;\" src=\"images/DERM/109072_Buschke-Ollendorff_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiologically dense opacities seen in femur and pelvis in Buschke-Ollendorff syndrome.</div><div class=\"graphic_reference\">Reproduced from: McCuaig CC, Vera C, Kokta V, et al. Connective tissue nevi in children: Institutional experience and review. J Am Acad Dermatol 2012; 67:890. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109072 Version 1.0</div></div></div>"},"109086":{"type":"graphic_figure","displayName":"Hemoglobin during development","title":"Globin gene expression and hemoglobin compositionÂ during development","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Globin gene expression and hemoglobin composition&nbsp;during development</div><div class=\"cntnt\"><img style=\"width:446px; height:285px;\" src=\"images/HEME/109086_Hemoglobin_during_development.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemoglobin consists of a heterotetramer of two alpha-like chains (shown in red) and two beta-like chains (shown in blue). Globin gene expression varies during development, with embryonic globin genes expressed early in gestation, followed by production of alpha globin and gamma globin (to produce Hb F) at later gestational ages. After birth, Hb F gradually declines and is replaced by adult hemoglobin&nbsp;(Hb A), which consists of alpha and beta globin chains. Refer to UpToDate for information regarding normal hemoglobin development, hemoglobinopathies, and methods of hemoglobin analysis.</div><div class=\"graphic_footnotes\">Hb: Hemoglobin.</div><div id=\"graphicVersion\">Graphic 109086 Version 1.0</div></div></div>"},"109092":{"type":"graphic_table","displayName":"Gadolinium-based contrast agents approved for clinical use","title":"Gadolinium-based contrast agents approved for clinical use: Biochemical properties","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gadolinium-based contrast agents approved for clinical use: Biochemical properties</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Chemical structure</td> <td class=\"subtitle1\">Trade name</td> <td class=\"subtitle1\">Thermodynamic stability constant</td> <td class=\"subtitle1\">Conditional stability constant</td> <td class=\"subtitle1\">Elimination pathway</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Linear</td> </tr> <tr> <td class=\"subtitle2_left indent1\" colspan=\"5\">Nonionic</td> </tr> <tr> <td class=\"indent2\">Gadodiamide</td> <td>Omniscan, 0.5 mmol/mL</td> <td class=\"centered\">16.8</td> <td class=\"centered\">14.9</td> <td>Renal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Gadoversetamide</td> <td>OptiMARK, 0.5 mmol/mL</td> <td class=\"centered\">16.6</td> <td class=\"centered\">15</td> <td>Renal</td> </tr> <tr> <td class=\"subtitle2_left indent1\" colspan=\"5\">Ionic</td> </tr> <tr> <td class=\"indent2\">Gadopentetate dimeglumine</td> <td>Magnevist, 0.5 mmol/mL</td> <td class=\"centered\">22.1</td> <td class=\"centered\">17.7</td> <td>Renal</td> </tr> <tr> <td class=\"indent2\">Gadobenate dimeglumine</td> <td>MultiHance, 0.5 mmol/mL</td> <td class=\"centered\">22.6</td> <td class=\"centered\">18.4</td> <td>93% Renal<br /> 3% Biliary</td> </tr> <tr> <td class=\"indent2\">Gadoxetic acid disodium</td> <td>Primovist, 0.25 mmol/mL</td> <td class=\"centered\">23.5</td> <td class=\"centered\">NA</td> <td>50% Renal<br /> 50% Biliary</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Gadofosveset trisodium</td> <td>Vasovist, 0.25 mmol/mL</td> <td class=\"centered\">22</td> <td class=\"centered\">NA</td> <td>91% Renal<br /> 9% Biliary</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Macrocyclic</td> </tr> <tr> <td class=\"subtitle2_left indent1\" colspan=\"5\">Nonionic</td> </tr> <tr> <td class=\"indent2\">Gadoteridol</td> <td>ProHance, 0.5 mmol/mL</td> <td class=\"centered\">22.8</td> <td class=\"centered\">17.1</td> <td>Renal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Gadobutrol</td> <td>Gadavist, 0.5 mmol/mL</td> <td class=\"centered\">21.8</td> <td class=\"centered\">NA</td> <td>Renal</td> </tr> <tr> <td class=\"subtitle2_left indent1\" colspan=\"5\">Ionic</td> </tr> <tr> <td class=\"indent2\">Gadoterate meglumine</td> <td>Dotarem, 0.5 mmol/mL</td> <td class=\"centered\">25.4</td> <td class=\"centered\">19</td> <td>Renal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: not applicable.</div><div class=\"graphic_reference\">Reproduced with permission of the American Society of Neuroradiology, from: Ramalho J, Semelka RC, Ramalho M, et al. Gadolinium-based contrast agent accumulation and toxicity: An update. AJNR Am J Neuroradiol 2016; 37(7):1192-8; permission conveyed through Copyright Clearance Center, Inc. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 109092 Version 2.0</div></div></div>"},"109096":{"type":"graphic_figure","displayName":"US trends in ESRD cases using home dialysis, 1996-2013","title":"Trends in the number of incident ESRD cases (in thousands) using home dialysis, by type of therapy, in the US population, 1996 to 2013","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Trends in the number of incident ESRD cases (in thousands) using home dialysis, by type of therapy, in the US population, 1996 to 2013</div><div class=\"cntnt\"><img style=\"width:550px; height:376px;\" src=\"images/NEPH/109096_US_trnds_ESRD_home_dialysis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PD consists of CAPD and CCPD only.</div><div class=\"graphic_footnotes\">ESRD: end-stage renal disease; PD: peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; CCPD: continuous cycler peritoneal dialysis.</div><div class=\"graphic_reference\">Reproduced from: US Renal Data System, USRDS 2015 Annual Data Report: End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2015.</div><div id=\"graphicVersion\">Graphic 109096 Version 1.0</div></div></div>"},"109102":{"type":"graphic_table","displayName":"Prevention and management of DD and SCS device infection","title":"Recommendations for the prevention and management of DD and SCS device infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for the prevention and management of DD and SCS device infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Patient selection, preparation, surgical planning, and preoperative hand and forearm antisepsis</td> </tr> <tr> <td class=\"subtitle2_single\">Category IA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Identify and treat all remote infections before elective operation; postpone surgery until treated. </li> <li>Do not remove hair unless removal is necessary to facilitate surgery. </li> <li>If hair is removed, do so immediately before surgery, preferably with electric clippers. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Category IB</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Control serum blood glucose perioperatively. </li> <li>Patients should discontinue tobacco use 30 days before surgery. </li> <li>Do not withhold necessary blood products to prevent SSI. </li> <li>Require patients to shower or bathe with an antiseptic agent at least the night before surgery. </li> <li>Perform surgical scrub for at least 2 to 5 minutes with an appropriate antiseptic. </li> <li>After scrub, keep hands up and away from body, dry hands with sterile towel; don sterile gown and gloves. </li> <li>Wash incision site before performing antiseptic skin preparation with approved agent. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Category II</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Prepare skin in concentric circles from incision site. </li> <li>Keep preoperative stay in hospital as short as possible. </li> <li>Device implantation may proceed, albeit at increased risk, in patients &ndash; especially those with spasticity or cancer pain &ndash; in whom remote infections or other risk factors cannot be eradicated or resolved completely. </li> <li>Select device or model suitable for patient's size and body habitus. </li> <li>Consider surgical scars, ostomies, seat belt or wheelchair use, and clothing or belt line in selection of device pocket site. </li> <li>If practical, mark the device pocket site preoperatively with the patient in the standing position. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Surgical and operating room management</td> </tr> <tr> <td class=\"subtitle2_single\">Category II</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Perform implant surgery in an operating room rather than a procedure room. </li> <li>Minimize operating room traffic during implant surgery. </li> <li>Use sterile-draped fluoroscope to expedite case and to avoid contamination by portable x-ray equipment. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Antimicrobial prophylaxis</td> </tr> <tr> <td class=\"subtitle2_single\">Category IA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Administer antimicrobial agent only when indicated, and with efficacy against most common pathogens. </li> <li>Use intravenous route to achieve adequate serum concentrations during surgery and for at most a few hours after incision is closed. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Category IB</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Do not routinely use vancomycin for antimicrobial prophylaxis. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Surgical procedure</td> </tr> <tr> <td class=\"subtitle2_single\">Category II</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Use double glove and minimal-touch or no-touch surgical techniques. </li> <li>Avoid placing devices directly under incision lines. </li> <li>Close the implant site incisions in anatomical layers, consider subfascial placement in small or underweight patients. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Postoperative care</td> </tr> <tr> <td class=\"subtitle2_single\">Category II</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Apply occlusive, antiseptic wound dressings; perform the initial dressing change using sterile technique. </li> <li>Treat threatened incisions and external CSF leaks promptly and aggressively. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Treatment of established infection</td> </tr> <tr> <td class=\"subtitle2_single\">Category II</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Remove infected components or entire system as indicated. </li> <li>Taper intrathecal drugs or administer substitute medication systemically or both to prevent or treat intrathecal baclofen or opioid withdrawal when a drug delivery system is removed because of infection. </li> <li>Administer antibiotics directed at the responsible organism as determined by wound cultures and stains. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Device reimplantation after treatment of infection</td> </tr> <tr> <td class=\"subtitle2_single\">Category II</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Ensure complete and permanent eradication of the infection off antibiotic therapy before device reimplantation. </li> <li>Implant the new device in a site that was not involved in the previous infection. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Surveillance</td> </tr> <tr> <td class=\"subtitle2_single\">Categories IB and II</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Use CDC definitions and a combination of direct and indirect case-finding methods to identify SSI among inpatients and outpatients. </li> <li>Prospectively record surgical wound classification and other factors associated with SSI risk. </li> <li>Periodically calculate risk-stratified, operation-specific SSI rates, and report the results to surgical team members. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Definitions of category rankings: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>IA = strongly recommended for implementation and supported by well-designed experimental, clinical, or epidemiologic studies.<SUP>[1,2]</SUP></LI>&#xD;&#xA;<LI>IB = strongly recommended for implementation and supported by some experimental, clinical, or epidemiologic studies and strong theoretical rationale.<SUP>[1,2]</SUP></LI>&#xD;&#xA;<LI>II = suggested for implementation and supported by suggestive clinical or epidemiologic studies or theoretical rationale. &#xD;&#xA;<UL>&#xD;&#xA;<LI>Category II recommendations have not necessarily been validated by controlled studies.</LI></UL></LI></UL></div><div class=\"graphic_footnotes\">DD: drug delivery; SCS: spinal cord stimulation; SSI: surgical site infection; CSF: cerebrospinal fluid; CDC: Centers for Disease Control.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection. Infect Control Hosp Epidemiol 1999; 20:247.</LI>&#xD;&#xA;<LI>Nichols RL. Preventing surgical site infections: A surgeonâ€™s perspective. Emerg Infect Dis 2001; 7:220.</LI></OL>From: Follett KA, Boortz-Marx RL, Drake JM, et al. Prevention and management of intrathecal drug delivery and spinal cord stimulation system infections. Anesthesiology 2004; 100:1582. Copyright Â© 2004 American Society of Anesthesiologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 109102 Version 1.0</div></div></div>"},"109103":{"type":"graphic_picture","displayName":"Angular cheilitis in iron deficiency","title":"Angular cheilitis in a patient withÂ iron deficiency","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Angular cheilitis in a patient with&nbsp;iron deficiency</div><div class=\"cntnt\"><img style=\"width:616px; height:400px;\" src=\"images/HEME/109103_Angulr_cheilitis_irn_dfcncy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angular cheilitis, also called \"perlÃ¨che,\"&nbsp;is a finding that may occur in individuals with iron deficiency. Refer to UpToDate topics on the clinical manifestations of&nbsp;iron deficiency for additional clinical findings, and on cheilitis for additional causes of cheilitis.</div><div class=\"graphic_reference\">From: Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol 2016; 91:31. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24201/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24201/abstract</A>. Copyright Â© 2016. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 109103 Version 1.0</div></div></div>"},"109104":{"type":"graphic_table","displayName":"GemCap for adjuvant therapy of pancreatic cancer","title":"Gemcitabine and capecitabine (GemCap) for adjuvant therapy of pancreatic cancer [1]","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gemcitabine and capecitabine (GemCap) for adjuvant therapy of pancreatic cancer [1]</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 28 days.<br /> Duration: six months.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Gemcitabine</strong>*</td> <td>1000 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (concentration no greater than 40 mg/mL) and administer over 30 minutes.</td> <td>Days 1, 8, and 15</td> </tr> <tr> <td><strong>Capecitabine</strong><sup>&#916;</sup></td> <td>830 mg/m<sup>2</sup> per dose by mouth.</td> <td>Twice daily (total dose 1660 mg/m<sup>2</sup> per day). Swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets<sup>&#9674;</sup>.</td> <td>Days 1 through 21</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with G-CSF is not indicated based on a low risk for febrile neutropenia with this regimen<sup>[1]</sup>. Refer to UpToDate topic on \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline renal dysfunction:</strong> A lower starting dose of gemcitabine may be needed for patients with liver impairment. A lower starting dose of capecitabine may be needed for patients with moderate renal impairment<sup>[2]</sup>. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count weekly during treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess basic metabolic panel (including serum creatinine) and liver function tests every three weeks prior to each new cycle and otherwise as indicated during treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for diarrhea and palmar-plantar erythrodysesthesias during treatment. <strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topics on \"Enterotoxicity of chemotherapeutic agents\" and \"Cutaneous complications of conventional chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Dose modifications were not presented with the abstract<sup>[1]</sup>. Other studies using gemcitabine plus capecitabine have suggested dose modifications for hematologic toxicity<sup>[3]</sup>. Do not initiate a new cycle unless neutrophils are &#8805;1500/microL and platelets are &#8805;100,000/microL. Reduce the day 8 (or day 15) gemcitabine dose by 25 percent for an absolute neutrophil count of 500 to 1000/microL or a platelet count of 50,000 to 100,000/microL. Decrease gemcitabine by 25 percent for subsequent cycles for febrile neutropenia, grade 4 hematologic toxicity lasting for more than seven days, or bleeding-associated thrombocytopenia.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>&#8226; <strong>Nonhematologic toxicity (including hepatotoxicity): <span style=\"color: #ff0000;\"></span></strong>For the first, second, and third occurrence of grade 2 toxicity, hold capecitabine therapy<sup>[2]</sup>. After resolution to grade 1 or less, resume treatment (first occurrence, no dosage adjustment; second occurrence, 75 percent of the starting dose; third occurrence, 50 percent of the starting dose)<sup>[2]</sup>. For the fourth occurrence of a grade 2 toxicity, discontinue capecitabine therapy. Grade 3: For the first and second occurrence, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment at a reduced dose (first occurrence, 75 percent of the starting dose; second occurrence, 50 percent of the starting dose). For the third occurrence of a grade 3 toxicity, discontinue capecitabine therapy. Grade 4: Discontinue capecitabine therapy. Alternatively, hold capecitabine therapy, and begin next treatment at 50 percent of the starting dose when toxicity resolves to grade 1 or less; discontinue treatment for fist recurrence of grade 4 toxicity. Omitted capecitabine doses for toxicity are not replaced or restored. Resume treatment with the planned next cycle. </p> <p>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</p> <p>Hold gemcitabine for other &#8805;grade 3 nonhematologic toxicity that is likely related to gemcitabine until it decreases to &#8804;grade 1<sup>[4]</sup>. Restart gemcitabine with a 25 percent dose reduction.</p> </td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Pulmonary toxicity:</strong> A variety of manifestations of pulmonary toxicity have been reported in patients treated with gemcitabine. Discontinue gemcitabine immediately and permanently. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Thrombotic microangiopathy:</strong> Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine in individuals who have received a large or small cumulative dose<sup>[4]</sup>. Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP. Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\".</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factor; CBC: complete blood count; INR: international normalized ratio; ULN: upper limit of normal.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br /><SPAN style=\"COLOR: black\">Î”</SPAN><SPAN style=\"COLOR: black\">&nbsp;Capecitabine is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br />â—Š Extemporaneous compounding of liquid dosage forms is possible, but not routinely recommended.</SPAN><br /></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Neoptolemos JP, et al. J Clin Oncol 2016 34:(suppl; abstr LBA4006).</LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI>&#xD;&#xA;<LI>Knox JJ, et al. J Clin Oncol 2005; 23:2332.</LI>&#xD;&#xA;<LI>Gemcitabine injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 109104 Version 7.0</div></div></div>"},"109105":{"type":"graphic_table","displayName":"Hand-foot skin reaction incidence","title":"Targets and incidences of hand-foot skin reaction caused by tyrosine kinase inhibitors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Targets and incidences of hand-foot skin reaction caused by tyrosine kinase inhibitors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">TKI</td> <td class=\"subtitle1\">Targets</td> <td class=\"subtitle1\">Incidence of all-grade HFSR (%)</td> <td class=\"subtitle1\">Incidence of high-grade HFSR (%)</td> </tr> <tr> <td>Axitinib<sup>[1]</sup></td> <td>VEGFR-1, 2, and 3</td> <td class=\"centered\">29.2<span class=\"centered\"></span></td> <td class=\"centered\">9.6</td> </tr> <tr> <td>Cabozantinib<sup>[2,3]</sup></td> <td>VEGFR-2, c-MET, RET, c-KIT, FLT3, Tie-2</td> <td class=\"centered\">35.3</td> <td class=\"centered\">9.5</td> </tr> <tr> <td>Pazopanib<sup>[4]</sup></td> <td>RAF, VEGFR-2 and 3, PDGFR-beta, c-KIT, FLT3, RET</td> <td class=\"centered\">4.5</td> <td class=\"centered\">1.8</td> </tr> <tr> <td>Regorafenib<sup>[5]</sup></td> <td>VEGFR-1, 2, and 3; Tie-2; FGFR-1; PDGFR-alpha and beta; c-KIT; RET; RAF; p38 MAPK</td> <td class=\"centered\">60.5</td> <td class=\"centered\">20.4</td> </tr> <tr> <td>Sorafenib<sup>[6]</sup></td> <td>VEGFR-2 and 3, PDGFR, A-RAF, B-RAF, C-RAF, FLT3</td> <td class=\"centered\">33.8</td> <td class=\"centered\">8.9<span class=\"centered\"></span></td> </tr> <tr> <td>Sunitinib<sup>[7]</sup></td> <td>VEGFR-2, PDGFR, c-KIT, FLT3</td> <td class=\"centered\">18.9</td> <td class=\"centered\">5.5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TKI: tyrosine kinase inhibitor; HFSR: hand-foot skin reaction; VEGFR: vascular endothelial growth factor receptor; c-MET: cellular mesenchymal to epithelial transition factor; RET: rearranged during transfection; c-KIT: mast/stem cell growth factor; FLT3: FMS-like tyrosine kinase 3; Tie-2: tyrosine-protein kinase receptor; RAF: rapidly accelerated fibrosarcoma; PDGFR: platelet-derived growth factor receptor; FGFR: fibroblast growth factor receptor;&nbsp;MAPK: mitogen-activated protein kinase.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2013; 31:787.</li>&#xD;&#xA;    <li>Belum VR, Serna-Tamayo C, Wu S, Lacouture ME. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. Clin Exp Dermatol 2016; 41:8.</li>&#xD;&#xA;    <li>Zuo RC, Apolo AB, DiGiovanna JJ, et al. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol 2015; 151:170.</li>&#xD;&#xA;    <li>Balagula Y, Wu S, Su X, et al. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2012; 30:1773.</li>&#xD;&#xA;    <li>Belum VR, Wu S, Lacouture ME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs 2013; 31:1078.</li>&#xD;&#xA;    <li>Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008; 47:176.</li>&#xD;&#xA;    <li>Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 2009; 7:11.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109105 Version 1.0</div></div></div>"},"109108":{"type":"graphic_table","displayName":"Predictors of difficult and impossible mask ventilation","title":"Predictors of difficult and impossible mask ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictors of difficult and impossible mask ventilation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Difficult mask ventilation</td> <td class=\"subtitle1\">Impossible mask ventilation</td> </tr> <tr> <td> <ul> <li>Mallampati grade 3 to 4</li> <li>Decreased mandibular protrusion</li> <li>Presence of beard</li> <li>Obesity (BMI &#8805;30)</li> <li>Age &#62;57 years</li> <li>Lack of teeth</li> <li>History of snoring</li> </ul> </td> <td> <ul> <li>Mallampati grade 3 to 4</li> <li>Male sex</li> <li>Presence of beard</li> <li>OSA*</li> <li>Neck radiation changes </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">At least three predictors should be present in each category for a reasonably high probability of the event.</div><div class=\"graphic_footnotes\">BMI: body mass index; OSA: obstructive sleep apnea; CPAP: continuous positive airway pressure; BiPAP: bilevel positive airway pressure.<br />* Moderate-to-severe OSA, associated with the use of CPAP/BiPAP or a history of OSA surgery.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Langeron O, Masso E, Huraux C, et al. Prediction of difficult mask ventilation. Anesthesiology 2000; 92:1229.</li>&#xD;&#xA;    <li>Kheterpal S, Han R, Tremper KK, et al. Incidence and predictors of difficult and impossible mask ventilation. Anesthesiology 2006; 105:885.</li>&#xD;&#xA;    <li>Kheterpal S, Martin L, Shanks AM, Tremper KK. Prediction and outcomes of impossible mask ventilation: a review of 50,000 anesthetics. Anesthesiology 2009; 110:891.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Dr. Vladimir Nekhendzy.</div><div id=\"graphicVersion\">Graphic 109108 Version 3.0</div></div></div>"},"109110":{"type":"graphic_figure","displayName":"Anatomy: Adrenal venous sampling","title":"Genitourinary anatomy: Adrenal venous sampling","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Genitourinary anatomy: Adrenal venous sampling</div><div class=\"cntnt\"><img style=\"width:540px; height:602px;\" src=\"images/ENDO/109110_Anatomy_adrenal_venous_sampling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adrenal vein sampling (AVS) can be completed with simultaneous or sequential cannulation of the adrenal veins. As shown in this image, a percutaneous femoral vein approach is used. Under fluoroscopic guidance, correct catheter tip location is confirmed with injection of a small amount of contrast medium. With gentle aspiration, blood is obtained from both adrenal veins and the external iliac vein. The right adrenal vein can be difficult to catheterize because it is small in caliber, short length, and angulated path. The short length of the right adrenal vein is problematic because it may not support a stable catheter position during respiratory motion. The left adrenal vein is a tributary of the inferior phrenic vein and the blood sample on the left is usually obtained from the common trunk of the inferior phrenic vein just proximal to the inflow from the left adrenal vein. In the sequential sampling technique, only one femoral vein puncture site is used, and the right adrenal vein is sampled first because it is usually more time consuming. Then, with a different catheter, the left adrenal vein is rapidly sampled, followed by the external iliac vein. Aldosterone and cortisol concentrations are measured from all&nbsp;three sites. Because absolute values are required, the blood samples should be assayed at serial dilutions: 1:1, 1:10, and 1:50. Complication rates with AVS are very low at centers with experienced interventional radiologists.</div><div id=\"graphicVersion\">Graphic 109110 Version 1.0</div></div></div>"},"109112":{"type":"graphic_table","displayName":"Predictors of combined difficulty with mask ventilation and DL","title":"Predictors of combined difficulty with mask ventilation and direct laryngoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictors of combined difficulty with mask ventilation and direct laryngoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Predictors of difficult/impossible mask ventilation</td> <td class=\"subtitle1\"><em>Modified and additional predictors</em></td> </tr> <tr> <td> <ul> <li>Mallampati grade 3 to 4 </li> <li>Decreased mandibular protrusion </li> <li>Presence of beard </li> <li>Obesity (BMI &#8805;30) </li> <li>Male sex </li> <li>OSA* </li> </ul> </td> <td> <ul> <li><em>Age &#8805;46 years</em> </li> <li><em>Presence of teeth</em> </li> <li><em>Neck radiation changes or a neck mass</em> </li> <li><em>Thick or obese neck</em> </li> <li><em>Unstable neck or decreased neck extension</em> </li> <li><em>Decreased thyromental distance</em> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The association of DMV with difficult DL includes many predictors of DMV and impossible mask ventilation, as well as the modified and additional factors, listed in italics. At least five predictors (risk factors) total should be present for a reasonably high probability of both DMV and difficult DL. Class III patients (five risk factors) comprise 5 percent of all DMV+DL cases, and patients from Classes IV (six risk factors) and V (7 to 11 risk factors) comprise the largest group (85 percent) of these cases.</div><div class=\"graphic_footnotes\">DL: direct laryngoscopy; BMI: body mass index; OSA: obstructive sleep apnea; DMV: difficult mask ventilation; CPAP: continuous positive airway pressure; BiPAP: bilevel positive airway pressure.<br />* Moderate-to-severe OSA associated with the use of CPAP/BiPAP or a history of OSA surgery.</div><div class=\"graphic_reference\">Adapted from: Kheterpal S, Healy D, Aziz MF, et al. Incidence, predictors, and outcome of difficult mask ventilation combined with difficult laryngoscopy: a report from the multicenter perioperative outcomes group. Anesthesiology 2013; 119:1360.<br /><br />â€‹Courtesy of Dr. Vladimir Nekhendzy.</div><div id=\"graphicVersion\">Graphic 109112 Version 4.0</div></div></div>"},"109114":{"type":"graphic_algorithm","displayName":"Evaluation and management of suspected meningioma","title":"Evaluation and management of suspected meningioma","html":"<div class=\"graphic\"><div style=\"width: 762px\" class=\"figure\"><div class=\"ttl\">Evaluation and management of suspected meningioma</div><div class=\"cntnt\"><img style=\"width:742px; height:610px;\" src=\"images/NEURO/109114_Eval_mngmnt_susp_meningioma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an approach to the evaluation and initial management of patients with a suspected meningioma. While meningioma is by far the most common cause of a discrete, dural-based mass lesion, the differential diagnosis also includes other tumors (eg, metastatic cancer, lymphoid malignancy, solitary fibrous tumor), inflammatory lesions such as sarcoidosis, and infections such as tuberculosis. Patients who are being considered for observation or empiric radiation may benefit from more extensive systemic evaluation to help exclude alternative etiologies, particularly when imaging features are atypical.</div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.<br />* Surgical candidacy varies based on tumor location (eg, deep verus superficial, proximity to critical structures), imaging evidence of invasion, and presurgical status of the patient. Refer to UpToDate topic review for details.<br />Â¶ The threshold for intervention may be lower for young and healthy patients, based on the expectation that tumor progression will inevitably require active treatment. Some young patients with small, asymptomatic tumors may reasonably choose early definitive intervention for a presumed meningioma rather than active surveillance.<br />Î” For nonresectable tumors with atypical neuroimaging features, biopsy may be indicated to confirm diagnosis before proceeding with radiation. Some large, nonresectable tumors may not be safe candidates for radiation without partial tumor debulking first.<br /><FONT class=lozenge>â—Š</FONT> Empiric radiation may be a reasonable alternative in selected patients who wish to avoid surgery, such as those with small to intermediate-sized tumors that are typical in appearance for meningioma.<br />Â§ Postoperative management depends upon meningioma grade and extent of resection. Refer to UpToDate topic reviews on the treatment of benign, atypical, and malignant meningiomas for details.</div><div id=\"graphicVersion\">Graphic 109114 Version 1.0</div></div></div>"},"109116":{"type":"graphic_algorithm","displayName":"Antiviral selection for HCV genotype 1 in treatment-experienced","title":"Antiviral selection for HCV genotype 1 infection in treatment-experienced adults","html":"<div class=\"graphic\"><div style=\"width: 1258px\" class=\"figure\"><div class=\"ttl\">Antiviral selection for HCV genotype 1 infection in treatment-experienced adults</div><div class=\"cntnt\"><img style=\"width:1238px; height:1030px;\" src=\"images/ID/109116_Antvrl_HCV_1_tx_exprncd.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>The preferred and first-line regimen options listed for each patient population are likely of comparably high efficacy. The choice between them is based on potential drug interactions, local availability, and individual financial or insurance limitations. Overall, we favor glecaprevir-pibrentasvir, ledipasvir-sofosbuvir, or sofosbuvir-velpatasvir for their simplicity of administration (once-daily dosing without the need to evaluate for baseline polymorphisms) and extensive data to support their use. Drug interactions are generally manageable but should be evaluated prior to initiation, particularly with NS3/4A protease inhibitor-containing regimens (such as glecaprevir-pibrentasvir). Alternative regimens either require longer durations for equivalent efficacy or are of less certain efficacy.</li>&#xD;&#xA;    <li>Doses of direct-acting antivirals are standard. Daclatasvir dose adjustment is warranted with concomitant use of P450 inducers and inhibitors. If ribavirin is used, dosing is weight based: 1000 mg daily if &lt;75 kg and 1200 mg daily if &ge;75 kg.</li>&#xD;&#xA;    <li>This algorithm does not apply to patients with estimated glomerular filtration rate &lt;30 mL/min per 1.73 m<sup>2</sup> (or on dialysis). Refer to UpToDate content on HCV treatment in patients with renal impairment for more details.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">HCV: hepatitis C virus; RASs: resistance-associated substitutions.<br />* Ascites, hepatic encephalopathy, prolonged prothrombin time, decreased serum albumin, and/or hyperbilirubinemia.<br />Â¶ For subtype 1a-infected patients in whom elbasvir is being considered, testing for NS5A RASs should be performed. RASs that confer reduced susceptibility to elbasvir-grazoprevir include polymorphisms at M28, Q30, L31, and Y93. If these are present, the recommended regimen is elbasvir-grazoprevir with ribavirin for 16 weeks.<br />Î” In the United States, daclatasvir plus sofosbuvir is not approved by the Food and Drug Administration for genotype 1 infection, so may not be a feasible option for most patients. The optimal administration of this regimen (ie, duration and with or without ribavirin) is uncertain for patients with cirrhosis.<br /><FONT class=lozenge>â—Š</FONT> For subtype 1a-infected patients with cirrhosis, some experts, including some UpToDate contributors, check for NS5A RASs and choose other regimens (sofosbuvir-velpatasvir or glecaprevir-pibrentasvir) if present. Data to inform the optimal approach in this setting are limited.<br />Â§ If ombitasvir-paritaprevir-ritonavir plus dasabuvir is used in patients with cirrhosis, close monitoring for hepatic decompensation is warranted. This regimen is contraindicated in patients with Child Pugh Classes B and C cirrhosis.<br />Â¥ For subtype 1a-infected patients with cirrhosis in whom simeprevir plus sofosbuvir is being considered, testing for NS3/4A RASs should be performed. The Q80K mutation is associated with reduced susceptibility to simeprevir plus sofosbuvir. If this is present, we do not use simeprevir plus sofosbuvir in these patients.</div><div class=\"graphic_reference\">Reference: AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed August 23, 2017.</div><div id=\"graphicVersion\">Graphic 109116 Version 3.0</div></div></div>"},"109119":{"type":"graphic_table","displayName":"Rectal prolapse surgery recurrence and complication rates","title":"Comparison of recurrence and complication rates of procedures performed for rectal prolapse","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of recurrence and complication rates of procedures performed for rectal prolapse</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Recurrence rate</td> <td class=\"subtitle1\">Complication rate</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Abdominal procedures</td> </tr> <tr> <td class=\"indent1\">Suture rectopexy</td> <td class=\"centered\">3 to 9 percent</td> <td class=\"centered\">Approximately 14 percent</td> </tr> <tr> <td class=\"indent1\">Resection alone</td> <td class=\"centered\">7 to 12 percent</td> <td class=\"centered\">15 to 29 percent</td> </tr> <tr> <td class=\"indent1\">Resection rectopexy</td> <td class=\"centered\">2 to 5 percent</td> <td class=\"centered\">0 to 20 percent</td> </tr> <tr> <td class=\"indent1\">Anterior mesh rectopexy (modified Ripstein)</td> <td class=\"centered\">4 to 10 percent</td> <td class=\"centered\">Approximately 20 percent</td> </tr> <tr> <td class=\"indent1\">Posterior mesh rectopexy (modified Wells)</td> <td class=\"centered\">0 to 3 percent</td> <td class=\"centered\">0 to 19 percent</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ventral mesh rectopexy</td> <td class=\"centered\">2 to 4.8 percent</td> <td class=\"centered\">14 to 47 percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Perineal procedures</td> </tr> <tr> <td class=\"indent1\">Delorme procedure</td> <td class=\"centered\">10 to 15 percent</td> <td class=\"centered\">4 to 12 percent</td> </tr> <tr> <td class=\"indent1\">Altemeier procedure</td> <td class=\"centered\">16 to 30 percent</td> <td class=\"centered\">&#60;10 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Varma M, Rafferty J, Buie WD. Practice parameters for the management of rectal prolapse. Dis Colon Rectum 2011; 54:1339.</LI>&#xD;&#xA;<LI>Novell JR, Osborne MJ, Winslet MC, Lewis AA. Prospective randomized trial of Ivalon sponge versus sutured rectopexy for full-thickness rectal prolapse. Br J Surg 1994; 81:904.</LI>&#xD;&#xA;<LI>Madbouly KM, Senagore AJ, Delaney CP, et al. Clinically based management of rectal prolapse. Surg Endosc 2003; 17:99.</LI>&#xD;&#xA;<LI>Dulucq JL, Wintringer P, Mahajna A. Clinical and functional outcome of laparoscopic posterior rectopexy (Wells) for full-thickness rectal prolapse. A prospective study. Surg Endosc 2007; 21:2226.</LI></OL></div><div id=\"graphicVersion\">Graphic 109119 Version 2.0</div></div></div>"},"109123":{"type":"graphic_picture","displayName":"Ganglion cyst PI","title":"Ganglion cyst","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Ganglion cyst</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/PI/109123_Ganglion_cyst_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The wrist is a common place for a ganglion cyst.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109123 Version 1.0</div></div></div>"},"109124":{"type":"graphic_picture","displayName":"Soft tissue filler skin necrosis","title":"Skin necrosis following injection of soft tissue fillers","html":"<div class=\"graphic\"><div style=\"width: 697px\" class=\"figure\"><div class=\"ttl\">Skin necrosis following injection of soft tissue fillers</div><div class=\"cntnt\"><img style=\"width:677px; height:764px;\" src=\"images/DERM/109124_Sft_tss_fllr_skn_ncrss_edt1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Impending necrosis from diluted cross-linked hyaluronic acid injected into midforehead wrinkle with evidence of retrograde flow toward the orbit as well as distal embolization.<br />(B) Complete resolution with nitropaste and hyaluronidase.</div><div class=\"graphic_reference\">Courtesy of Shawn Allen, MD.</div><div id=\"graphicVersion\">Graphic 109124 Version 2.0</div></div></div>"},"109125":{"type":"graphic_picture","displayName":"Inferior labial artery","title":"Inferior labial artery","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Inferior labial artery</div><div class=\"cntnt\"><img style=\"width:640px; height:478px;\" src=\"images/DERM/109125_Inferior_labial_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inferior labial artery exposed overlying scissors. Note location is deep within the mucosal lip.</div><div class=\"graphic_reference\">Courtesy of Shawn Allen, MD.</div><div id=\"graphicVersion\">Graphic 109125 Version 1.0</div></div></div>"},"109129":{"type":"graphic_table","displayName":"Patient monitoring during IFN","title":"Monitoring of patients receiving interferon therapy for the treatment of HBV","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring of patients receiving interferon therapy for the treatment of HBV</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Assessment point&nbsp;</td> <td class=\"subtitle1\">Laboratory tests</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Baseline</strong></td> <td> <ul> <li>CBC with differential </li> <li>Hepatic panel* </li> <li>HBV DNA </li> <li>HBeAg and anti-HBe<sup>&#182;</sup> </li> <li>HBsAg </li> <li>Quantitative HBsAg<sup>&#916;</sup> </li> <li>INR </li> <li>TSH </li> <li>Creatinine </li> <li>Triglycerides </li> <li>Glucose </li> <li>Pregnancy test<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Week 4</strong></td> <td> <ul> <li>CBC with differential </li> <li>Hepatic panel* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Week 12</strong></td> <td> <ul> <li>CBC with differential </li> <li>Hepatic panel* </li> <li>HBV DNA </li> <li>Quantitative HBsAg<sup>&#916;</sup> </li> <li>TSH </li> <li>Pregnancy test<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Week 24</strong></td> <td> <ul> <li>CBC with differential </li> <li>Hepatic panel* </li> <li>HBV DNA </li> <li>HBeAg and anti-HBe<sup>&#182;</sup> </li> <li>TSH </li> <li>Pregnancy test<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Week 48</strong></td> <td> <ul> <li>CBC with differential </li> <li>Hepatic panel* </li> <li>HBV DNA </li> <li>HBeAg and anti-HBe<sup>&#182;</sup> </li> <li>HBsAg<sup>&#167;</sup> </li> <li>TSH </li> <li>Pregnancy test<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Week 12 post treatment</strong></td> <td> <ul> <li>CBC with differential </li> <li>Hepatic panel* </li> <li>HBV DNA </li> <li>HBeAg and anti-HBe<sup>&#182;</sup> </li> <li>TSH </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Week 24 post treatment</strong></td> <td> <ul> <li>CBC with differential </li> <li>Hepatic panel* </li> <li>HBV DNA </li> <li>HBeAg and anti-HBe<sup>&#182;</sup> </li> <li>HBsAg<sup>&#167;</sup> </li> </ul> </td> </tr> <tr> <td><strong>Week 48 post treatment</strong></td> <td> <ul> <li>CBC with differential </li> <li>Hepatic panel* </li> <li>HBV DNA </li> <li>HBeAg and anti-HBe<sup>&#182;</sup> </li> <li>HBsAg<sup>&#167;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; AST: aspartate aminotransferase; anti-HBe: hepatitis B e antibody; CBC: complete blood count; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; INR: international normalized ratio; TSH: thyroid stimulating hormone.<br />* Hepatic panel includes: ALT, AST, albumin, bilirubin, and alkaline phosphatase.<br />Â¶ Only for patients who are HBeAg-positive at baseline.<br />Î” If available to assess utility of continued therapy.<br /><FONT class=lozenge>â—Š</FONT> Only for women of childbearing age.<br />Â§ Only for HBeAg-negative patients if HBV DNA is undetectable and for HBeAg-positive patients who have undergone HBeAg seroconversion.</div><div class=\"graphic_reference\">Adapted from: Konerman MA, Lok AS. Interferon treatment for hepatitis B. Clin Liver Dis 2016 (in press).</div><div id=\"graphicVersion\">Graphic 109129 Version 1.0</div></div></div>"},"109134":{"type":"graphic_table","displayName":"Overview of enteral feeding for VLBW infants","title":"Overview of feeding initiation and advancement for infants â‰¤32 wk gestation and/or birth weight â‰¤1800 g (tube-fed)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of feeding initiation and advancement for infants &le;32 wk gestation and/or birth weight &le;1800 g (tube-fed)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"18%\"></colgroup><colgroup width=\"8%\"></colgroup><colgroup width=\"16%\"></colgroup><colgroup width=\"8%\"></colgroup><colgroup width=\"16%\"></colgroup><colgroup width=\"8%\"></colgroup><colgroup width=\"16%\"></colgroup> <tbody> <tr> <td class=\"centered highlight_blue_text\" style=\"vertical-align: middle;\" rowspan=\"8\"><strong><br /> <span style=\"font-size: 36px;\">&#8595;</span><br /> <br /> A<br /> D<br /> V<br /> A<br /> N<br /> C<br /> I<br /> N<br /> G<br /> <br /> A<br /> G<br /> E<br /> <br /> <span style=\"font-size: 36px;\">&#8595;</span><br /> <br /> </strong></td> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Birthweight &#8804;1000 g</td> <td class=\"subtitle1\" colspan=\"2\">Birthweight 1001 to 1500 g</td> <td class=\"subtitle1\" colspan=\"2\">Birthweight 1501 to 1800 g</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Ideal schedule*</td> <td class=\"subtitle2\" colspan=\"2\">Ideal schedule*</td> <td class=\"subtitle2\" colspan=\"2\">Ideal schedule*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Oropharyngeal colostrum</strong><sup>&#182;</sup></td> <td>DOL 0 to 9</td> <td>Swab on buccal mucosa every 3 hours</td> <td>DOL 0 to 6</td> <td>Swab on buccal mucosa every 3 hours</td> <td>DOL 0 to 4</td> <td>Swab on buccal mucosa every 3 hours</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Trophic feeds</strong><br /> (20 cal/oz)<sup>&#916;</sup></td> <td>DOL 1 to 3</td> <td>15 mL/kg/day for 3 days</td> <td>DOL 1 to 2</td> <td>20 mL/kg/day for 1 to 2 days</td> <td>DOL 1</td> <td>25 mL/kg/day for 1 day</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Feeding advancement</strong><br /> (mL/kg added each day)</td> <td>DOL 4 to 9</td> <td>Start increasing DOL 4; add 15 mL/kg each day</td> <td>DOL 3 to 6</td> <td>Start increasing DOL 3; add 20 mL/kg each day</td> <td>DOL 2 to 4</td> <td>Start increasing DOL 2; add 25 mL/kg/day each day</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Start fortified feeds</strong><br /> (24 cal/oz)<sup>&#9674;</sup></td> <td>DOL 10</td> <td>Start fortifying day after feed volume reaches 80 mL/kg/day</td> <td>DOL 7</td> <td>Start fortifying day after feed volume reaches 80 mL/kg/day</td> <td>DOL 5</td> <td>Start fortifying day after feed volume reaches 80 mL/kg/day</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Further feeding advancement</strong><br /> (start increasing day after fortifying feeds)</td> <td>DOL 11 to 15</td> <td>Next day, start adding 15 mL/kg each day</td> <td>DOL 8 to 11</td> <td>Next day, start adding 20 mL/kg each day</td> <td>DOL 6 to 9</td> <td>Next day, start adding 25 mL/kg each day</td> </tr> <tr> <td><strong>Target feeding volume</strong></td> <td>DOL 15 and thereafter</td> <td>160 mL/kg/day</td> <td>DOL 11 and thereafter</td> <td>160 mL/kg/day</td> <td>DOL 9 and thereafter</td> <td>160 mL/kg/day</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table describes the author's approach to initiating and advancing feeds in very premature infants. Most neonatal intensive care units (NICUs) use a similar protocol, but specifics of timing, composition, and advancement of feeds vary.</div><div class=\"graphic_footnotes\">DOL: day of life.<br />* This \"ideal schedule\" describes the progress for a premature infant who has no problems with feeding intolerance or other issues that delay advances in feeds. Some premature infants will progress more slowly.<br />Â¶ We swab the oropharyngeal mucosa with expressed colostrum approximately every three hours. We continue to swab the oropharynx with mother's milk for at least a few days; some clinicians continue this practice until the infant is taking some feeds orally.<br />Î” Start trophic feeds on DOL 1 for all infants, using mother's milk if possible. For infants â‰¤1500 g, use donor milk if no mother's milk is available, or premature infant formula if no donor milk is available/consented. For infants 1500 to 1800 g, use donor milk only when necessary as a bridge to feedings of mother's milk.<br /><FONT class=lozenge>â—Š</FONT> 24 cal/oz is achieved by adding human milk fortifier to expressed human milk, or by changing from 20 cal/oz preterm formula to 24 cal/oz preterm formula.</div><div class=\"graphic_reference\">Courtesy of Dr. Richard Schanler.</div><div id=\"graphicVersion\">Graphic 109134 Version 2.0</div></div></div>"},"109135":{"type":"graphic_picture","displayName":"Hand-foot skin reaction","title":"Hand-foot skin reaction","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Hand-foot skin reaction</div><div class=\"cntnt\"><img style=\"width:466px; height:659px;\" src=\"images/DERM/109135_Hand-foot_skin_reaction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratotic lesions on an erythematous background on the pressure areas of the soles in a patient treated with multitargeted tyrosine kinase inhibitor.</div><div class=\"graphic_reference\">Courtesy of Mario Lacouture, MD.</div><div id=\"graphicVersion\">Graphic 109135 Version 1.0</div></div></div>"},"109138":{"type":"graphic_picture","displayName":"Debridement of Fournier's gangrene","title":"Debridement of Fournier's gangrene","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Debridement of Fournier's gangrene</div><div class=\"cntnt\"><img style=\"width:764px; height:509px;\" src=\"images/SURG/109138_Dbrdmnt_Fourniers_gangrene.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures illustrate a case of Fournierâ€™s gangrene in a 58-year-old patient with diabetes and with benign prostatic hypertrophy. The patient presented with perineal pain and overt sepsis. The results of debridement of the scrotum and perineum is shown in the figure (A). Urinary and rectal diversion including a Foley catheter and rectal tube were used to keep the wound clean; a loop diverting colostomy had also been performed. A negative pressure wound therapy device (B) was applied with a seal obtained around the two tubes. Sheet skin grafting was subsequently performed to cover the penile shaft and the remaining open areas in the suprapubic and perianal regions.</div><div id=\"graphicVersion\">Graphic 109138 Version 1.0</div></div></div>"},"109139":{"type":"graphic_picture","displayName":"Right flank necrotizing soft tissue infection","title":"Right flank necrotizing soft tissue infection","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">Right flank necrotizing soft tissue infection</div><div class=\"cntnt\"><img style=\"width:655px; height:495px;\" src=\"images/SURG/109139_Debrided_right_flank.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures show wound management of a 48-year-old patient with severe idiopathic necrotizing soft tissue infection (NSTI) of the right flank. The first image (A) shows the right flank after two debridement procedures, including the initial debridement at the referring hospital and one at a burn center. After additional debridement (B)&nbsp;using a Versajet, a negative pressure wound dressing (C) was used to manage the wound.&nbsp;After allografting and autografting, the appearance of the healed skin grafts is&nbsp;shown at one year follow-up (D).</div><div id=\"graphicVersion\">Graphic 109139 Version 1.0</div></div></div>"},"109140":{"type":"graphic_picture","displayName":"Hand-foot skin reaction 2","title":"Hand-foot skin reaction","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Hand-foot skin reaction</div><div class=\"cntnt\"><img style=\"width:550px; height:756px;\" src=\"images/DERM/109140_Hand_foot_skin_reaction_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema, hyperkeratosis, and desquamation of the soles in a patient treated with multitargeted tyrosine kinase inhibitor.</div><div class=\"graphic_reference\">Courtesy of Mario Lacouture, MD.</div><div id=\"graphicVersion\">Graphic 109140 Version 1.0</div></div></div>"},"109141":{"type":"graphic_picture","displayName":"Bilateral thigh necrotizing soft tissue infection","title":"Bilateral thigh necrotizing soft tissue infection","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Bilateral thigh necrotizing soft tissue infection</div><div class=\"cntnt\"><img style=\"width:495px; height:655px;\" src=\"images/SURG/109141_Bilateral_thigh_NSTI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures illustrate a case of necrotizing soft tissue infection that presented as increasing confusion over a few days&nbsp;in a 72-year-old with diabetes but no history of dementia. The patient presented&nbsp;late with tenderness and&nbsp;skin changes of the bilateral thighs (A, left thigh). During surgical exploration and debridement (B, C) the characteristic appearance of necrotic skin, underlying fascia, and dish-water fluid drainage can be seen.</div><div id=\"graphicVersion\">Graphic 109141 Version 1.0</div></div></div>"},"109150":{"type":"graphic_figure","displayName":"Placement of transcutaneous pacemaker/defibrillator pads","title":"Placement of transcutaneous pacemaker/defibrillator pads","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Placement of transcutaneous pacemaker/defibrillator pads</div><div class=\"cntnt\"><img style=\"width:507px; height:346px;\" src=\"images/ANEST/109150_Placement_of_transcutaneous_pacemaker_defibrillator_pads.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pads are placed to: (1) Ensure that the heart is between the two pads; (2) Ensure that a <SPAN style=\"COLOR: black\">cardiac </SPAN>implantable electronic device (CIED), if present, is not directly underneath the anterior pad.</div><div id=\"graphicVersion\">Graphic 109150 Version 1.0</div></div></div>"},"109158":{"type":"graphic_table","displayName":"CTCAE grading for hand-foot skin reaction","title":"Common Terminology Criteria for Adverse EventsÂ grading for hand-foot skin reaction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common Terminology Criteria for Adverse Events&nbsp;grading for hand-foot skin reaction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Palmar-plantar erythrodysesthesia syndrome</td> <td>Minimal skin changes or dermatitis (eg, erythema, edema, or hyperkeratosis) without pain</td> <td>Skin changes (eg, peeling, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting instrumental ADL</td> <td>Severe skin changes (eg, peeling blisters, bleeding, edema, or hyperkeratosis) with pain; limiting self-care ADL</td> <td>&ndash;</td> <td>&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADL: activities of daily living.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0, June 2010, National Institutes of Health, National Cancer Institute. Available at: <a href=\"http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\" target=\"_blank\">http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf</a> (Accessed on July 21, 2016).</div><div id=\"graphicVersion\">Graphic 109158 Version 1.0</div></div></div>"},"109162":{"type":"graphic_picture","displayName":"Atrophoderma of Pasini and Pierini close view","title":"Atrophoderma of Pasini and Pierini","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Atrophoderma of Pasini and Pierini</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109162_Atrophoderma_Pasini_Pierini.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-demarcated, depressed areas of the skin with subtle hyperpigmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109162 Version 1.0</div></div></div>"},"109166":{"type":"graphic_picture","displayName":"Atrophoderma of Pasini and Pierini on the back","title":"Atrophoderma of Pasini and Pierini","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Atrophoderma of Pasini and Pierini</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109166_Atropho_Pasini_Pierini_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hyperpigmented, atrophic areas on the back.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109166 Version 1.0</div></div></div>"},"109172":{"type":"graphic_algorithm","displayName":"Pneumococcal vaccination asplenic adults","title":"UpToDate recommendations* for pneumococcal vaccination in asplenic<sup>Â¶</sup> adults (â‰¥19 years) in the United States","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">UpToDate recommendations* for pneumococcal vaccination in asplenic<sup>&para;</sup> adults (&ge;19 years) in the United States</div><div class=\"cntnt\"><img style=\"width:430px; height:250px;\" src=\"images/ID/109172_Pneumococcalvaccasplenic.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PCV13: 13-valent pneumococcal conjugate vaccine (Prevnar 13); PPSV23: 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23).<br />* UpToDate's recommendations differ from those of the United States Advisory Committee on Immunization Practices (ACIP). Refer to the relevant UpToDate topics for additional information.<br />Â¶ Anatomic or functional asplenia that are indications for pneumococcal vaccination are: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Sickle cell disease and other hemoglobinopathies</LI>&#xD;&#xA;<LI>Congenital asplenia&nbsp;or congenital splenic hypoplasia</LI>&#xD;&#xA;<LI>Acquired asplenia (eg, history of splenectomy or splenic atrophy following infection)</LI>&#xD;&#xA;<LI>Other causes of functional asplenia</LI></UL>Î” For asplenic patients, UpToDate recommends revaccination with PPSV23 every&nbsp;five years. This differs from the ACIP guidelines, which recommend that patients &lt;65 years of age receive&nbsp;two doses of PPSV given at least&nbsp;five years apart; if both doses were given before age 65, the ACIP recommends an additional dose of PPSV23 at or after age 65 and at least&nbsp;five years after the previous dose.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.</li>&#xD;&#xA;    <li>Mourtzoukou EG, Pappas G, Peppas G, Falagas ME. Vaccination of asplenic or hyposplenic adults. Br J Surg 2008; 95:273.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109172 Version 3.0</div></div></div>"},"109173":{"type":"graphic_algorithm","displayName":"Management of suspected and confirmed BIA-ALCL","title":"Management of suspected and confirmed BIA-ALCL","html":"<div class=\"graphic\"><div style=\"width: 672px\" class=\"figure\"><div class=\"ttl\">Management of suspected and confirmed BIA-ALCL</div><div class=\"cntnt\"><img style=\"width:652px; height:570px;\" src=\"images/SURG/109173_Mgmt_suspctd_confrmd_BIALCL.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BIA-ALCL: breast implant-associated anaplastic large cell lymphoma; PROFILE: Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma (ALCL) Etiology and Epidemiology; PET-CT: positive emission tomography-computed tomography; ALK: anaplastic lymphoma kinase; MRI: magnetic resonance imaging.<br />* Physical symptoms/signs include effusion surrounding breast implant; breast mass adjacent to implant; and swelling, pain, and/or skin lesion/ulceration of the breast. They typically occur &gt;1 year after implantation (average 10 years) but can occur earlier.<br />Â¶ If breast ultrasound is not conclusive, the next line of imaging is breast MRI or PET-CT.<br />Î” Aspiration of effusion should be sent for CD30 immunohistochemistry, cell block cytology to evaluate for large anaplastic cells, and flow cytometry to evaluate for clonal expansion of a T-cell population.<br /><FONT class=lozenge>â—Š</FONT> BIA-ALCL is confirmed histologically with demonstration of a neoplasm that has large lymphoid cells with abundant cytoplasm and pleomorphic nuclei and is negative for ALK and positive for CD30.<br />Â§ Differentiate BIA-ALCL from other types of lymphoma, primary cutaneous ALCL, and systemic ALCL with breast involvement.<br />Â¥ For more information, visit the PROFILE website at www.thepsf.org/PROFILE/.<br />â€¡ Complete surgical excision includes removal of the implant including the surrounding capsule, removal of any disease mass with negative margins, and excision of involved lymph nodes.<br />â€  Based upon imaging findings (PET-CT) and pathologic findings at the time of surgical resection. Local therapy only: Stage IE (Lugano), Stage 1A to 2A (MD Anderson). Radiation or adjuvant chemotherapy: Stage IIE (Lugano), Stage 2B through 4 (MD Anderson).<br />** Obtain biopsies to confirm residual, disseminated, or recurrent disease suspected on imaging.<br />Â¶Â¶ Patients are observed with a clinical follow-up, history, and physical every six months for two years and then as clinically indicated. Physicians may include chest/abdominal/pelvic computed tomography (CT) scans with contrast or PET scan every 6 months for 2 years as clinically indicated.<br />Î”Î” Chemotherapy with either brentuximab vedotin or anthracycline-based regimen (ie, CHOP, cyclophosphamide, vincristine, doxorubicin, prednisone) as for de novo ALK-negative ALCL.</div><div id=\"graphicVersion\">Graphic 109173 Version 2.0</div></div></div>"},"109178":{"type":"graphic_algorithm","displayName":"Hand-foot skin reaction management","title":"Prevention and management of hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors<SUP>[1-4]</SUP>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prevention and management of hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors<SUP>[1-4]</SUP></div><div class=\"cntnt\"><img style=\"width:366px; height:578px;\" src=\"images/DERM/109178_Hand-foot_skin_reactn_mgmt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TKI: tyrosine kinase inhibitor; HFSR: hand-foot skin reaction.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>McLellan B, Ciardiello F, Lacouture ME, et al. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 2015; 26:2017.</LI>&#xD;&#xA;<LI>â€‹Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13:1001.</LI>&#xD;&#xA;<LI>Anderson R, Jatoi A, Robert C, et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009; 14:291.</LI>&#xD;&#xA;<LI>Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.&nbsp;J Support Oncol 2011; 9:13.</LI></OL></div><div id=\"graphicVersion\">Graphic 109178 Version 2.0</div></div></div>"},"109179":{"type":"graphic_figure","displayName":"Transthoracic Collis gastroplasty","title":"Transthoracic Collis gastroplasty","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Transthoracic Collis gastroplasty</div><div class=\"cntnt\"><img style=\"width:539px; height:694px;\" src=\"images/SURG/109179_Transthoracic_Collis_gastrectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Collis gastroplasty is the most common esophageal-lengthening procedure performed with paraesophageal hernia repair. A large-caliber bougie is passed via the mouth into the stomach and placed along the lesser curvature. A surgical stapler is then used to create an incision from the angle of His parallel to the bougie. The stapling creates a tubularized proximal stomach that becomes a natural extension or elongation of the esophagus. As a result, the esophagogastric junction is extended into the abdomen for approximately 5 cm. A Collis gastroplasty was traditionally performed via a left thoracotomy (panel E) but has been modified for performance via a right thoracoscopic approach (panel F).</div><div class=\"graphic_reference\">Panels A-D modified from: DeMeester TR, Hagen JA. Transthoracic antireflux procedures. In: Mastery of Surgery, 3rd Edition, Nyhus LM, Baker RJ, Fischer JE (eds), Boston: Little, Brown and Company, 1997.</div><div id=\"graphicVersion\">Graphic 109179 Version 2.0</div></div></div>"},"109180":{"type":"graphic_figure","displayName":"Transabdominal Collis gastroplasty","title":"Transabdominal Collis gastroplasty","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Transabdominal Collis gastroplasty</div><div class=\"cntnt\"><img style=\"width:514px; height:646px;\" src=\"images/SURG/109180_Transabdominal_Collis_gastroplasty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Collis gastroplasty is the most common esophageal-lengthening procedure performed with paraesophageal hernia repair. A large-caliber bougie is passed via the mouth into the stomach and placed along the lesser curvature. A surgical stapler is then used to create an incision from the angle of His parallel to the bougie. The stapling creates a tubularized proximal stomach that becomes a natural extension or elongation of the esophagus. As a result, the esophagogastric junction is extended into the abdomen for approximately 5 cm. In open laparotomy,&nbsp;a&nbsp;Collis gastroplasty is typically performed after creation of a circular defect in the stomach using an EEA stapler (panels A and B). In laparoscopic surgery, a Collis gastroplasty is performed&nbsp;with a wedge fundectomy, which permits vertical placement of the stapler parallel to the lesser curvature&nbsp;(panels C and&nbsp;D).</div><div id=\"graphicVersion\">Graphic 109180 Version 2.0</div></div></div>"},"109181":{"type":"graphic_algorithm","displayName":"Treatment of adult dialysis patients with CUA","title":"Treatment of adult dialysis patients who have calcific uremic arteriolopathy","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Treatment of adult dialysis patients who have calcific uremic arteriolopathy</div><div class=\"cntnt\"><img style=\"width:640px; height:656px;\" src=\"images/NEPH/109181_Trtmt_adult_dialysis_CUA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous; PTH: parathyroid hormone; CUA: calcific uremic arteriolopathy.<br />* For patients on intermittent hemodialysis, sodium thiosulfate is generally given during the last hour or after hemodialysis. For patients on peritoneal dialysis who have residual renal function, we administer 25 grams four times weekly. For patients who weigh &lt;60 kg, we reduce each individual dose of sodium thiosulfate to 12.5 grams.</div><div id=\"graphicVersion\">Graphic 109181 Version 2.0</div></div></div>"},"109194":{"type":"graphic_figure","displayName":"Tips to enhance patient-centered EMR use","title":"Tips to enhance patient-centered EMR use","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Tips to enhance patient-centered EMR use</div><div class=\"cntnt\"><img style=\"width:538px; height:926px;\" src=\"images/PC/109194_Tips_patient-cntrd_EMR_use.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EMR: electronic medical record.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>LEVEL section reprinted from The Permanente Journal, Vol 8 (issue 4), Mann WR, Slaboch J, Computers in the exam roomâ€”friend or foe?, pages 49-51, Copyright Â© 2004, with permission from The Permanente Press. <A href=\"http://www.thepermanentejournal.org/\" target=_blank>www.thepermanentejournal.org</A>.</LI>&#xD;&#xA;<LI>HUMAN LEVEL adaptation reproduced with permission from: Alkureishi M, Lee W, Farnan J, Arora V. Breaking away from the iPatient to care for the real patient: implementing a patient-centered EMR use curriculum. MedEdPORTAL Publications 2014; 10:9953.</LI></OL></div><div id=\"graphicVersion\">Graphic 109194 Version 1.0</div></div></div>"},"109195":{"type":"graphic_picture","displayName":"Psychogenic purpura legs","title":"Psychogenic purpura on legs","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Psychogenic purpura on legs</div><div class=\"cntnt\"><img style=\"width:516px; height:476px;\" src=\"images/HEME/109195_Psychogenicpurpuralegs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) On the left thigh are confluent, blue-black skin bleeding greater than palm-size.<br />(B) The close-up shows sparing of the popliteal groove and the ostia of the hair follicles.</div><div class=\"graphic_reference\">Reprinted by permission from: Springer: Der Hautarzt. Behrendt C, Goos M, Thiel H, et al.&nbsp;[Painful bruising syndrome]. Hautarzt 2001; 52:634. Copyright Â© 2001. <A spellcheck=true href=\"https://link.springer.com/journal/105\" target=_blank>https://link.springer.com/journal/105</A>.</div><div id=\"graphicVersion\">Graphic 109195 Version 2.0</div></div></div>"},"109196":{"type":"graphic_picture","displayName":"Primary cutaneous gamma-delta T cell lymphoma","title":"Primary cutaneous gamma-delta T cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous gamma-delta T cell lymphoma</div><div class=\"cntnt\"><img style=\"width:427px; height:728px;\" src=\"images/DERM/109196_PCGD-TCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular and ulceronecrotic skin lesions in a patient with primary cutaneous gamma-delta T cell lymphoma.</div><div class=\"graphic_reference\">Image courtesy of Rein Willemze, MD. This research was originally published in Blood. Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111:838-45. Copyright &copy; 2008 the American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 109196 Version 1.0</div></div></div>"},"109197":{"type":"graphic_picture","displayName":"PCGD-TCL histopathology","title":"Histopathologic features of primary cutaneous gamma-delta T cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 690px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of primary cutaneous gamma-delta T cell lymphoma</div><div class=\"cntnt\"><img style=\"width:670px; height:756px;\" src=\"images/DERM/109197_PCGD-TCL_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Detail of dermal infiltrate showing medium-sized pleomorphic T cells.</div><div class=\"graphic_reference\">Courtesy of Rein Willemze, MD.</div><div id=\"graphicVersion\">Graphic 109197 Version 1.0</div></div></div>"},"109198":{"type":"graphic_picture","displayName":"PCGD-TCL immunophenotype","title":"Immunophenotype of primary cutaneous gamma-delta T cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Immunophenotype of primary cutaneous gamma-delta T cell lymphoma</div><div class=\"cntnt\"><img style=\"width:766px; height:416px;\" src=\"images/DERM/109198_PCGD-TCL_immunophenotype.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A serial section shows that the neoplastic cells express TCR-gamma.<br />(B) A serial section shows that the neoplastic cells are negative for beta-F1 (TCR-beta).</div><div class=\"graphic_footnotes\">TCR: T cell receptor.</div><div class=\"graphic_reference\">Courtesy of Rein Willemze, MD.</div><div id=\"graphicVersion\">Graphic 109198 Version 1.0</div></div></div>"},"109199":{"type":"graphic_table","displayName":"SPTCL and PCGD-TCL differential","title":"Distinguishing features between subcutaneous panniculitis-like T cell lymphoma and primary cutaneous gamma-delta T cell lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing features between subcutaneous panniculitis-like T cell lymphoma and primary cutaneous gamma-delta T cell lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">SPTCL</td> <td class=\"subtitle1\">PCGD-TCL</td> </tr> <tr> <td><strong>Immunophenotype</strong></td> <td>TCR-beta, CD4-, CD8+, CD56-</td> <td>TCR-gamma-delta+, CD4-, CD8-, CD56&#177;</td> </tr> <tr> <td><strong>Architecture</strong></td> <td>Subcutaneous</td> <td>Subcutaneous and/or epidermal/dermal</td> </tr> <tr> <td><strong>Clinical features</strong></td> <td>Nodules and plaques, rarely ulceration, association with autoimmune disorders (20%)</td> <td>Nodules and plaques, ulceration common</td> </tr> <tr> <td><strong>HPS</strong></td> <td>Uncommon (17%)</td> <td>Common (50%)</td> </tr> <tr> <td><strong>Five-year survival</strong></td> <td>91% (without HPS), 46% (with HPS)</td> <td>11%</td> </tr> <tr> <td><strong>Treatment</strong></td> <td>Systemic steroids</td> <td>Systemic chemotherapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SPTCL: subcutaneous panniculitis-like T cell lymphoma; PCGD-TCL: primary cutaneous gamma-delta T cell lymphoma; TCR: T cell receptor; HPS: hemophagocytic syndrome.</div><div class=\"graphic_reference\">Adapted from: Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111:838.</div><div id=\"graphicVersion\">Graphic 109199 Version 2.0</div></div></div>"},"109201":{"type":"graphic_picture","displayName":"CD8+ AECTCL","title":"Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma</div><div class=\"cntnt\"><img style=\"width:486px; height:756px;\" src=\"images/DERM/109201_CD8+_AECTCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulceronecrotic lesions on the right arm.</div><div id=\"graphicVersion\">Graphic 109201 Version 2.0</div></div></div>"},"109202":{"type":"graphic_picture","displayName":"CD8+ AECTCL histopathology","title":"Histopathologic features of CD8+ aggressive epidermotropic cutaneous T cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of CD8+ aggressive epidermotropic cutaneous T cell lymphoma</div><div class=\"cntnt\"><img style=\"width:756px; height:521px;\" src=\"images/DERM/109202_CD8+_AECTCL_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prominent epidermotropism by neoplastic T cells.</div><div id=\"graphicVersion\">Graphic 109202 Version 2.0</div></div></div>"},"109205":{"type":"graphic_table","displayName":"Using powder inhalers PI II","title":"Technique for use of various dry powder inhalers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Technique for use of various dry powder inhalers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">RespiClick</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Make sure the cap is closed before use. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hold the inhaler upright and open the cap all the way, until you hear it click. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Breathe out as much air as you can from your lungs. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Close your lips tightly around the mouthpiece. Do not let your fingers or lips block the vents above the mouthpiece. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Breathe in as deeply as possible, then hold your breath for about 10 seconds (or as long as you comfortably can). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Remove the inhaler from your mouth. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Close the cap. Repeat steps above if you need another dose. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Keep inhaler clean and dry. If the mouthpiece needs cleaning, use a clean, dry cloth or tissue. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Turbuhaler</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Twist and remove the cover. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hold the inhaler upright with mouthpiece facing up. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Turn the grip right then left until it clicks. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Inhaler may be held upright or horizontal. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Breathe in rapidly and steadily, as deeply as possible, then hold your breath. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Remove the device from your mouth and exhale outside the device. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Replace the cover and twist to close. Store the device in a cool, dry place. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Twisthaler</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hold the inhaler straight up with the pink part (the base) on the bottom. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Remove the cap while it is in the upright position to make sure you get the right amount of medicine with each dose. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hold the pink base and twist the cap in a counter-clockwise direction to remove it. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>As you lift off the cap, the dose counter on the base will count down by 1. This action loads the medicine that you are now ready to inhale. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Make sure the indented arrow located on the white part (directly above the pink base) is pointing to the dose counter. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Breathe out normally. Do not exhale into the device. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Place the mouthpiece into your mouth, with the mouthpiece facing towards you, and close your lips tightly around it. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Inhale dose with a rapid and steady flow while holding the Twisthaler horizontal. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Remove the mouthpiece from your mouth and hold your breath for 5 to 10 seconds (or as long as you comfortably can). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>When you exhale, be sure that you are not exhaling into the device. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Replace the cap right away, and turn it in a clockwise direction as you gently press down, until you hear a click. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Firmly close the Twisthaler to assure that your next dose is properly loaded. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Be sure that the arrow is in line with the dose-counter window. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Store the device in a cool, dry place. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>The dose counter displays the number of doses remaining. When the unit reads 01, this indicates the last remaining dose. When the counter reads 00, the unit must then be discarded. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Ellipta</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Remove the inhaler from the foil tray. Do not open the cover of the inhaler until you are ready to use it. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Write the \"Tray opened\" and \"Discard\" dates on the inhaler label. The \"Discard\" date should be 6 weeks from the date you open the tray. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Check the dose counter on the inhaler. Before you use the inhaler for the first time, the counter should show the number 30. This is the number of doses in the inhaler. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Open the cover of the inhaler. Each time you fully open the cover it should produce a clicking sound, and the number on the counter should go down by one. This means a dose is ready to be inhaled. (If you open and close the cover without inhaling the medicine, you will lose the dose. The lost dose will be held in the inhaler, but it will no longer be available to be inhaled. It is not possible to accidentally take a double dose or an extra dose in 1 inhalation.)</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>If the counter does not count down as you hear the click, the inhaler will not deliver the medicine. Call your healthcare provider or pharmacist if this happens. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>While holding the inhaler away from your mouth, breathe out (exhale) fully. Do not exhale into the mouthpiece. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hold the inhaler in a horizontal position. You do not need to shake it. Do not block the air vent in the inhaler with your fingers. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Put the mouthpiece between your lips, and close your lips tightly around it. Your lips should fit over the curved shape of the mouthpiece. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Take one long, steady, deep breath in through your mouth. Do not breathe in through your nose. You might not taste or feel the medicine, even when you are using the inhaler correctly. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Remove the mouthpiece from your mouth and hold your breath for about 3 to 4 seconds (or as long as you comfortably can). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Breathe out slowly and gently. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Slide the cover up and over the mouthpiece as far as it will go to close the inhaler. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Clean the mouthpiece if needed, using a dry tissue, before you close the cover. Regular cleaning is not required. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>When you have less than 10 doses remaining in your inhaler, the left half of the counter shows red as a reminder to get a refill. After you have inhaled the last dose, the counter will show \"0\" and the inhaler should be thrown away. </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 109205 Version 3.0</div></div></div>"},"109206":{"type":"graphic_table","displayName":"CD8+ cutaneous T cell lymphoma differential diagnosis","title":"Differential diagnosis of CD8+ cutaneous T cell lymphomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of CD8+ cutaneous T cell lymphomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of cutaneous lymphoma</td> <td class=\"subtitle1\"> <p>Frequency of CD8 expression (%)</p> </td> <td class=\"subtitle1\">Helpful distinguishing features</td> </tr> <tr> <td>Aggressive epidermotropic CD8+ cytotoxic CTCL</td> <td class=\"centered\">100</td> <td>Ulcerating plaques, nodules and tumors, no prior or concurrent eczematous patches/plaques</td> </tr> <tr> <td>Early patch/plaque-stage MF</td> <td class=\"centered\">~15</td> <td>Prior or concurrent eczematous patches/plaques*</td> </tr> <tr> <td>Tumor-stage/transformed MF</td> <td class=\"centered\">~5</td> <td>(Ulcerating) tumors, prior or concurrent eczematous patches/plaques*</td> </tr> <tr> <td>Pagetoid reticulosis</td> <td class=\"centered\">~50</td> <td>Solitary, slowly expanding plaque usually on the extremities</td> </tr> <tr> <td>C-ALCL</td> <td class=\"centered\">&#60;5</td> <td>Solitary or localized (ulcerating) tumors, tendency to spontaneous remission*</td> </tr> <tr> <td>LyP, type D</td> <td class=\"centered\">100</td> <td>Recurrent self-healing popular, nodular or ulceronecrotic skin lesions*</td> </tr> <tr> <td>SPTCL</td> <td class=\"centered\">&#62;90</td> <td>Subcutaneous nodules and plaques, no ulceration, no epidermal involvement</td> </tr> <tr> <td>Primary cutaneous acral CD8+ T cell lymphoma</td> <td class=\"centered\">100</td> <td>Slowly progressive nodule on ear and other acral sites, no ulceration, no epidermal involvement, low proliferation rate</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CTCL: cutaneous T cell lymphoma; MF: mycosis fungoides; C-ALCL: cutaneous anaplastic large cell lymphoma; LyP: lymphomatoid papulosis; SPTCL: subcutaneous panniculitis-like T cell lymphoma.<br />* No difference in clinical presentation and prognosis between CD8+ and more common CD4+ cases.</div><div class=\"graphic_reference\">Original figure modified for this publication. Willemze R. CD30-Negative Cutaneous T-Cell Lymphomas Other than Mycosis Fungoides. Surg Pathol Clin 2014; 7:229. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109206 Version 1.0</div></div></div>"},"109207":{"type":"graphic_picture","displayName":"CD8+ AECTCL immunophenotype","title":"Immunophenotype of CD8+ aggressive epidermotropic cutaneous T cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Immunophenotype of CD8+ aggressive epidermotropic cutaneous T cell lymphoma</div><div class=\"cntnt\"><img style=\"width:756px; height:539px;\" src=\"images/DERM/109207_CD8+_AECTCL_immunophenotype.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The epidermotropic cells show a strong expression of CD8.</div><div class=\"graphic_reference\">Courtesy of Rein Willemze, MD.</div><div id=\"graphicVersion\">Graphic 109207 Version 2.0</div></div></div>"},"109210":{"type":"graphic_picture","displayName":"Staining to show tissue destruction in aortic aneurysm","title":"Staining to show tissue destruction in aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Staining to show tissue destruction in aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:591px; height:450px;\" src=\"images/SURG/109210_Tissue_dstrctn_aortc_anrysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verhoeff's elastic staining at 10x magnification (B) and 20x magnification (D)&nbsp;shows elastic fiber destruction in aortic aneurysm compared with control aorta specimens at 10x magnification&nbsp;(A) and 20x magnification (C).</div><div class=\"graphic_reference\">Reproduced with permission from: Jayer Chung, MD, MSc, Baylor College of Medicine.</div><div id=\"graphicVersion\">Graphic 109210 Version 1.0</div></div></div>"},"109211":{"type":"graphic_picture","displayName":"Staining to show muscle loss in abdominal aortic aneurysm","title":"Staining to show muscle loss in abdominal aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 906px\" class=\"figure\"><div class=\"ttl\">Staining to show muscle loss in abdominal aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:886px; height:445px;\" src=\"images/SURG/109211_Muscle_loss_ab_aortc_anrysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin staining of aortic specimens. Panels (A), (B), and (C) are magnified 100x; panels (D), (E), and (F) are magnified 200x. Control segments of the aorta (A,D) exhibit an abundance of vascular smooth muscle cells&nbsp;with&nbsp;dark nuclei apparent and&nbsp;thick, well-ordered layers of elastin. By contrast,&nbsp;the segment of aortic aneurysm (B,D) shows depletion of smooth muscle cells, as shown by marked decrease in nuclei and vacuolization (prominent in B).&nbsp;The elastin fibrils are also&nbsp;thinned and disordered (C,F).</div><div class=\"graphic_reference\">Reproduced with permission from: Jayer Chung, MD, MSc, Baylor College of Medicine.</div><div id=\"graphicVersion\">Graphic 109211 Version 1.0</div></div></div>"},"109231":{"type":"graphic_picture","displayName":"Acinetobacter leg infection","title":"Acinetobacter baumannii skin and soft tissue infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acinetobacter baumannii skin and soft tissue infection</div><div class=\"cntnt\"><img style=\"width:343px; height:203px;\" src=\"images/ID/109231_Ulcers_of_the_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most Acinetobacter skin infections start with a break in the skin. Cellulitis can start&nbsp;as a well demarcated, erythematous and edematous patch with erythema that can progress to a sandpaper-like texture and ultimately hemorrhagic bullae.</div><div class=\"graphic_reference\">Reproduced from: Nawas Z, Tong Y, Kollipara R, et al. Emerging infectious diseases with cutaneous manifestations: Viral and bacterial infections. J Am Acad Dermatol 2016; 75:1. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109231 Version 2.0</div></div></div>"},"109232":{"type":"graphic_table","displayName":"DIRE score","title":"DIRE Score: Patient selection for chronic opioid analgesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DIRE Score: Patient selection for chronic opioid analgesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle2_left\" style=\"font-size:1.2em;\" colspan=\"3\">For each factor, rate the patient's score from 1 to 3 based on the explanations in the right-hand column</td> </tr> <tr> <td class=\"subtitle1\">Score</td> <td class=\"subtitle1\">Factor</td> <td class=\"subtitle1\">Explanation</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"3\"><strong>D</strong>iagnosis</td> <td>1 = Benign chronic condition with minimal objective findings or no definite medical diagnosis (eg, fibromyalgia, migraine headaches, nonspecific back pain)</td> </tr> <tr> <td>2 = Slowly progressive condition concordant with moderate pain, or fixed condition with moderate objective findings (eg, failed back surgery syndrome, back pain with moderate degenerative changes, neuropathic pain)</td> </tr> <tr class=\"divider_bottom\"> <td>3 = Advanced condition concordant with severe pain with objective findings (eg, severe ischemic vascular disease, advanced neuropathy, severe spinal stenosis)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"3\"><strong>I</strong>ntractability</td> <td>1 = Few therapies have been tried and the patient takes a passive role in his/her pain management process</td> </tr> <tr> <td>2 = Most customary treatments have been tried, but the patient is not fully engaged in the pain management process, or barriers prevent (eg, insurance, transportation, medical illness)</td> </tr> <tr class=\"divider_bottom\"> <td>3 = Patient fully engaged in a spectrum of appropriate treatments, but with inadequate response</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><strong>R</strong>isk</td> <td>R = Total of P + C + R + S</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"12\">&nbsp;</td> <td class=\"indent1 sublist1 divider_bottom\" rowspan=\"3\"><strong>P</strong>sychological</td> <td class=\"indent1\">1 = Serious personality dysfunction or mental illness interfering with care (eg, personality disorder, severe affective disorder, significant personality issues)</td> </tr> <tr> <td class=\"indent1\">2 = Personality or mental health interferes moderately (eg, depression or anxiety disorder)</td> </tr> <tr> <td class=\"indent1 divider_bottom\">3 = Good communication with clinic; no significant personality dysfunction or mental illness</td> </tr> <tr> <td class=\"indent1 sublist1 divider_bottom\" rowspan=\"3\"><strong>C</strong>hemical health</td> <td class=\"indent1\">1 = Active or very recent use of illicit drugs, excessive alcohol, or prescription drug abuse</td> </tr> <tr> <td class=\"indent1\">2 = Chemical coper (uses medications to cope with stress) or history of CD in remission</td> </tr> <tr> <td class=\"indent1 divider_bottom\">3 = No CD history; not drug-focused or chemically reliant</td> </tr> <tr> <td class=\"indent1 sublist1 divider_bottom\" rowspan=\"3\"><strong>R</strong>eliability</td> <td class=\"indent1\">1 = History of numerous problems (eg, medication misuse, missed appointments, rarely follows through)</td> </tr> <tr> <td class=\"indent1\">2 = Occasional difficulties with compliance, but generally reliable</td> </tr> <tr> <td class=\"indent1 divider_bottom\">3 = Highly reliable patient with medications, appointments, and treatment</td> </tr> <tr> <td class=\"indent1 sublist1 divider_bottom\" rowspan=\"3\"><strong>S</strong>ocial support</td> <td class=\"indent1\">1 = Life in chaos (eg, little family support and few close relationships, loss of most normal life roles)</td> </tr> <tr> <td class=\"indent1\">2 = Reduction in some relationships and life roles</td> </tr> <tr> <td class=\"indent1 divider_bottom\">3 = Supportive family/close relationships; involved in work or school and no social isolation</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"3\"><strong>E</strong>fficacy</td> <td>1 = Poor function or minimal pain relief despite moderate to high doses</td> </tr> <tr> <td>2 = Moderate benefit with function improved in a number of ways (or insufficient info&nbsp;&ndash; hasn't tried opioid yet, or very low doses, or too short of a trial)</td> </tr> <tr class=\"divider_bottom\"> <td>3 = Good improvement in pain and function and quality of life with stable doses over time</td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\">&nbsp;</td> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"2\"><strong>Total score = D + I + R + E</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Score 7 to 13 = Not a suitable candidate for long-term opioid analgesia.<br />Score 14 to 21 = May be a candidate for long-term opioid analgesia.</div><div class=\"graphic_footnotes\">CD: chemical dependency.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2005 Miles Belgrade, MD. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109232 Version 1.0</div></div></div>"},"109233":{"type":"graphic_table","displayName":"Addiction Behaviors Checklist (ABC)","title":"Addiction Behaviors Checklist (ABC)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Addiction Behaviors Checklist (ABC)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Addition Behaviors Checklist (ABC)</td> </tr> <tr> <td colspan=\"4\"><strong>Instructions: Code only for patients prescribed opioid or sedative analgesics on behaviors exhibited \"since last visit\" and \"within the current visit\" (NA = not assessed).</strong></td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td colspan=\"4\"><strong>Addiction behaviors - since last visit</strong></td> </tr> <tr> <td> <ol> <li>Patient used illicit drugs or evidences problem drinking* </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"2\"> <li>Patient has hoarded meds </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"3\"> <li>Patient used more narcotic than prescribed </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"4\"> <li>Patient ran out of meds early </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"5\"> <li>Patient has increased use of narcotics </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"6\"> <li>Patient used analgesics PRN when prescription is for time contingent use </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"7\"> <li>Patient received narcotics from more than one provider </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"8\"> <li>Patient bought meds on the streets </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td colspan=\"4\"><strong>Addiction behaviors - within current visit</strong></td> </tr> <tr> <td> <ol> <li>Patient appears sedated or confused (eg, slurred speech, unresponsive) </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"2\"> <li>Patient expresses worries about addiction </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"3\"> <li>Patient expressed a strong preference for a specific type of analgesic or a specific route of administration </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"4\"> <li>Patient expresses concern about future availability of narcotic </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"5\"> <li>Patient reports worsened relationships with family </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"6\"> <li>Patient misrepresents analgesic prescription or use </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"7\"> <li>Patient indicates she or he \"needs\" or \"must have\" analgesic meds </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"8\"> <li>Discussion of analgesic meds is the predominant issue of visit </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"9\"> <li>Patient exhibits lack of interest in rehab or self-management </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"10\"> <li>Patient reports minimal/inadequate relief from narcotic analgesic </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td> <ol start=\"11\"> <li>Patient indicates difficulty with using medication agreement </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td colspan=\"4\"><strong>Other</strong></td> </tr> <tr> <td> <ol> <li>Significant others express concern over patient's use of analgesics </li> </ol> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">NA</td> </tr> <tr> <td class=\"sublist1 divider_bottom\" colspan=\"4\">&nbsp;</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">ABC SCORE:</td> <td class=\"subtitle1_left\" colspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Score of &#8805;3 indicated possible inappropriate opioid use and should flag for further examination of specific signs of misuse and more careful patient monitoring (ie, urine screening, pill counts, removal of opioid).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Designed to track behaviors characteristic of addiction related to prescription opioid medications in chronic pain patients. Items are focused on observable behaviors noted both during and between visits. ABC is focused on longitudinal assessment and tracking of problematic behaviors.</div><div class=\"graphic_footnotes\">PRN: As needed<br />* Item 1 original phrasing: (\"Patient used ETOH or illicit drugs\"), had a low correlation with global clinical judgment. This is possibly associated with difficulty in content interpretation, in that if a patient endorsed highly frequent alcohol use, he or she would receive a positive rating on this item, but not be considered as using the prescription opioid medications inappropriately. Therefore, we include in this version of the ABC a suggested wording change for this item that specifies problem drinking as the criterion for alcohol use.</div><div class=\"graphic_reference\">Originally published in: Wu SM, Compton P, Bolus R, et al. The addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. J Pain Symptom Manage 2006; 32:342. Reproduced with permission. Copyright &copy; 2006 Bruce D. Naliboff, PH.D. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109233 Version 1.0</div></div></div>"},"109234":{"type":"graphic_picture","displayName":"Primary cutaneous acral CD8+ T cell lymphoma","title":"Primary cutaneous CD8<SUP>+</SUP> T cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous CD8<SUP>+</SUP> T cell lymphoma</div><div class=\"cntnt\"><img style=\"width:754px; height:566px;\" src=\"images/DERM/109234_Prmry_cutans_acrl_CD8_TCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary cutaneous acral CD8<SUP>+</SUP> T cell lymphoma presenting with a solitary nodule on the right ear.</div><div class=\"graphic_reference\">Reproduced from: Willemze R. CD30-Negative Cutaneous T-Cell Lymphomas Other than Mycosis Fungoides. Surg Pathol Clin 2014; 7:229. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109234 Version 1.0</div></div></div>"},"109235":{"type":"graphic_picture","displayName":"Primary cutaneous acral CD8+ TCL histopathology","title":"Histopathologic features of primary cutaneous acral CD8+ T cell lymphomaâ€‹","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of primary cutaneous acral CD8+ T cell lymphomaâ€‹</div><div class=\"cntnt\"><img style=\"width:765px; height:531px;\" src=\"images/DERM/109235_Prmry_cutans_acral_CD8_TCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary cutaneous acral CD8<SUP>+</SUP> T cell lymphoma. <br />(A) Diffuse nonepidermotropic dermal infiltrate.<br />(B) Immunophenotyping shows strong expression of CD8.</div><div class=\"graphic_reference\">Courtesy of Rein Willemze, MD.</div><div id=\"graphicVersion\">Graphic 109235 Version 1.0</div></div></div>"},"109236":{"type":"graphic_diagnosticimage","displayName":"Measurement of normal LV diameter","title":"TEE measurement of LV end-diastolic diameter in the transgastric mid-papillary view in a patient with normal ventricular size","html":"<div class=\"graphic\"><div style=\"width: 760px\" class=\"figure\"><div class=\"ttl\">TEE measurement of LV end-diastolic diameter in the transgastric mid-papillary view in a patient with normal ventricular size</div><div class=\"cntnt\"><img style=\"width:740px; height:560px;\" src=\"images/ANEST/109236_Msrmnt_normal_LV_diameter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TEE measurement of LV end-diastolic diameter in the transgastric mid-papillary short-axis view in a patient with normal LV size. Note that the chamber diameter is measured at end-diastole from the endocardial border of the anterior septum to the endocardial border of the inferolateral wall.</div><div class=\"graphic_footnotes\">LV: left ventricular; TEE: transesophageal echocardiography; bpm: beats/minute.</div><div id=\"graphicVersion\">Graphic 109236 Version 3.0</div></div></div>"},"109246":{"type":"graphic_table","displayName":"Sacral nerve stimulation for low anterior resection syndrome","title":"Sacral nerve stimulation for low anterior resection syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sacral nerve stimulation for low anterior resection syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Number of patients undergoing temporary stimulation</td> <td class=\"subtitle1\">Number of patients undergoing permanent stimulation</td> <td class=\"subtitle1\">Percentage (%)</td> <td class=\"subtitle1\">Follow-up</td> </tr> <tr> <td>Matzel 2002</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">100</td> <td>18 months</td> </tr> <tr> <td>Ratto 2005</td> <td class=\"centered\">4</td> <td class=\"centered\">4</td> <td class=\"centered\">100</td> <td>19 months</td> </tr> <tr> <td>Jarrett 2005</td> <td class=\"centered\">3</td> <td class=\"centered\">2</td> <td class=\"centered\">66</td> <td>12 months</td> </tr> <tr> <td>Melenhorst 2007</td> <td class=\"centered\">3</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td>Not applicable</td> </tr> <tr> <td>Holzer 2008</td> <td class=\"centered\">8</td> <td class=\"centered\">7</td> <td class=\"centered\">87</td> <td>32 months</td> </tr> <tr> <td>de Miguel 2011</td> <td class=\"centered\">15</td> <td class=\"centered\">7</td> <td class=\"centered\">46</td> <td>12 months</td> </tr> <tr> <td>Moya 2012</td> <td class=\"centered\">4</td> <td class=\"centered\">4</td> <td class=\"centered\">100</td> <td>Not available</td> </tr> <tr class=\"divider_bottom\"> <td>Schwandner 2013</td> <td class=\"centered\">9</td> <td class=\"centered\">9</td> <td class=\"centered\">100</td> <td>12 months</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\"><strong>47</strong></td> <td class=\"centered\"><strong>34</strong></td> <td class=\"centered\"><strong>72</strong></td> <td><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Sacral nerve stimulation&nbsp;involves placement of a temporary electrode into the sacral foramen to provide low-grade electrical stimulation. Patients who respond to a two-week trial with a temporary electrode then undergo placement of a permanent electrode connected to a generator embedded subcutaneously. Sacral nerve stimulation has been shown to improve fecal incontinence and the ability to defer defecation in patients with low anterior resection syndrome. </div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Matzel KE, Stadelmaier U, Bittorf B, et al. Bilateral sacral spinal nerve stimulation for fecal incontinence after low anterior rectum resection. Int J Colorectal Dis 2002; 17:430.</li>&#xD;&#xA;    <li>Ratto C, Grillo E, Parello A, et al. Sacral neuromodulation in treatment of fecal incontinence following anterior resection and chemoradiation for rectal cancer. Dis Colon Rectum 2005; 48:1027.</li>&#xD;&#xA;    <li>Jarrett ME, Matzel KE, St&ouml;sser M, et al. Sacral nerve stimulation for faecal incontinence following a rectosigmoid resection for colorectal cancer. Int J Colorectal Dis 2005; 20:446.</li>&#xD;&#xA;    <li>Melenhorst J, Koch SM, Uludag O, et al. Sacral neuromodulation in patients with faecal incontinence: results of the first 100 permanent implantations. Colorectal Dis 2007; 9:725.</li>&#xD;&#xA;    <li>Holzer B, Rosen HR, Zaglmaier W. Sacral nerve stimulation in patients after rectal resection--preliminary report. J Gastrointest Surg 2008; 12:921.</li>&#xD;&#xA;    <li>de Miguel M, Oteiza F, Ciga MA, et al. Sacral nerve stimulation for the treatment of faecal incontinence following low anterior resection for rectal cancer. Colorectal Dis 2011; 13:72.</li>&#xD;&#xA;    <li>Moya P, Arroyo A, Soriano-Irigaray L, et al. Sacral nerve stimulation in patients with severe fecal incontinence after rectal resection. Tech Coloproctol 2012; 16:263.</li>&#xD;&#xA;    <li>Schwandner O. Sacral neuromodulation for fecal incontinence and \"low anterior resection syndrome\" following neoadjuvant therapy for rectal cancer. Int J Colorectal Dis 2013; 28:665.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109246 Version 1.0</div></div></div>"},"109247":{"type":"graphic_algorithm","displayName":"First-line therapy for metastatic colorectal cancer","title":"Approach to selection of first-line chemotherapy for metastatic colorectal cancer","html":"<div class=\"graphic\"><div style=\"width: 1208px\" class=\"figure\"><div class=\"ttl\">Approach to selection of first-line chemotherapy for metastatic colorectal cancer</div><div class=\"cntnt\"><img style=\"width:1188px; height:901px;\" src=\"images/ONC/109247_FLthrpymtsttcclrctlcncr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PS: performance status; FOLFOXIRI: infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan; FOLFOX: oxaliplatin plus leucovorin and short-term infusional fluorouracil; FOLFIRI: irinotecan plus leucovorin and short-term infusional fluorouracil; EGFR: epidermal growth factor receptor.<br />* For example, high tumor burden, highly symptomatic disease, initially unresectable but potentially resectable liver metastases.<br />Â¶ Use of cetuximab and panitumumab contraindicated in patients with tumoral RAS mutations or BRAF V006E mutations.<br />Î” Contraindications to bevacizumab may include: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Major surgery within 28 days.</LI>&#xD;&#xA;<LI>Active bleeding.</LI>&#xD;&#xA;<LI>Untreated hemorrhagic brain metastases.</LI>&#xD;&#xA;<LI>Arterial thromboembolic event within the last 6 to 12 months.</LI></UL><FONT class=lozenge>â—Š</FONT> Backbone chemotherapy doublets appropriate for use with cetuximab or panitumumab include FOLFOX or FOLFIRI. An additional doublet that can be used alone or in combination with bevacizumab is oxaliplatin plus capecitabine (CAPOX, XELOX). FOLFIRI is preferred over an oxaliplatin-containing regimen for patients who received adjuvant oxaliplatin-based chemotherapy within the last 12 months or if there was any oxaliplatin-related neuropathy.</div><div id=\"graphicVersion\">Graphic 109247 Version 4.0</div></div></div>"},"109248":{"type":"graphic_diagnosticimage","displayName":"Mid-RCA with noncalcified plaque causing severe stenosis","title":"Mid-RCA with noncalcified plaque causing severe stenosis","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Mid-RCA with noncalcified plaque causing severe stenosis</div><div class=\"cntnt\"><img style=\"width:763px; height:380px;\" src=\"images/CARD/109248_Mid-RCA_noncalcified_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CCTA (Left panel) showing midRCA with noncalcified plaque causing severe stenosis; and corresponding ICA image (right panel).</div><div class=\"graphic_footnotes\">RCA: right coronary artery; CCTA: coronary computed tomography angiography; ICA: intracoronary angiography.</div><div id=\"graphicVersion\">Graphic 109248 Version 1.0</div></div></div>"},"109249":{"type":"graphic_algorithm","displayName":"Algorithm for enteral feeding in premature infants","title":"Algorithm for enteral feeding in a premature infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for enteral feeding in a premature infant</div><div class=\"cntnt\"><img style=\"width:426px; height:740px;\" src=\"images/PEDS/109249_Enteral_feeding_prem_infant.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This table describes the author's approach to initiating and advancing feeds in very premature infants. Most neonatal intensive care units (NICUs) use a similar protocol, but specifics of timing, composition, and advancement of feeds vary.</div><div class=\"graphic_footnotes\">NICU: neonatal intensive care unit; NG: nasogastric; DOL: day of life.<br />* Oral feeding should be initiated as soon as the infant demonstrates signs of readiness, which typically occurs when the tube-fed infant is between 32 and 34 weeks gestational age. Although there is some variability, most preterm infants born at &gt;34 weeks gestation do not require a prolonged period of tube feeding, and many can be completely fed orally from birth.<br />&para; We swab the oropharyngeal mucosa with expressed colostrum or breast milk approximately every three hours. We continue to swab the oropharynx with mother's milk for at least a few days; some clinicians continue this practice until the infant is taking some feeds orally.<br />&Delta; Start trophic feeds on DOL 1 for all infants, using mother's milk, if possible. For infants &le;1500 g, use donor milk if no mother's milk is available, or premature infant formula if no donor milk is available. For infants 1500 to 1800 g, use donor milk only when necessary as a bridge to feedings of mother's milk.<br /><span class=\"lozenge\">&loz;</span> Fortification consists of adding human milk fortifier to expressed human milk. Formula-fed infants are changed to 24 cal/oz preterm formula (eg, Similac Special Care 24).<br />&sect; Oral feeds are ideally with breastmilk, usually with human milk fortifier.</div><div class=\"graphic_reference\">Courtesy of Dr. Richard Schanler.</div><div id=\"graphicVersion\">Graphic 109249 Version 2.0</div></div></div>"},"109258":{"type":"graphic_algorithm","displayName":"Diagnostic testing Fe deficiency","title":"Algorithm for evaluating suspected iron deficiency","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluating suspected iron deficiency</div><div class=\"cntnt\"><img style=\"width:708px; height:493px;\" src=\"images/HEME/109258_DiagnostictestngFedfcncy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a general approach and should not substitute for the judgment of the treating clinician. It presumes the patient has already had a history, examination, and CBC including RBC count and RBC indices (eg, MCV, MCH) and that suspected iron deficiency is the primary clinical concern. Refer to UpToDate for additional information and details of the evaluation, the importance of identifying the source of iron deficiency or blood loss, the need to address comorbidities and other possible diagnoses, and recommendations for individuals whose iron deficiency and/or anemia does not resolve with treatment. Other approaches such as a therapeutic trial of iron (without performing iron studies) may be appropriate in some settings (eg, resource-limited countries).</div><div class=\"graphic_footnotes\">FH: family history; GI: gastrointestinal; RBC: red blood cell; TIBC: total iron binding capacity; TSAT: transferrin saturation; CBC: complete blood count; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; sTfR: soluble transferrin receptor.<br />* A serum ferritin level (without other testing) may be sufficient for diagnosis in individuals with a high likelihood of iron deficiency (eg, young woman with menorrhagia, pregnancy). If the ferritin level is low, no additional testing is needed. The decision regarding whether to order a serum ferritin alone or a full iron studies panel depends on clinician judgment regarding the likelihood of iron deficiency and local institutional and laboratory factors such as the ease of \"adding on\" additional tests to the original sample or obtaining an additional sample if needed.<br />Â¶ There may be instances in which iron repletion is not indicated, such as in patients who are intentionally rendered iron deficient as part of their treatment for another condition (eg, hereditary hemochromatosis, polycythemia vera).<br />Î” The optimal threshold for TSAT has not been established. Confidence in the diagnosis of iron deficiency is very high if TSAT is &lt;10% (&lt;20% if concomitant inflammation); some experts use a threshold of &lt;16%.<br /><FONT class=lozenge>â—Š</FONT> For patients with a very strong suspicion of iron deficiency, the sTfR or sTfR-ferritin index may be useful. Bone marrow iron stain is rarely needed. Hematology consultation may be helpful.</div><div id=\"graphicVersion\">Graphic 109258 Version 4.0</div></div></div>"},"109259":{"type":"graphic_algorithm","displayName":"Rx drug-susceptible pulmonary TB in adults","title":"Approach to treatment of drug-susceptible pulmonary tuberculosis in adults","html":"<div class=\"graphic\"><div style=\"width: 1664px\" class=\"figure\"><div class=\"ttl\">Approach to treatment of drug-susceptible pulmonary tuberculosis in adults</div><div class=\"cntnt\"><img style=\"width:1644px; height:873px;\" src=\"images/ID/109259_RxdrugsscptplmTBHIVun.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Drug dosing is summarized separately (refer to the UpToDate text and related tables).</LI>&#xD;&#xA;<LI>The algorithm is designed based on assumption that positive AFB smears and cultures reflect <EM>Mycobacterium tuberculosis</EM>; identification of non-tuberculous mycobacteria should prompt adjustment of therapy accordingly (refer to the UpToDate content on nontuberculous mycobacteria).</LI>&#xD;&#xA;<LI>The algorithm is designed based on the assumption that the patient has drug-susceptible disease; drug susceptibility data should be reviewed, and identification of drug resistance should prompt adjustment of therapy accordingly (refer to the UpToDate content on drug-resistant tuberculosis).</LI>&#xD;&#xA;<LI>During treatment of pulmonary tuberculosis, sputum should be obtained for AFB smear and culture at monthly intervals until two consecutive cultures are negative. Presence of positive sputum cultures after four months of antituberculous therapy reflects treatment failure (refer to the UpToDate text for discussion of management).</LI>&#xD;&#xA;<LI>Directly observed therapy is preferred for all patients to ensure adherence and prevent emergence of drug resistance.</LI></UL></div><div class=\"graphic_footnotes\">AFB: acid-fast bacilli; HIV: human immunodeficiency virus; TB: tuberculosis.<br />* Ethambutol may be discontinued when results of drug susceptibility testing indicate no drug resistance to first-line agents.<br />&para; Pyrazinamide may be discontinued after it has been taken for two months (56 doses).<br />&Delta; Worsening chest radiograph findings or clinical manifestations prior to initiation of continuation phase should prompt consideration of drug-resistant tuberculosis or alternate diagnosis (refer to the UpToDate text for further discussion).<br /><span class=\"lozenge\">&loz;</span> During treatment of pulmonary tuberculosis, sputum should be obtained for AFB smear and culture at monthly intervals until two consecutive cultures are negative. Positive sputum culture should prompt drug susceptibility testing and review of causes for treatment failure (refer to the UpToDate content on treatment of pulmonary tuberculosis). Patients with drug-resistant isolates should be treated as discussed separately (refer to the UpToDate content on drug-resistant tuberculosis).<br />&sect; Rifapentine should not be used in patients with extrapulmonary tuberculosis.<br />&yen; Tuberculosis is unlikely if initial sputum culture is negative.<br />&Dagger; If rifampin and pyrazinamide were included in the treatment regimen for at least two months, no further treatment for latent TB is needed; otherwise, a regimen for treatment of latent TB should be completed with rifampin and/or isoniazid (refer to the UpToDate topic on treatment of latent TB infection for further discussion).<br />&dagger; The continuation phase may warrant extension to seven months (total duration nine months) in patients with additional risk factors for relapse, including those who have bilateral pulmonary disease or are underweight.</div><div class=\"graphic_reference\">Adapted from: American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52:1.</div><div id=\"graphicVersion\">Graphic 109259 Version 2.0</div></div></div>"},"109261":{"type":"graphic_table","displayName":"Mosquito prevention Zika PI","title":"Tips for avoiding the mosquitoes that carry the Zika virus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for avoiding the mosquitoes that carry the Zika virus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Stay inside when the mosquitoes are most active. They bite mostly during the daytime and at&nbsp;twilight (the very early morning, and the few hours before sunset). Buildings with screens and air conditioning are safest. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Wear shoes, long-sleeved shirts, long pants, and a hat when you go outside. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Wear bug spray or cream that contains DEET or a chemical called \"picaridin.\" Check the label to make sure. Do not use DEET on babies younger than 2 months. </li> </ul> </td> </tr> <tr> <td> <ul> <li>On your clothes and gear, use bug repellents that have a chemical called \"permethrin.\" </li> </ul> </td> </tr> <tr> <td> <ul> <li>Drain any standing water if possible, such as wading pools, buckets, and potted plants with saucers. Mosquitoes breed in standing water. </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 109261 Version 1.0</div></div></div>"},"109270":{"type":"graphic_picture","displayName":"Immersion scald burn due to child abuse","title":"Immersion scald burn due to child abuse","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Immersion scald burn due to child abuse</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/EM/109270_Imrsn_scald_brn_child_abuse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the sharp line of demarcation of the burn (\"high water mark\") on the leg and the extensive deep second degree burns of the buttocks.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109270 Version 1.0</div></div></div>"},"109271":{"type":"graphic_table","displayName":"Indications for obtaining a skeletal survey","title":"Indications for obtaining a skeletal survey","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for obtaining a skeletal survey</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td> <ul> <li>All children &#60;2 years with obvious abusive injuries</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>All children &#60;2 years with any suspicious injury, including: <ul> <li>Bruises or other skin injuries in nonambulatory infants;</li> <li>Oral injuries in nonambulatory infants; and</li> <li>Injuries not consistent with the history provided</li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Infants with unexplained, unexpected sudden death (consult with medical examiner/coroner first)</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Infants and young toddlers with unexplained intracranial injuries, including hemorrhage and hypoxic-ischemic injury</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Infants and siblings &#60;2 years and household contacts of an abused child</li> </ul> </td> </tr> <tr> <td> <ul> <li>Twins of abused infants and toddlers</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 135, Pages e1337-54, Copyright &copy; 2015 by the AAP.</div><div id=\"graphicVersion\">Graphic 109271 Version 2.0</div></div></div>"},"109272":{"type":"graphic_table","displayName":"Child abuse screening tool","title":"Child abuse emergency department screening tool","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Child abuse emergency department screening tool</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">1. Is the history consistent?</td> <td class=\"centered\">Yes</td> <td class=\"centered highlight_gray_text\">No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">2. Was seeking medical help unnecessarily delayed?</td> <td class=\"centered highlight_gray_text\">Yes</td> <td class=\"centered\">No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">3. Does the onset of the injury fit with the developmental level of the child?</td> <td class=\"centered\">Yes/NA</td> <td class=\"centered highlight_gray_text\">No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">4. Is the behavior of the child, his or hers carers, and their interaction appropriate?</td> <td class=\"centered\">Yes</td> <td class=\"centered highlight_gray_text\">No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">5. Are findings of the head-to-toe examination in accordance with the history?</td> <td class=\"centered\">Yes</td> <td class=\"centered highlight_gray_text\">No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">6. Are there other signals that make you doubt the safety of the child or other family members?</td> <td class=\"centered highlight_gray_text\">Yes*</td> <td class=\"centered\">No</td> </tr> <tr> <td><strong>Other comments</strong></td> <td colspan=\"2\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">N/A: not applicable. <br />The screening instrument for child abuse used at the emergency departments. One (or more) ticked answers in the dark boxes indicate the possibility of an increased risk of child abuse and further action is recommended.</div><div class=\"graphic_footnotes\">* If \"Yes,\" describe the signals in the box \"Other comments\".</div><div class=\"graphic_reference\">Reproduced from: Louwers E, Korfage IJ, Affourtit MJ, et al. Accuracy of a screening instrument to identify potential child abuse in emergency departments. Child Abuse Negl 2014:1275. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109272 Version 1.0</div></div></div>"},"109276":{"type":"graphic_table","displayName":"The Pediatric Anesthesia Emergence Delirium (PAED) scale","title":"The Pediatric Anesthesia Emergence Delirium (PAED) scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Pediatric Anesthesia Emergence Delirium (PAED) scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td> <ol class=\"numbers_to_nine\"> <li>The child makes eye contact with the caregiver/parent </li> </ol> </td> <td>4 = not at all; to 0 = extremely</td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"2\"> <li>The child's actions are purposeful </li> </ol> </td> <td>4 = not at all; to 0 = extremely</td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"3\"> <li>The child is aware of his/her surroundings </li> </ol> </td> <td>4 = not at all; to 0 = extremely</td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"4\"> <li>The child is restless </li> </ol> </td> <td>0 = not at all; to 4 = extremely</td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"5\"> <li>The child is inconsolable </li> </ol> </td> <td>0 = not at all; to 4 = extremely</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The scores for each of the five listed behaviors are added to achieve a total scale score. A score of â‰¥10 makes it highly likely that a child has emergence delirium. For further information, refer to UpToDate content on emergence delirium and agitation in children.</div><div class=\"graphic_reference\">From: Sikich N, Lerman J. Development and psychometric evaluation of the pediatric anesthesia emergence delirium scale. Anesthesiology 2004; 100:1138. Copyright &copy; 2004 American Society of Anesthesiologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 109276 Version 2.0</div></div></div>"},"109277":{"type":"graphic_table","displayName":"Risk factors for ED","title":"Factors that may or may not be associated with emergence delirium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that may or may not be associated with emergence delirium</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Factors that predispose to ED</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Age: Most frequent between two and six years<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Anesthetics: Sevoflurane &#8776; desflurane &#8776; isoflurane &#62;&#62; TIVA &#62; halothane<sup>[2-6]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Preoperative mental state: Increased anxiety, temperament*<sup>[7,8]</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Factors that do not predispose to ED</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Rapid emergence<sup>[9]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Deep&nbsp;anesthesia (bispectral index &#60;45.5)<sup>[10,11]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Preoperative anxiety*<sup>[12,13]</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The factors that have been associated with a greater probability of developing ED are shown in the top portion of this table; those that have been found to not be associated with development of ED are shown in the bottom portion. Administration of sevoflurane, desflurane, and isoflurane confer&nbsp;approximately equivalent risk, and greater risk than TIVA. ED is least likely after halothane anesthesia.</div><div class=\"graphic_footnotes\">ED: emergence delirium; TIVA: total intravenous anesthesia.<br />*Conflicting data, further studies required</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Aono J, Ueda W, Mamiya K, Takimoto E, Manabe M. Greater incidence of delirium during recovery from sevoflurane anesthesia in preschool boys. Anesthesiology 1997; 87:1298.</LI>&#xD;&#xA;<LI>Beksow A, Westrin P. Sevoflurane causes more postoperative agitation in children than does halothane. Acta Anaesth Scand 1999; 43:536.</LI>&#xD;&#xA;<LI>Meyer RR, Munster P, Werner C, Brambrink AM. Isoflurane is associated with a similar incidence of emergence agitation/delirium as sevoflurane in young children â€“ a randomized controlled study. Paediatr Anaesth 2007; 17:56.</LI>&#xD;&#xA;<LI>Hasani A, Ozgen S, Baftiu N. Emergence agitation in children after propofol versus halothane anesthesia. Med Sci Monit 2009; 15:CR302.</LI>&#xD;&#xA;<LI>Chandler JR, Myers D, Mehta D, et al. Emergence delirium in children: a randomized trial to compare total intravenous anesthesia with propofol and remifentanil to inhalational sevoflurane anesthesia. Paediatr Anaesth 2013; 23:309.</LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Costi D, Cyna AM, Ahmed S, et al. Effects of sevoflurane versus other general anaesthesia on emergence agitation in children. Cochrane Database Syst Rev 2014; 12:CD007084.</SPAN></LI>&#xD;&#xA;<LI>Aono J, Mamiya K, Manabe M. Preoperative anxiety is associated with a high incidence of problematic behavior on emergence after halothane anesthesia in boys. Acta Anaesthiol Scand 1999; 43:542.</LI>&#xD;&#xA;<LI>Kain ZN, Caldwell-Andrews AA, Maranets I, et al. Preoperative anxiety and emergence delirium and postoperative maladaptive behaviors. Anesth Analg 2004; 99:1648.</LI>&#xD;&#xA;<LI>Cohen IT, Finkel JC, Hannallah RS, et al. Rapid emergence does not explain agitation following sevoflurane anaesthesia in infants and children: a comparison with propofol. Paediatr Anaesth 2003; 13:63.</LI>&#xD;&#xA;<LI>Faulk DJ, Twite MD, Zuk J, et al. Hypnotic depth and the incidence of emergence agitation and negative postoperative behavioral changes. Paediatr Anaesth 2010; 20:72.</LI>&#xD;&#xA;<LI>Frederick HJ, Wofford K, Dear GL, Schulman SR. A randomized controlled trial to determine the effect of depth of anesthesia on emergence agitation in children. Anesth Analg 2016; 122:1141.</LI>&#xD;&#xA;<LI>Berghmans JM, Poley M, Weber F, et al. Does the child behavior checklist predict levels of preoperative anxiety at anesthetic induction and postoperative emergence delirium? A prospective cohort study. Minerva Anestesiol 2015; 81:145.</LI>&#xD;&#xA;<LI>Joo J, Lee Sm Lee Y. Emergence delirium is related to the invasiveness of strabismus surgery in preschool-age children. J Internat Med Res 2014; 42:1311.</LI></OL></div><div id=\"graphicVersion\">Graphic 109277 Version 3.0</div></div></div>"},"109278":{"type":"graphic_table","displayName":"Therapeutic monitoring of antituberculous drugs in adults","title":"Therapeutic serum concentration monitoring of antituberculous drugs in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapeutic serum concentration monitoring of antituberculous drugs in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"14%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug name</td> <td class=\"subtitle1\">Time from administration to peak concentration</td> <td class=\"subtitle1\">Target peak concentration</td> <td class=\"subtitle1\">Time for additional&nbsp;sampling<br /> to assess for delayed absorption or malabsorption of orally administered drug<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Amikacin</td> <td> <p>Intramuscular: 2 and 6 hours</p> Intravenous: 2 and 6 hours after completion of a 30 to 60 minute infusion*</td> <td> <p>Target for calculated peak concentration:*</p> <p>35 to 45 mcg/mL (for 15 mg/kg once daily dose)</p> 65 to 80 mcg/mL (for 25 mg/kg twice weekly dose)</td> <td>Not applicable</td> </tr> <tr class=\"divider_bottom\"> <td>Capreomycin</td> <td> <p>Intramuscular: 2 and 6 hours</p> Intravenous: 2 and 6 hours after completion of a 30 to 60 minute infusion*</td> <td> <p>Target&nbsp;for calculated peak concentration:*&nbsp;</p> <p>35 to 45 mcg/mL (for 15 mg/kg daily dose)</p> 65 to 80 mcg/mL (for 25 mg/kg twice weekly dose)</td> <td>Not applicable</td> </tr> <tr class=\"divider_bottom\"> <td>Clarithromycin</td> <td>Oral: 2 to 3 hours</td> <td>2 to 7 mcg/mL (for 500 mg twice daily dose)</td> <td>6 to 7 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Clofazimine</td> <td>Oral: 2 to 3 hours (fasting), 4 to 8 hours (when given with food)</td> <td>0.5 to 2 mcg/mL</td> <td>6 to 7 hours (fasting only)</td> </tr> <tr class=\"divider_bottom\"> <td>Cycloserine</td> <td>Oral: 2 hours</td> <td>20 to 35 mcg/mL<sup>&#916;</sup></td> <td>6 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Ethambutol</td> <td>Oral: 2 to 3 hours</td> <td> <p>2 to 6 mcg/mL (for 15 to 25 mg/kg daily dose)</p> 4 to 12 mcg/mL (for 50 mg/kg thrice or twice weekly dose)</td> <td> <p>6 to 7 hours</p> Delayed or erratic absorption occurs frequently</td> </tr> <tr class=\"divider_bottom\"> <td>Ethionamide</td> <td>Oral: 2 hours</td> <td>1 to 5 mcg/mL</td> <td> <p>6 hours</p> Delayed or erratic absorption occurs frequently</td> </tr> <tr class=\"divider_bottom\"> <td>Isoniazid</td> <td>Oral: 2 hours (fasting); some also check 6-hour levels</td> <td> <p>3 to 5 mcg/mL (for 5 mg/kg up to 300 mg daily dose)</p> 9 to 15 mcg/mL (for 15 to 25 mg/kg twice weekly dose)</td> <td>6 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Kanamycin</td> <td> <p>Intramuscular: 2 and 6 hours</p> Intravenous: 2 and&nbsp;6 hours after completion of a 30 to 60 minute infusion*</td> <td> <p>Target for calculated peak concentration:*&nbsp;</p> <p>35 to 45 mcg/mL (for 15 mg/kg daily dose)</p> 65 to 80 mcg/mL (for 25 mg/kg twice weekly dose)</td> <td>Not applicable</td> </tr> <tr class=\"divider_bottom\"> <td>Levofloxacin</td> <td>Oral: 2 hours</td> <td>8 to 12 mcg/mL</td> <td>6 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Linezolid</td> <td> <p>Oral: 2 hours</p> <p>Intravenous: 30 minutes after completion of infusion</p> </td> <td>12 to 24 mcg/mL</td> <td>Not generally performed</td> </tr> <tr class=\"divider_bottom\"> <td>Moxifloxacin</td> <td>Oral: 2 hours<sup>&#182;</sup></td> <td>3 to 5 mcg/mL</td> <td>6 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Para-aminosalicylic acid</td> <td>Oral: 6 hours (enteric-coated sustained release PASER formulation)</td> <td>20 to 60 mcg/mL</td> <td>Not applicable</td> </tr> <tr class=\"divider_bottom\"> <td>Pyrazinamide<sup>&#9674;</sup></td> <td>Oral: 2 hours</td> <td> <p>20 to 40 mcg/mL (for 25 mg/kg daily dose)</p> 60 to 80 mcg/mL (for 50 mg/kg thrice or twice weekly dose)</td> <td>6 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Rifabutin<sup>&#167;</sup></td> <td>Oral: 3 hours</td> <td>0.45 to 0.9 mcg/mL</td> <td>7 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Rifampin (rifampicin)</td> <td>Oral: 2 hours</td> <td>8 to 24 mcg/mL</td> <td> <p>6 hours</p> <p>We routinely perform 6-hour levels in <strong>all</strong> patients receiving rifampin to assess for delayed absorption or malabsorption<sup>&#182;</sup></p> </td> </tr> <tr> <td>Streptomycin</td> <td> <p>Intramuscular: 2 and 6 hours</p> Intravenous: 2 and 6 hours after completion of a 30 to 60 minute infusion*</td> <td> <p>Target for calculated peak concentration:* </p> <p>35 to 45 mcg/mL (for 15 mg/kg daily dose)</p> 65 to 80 mcg/mL (for 25 mg/kg twice weekly dose)</td> <td>Not applicable</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Therapeutic drug monitoring (TDM) is warranted for the injectable antituberculous agents (amikacin, streptomycin, kanamycin, and capreomycin), especially in patients with renal impairment, and for oral antituberculous agents when needed to assess for delayed or malabsorption. For specific recommendations on other clinical situations in which drug concentration monitoring should be pursued, refer to the accompanying UpToDate text. Serum concentration monitoring should be performed after the patient has received therapy for three to five half-lives of the drug, typically after two or three maintenance doses at a fixed-dose interval.&nbsp;</div><div class=\"graphic_footnotes\">* Serum levels of aminoglycosides (amikacin, streptomycin, kanamycin) and capreomycin obtained less than 2 hours after an&nbsp;intramuscular dose or completion of an intravenous infusion may be falsely elevated due to incomplete distribution of drug to body tissues. To avoid misinterpretation, two post-distribution concentrations should be drawn and the peak concentration determined by pharmacokinetic calculation using linear regression to 1 hour post-intramuscular dose or end of&nbsp;intravenous infusion. These calculations are usually performed by pharmacists skilled in aminoglycoside clinical pharmacokinetics. Trough concentrations (target &lt;5 mcg/mL to undetectable) may also be evaluated to confirm drug clearance following a 24-hour dose. Refer to the UpToDate topic review of aminoglycosides dosing and administration for detail. <br />Â¶ To assess for delayed or malabsorption, a second sample should be collected approximately 6 to 7 hours after an oral dose (depending on the drug as noted above). This is particularly important for patients with a history of diabetes mellitus, gastrointestinal disorders, HIV, cystic fibrosis, or alcohol abuse and in all patients receiving ethambutol or ethionamide. In delayed absorption, the 6- or 7-hour concentration is similar to or higher than 2-hour values. If both values are beneath the expected peak, malabsorption should be suspected.<br />Î” Central nervous system toxicity is associated with cycloserine concentrations &gt;35 mcg/mL but may occur at even lower concentrations. Some experts prefer to maintain the concentration &lt;30 mcg/mL.<br /><FONT class=lozenge>â—Š</FONT> An elevated uric acid is an expected additional finding in patients on pyrazinamide. If not present, it may indicate that the patient is not taking the drug or there is malabsorption.<br />Â§ Rifabutin is absorbed more slowly than most other oral agents. On the day of sampling only, rifabutin can be given 1 hour before the other drugs, so that rifabutin sample times match the 2- and 6-hour times for other drugs. This limits the collection to two venipunctures.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Nahid P, Dorman S, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</li>&#xD;&#xA;    <li>Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: An update. Drugs 2014; 74:839.</li>&#xD;&#xA;    <li>Curry International Tuberculosis Center and California Department of Public Health. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition. 2016. Available at http://www.currytbcenter.ucsf.edu/products/cover-pages/drug-resistant-tuberculosis-survival-guide-clinicians-3rd-edition.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109278 Version 2.0</div></div></div>"},"109281":{"type":"graphic_table","displayName":"Interventions for the prevention of ED in children","title":"Interventions for the prevention of emergence delirium in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interventions for the prevention of emergence delirium in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adjunctive agent</td> <td class=\"subtitle1\">Timing of administration</td> </tr> <tr> <td class=\"subtitle2_left highlight_gray_text\" colspan=\"2\">Prevention<sup>[1]</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Propofol IV</td> <td> <ul> <li>TIVA<sup>[2,3]</sup>, a brief infusion of 3 mg/kg IV over three minutes after sevoflurane<sup>[4]</sup>; a single dose at the end of anesthesia (1 mg/kg IV)<sup>[5-9]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Thiopental* IV</td> <td> <ul> <li>After sevoflurane induction, 2 to 3 mg/kg IV<sup>[1]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Opioid IV</td> <td> <ul> <li>Meta-analysis<sup>[10]</sup> of fentanyl, remifentanil, sufentanil, alfentanil </li> <li>Nalbuphine 0.1 mg/kg IV<sup>[11]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Midazolam</td> </tr> <tr> <td class=\"indent2\">IV</td> <td> <ul> <li>0.03 to 0.05 mg/kg IV at end of anesthesia<sup>[9,12]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Oral</td> <td> <ul> <li>0.2 to 0.5 mg/kg orally<sup>[13]</sup>; 0.5 mg/kg orally with parental presence<sup>[14]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Alpha<sub>2</sub> agonist</td> </tr> <tr> <td class=\"indent2\">IV</td> <td> <ul> <li>Clonidine 2 mcg/kg IV at induction<sup>[13,15,16]</sup> </li> <li>Dexmedetomidine 0.3 to 1 mcg/kg IV at emergence<sup>[17-21]</sup> </li> <li>Meta-analysis dexmedetomidine<sup>[17,22]</sup> </li> <li>Dexmedetomidine 1 mcg/kg IV followed by 1 mcg/kg/hour<sup>[23]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Caudal</td> <td> <ul> <li>Clonidine 1 mcg/kg<sup>[24]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ketamine IV</td> <td> <ul> <li>Ketamine 1 mg/kg IV followed by 1 mg/kg/hour<sup>[23]</sup> or 0.25 mg/kg<sup>[11]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Melatonin oral</td> <td> <ul> <li>0.25 or 0.5 mg/kg premedication orally<sup>[25]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tropisetron<sup>&#182;</sup> IV (refer to 5HT<sub>3</sub> receptor antagonists IV below)</td> <td> <ul> <li>0.1 mg/kg IV at induction<sup>[26]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Magnesium sulfate IV</td> <td> <ul> <li>30 mg/kg IV followed by 10 mg/kg/hour<sup>[27]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Regional anesthesia<sup>&#916;</sup></td> <td> <ul> <li>Infraorbital block<sup>[28]</sup>, fascia iliaca block<sup>[29]</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left highlight_gray_text\" colspan=\"2\">Ineffective measures</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Midazolam</td> </tr> <tr> <td class=\"indent2\">Oral</td> <td> <ul> <li>Premedication<sup>[14,30,31]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">PR</td> <td> <ul> <li>0.5 to 1 mg/kg PR<sup>[32]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Alpha<sub>2</sub> agonist</td> </tr> <tr> <td class=\"indent2\">IV</td> <td> <ul> <li>Clonidine 1.5 mcg/kg IV at induction<sup>[26]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Caudal</td> <td> <ul> <li>Clonidine 0.75 mcg/kg caudally<sup>[24]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Parental presence<sup>[14]</sup></td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">5HT<sub>3</sub> receptor antagonists IV</td> <td> <ul> <li>Ondansetron 4 mg oral disintegrating tablet preoperatively<sup>[33]</sup>, 0.1 mg/kg IV<sup>[34]</sup></li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left highlight_gray_text\" colspan=\"2\">Anecdotal reports</td> </tr> <tr> <td class=\"indent1\">Guanfacine (potency one-tenth of dexmedetomidine)</td> <td> <ul> <li>75 mcg/kg oral premedication, single child report<sup>[35]</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows the interventions for prevention of ED that have been studied, including the doses of medications studied, and whether interventions were found to be effective or ineffective in those studies.</div><div class=\"graphic_footnotes\">ED: emergence delirium; IV: intravenous; TIVA: total intravenous anesthesia; PR: by rectum.<br />* Thiopental is not available in the United States or Canada; limited availability elsewhere.<br />Â¶ Tropisetron is not available in the United States or Canada.<br />Î” These studies were complicated by the presence of pain in the control groups greater than in the block group.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Costi D, Cyna AM, Ahmed S, et al. Effect of sevoflurane versus other general anaesthesia on emergence agitation in children. Cochrane Database Syst Rev 2014; 9:CD007084.</LI>&#xD;&#xA;<LI>Picard V, Dumont L, Pellegrini M. Quality of recovery in children: sevoflurane versus propofol. Acta Anaesth Scand 2000; 44:307.</LI>&#xD;&#xA;<LI>Uezono S, Goto T, Terui K, et al. Emergence agitation after sevoflurane versus propofol in pediatrics patients. Anesth Analg 2000; 91:563.</LI>&#xD;&#xA;<LI>Costi D, Ellwood J, Wallace A, et al. Transition to propofol after sevoflurane anesthesia to prevent emergence agitation: a randomized controlled trial. Paediatr Anaesth 2015; 25:517.</LI>&#xD;&#xA;<LI>Aouad MT, Yazbeck-Karam VG, Nasr VG, et al. A single dose of propofol at the end of surgery for the prevention of emergence agitation in children undergoing strabismus surgery during sevoflurane anesthesia. Anesthesiology 2007; 107:733.</LI>&#xD;&#xA;<LI>Kim MS, Moon BE, Kim H, Lee JR. Comparison of propofol and fentanyl administered at the end of anaesthesia for prevention of emergence agitation after sevoflurane anaesthesia in children. Br J Anaesth 2013; 110:274.</LI>&#xD;&#xA;<LI>Abu-Shahwan I. Effect of propofol on emergence behavior in children after sevoflurane general anesthesia. Paediatr Anaesth 2008; 18:55.</LI>&#xD;&#xA;<LI>van Hoff SL, O'Neill ES, Cohen LC, Collins BA. Does a prophylactic dose of propofol reduce emergence agitation in children receiving anesthesia? A systematic review and meta-analysis. Paediatr Anaesth 2015; 25:668.</LI>&#xD;&#xA;<LI>Chen J, Li W, Hu X, Wang D. Emergence agitation after cataract surgery in children: a comparison of midazolam, propofol and ketamine. Pediatr Anseth 2010; 20:873.</LI>&#xD;&#xA;<LI>Tan Y, Shi Y, Ding H, et al. Âµ-Opioid agonists for preventing emergence agitation under sevoflurane anesthesia in children: a meta-analysis of randomized controlled trials. Paediatr Anaesth 2016; 26:139.</LI>&#xD;&#xA;<LI>Dalens BJ, Pinard AM, LÃ©tourneau DR, et al. Prevention of emergence agitation after sevoflurane anesthesia for pediatric cerebral magnetic resonance imaging by small doses of ketamine or nalbuphine administered just before discontinuing anesthesia. Anesth Analg 2006; 102:1056.</LI>&#xD;&#xA;<LI>Cho EJ, Yoon SXZ, Cho JE, Lee HW. Comparison of the effects of 0.03 and 0.05 mg/kg midazolam with placebo on prevention of emergence agitation in children having strabismus surgery. Anesthesiology 2014; 120:1354.</LI>&#xD;&#xA;<LI>Zhang C, Li J, Zhao D, Wang Y. Prophylactic midazolam and clonidine for emergence from agitation in children after emergence from sevoflurane anesthesia: a meta-analysis. Clin Ther 2013; 35:1622.</LI>&#xD;&#xA;<LI>Arai YC P, Ito H, Kandatsu N, et al. Parental presence during induction enhances the effect of oral midazolam on emergence behavior of children undergoing general anesthesia. Acta Anaesthesiol Scand 2007; 51;858.</LI>&#xD;&#xA;<LI>Tesoro S, Mezzetti D, Marchesini L, Peduto VA. Clonidine treatment for agitation in children after sevoflurane anesthesia. Anesth Analg 2005; 101:1619.</LI>&#xD;&#xA;<LI>Malviya S, Voepel-Lewis T, Ramamurthi RJ, Burke C, Tait AR. Clonidine for the prevention of emergence agitation in young children: efficacy and recovery profile. Paediatr Anaesth 2006; 16:554.</LI>&#xD;&#xA;<LI>Zhu M, Wang H, Zhu A, et al. Meta-analysis of dexmedetomidine on emergence agitation and recovery profiles in children after sevoflurane anesthesia: different administration and different dosage. PLoS One 2015; 10:e0123728.</LI>&#xD;&#xA;<LI>Guler G, Akin A, Tosun Z, et al. Single-dose dexmedetomidine reduces agitation and provides smooth extubation after pediatric adenotonsillectomy. Paediatr Anaesth 2005; 15:762.</LI>&#xD;&#xA;<LI>Erdil F, Demirbilek S, Begec Z, et al. The effects of dexmedetomidine and fentanyl on emergence characteristics after adenoidectomy in children. Anaesth Intensive Care 2009; 37:571.</LI>&#xD;&#xA;<LI>Hauber JA, Davis PJ, Bende LP, et al. Dexmedetomidine as a rapid bolus for treatment and prophylactic prevention of emergence agitation in anesthetized children. Anesth Analg 2015; 121:1308.</LI>&#xD;&#xA;<LI>Makkar JK, Bhatia N, Bala I, et al. A comparison of single dose dexmedetomidine with propofol for the prevention of emergence delirium after desflurane anaesthesia in children. Anaesthesia 2016; 71:50.</LI>&#xD;&#xA;<LI>Sun L, Guo R, Sun L. Dexmedetomidine for preventing sevoflurane-related emergence agitation in children: a meta-analysis of randomized controlled trials. Acta Anaesthesiol Scand 2014; 58:642.</LI>&#xD;&#xA;<LI>Chen JY, Jia JE, Liu TJ, et al. Comparison of the effects of dexmedetomidine, ketamine, and placebo on emergence agitation after strabismus surgery in children. Can J Anesth 2013; 60:385.</LI>&#xD;&#xA;<LI>Ghosh SM, Agarwala RB, Pandey M, Vajifdar H. Efficacy of low-dose caudal clonidine in reduction of sevoflurane-induced agitation in children undergoing urogenital and lower limb surgery: a prospective randomised double-blind study. Eur J Anaesthesiol 2011; 28:329.</LI>&#xD;&#xA;<LI>Smarkandi A, Naguib M, Riad W, et al. Melatonin vs. midazolam premedication in children: a double-blind, placebo-controlled study. Euro J Anaesth 2005; 22:189.</LI>&#xD;&#xA;<LI>Lankinen U, Avela R, Tarkkila P. The prevention of emergence agitation with tropisetron or clonidine after sevoflurane anesthesia in small children undergoing adenoidectomy. Anesth Analg 2006; 102:1383.</LI>&#xD;&#xA;<LI>Abdulatif M, Ahmed A, Mukhtar A, Badawy S. The effect of magnesium sulphate infusion on the incidence and severity of emergence agitation in children undergoing adenotonsillectomy using sevoflurane anaesthesia. Anaesthesia 2013; 68:1045.</LI>&#xD;&#xA;<LI>Wang H, Liu G, Fu W, Li S. The effect of intraorbital nerve block on emergence agitation in children undergoing cleft lip surgery under general anesthesia with sevoflurane. Paediatr Anaesth 2015; 25:906.</LI>&#xD;&#xA;<LI>Kim HS, Kim CS, Kim SD, Lee JR. Fascia iliaca compartment block reduces emergence agitation by providing effective analgesic properties in children. J Clin Anesth 2011; 23:119.</LI>&#xD;&#xA;<LI>Dahmani S, Stany I, Brasher C, et al. Pharmacological prevention of sevoflurane- and desflurane-related emergence agitation in children: a meta-analysis of published studies. Br J Anaesth 2010; 104:216.</LI>&#xD;&#xA;<LI>El Batawi HY. Effect of preoperative oral midazolam sedation on separation anxiety and emergence delirium among children undergoing dental treatment under general anesthesia. J Int Soc Prev Community Dent 2015; 5:88.</LI>&#xD;&#xA;<LI>Breschan C, Platzer M, Jost R, et al. Midazolam does not reduce emergence delirium after sevoflurane anesthesia in children. Paediatr Anaesth 2007; 17:347.</LI>&#xD;&#xA;<LI>Cohen IT, Joffe D, Hummer K, Soluri A. Ondansetron oral disintegrating tablets: acceptability and efficacy in children undergoing adenotonsillectomy. Anesth Analg 2005; 101:59.</LI>&#xD;&#xA;<LI>Hosten T, Solak M, Elemen L, et al. Ondansetron does not modify emergence agitation in children. Anaesth Intens Care 2011; 39:640.</LI>&#xD;&#xA;<LI>Harvey S, Blair J. Guanfacine for emergence delirium in children-a case report in twins. Society for Neuroscience in Anesthesia and Critical Care (SNACC) 2013 (abstract).</LI></OL></div><div id=\"graphicVersion\">Graphic 109281 Version 5.0</div></div></div>"},"109282":{"type":"graphic_table","displayName":"Therapeutic interventions for ED in children","title":"Therapeutic interventions for emergence delirium in children<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapeutic interventions for emergence delirium in children<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Propofol 1 mg/kg IV</li> </ul> </td> </tr> <tr> <td> <ul> <li>Midazolam 0.1 mg/kg IV</li> </ul> </td> </tr> <tr> <td> <ul> <li>Fentanyl (1 to 2 mcg/kg IV) or other opioids</li> </ul> </td> </tr> <tr> <td> <ul> <li>Parental presence</li> </ul> </td> </tr> <tr> <td> <ul> <li>Maternal voice recording<sup>[2]</sup></li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ED: emergence delirium; IV: intravenous.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Dahmani S, Delivet H, Hilly J. Emergence delirium in children: an update. Curr Opin Anaesthesiol 2014; 27:309.</li>&#xD;&#xA;    <li>Kim SJ, Oh YJ, Kim KJ, et al. The effect of recorded maternal voice on perioperative anxiety and emergence in children. Anaesth Intensive Care 2010; 38;1064.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109282 Version 2.0</div></div></div>"},"109285":{"type":"graphic_figure","displayName":"POEM procedure","title":"POEM procedure","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">POEM procedure</div><div class=\"cntnt\"><img style=\"width:620px; height:581px;\" src=\"images/SURG/109285_POEM_procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Mucosal incision<br />(B) Creation of submucosal tunnel<br />(C, D) Myotomy<br />(E) Closure of mucosal incision</div><div class=\"graphic_footnotes\">POEM: peroral endoscopic myotomy.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Haru Inoue. Image originally published in Inoue H, Minami H, Kobayashi T, et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 2010; 42:265. Copyright &copy; 2010 Georg Thieme Verlag KG. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109285 Version 1.0</div></div></div>"},"109286":{"type":"graphic_figure","displayName":"Transcatheter aortic valves","title":"Transcatheter aortic valves","html":"<div class=\"graphic\"><div style=\"width: 760px\" class=\"figure\"><div class=\"ttl\">Transcatheter aortic valves</div><div class=\"cntnt\"><img style=\"width:740px; height:766px;\" src=\"images/CARD/109286_Transcatheter_aortic_valves.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A. Medtronic CoreValve; B. Medtronic CoreValve Evolut R; C. St. Jude Portico Hero valve; and&nbsp;D.&nbsp;Edwards Sapien 3 valve. </div><div class=\"graphic_reference\">Panels A, B: Reproduced with permission. Copyright Â© 2017 Medtronic.<br />Panel C: Reproduced with permission. Copyright Â© 2017 St. Jude Medical.<br />Panel D: Reproduced with permission. Copyright Â© 2017 Edwards Lifesciences Corporation.</div><div id=\"graphicVersion\">Graphic 109286 Version 1.0</div></div></div>"},"109297":{"type":"graphic_algorithm","displayName":"Diagnostic approach to intestinal malrotation","title":"Diagnostic approach to intestinal malrotation","html":"<div class=\"graphic\"><div style=\"width: 654px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to intestinal malrotation</div><div class=\"cntnt\"><img style=\"width:634px; height:626px;\" src=\"images/EM/109297_Diagn_appr_intestinl_mlrttn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to UpToDate topics on the causes and evaluation of abdominal pain in children.<br />Â¶ Radiologists performing the limited upper gastrointestinal series should have experience with the performance and interpretation of an upper gastrointestinal series with oral contrast in children.<br />Î” Refer to UpToDate topics on recognition and treatment of septic shock in children.</div><div id=\"graphicVersion\">Graphic 109297 Version 1.0</div></div></div>"},"109339":{"type":"graphic_table","displayName":"Physiologic effects of deep hypothermia","title":"Physiologic effects of deep hypothermia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic effects of deep hypothermia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td><strong>Bleeding diathesis</strong></td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Decreased platelet count <ul> <li>Splanchnic sequestration of platelets </li> <li>Partial activation of circulating platelets causing aggregation and adhesion </li> </ul> </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Slowing of enzymatic reactions in the coagulation cascade </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Enhanced fibrinolysis as a consequence of vascular injury </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Impairment of tissue factor activity </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Inflammatory responses to CPB </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Ischemia-reperfusion injury that further exacerbates coagulopathy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Disseminated intravascular coagulation may occur </li> </ul> </td> </tr> <tr> <td><strong>Cardiovascular effects</strong></td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Prolongation of PR interval and QRS complex on the ECG </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Decreased heart rate </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Decreased cardiac output </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Vasoconstriction during cooling and hypothermia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Vasodilation during rewarming and reperfusion </li> </ul> </td> </tr> <tr> <td><strong>Hyperglycemia due to:</strong></td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Stress response </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Glucocorticoid administration </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Catecholamine administration </li> </ul> </td> </tr> <tr> <td><strong>Changes in metabolic rate</strong></td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Decreased metabolic rate and oxygen consumption during hypothermia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Increased metabolic rate during rewarming, particularly with shivering (mitigated by administration of neuromuscular blocking agents) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Decreased metabolism of drugs</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Decreased anesthetic requirements</strong></td> </tr> <tr> <td><strong>Leftward shift of the oxygen-hemoglobin dissociation curve, with increased binding affinity of hemoglobin to oxygen</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CPB: cardiopulmonary bypass; ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 109339 Version 2.0</div></div></div>"},"109353":{"type":"graphic_table","displayName":"Proposed definitions of ICUS, CHIP, and CCUS","title":"Proposed definitions of ICUS, CHIP, and CCUS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed definitions of ICUS, CHIP, and CCUS</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Proposed entity</td> <td class=\"subtitle1\">Definition</td> </tr> <tr class=\"divider_bottom\"> <td>Idiopathic cytopenia of undetermined significance (ICUS)</td> <td>Single or multiple blood cytopenias that remain unexplained despite appropriate evaluation including marrow examination. If present, dysplasia is not prominent (&#60;10% of cells per lineage). Patients with ICUS are not known to have a clonal disorder either because no clonality testing has been performed or because testing was performed but the assay did not reveal a clonal mutation.</td> </tr> <tr class=\"divider_bottom\"> <td>Clonal hematopoiesis of indeterminate potential (CHIP)</td> <td>Identification of a clonal mutation associated with hematologic neoplasia in an individual who does not yet meet WHO criteria for diagnosis of a hematologic neoplasm. Individuals with CHIP usually have normal complete blood counts, normal erythrocyte indices or mild red cell macrocytosis without anemia, or minimal and clinically insignificant cytopenias. If present, dysplasia is not prominent (&#60;10% of cells per lineage).</td> </tr> <tr> <td>Clonal cytopenia of undetermined significance (CCUS)</td> <td>Patients who have clinically meaningful unexplained cytopenias (ICUS) and are also found to have a clonal mutation, yet meet no other WHO-defined criteria for MDS or another hematologic neoplasm.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO: World Health Organization; MDS: myelodysplastic syndromes.</div><div id=\"graphicVersion\">Graphic 109353 Version 1.0</div></div></div>"},"109356":{"type":"graphic_figure","displayName":"Timeline of cases of BIA-ALCL","title":"Timeline of cases of BIA-ALCL","html":"<div class=\"graphic\"><div style=\"width: 766px\" class=\"figure\"><div class=\"ttl\">Timeline of cases of BIA-ALCL</div><div class=\"cntnt\"><img style=\"width:746px; height:358px;\" src=\"images/SURG/109356_Time_BI-ALCL_DX_rel_implant.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Timeline of cases by year of implant placement and diagnosis of BIA-ALCL.</div><div class=\"graphic_footnotes\">BIA-ALCL: breast implant-associated anaplastic large cell lymphoma.</div><div id=\"graphicVersion\">Graphic 109356 Version 2.0</div></div></div>"},"109357":{"type":"graphic_algorithm","displayName":"Bell's palsy management","title":"Management of Bell's palsy","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Management of Bell's palsy</div><div class=\"cntnt\"><img style=\"width:714px; height:410px;\" src=\"images/NEURO/109357_Bells_palsy_management.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* House-Brackmann classification of facial nerve dysfunction (refer to text for complete description):&#xD;&#xA;<ol style=\"list-style-type: upper-roman;\">&#xD;&#xA;    <li>Normal</li>&#xD;&#xA;    <li>Mild dysfunction</li>&#xD;&#xA;    <li>Moderate dysfunction</li>&#xD;&#xA;    <li>Moderately severe dysfunction</li>&#xD;&#xA;    <li>Severe dysfunction</li>&#xD;&#xA;    <li>Total paralysis</li>&#xD;&#xA;</ol></div><div class=\"graphic_reference\">Adapted from: de Almeida JR, Guyatt GH, Sud S, et al. Management of Bell palsy: clinical practice guideline. CMAJ 2014; 186:917.</div><div id=\"graphicVersion\">Graphic 109357 Version 1.0</div></div></div>"},"109361":{"type":"graphic_table","displayName":"Convective volumes in postdilution HDF","title":"Convective volumes in postdilution HDF in relation to treatment time, blood flow rate, and filtration fraction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Convective volumes in postdilution HDF in relation to treatment time, blood flow rate, and filtration fraction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"14\" width=\"6%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">FF (%)</td> <td class=\"subtitle1\">20</td> <td class=\"subtitle1\">21</td> <td class=\"subtitle1\">22</td> <td class=\"subtitle1\">23</td> <td class=\"subtitle1\">24</td> <td class=\"subtitle1\">25</td> <td class=\"subtitle1\">26</td> <td class=\"subtitle1\">27</td> <td class=\"subtitle1\">28</td> <td class=\"subtitle1\">29</td> <td class=\"subtitle1\">30</td> <td class=\"subtitle1\">31</td> <td class=\"subtitle1\">32</td> <td class=\"subtitle1\">33</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">Treatment time = 3 hours 30 min</td> </tr> <tr> <td class=\"indent1\">Q<sub>B</sub> = 300 mL/min</td> <td class=\"centered\">12.6</td> <td class=\"centered\">13.2</td> <td class=\"centered\">13.9</td> <td class=\"centered\">14.5</td> <td class=\"centered\">15.1</td> <td class=\"centered\">15.8</td> <td class=\"centered\">16.4</td> <td class=\"centered\">17.0</td> <td class=\"centered\">17.6</td> <td class=\"centered\">18.3</td> <td class=\"centered\">18.9</td> <td class=\"centered\">19.5</td> <td class=\"centered\">20.2</td> <td class=\"centered\">20.8</td> </tr> <tr> <td class=\"indent1\">Q<sub>B</sub> = 350 mL/min</td> <td class=\"centered\">14.7</td> <td class=\"centered\">15.4</td> <td class=\"centered\">16.2</td> <td class=\"centered\">16.9</td> <td class=\"centered\">17.6</td> <td class=\"centered\">18.4</td> <td class=\"centered\">19.1</td> <td class=\"centered\">19.9</td> <td class=\"centered\">20.6</td> <td class=\"centered\">21.3</td> <td class=\"centered\">22.1</td> <td class=\"centered\">22.8</td> <td class=\"centered highlight_blue_text\">23.5</td> <td class=\"centered highlight_blue_text\">24.3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Q<sub>B</sub> = 400 mL/min</td> <td class=\"centered\">16.8</td> <td class=\"centered\">17.6</td> <td class=\"centered\">18.5</td> <td class=\"centered\">19.3</td> <td class=\"centered\">20.2</td> <td class=\"centered\">21.0</td> <td class=\"centered\">21.8</td> <td class=\"centered\">22.7</td> <td class=\"centered highlight_blue_text\">23.5</td> <td class=\"centered highlight_blue_text\">24.4</td> <td class=\"centered highlight_blue_text\">25.2</td> <td class=\"centered highlight_blue_text\">26.0</td> <td class=\"centered highlight_blue_text\">26.9</td> <td class=\"centered highlight_blue_text\">27.7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">Treatment time = 4 hours 00 min</td> </tr> <tr> <td class=\"indent1\">Q<sub>B</sub> = 300 mL/min</td> <td class=\"centered\">14.5</td> <td class=\"centered\">15.1</td> <td class=\"centered\">15.8</td> <td class=\"centered\">16.6</td> <td class=\"centered\">17.3</td> <td class=\"centered\">18.0</td> <td class=\"centered\">18.7</td> <td class=\"centered\">19.4</td> <td class=\"centered\">20.2</td> <td class=\"centered\">20.9</td> <td class=\"centered\">21.6</td> <td class=\"centered\">22.3</td> <td class=\"centered\">23.0</td> <td class=\"centered highlight_blue_text\">23.8</td> </tr> <tr> <td class=\"indent1\">Q<sub>B</sub> = 350 mL/min</td> <td class=\"centered\">16.8</td> <td class=\"centered\">17.6</td> <td class=\"centered\">18.5</td> <td class=\"centered\">19.3</td> <td class=\"centered\">20.2</td> <td class=\"centered\">21.0</td> <td class=\"centered\">21.8</td> <td class=\"centered\">22.7</td> <td class=\"centered highlight_blue_text\">23.5</td> <td class=\"centered highlight_blue_text\">24.4</td> <td class=\"centered highlight_blue_text\">25.2</td> <td class=\"centered highlight_blue_text\">26.0</td> <td class=\"centered highlight_blue_text\">26.9</td> <td class=\"centered highlight_blue_text\">27.7</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Q<sub>B</sub> = 400 mL/min</td> <td class=\"centered\">19.2</td> <td class=\"centered\">20.2</td> <td class=\"centered\">21.1</td> <td class=\"centered\">22.1</td> <td class=\"centered\">23.0</td> <td class=\"centered highlight_blue_text\">24.0</td> <td class=\"centered highlight_blue_text\">25.0</td> <td class=\"centered highlight_blue_text\">25.9</td> <td class=\"centered highlight_blue_text\">26.9</td> <td class=\"centered highlight_blue_text\">27.8</td> <td class=\"centered highlight_blue_text\">28.8</td> <td class=\"centered highlight_blue_text\">29.8</td> <td class=\"centered highlight_blue_text\">30.7</td> <td class=\"centered highlight_blue_text\">31.7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">Treatment time = 4 hours 30 min</td> </tr> <tr> <td class=\"indent1\">Q<sub>B</sub> = 300 mL/min</td> <td class=\"centered\">16.2</td> <td class=\"centered\">17.0</td> <td class=\"centered\">17.8</td> <td class=\"centered\">18.6</td> <td class=\"centered\">19.4</td> <td class=\"centered\">20.3</td> <td class=\"centered\">21.1</td> <td class=\"centered\">21.9</td> <td class=\"centered\">22.7</td> <td class=\"centered highlight_blue_text\">23.5</td> <td class=\"centered highlight_blue_text\">24.3</td> <td class=\"centered highlight_blue_text\">25.1</td> <td class=\"centered highlight_blue_text\">25.9</td> <td class=\"centered highlight_blue_text\">26.7</td> </tr> <tr> <td class=\"indent1\">Q<sub>B</sub> = 350 mL/min</td> <td class=\"centered\">18.9</td> <td class=\"centered\">19.8</td> <td class=\"centered\">20.8</td> <td class=\"centered\">21.7</td> <td class=\"centered\">22.7</td> <td class=\"centered highlight_blue_text\">23.6</td> <td class=\"centered highlight_blue_text\">24.6</td> <td class=\"centered highlight_blue_text\">25.5</td> <td class=\"centered highlight_blue_text\">26.5</td> <td class=\"centered highlight_blue_text\">27.4</td> <td class=\"centered highlight_blue_text\">28.4</td> <td class=\"centered highlight_blue_text\">29.3</td> <td class=\"centered highlight_blue_text\">30.2</td> <td class=\"centered highlight_blue_text\">31.2</td> </tr> <tr> <td class=\"indent1\">Q<sup>B</sup> = 400 mL/min</td> <td class=\"centered\">21.6</td> <td class=\"centered\">22.7</td> <td class=\"centered highlight_blue_text\">23.8</td> <td class=\"centered highlight_blue_text\">24.8</td> <td class=\"centered highlight_blue_text\">25.9</td> <td class=\"centered highlight_blue_text\">27.0</td> <td class=\"centered highlight_blue_text\">28.1</td> <td class=\"centered highlight_blue_text\">29.2</td> <td class=\"centered highlight_blue_text\">30.2</td> <td class=\"centered highlight_blue_text\">31.3</td> <td class=\"centered highlight_blue_text\">32.4</td> <td class=\"centered highlight_blue_text\">33.5</td> <td class=\"centered highlight_blue_text\">34.6</td> <td class=\"centered highlight_blue_text\">35.6</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Percentages represent filtration fractions (ie, convective flow rate divided by blood flow). Convective volumes &gt;23 L per treatment are indicated in the shaded cells. Values represent convective volumes in liters per treatment.</div><div class=\"graphic_footnotes\">FF: filtration fraction; Q<sub>B</sub>: dialyzer blood flow.</div><div class=\"graphic_reference\">Adapted from: Penne EL, van Berkel T, van der Weerd NC, et al. Optimizing haemodifiltration: Tools, strategy and remaining questions. Nephrol Dial Transplant 2009; 24:3579.</div><div id=\"graphicVersion\">Graphic 109361 Version 2.0</div></div></div>"},"109363":{"type":"graphic_table","displayName":"Concomitant use of DAA agents for HCV infection and ART agents","title":"Concomitant use of direct-acting antiviral agents for HCV infection and antiretroviral agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Concomitant use of direct-acting antiviral agents for HCV infection and antiretroviral agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"7\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Sofosbuvir</td> <td class=\"subtitle1\">Ledipasvir</td> <td class=\"subtitle1\">Velpatasvir</td> <td class=\"subtitle1\">Glecaprevir-pibrentasvir</td> <td class=\"subtitle1\">Elbasvir-grazoprevir</td> <td class=\"subtitle1\">Ombitasvir-paritaprevir-ritonavir with or without dasabuvir</td> <td class=\"subtitle1\">Voxilaprevir</td> <td class=\"subtitle1\">Daclatasvir</td> <td class=\"subtitle1\">Simeprevir</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Dolutegravir</td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span>*</td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span>*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Elvitegravir (cobicistat boosted)</td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span>*</td> <td>Caution when used with TDF<sup>&#182;</sup></td> <td>Caution when used with TDF<sup>&#182;</sup></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td><strong>Not</strong> recommended</td> <td><strong>Not</strong> recommended*</td> <td>Caution when used with TDF<sup>&#182;</sup><sup>&#916;</sup></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span>*</td> <td><strong>Not</strong> recommended*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Raltegravir</td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span>*</td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Rilpivirine</td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td><strong>Not</strong> recommended</td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span>*</td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Efavirenz</td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td><strong>Not</strong> recommended</td> <td><strong>Not</strong> recommended</td> <td><strong>Not</strong> recommended</td> <td><strong>Not</strong> recommended</td> <td><strong>Not</strong> recommended</td> <td>Caution: increase daclatasvir to 90 mg daily</td> <td><strong>Not</strong> recommended</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Darunavir (boosted)</td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td>Caution when used with TDF<sup>&#182;</sup></td> <td>Caution when used with TDF<sup>&#182;</sup></td> <td><strong>Not</strong> recommended</td> <td><strong>Not</strong> recommended</td> <td>Caution<sup>&#9674;</sup><sup>&#167;</sup></td> <td>Caution when used with TDF<sup>&#182;</sup><sup>&#916;</sup></td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span></td> <td><strong>Not</strong> recommended</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Atazanavir (boosted)</td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span>*</td> <td>Caution when used with TDF<sup>&#182;</sup></td> <td>Caution when used with TDF<sup>&#182;</sup></td> <td><strong>Not</strong> recommended</td> <td><strong>Not</strong> recommended</td> <td class=\"centered\"><span style=\"font-size:1.5em;\">âœ“</span><sup>&#167;</sup></td> <td><strong>Not</strong> recommended</td> <td>Caution: decrease daclatasvir to 30 mg daily</td> <td><strong>Not</strong> recommended*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Other contraindicated coadministrations</td> <td>Tipranavir</td> <td>Tipranavir</td> <td> <p>Etravirine</p> Tipranavir </td> <td>&nbsp;</td> <td> <p>Etravirine</p> <p>Lopinavir-ritonavir</p> Tipranavir </td> <td> <p>Lopinavir-ritonavir</p> Tipranavir </td> <td> <p>Etravirine<sup>&#916;</sup></p> Tipranavir<sup>&#916;</sup> </td> <td>Tipranavir</td> <td> <p>Nevirapine</p> <p>Tipranavir</p> Lopinavir-ritonavir </td> </tr> <tr> <td><strong>Other potential concerns or caution</strong></td> <td>&nbsp;</td> <td>Renal monitoring when used with TDF regimens<sup>&#182;</sup></td> <td>Renal monitoring when used with TDF regimens<sup>&#182;</sup></td> <td>&nbsp;</td> <td>Caution with maraviroc</td> <td>Caution with maraviroc</td> <td>Renal monitoring when used with TDF regimens<sup>&#182;</sup><sup>&#916;</sup></td> <td>Caution with etravirine: increase daclatasvir to 90 mg daily</td> <td>Caution with etravirine</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The checkmark indicates that the HCV antiviral and the antiretroviral agent can be coadministered safely. Abacavir-lamivudine and TAF-emtricitabine can be used with all acceptable combinations above. Caution with TDF-containing regimens is indicated in the table.</div><div class=\"graphic_footnotes\">TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate.<br />* These combinations have not been studied together; recommendations for coadminstration or avoidance are based on pharmacokinetic properties of the individual agents.<br />Â¶ Coadministration of ledipasvir or velpatasvir with TDF results in elevated levels of tenofovir, particularly when ritonavir-boosted protease inhibitors or cobicistat-containing regimens are also used. In contrast, coadministration of TAF with ledipasvir or velpatasvir does not result in elevated levels of tenofovir. If ledipasvir or velpatasvir is to be used in a patient taking a TDF-containing regimen, we switch the TDF to TAF, if possible. If that switch is not possible and no other HCV regimen can be used, we check a baseline creatinine, urinalysis, and phosphate level and monitor for tenofovir-associated renal toxicity (eg, with creatinine and phosphate at least monthly) while on HCV therapy.<br />Î” Contraindication or caution is warranted with these drugs because of the potential interactions with sofosbuvir and/or velpatasvir, with which voxilaprevir is coformulated.<br /><FONT class=lozenge>â—Š</FONT> Coadministration is not recommended by manufacturers because of reduced darunavir levels, but clinical evidence suggests coadministration results in adequate darunavir levels in patients who have no protease inhibitor resistance and are using the 800 mg once-daily darunavir dose.<br />Â§ If ombitasvir-paritaprevir-ritonavir with or without dasabuvir is used with a protease inhibitor, the additional boosting ritonavir typically given with the protease inhibitor should be held during the HCV treatment course.</div><div class=\"graphic_reference\">Reference: AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. <A href=\"http://www.hcvguidelines.org/\" target=_blank>http://www.hcvguidelines.org</A>. Accessed on August 1, 2016.</div><div id=\"graphicVersion\">Graphic 109363 Version 2.0</div></div></div>"},"109364":{"type":"graphic_picture","displayName":"Water jet debridement of open wound","title":"Water jet debridement of open wound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Water jet debridement of open wound</div><div class=\"cntnt\"><img style=\"width:279px; height:231px;\" src=\"images/SURG/109364_Water_jet_dbrdmnt_open_wnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture shows debridement being performed with the Versajet device prior to allografting and placement of a negative pressure wound therapy dressing.</div><div id=\"graphicVersion\">Graphic 109364 Version 1.0</div></div></div>"},"109365":{"type":"graphic_figure","displayName":"Convection volume per session for BSA volume of 23 L or more","title":"Convection volume per session needed for an individual patient to have a BSA adjusted convection volume of 23 L or more","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Convection volume per session needed for an individual patient to have a BSA adjusted convection volume of 23 L or more</div><div class=\"cntnt\"><img style=\"width:566px; height:514px;\" src=\"images/NEPH/109365_Cnvctn_vol_sess_BSA_vol_23L.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Convection volume per session needed for an individual patient to have a BSA-adjusted convection volume of 23 L or more. The formula used was convection volume = (23 Ã— individual BSA) / 1.73. Here, BSA (m<SUP>2</SUP>) = 0.0235 Ã— height (cm)<SUP>0.42246</SUP> Ã— weight (kg)<SUP>0.51456</SUP>.</div><div class=\"graphic_footnotes\">BSA: body surface area.</div><div class=\"graphic_reference\">Reproduced from: Peters SA, Bots ML, Canaud B, et al. Haemodiafiltration and mortality in end-stage kidney disease patients: A pooled individual participant data analysis from four randomized controlled trials. Nephrol Dial Transplant 2016; 31(6):978-84, by permission of Oxford University Press on behalf of the European Renal Association. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 109365 Version 3.0</div></div></div>"},"109366":{"type":"graphic_picture","displayName":"Perforated silastic sheet overlying viscera to prevent adhesions","title":"Perforated silastic sheet overlying viscera to prevent adhesions","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Perforated silastic sheet overlying viscera to prevent adhesions</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/SURG/109366_Perfd_silastic_sheet_adhsns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Placement of a perforated silastic sheet between the viscera and the abdominal wall prevents adhesions and allows abdominal wall movement toward the midline during management of the open abdomen.</div><div id=\"graphicVersion\">Graphic 109366 Version 1.0</div></div></div>"},"109367":{"type":"graphic_table","displayName":"Endometrial ca histologic types","title":"Endometrial carcinoma: Histologic subtypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endometrial carcinoma: Histologic subtypes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Proportion of endometrial carcinomas (%)</td> </tr> <tr> <td>Endometrioid</td> <td>77</td> </tr> <tr> <td>Mucinous</td> <td>1</td> </tr> <tr> <td>Serous</td> <td>7</td> </tr> <tr> <td>Clear cell</td> <td>2</td> </tr> <tr> <td>Mixed cell type</td> <td>8</td> </tr> <tr> <td>Carcinosarcoma</td> <td>3</td> </tr> <tr> <td>Miscellaneous</td> <td>1</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Steinhoff M, Brown University, 2016, personal communication. Data from 1300 cases from Women and Infants Hospital Cancer Registry 2010-2014, Providence, Rhode Island.</div><div id=\"graphicVersion\">Graphic 109367 Version 2.0</div></div></div>"},"109368":{"type":"graphic_figure","displayName":"Bruising patterns that suggest child abuse","title":"Bruising patterns that suggest child abuse","html":"<div class=\"graphic\"><div style=\"width: 716px\" class=\"figure\"><div class=\"ttl\">Bruising patterns that suggest child abuse</div><div class=\"cntnt\"><img style=\"width:696px; height:350px;\" src=\"images/EM/109368_Bruising_pttrns_child_abuse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A variety of instruments may be used to inflict injury on a child. Often the choice of an instrument is a matter of convenience. Marks tend to silhouette or outline the shape of the instrument. The possibility of intentional trauma should prompt a high degree of suspicion when injuries to a child are geometric, paired, mirrored, of various ages or types, or on relatively protected parts of the body. Early recognition of intentional trauma is important to provide therapy and prevent escalation to more serious injury.</div><div class=\"graphic_reference\">Reproduced from: Dubowitz H, Lane WG. Abused and neglected children. In: Nelson's Textbook of Pediatrics. Kliegman RM, Stanton BF, St. Geme JW, Schor NF (Eds), 20th ed, Elsevier: Philadelphia, 2015. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109368 Version 1.0</div></div></div>"},"109369":{"type":"graphic_figure","displayName":"Contact burn patterns suggesting abuse","title":"Contact burn patterns suggesting abuse","html":"<div class=\"graphic\"><div style=\"width: 702px\" class=\"figure\"><div class=\"ttl\">Contact burn patterns suggesting abuse</div><div class=\"cntnt\"><img style=\"width:682px; height:322px;\" src=\"images/EM/109369_Contact_burn_pttrns_abuse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marks from heated objects cause burns in a pattern that duplicates that of the object. Familiarity with the common heated objects that are used to traumatize children facilitates recognition of possible intentional injuries. The location of the burn is important in determining its cause. Children tend to explore surfaces with the palmar surface of the hand and rarely touch a heated object repeatedly or for a long time.</div><div class=\"graphic_reference\">Reproduced from: Dubowitz H, Lane WG. Abused and neglected children. In: Nelson's Textbook of Pediatrics. Kliegman RM, Stanton BF, St. Geme JW, Schor NF (Eds), 20th ed, Elsevier: Philadelphia, 2015. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109369 Version 1.0</div></div></div>"},"109373":{"type":"graphic_picture","displayName":"Granular parakeratosis pathology","title":"Granular parakeratosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Granular parakeratosis</div><div class=\"cntnt\"><img style=\"width:756px; height:386px;\" src=\"images/DERM/109373_Granlr_parakeratosis_path_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Psoriasiform hyperplasia, thick parakeratotic stratum corneum, and retention of the keratohyalin granules (4x).</div><div class=\"graphic_reference\">Courtesy of Jeff Zwerner, MD, PhD.</div><div id=\"graphicVersion\">Graphic 109373 Version 1.0</div></div></div>"},"109374":{"type":"graphic_picture","displayName":"Granular parakeratosis pathology 2","title":"Granular parakeratosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Granular parakeratosis</div><div class=\"cntnt\"><img style=\"width:756px; height:386px;\" src=\"images/DERM/109374_Granlr_parakeratosis_path_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Massive hyperkeratosis and parakeratosis with hypergranulosis (10x).</div><div class=\"graphic_reference\">Courtesy of Jeff Zwerner, MD, PhD.</div><div id=\"graphicVersion\">Graphic 109374 Version 1.0</div></div></div>"},"109377":{"type":"graphic_diagnosticimage","displayName":"POEMS osteosclerotic lesion","title":"Osteosclerotic lesion in a patient with POEMS syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Osteosclerotic lesion in a patient with POEMS syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:356px;\" src=\"images/HEME/109377_POEMS_OS_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT)&nbsp;demonstrating an osteosclerotic bone lesion in the vertebral body of a patient with POEMS syndrome.</div><div id=\"graphicVersion\">Graphic 109377 Version 1.0</div></div></div>"},"109378":{"type":"graphic_picture","displayName":"Temporal artery biopsy showing necrotizing arteritis","title":"Temporal artery biopsy showing necrotizing arteritis","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Temporal artery biopsy showing necrotizing arteritis</div><div class=\"cntnt\"><img style=\"width:712px; height:536px;\" src=\"images/RHEUM/109378_Temp_art_biop_ncrtzng_arter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Temporal artery biopsy of a patient with microscopic polyangiitis, demonstrating that the temporal artery can be involved by vasculitides other than giant cell arteritis. Note fibrinoid necrosis, which does not occur in giant cell (temporal) arteritis.</div><div class=\"graphic_reference\">Courtesy of William Docken, MD.</div><div id=\"graphicVersion\">Graphic 109378 Version 3.0</div></div></div>"},"109381":{"type":"graphic_table","displayName":"Rx invasive candidiasis in children","title":"General recommendations for the treatment of invasive candidiasis in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General recommendations for the treatment of invasive candidiasis in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Condition or treatment group</td> <td class=\"subtitle1\" colspan=\"3\">Treatment</td> </tr> <tr> <td class=\"subtitle2\">Primary</td> <td class=\"subtitle2\">Alternative</td> <td class=\"subtitle2\">Duration</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Candidemia</td> </tr> <tr> <td class=\"indent1\">Nonneutropenic</td> <td>Echinocandin or LAmB<sup>&#182;</sup></td> <td>Fluconazole<sup>&#916;</sup> or voriconazole<sup>&#9674;</sup></td> <td>14 days after first negative blood culture and resolution of signs and symptoms.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Neutropenic</td> <td>Echinocandin or LAmB<sup>&#182;</sup></td> <td>Fluconazole<sup>&#916;</sup> or voriconazole<sup>&#9674;</sup></td> <td>14 days after first negative blood culture and resolution of signs and symptoms and neutrophil count recovery.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Suspected candidiasis</td> </tr> <tr> <td class=\"indent1\">Nonneutropenic</td> <td>Echinocandin or LAmB<sup>&#182;</sup></td> <td>Fluconazole<sup>&#916;</sup></td> <td> <p>Stop after four to five days in patients with no clinical response who lack supporting evidence for fungal infection.</p> For patients with a clinical response, continuation for two weeks may be warranted.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Neutropenic</td> <td>Echinocandin or LAmB<sup>&#182;</sup></td> <td>Fluconazole<sup>&#916;</sup></td> <td>Until resolution of neutropenia in the absence of documented invasive candidiasis.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Suppurative thrombophlebitis</strong></td> <td>Echinocandin or LAmB<sup>&#182;</sup> or fluconazole<sup>&#916;</sup></td> <td>&ndash;</td> <td>At least two weeks after candidemia cleared and signs/symptoms resolve. Catheter removal and resection of vein recommended.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Endocarditis</strong></td> <td>LAmB<sup>&#182;</sup> &#177; flucytosine or high dose echinocandin</td> <td>Fluconazole<sup>&#916;</sup> or voriconazole<sup>&#9674;</sup><sup>&#167;</sup> or posaconazole<sup>&#167;</sup></td> <td>At least six weeks (valve replacement surgery recommended); chronic suppressive therapy with fluconazole for prosthetic valves<sup>[1]</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Central nervous system candidiasis</strong><sup>&#165;</sup></td> <td>LAmB<sup>&#182;</sup> &#177; flucytosine</td> <td>Fluconazole<sup>&#916;</sup></td> <td>Usually several weeks, until all signs and symptom and CSF and radiological abnormalities have resolved.</td> </tr> <tr class=\"divider_bottom\"> <td><strong><em>Candida</em> ocular infections</strong><sup>&#165;</sup></td> <td>Fluconazole<sup>&#916;</sup> or voriconazole<sup>&#9674;</sup> or LAmB<sup>&#182;</sup> &#177; flucytosine</td> <td>&ndash;</td> <td>At least four to six weeks depending upon resolution of lesions.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Intra-abdominal candidiasis</strong></td> <td>Echinocandin or LAmB<sup>&#182;</sup></td> <td>Fluconazole<sup>&#916;</sup> or voriconzole<sup>&#9674;</sup></td> <td>Determined by adequate source control and clinical response.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hepatosplenic candidiasis</strong></td> <td>Echinocandin or LAmB<sup>&#182;</sup>, followed by fluconazole<sup>&#916;</sup></td> <td>&ndash;</td> <td>Usually months, until lesions have resolved on repeat imaging and neutrophil count recovery.</td> </tr> <tr> <td><strong><em>Candida</em> pyelonephritis</strong><sup>&#165;</sup><sup>&#135;</sup></td> <td>LAmB<sup>&#182;</sup> or fluconazole<sup>&#916;</sup></td> <td>LAmB<sup>&#182;</sup> or fluconazole<sup>&#916;</sup></td> <td>Two weeks; for patients who have nephrostomy tubes or stents in place, removal or replacement may be warranted (if feasible).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LAmB: lipid formulation of amphotericin B; CSF: cerebrospinal fluid.<br />* Treatment of candidiasis in neonates is discussed separately. Refer to UpToDate content on treatment of <em>Candida</em> infection in neonates.<br />&para; Toxicity may limit its use.<br />&Delta; For patients who are not critically ill and not likely to have fluconazole-resistant isolates (eg, no past exposure to fluconazole).<br /><span class=\"lozenge\">&loz;</span> Generally used as step-down therapy in patients with invasive infection due to <em>C. krusei</em> and fluconazole-resistant, voriconazole-susceptible <em>C. glabrata</em>.<br />&sect; Data lacking in children for this indication.<br />&yen; Echinocandins are not recommended for candidiasis involving the eye, central nervous system, or urinary tract because they have relatively poor penetration at these sites.<br />&Dagger; Voriconazole is not recommended for patients with urinary candidiasis because the active form is minimally excreted in the urine.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</LI></OL>Adapted from: Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</div><div id=\"graphicVersion\">Graphic 109381 Version 1.0</div></div></div>"},"109383":{"type":"graphic_table","displayName":"Adnexal mass types","title":"Prevalence of specific adnexal mass pathologies in patients in the International Ovarian Tumor Analysis group (IOTA) study (n = 4848)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of specific adnexal mass pathologies in patients in the International Ovarian Tumor Analysis group (IOTA) study (n = 4848)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor pathology</td> <td class=\"subtitle1\">All patients, n (%)</td> <td class=\"subtitle1\">Patients from oncology centers, n (%)</td> <td class=\"subtitle1\">Patients from other hospitals, n (%)</td> </tr> <tr> <td class=\"subtitle2_left\">All benign pathologies</td> <td class=\"subtitle2_left centered\">3183 (65.7)</td> <td class=\"subtitle2_left centered\">1861 (57.0)</td> <td class=\"subtitle2_left centered\">1322 (83.4)</td> </tr> <tr> <td class=\"indent1\">Endometrioma</td> <td class=\"centered\">845 (17.4)</td> <td class=\"centered\">456 (14.0)</td> <td class=\"centered\">389 (24.5)</td> </tr> <tr> <td class=\"indent1\">Benign teratoma (dermoid)</td> <td class=\"centered\">512 (10.6)</td> <td class=\"centered\">334 (10.2)</td> <td class=\"centered\">178 (11.2)</td> </tr> <tr> <td class=\"indent1\">Simple/parasalpingeal cyst</td> <td class=\"centered\">285 (5.9)</td> <td class=\"centered\">147 (4.5)</td> <td class=\"centered\">138 (8.7)</td> </tr> <tr> <td class=\"indent1\">Functional cyst</td> <td class=\"centered\">128 (2.6)</td> <td class=\"centered\">69 (2.1)</td> <td class=\"centered\">59 (3.7)</td> </tr> <tr> <td class=\"indent1\">Hydrosalpinx</td> <td class=\"centered\">112 (2.3)</td> <td class=\"centered\">53 (1.6)</td> <td class=\"centered\">59 (3.7)</td> </tr> <tr> <td class=\"indent1\">Peritoneal pseudocyst</td> <td class=\"centered\">34 (0.7)</td> <td class=\"centered\">21 (0.6)</td> <td class=\"centered\">13 (0.8)</td> </tr> <tr> <td class=\"indent1\">Abscess</td> <td class=\"centered\">45 (0.9)</td> <td class=\"centered\">34 (1.0)</td> <td class=\"centered\">11 (0.7)</td> </tr> <tr> <td class=\"indent1\">Fibroma</td> <td class=\"centered\">245 (5.1)</td> <td class=\"centered\">168 (5.1)</td> <td class=\"centered\">77 (4.9)</td> </tr> <tr> <td class=\"indent1\">Serous cystadenoma</td> <td class=\"centered\">543 (11.2)</td> <td class=\"centered\">326 (10.0)</td> <td class=\"centered\">217 (13.7)</td> </tr> <tr> <td class=\"indent1\">Mucinous cystadenoma</td> <td class=\"centered\">359 (7.4)</td> <td class=\"centered\">203 (6.2)</td> <td class=\"centered\">156 (9.8)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rare benign pathologies</td> <td class=\"centered\">75 (1.5)</td> <td class=\"centered\">50 (1.5)</td> <td class=\"centered\">25 (1.6)</td> </tr> <tr> <td class=\"subtitle2_left\">All malignant pathologies</td> <td class=\"subtitle2_left centered\">1665 (34.3)</td> <td class=\"subtitle2_left centered\">1402 (43.0)</td> <td class=\"subtitle2_left centered\">263 (16.6)</td> </tr> <tr> <td class=\"indent1\">Primary invasive stage I</td> <td class=\"centered\">222 (4.6)</td> <td class=\"centered\">184 (5.6)</td> <td class=\"centered\">38 (2.4)</td> </tr> <tr> <td class=\"indent1\">Primary invasive stage II</td> <td class=\"centered\">82 (1.7)</td> <td class=\"centered\">64 (2.0)</td> <td class=\"centered\">18 (1.1)</td> </tr> <tr> <td class=\"indent1\">Primary invasive stage III</td> <td class=\"centered\">658 (13.6)</td> <td class=\"centered\">579 (17.7)</td> <td class=\"centered\">79 (5.0)</td> </tr> <tr> <td class=\"indent1\">Primary invasive stage IV</td> <td class=\"centered\">102 (2.1)</td> <td class=\"centered\">88 (2.7)</td> <td class=\"centered\">14 (0.9)</td> </tr> <tr> <td class=\"indent1\">Rare primary invasive pathologies*</td> <td class=\"centered\">113 (2.3)</td> <td class=\"centered\">80 (2.5)</td> <td class=\"centered\">33 (2.1)</td> </tr> <tr> <td class=\"indent1\">Borderline stage I</td> <td class=\"centered\">249 (5.1)</td> <td class=\"centered\">197 (6.0)</td> <td class=\"centered\">52 (3.3)</td> </tr> <tr> <td class=\"indent1\">Borderline stage II</td> <td class=\"centered\">9 (0.2)</td> <td class=\"centered\">6 (0.2)</td> <td class=\"centered\">3 (0.2)</td> </tr> <tr> <td class=\"indent1\">Borderline stage III</td> <td class=\"centered\">25 (0.5)</td> <td class=\"centered\">23 (0.7)</td> <td class=\"centered\">2 (0.1)</td> </tr> <tr> <td class=\"indent1\">Borderline stage IV</td> <td class=\"centered\">1 (0.02)</td> <td class=\"centered\">1 (0.03)</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Secondary metastatic cancer</td> <td class=\"centered\">204 (4.2)</td> <td class=\"centered\">180 (5.5)</td> <td class=\"centered\">24 (1.5)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Including malignant sex cord-stromal tumors, germ cell tumors, mesenchymal tumors, lymphomas, and rare malignant epithelial tumors (eg, malignant Brenner tumor).</div><div class=\"graphic_reference\">Reproduced from: Timmerman D, Van Calster B, Testa A, et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol 2016; 214:424. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109383 Version 1.0</div></div></div>"},"109384":{"type":"graphic_table","displayName":"Adnexal mass malig ultrasound features","title":"Ten simple rules for identifying a benign or malignant tumor on ultrasound from the International Ovarian Tumor Analysis (IOTA) group","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ten simple rules for identifying a benign or malignant tumor on ultrasound from the International Ovarian Tumor Analysis (IOTA) group</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Rules for predicting a malignant tumor (M-rules)</td> <td class=\"subtitle1\" colspan=\"3\">Rules for predicting a benign tumor (B-rules)</td> </tr> <tr> <td class=\"centered\">M1</td> <td>Irregular solid tumor</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\">B1</td> <td>Unilocular</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"centered\">M2</td> <td>Presence of ascites</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\">B2</td> <td>Presence of solid components where the largest solid component has a largest diameter &#60;7 mm</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"centered\">M3</td> <td>At least four papillary structures</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\">B3</td> <td>Presence of acoustic shadows</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"centered\">M4</td> <td>Irregular multilocular solid tumor with largest diameter &#8805;100 mm</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\">B4</td> <td>Smooth multilocular tumor with largest diameter &#60;100 mm</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"centered\">M5</td> <td>Very strong blood flow (color score 4)</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\">B5</td> <td>No blood flow (color score 1)</td> <td style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">If one or more M-rules apply in the absence of a B-rule, the mass is classified as malignant. If one or more B-rules apply in the absence of an M-rule, the mass is classified as benign. If both M-rules and B-rules apply, the mass cannot be classified. If no rule applies, the mass cannot be classified.</div><div class=\"graphic_reference\">From: Timmerman D, Testa AC, Bourne T, et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 2008; 31:681. DOI: <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/uog.5365/abstract\" target=\"_blank\">10.1002/uog.5365</a>. Copyright &copy; 2008 International Society of Ultrasound in Obstetrics and Gynecology. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 109384 Version 2.0</div></div></div>"},"109386":{"type":"graphic_diagnosticimage","displayName":"Ovarian follicular cyst ultrasound","title":"Ovarian follicular cyst on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Ovarian follicular cyst on ultrasound</div><div class=\"cntnt\"><img style=\"width:764px; height:460px;\" src=\"images/OBGYN/109386_Ovarian_follicular_cyst_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional transvaginal ultrasound image of the left ovary containing a normal dominant follicle. The follicle is round, contains clear fluid, and is surrounded by normal ovarian tissue. The thick arrow&nbsp;is pointing to the follicular cyst in one dimension.&nbsp; </div><div class=\"graphic_reference\">Courtesy of Lauri Hochberg, MD.</div><div id=\"graphicVersion\">Graphic 109386 Version 1.0</div></div></div>"},"109387":{"type":"graphic_diagnosticimage","displayName":"Ovarian corpus luteum cyst ultrasound","title":"Ovarian corpus luteum cyst on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 986px\" class=\"figure\"><div class=\"ttl\">Ovarian corpus luteum cyst on ultrasound</div><div class=\"cntnt\"><img style=\"width:966px; height:630px;\" src=\"images/OBGYN/109387_Ovarian_corpus_lutm_cyst_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Power Doppler outlines the single peripheral vessel that is seen typically in a corpus luteum cyst. The cyst has scalloped edges and can have internal echoes, hemorrhage, or a blood clot.</div><div class=\"graphic_reference\">Courtesy of Lauri Hochberg, MD.</div><div id=\"graphicVersion\">Graphic 109387 Version 1.0</div></div></div>"},"109388":{"type":"graphic_diagnosticimage","displayName":"Polycystic ovary ultrasound 2","title":"Polycystic ovary on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Polycystic ovary on ultrasound</div><div class=\"cntnt\"><img style=\"width:764px; height:491px;\" src=\"images/OBGYN/109388_Polycystic_ovary_ultrasnd_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional transvaginal ultrasound image of a polycystic ovary. There are typical features present, including multiple (&gt;10) small peripheral follicles &lt;1 cm in diameter (\"string of pearls\" sign). There is also typically increased central stroma, and overall volume of the ovary is increased to greater than 10 cc.</div><div class=\"graphic_reference\">Courtesy of Lauri Hochberg, MD.</div><div id=\"graphicVersion\">Graphic 109388 Version 1.0</div></div></div>"},"109389":{"type":"graphic_diagnosticimage","displayName":"Fallopian tube hydrosalpinx","title":"Fallopian tube hydrosalpinx on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 910px\" class=\"figure\"><div class=\"ttl\">Fallopian tube hydrosalpinx on ultrasound</div><div class=\"cntnt\"><img style=\"width:890px; height:660px;\" src=\"images/OBGYN/109389_Fallopian_tube_hydrosalpinx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound three-dimensional image of a hydrosalpinx. Features that suggest this entity include a cystic mass adjacent to the normal intact ovary, incomplete septations, and the mass is tubular in shape.</div><div class=\"graphic_reference\">Courtesy of Lauri Hochberg, MD.</div><div id=\"graphicVersion\">Graphic 109389 Version 1.0</div></div></div>"},"109390":{"type":"graphic_table","displayName":"Ovarian neoplasms bilaterality","title":"Bilaterality of ovarian neoplasms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bilaterality of ovarian neoplasms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Ovarian tumor histology<br /> (World Health Organization classification)</td> <td class=\"subtitle1\">Incidence of bilaterality<br /> (approximate %)</td> </tr> <tr> <td>Serous cystadenoma</td> <td class=\"centered\">12 to 23</td> </tr> <tr> <td>Serous borderline tumor</td> <td class=\"centered\">55</td> </tr> <tr> <td>Serous carcinoma</td> <td class=\"centered\">60</td> </tr> <tr> <td>Mucinous cystadenoma</td> <td class=\"centered\">5</td> </tr> <tr> <td>Mucinous borderline tumor</td> <td class=\"centered\">5</td> </tr> <tr> <td>Mucinous carcinoma</td> <td class=\"centered\">5</td> </tr> <tr> <td>Mature cystic teratoma (dermoid)</td> <td class=\"centered\">15</td> </tr> <tr> <td>Dysgerminoma</td> <td class=\"centered\">15</td> </tr> <tr> <td>Other malignant germ cell tumors</td> <td class=\"centered\">1</td> </tr> <tr> <td>Granulosa-stroma cell tumor</td> <td class=\"centered\">5</td> </tr> <tr> <td>Secondary tumors</td> <td class=\"centered\">70</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Kurman RJ, Ellenson LH, Ronnett B. Blaustein's Pathology of the Female Genital Tract, 6th ed, Springer, 2011.</div><div id=\"graphicVersion\">Graphic 109390 Version 1.0</div></div></div>"},"109392":{"type":"graphic_diagnosticimage","displayName":"Ovary mature teratoma ultrasound","title":"Benign mature ovarian teratoma (dermoid cyst) on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 971px\" class=\"figure\"><div class=\"ttl\">Benign mature ovarian teratoma (dermoid cyst) on ultrasound</div><div class=\"cntnt\"><img style=\"width:951px; height:676px;\" src=\"images/OBGYN/109392_Ovary_mature_teratoma_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound image of a benign teratoma that features heterogeneous contents, smooth outer surface. The arrow points to lines that are hair. There are hyperechoic portions and homogeneous echoes (mucin).</div><div class=\"graphic_reference\">Courtesy of Lauri Hochberg, MD.</div><div id=\"graphicVersion\">Graphic 109392 Version 1.0</div></div></div>"},"109393":{"type":"graphic_diagnosticimage","displayName":"Ovarian mature teratoma ultrasound 2","title":"Benign mature ovarian teratoma (dermoid cyst) on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 995px\" class=\"figure\"><div class=\"ttl\">Benign mature ovarian teratoma (dermoid cyst) on ultrasound</div><div class=\"cntnt\"><img style=\"width:975px; height:626px;\" src=\"images/OBGYN/109393_Ovarian_mature_teratoma_US2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound of a mature teratoma in the ovary containing heterogeneous contents, which often shadow. It is round and well circumscribed. This image contains the \"ovarian crescent\" sign, which is a rim of normal-appearing ovary with follicles. These features suggest a benign cyst.</div><div class=\"graphic_reference\">Courtesy of Lauri Hochberg, MD.</div><div id=\"graphicVersion\">Graphic 109393 Version 1.0</div></div></div>"},"109394":{"type":"graphic_diagnosticimage","displayName":"Ovarian endometrioma ultrasound","title":"Ovarian endometrioma on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 984px\" class=\"figure\"><div class=\"ttl\">Ovarian endometrioma on ultrasound</div><div class=\"cntnt\"><img style=\"width:964px; height:692px;\" src=\"images/OBGYN/109394_Ovarian_endometrioma_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound image of an endometrioma containing homogeneous internal echoes, which look like \"ground glass.\" Ovarian crescent sign present.</div><div class=\"graphic_reference\">Courtesy of Lauri Hochberg, MD.</div><div id=\"graphicVersion\">Graphic 109394 Version 1.0</div></div></div>"},"109395":{"type":"graphic_diagnosticimage","displayName":"Ovarian fibrothecoma ultrasound","title":"Ovarian fibrothecoma on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Ovarian fibrothecoma on ultrasound</div><div class=\"cntnt\"><img style=\"width:764px; height:491px;\" src=\"images/OBGYN/109395_Ovarian_fibrothecoma_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A through C) Ultrasound image of a smooth solid benign ovarian tumor, a fibrothecoma, which is a type of sex cord-stromal tumor.</div><div id=\"graphicVersion\">Graphic 109395 Version 1.0</div></div></div>"},"109397":{"type":"graphic_picture","displayName":"Paratubal cyst torsion","title":"Torsion of paratubal cyst (fallopian tube)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Torsion of paratubal cyst (fallopian tube)</div><div class=\"cntnt\"><img style=\"width:756px; height:436px;\" src=\"images/OBGYN/109397_Paratubal_cyst_torsion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mitchel Hoffman, MD.</div><div id=\"graphicVersion\">Graphic 109397 Version 1.0</div></div></div>"},"109401":{"type":"graphic_table","displayName":"Red flag history for child physical abuse","title":"Red flag history for child physical abuse","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Red flag history for child physical abuse</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>No history or denial of trauma despite severe injury </li> </ul> </td> </tr> <tr> <td> <ul> <li>Implausible history for degree or type of injury* </li> </ul> </td> </tr> <tr> <td> <ul> <li>Unexplained or excessive delay in seeking care </li> </ul> </td> </tr> <tr> <td> <ul> <li>Injury attributed to in-home resuscitation efforts </li> </ul> </td> </tr> <tr> <td> <ul> <li>Caregiver histories that change with retelling or conflict with versions from other observers </li> </ul> </td> </tr> <tr> <td> <ul> <li>Severe injury explained as self-inflicted or blamed on other young children or pets </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Examples of implausible histories include major trauma attributed to a \"fall down the stairs\" or other short fall such as a fall from a sitting position or an injury mechanism that requires the child to have capability beyond their developmental level (eg, severe scald burns in a 12-month old attributed to the patient \"turning on the hot water faucet\").</div><div id=\"graphicVersion\">Graphic 109401 Version 1.0</div></div></div>"},"109402":{"type":"graphic_table","displayName":"Red flags for child physical abuse on examination","title":"Red flags for child physical abuse on examination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Red flags for child physical abuse on examination</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td><strong>Bruises</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Any bruising in infants younger than six months of age </li> <li>More than one bruise in a pre-mobile infant and more than two bruises in a crawling child </li> <li>Bruises located on the torso, ear, neck, or buttocks </li> <li>Bruises with a pattern of the striking object (eg, slap, belt, or loop marks; spoons; spatulas; or other objects) </li> <li>Human bite marks </li> </ul> </td> </tr> <tr> <td><strong>Oral injuries</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Lip lacerations or bruising, especially in nonambulatory infants </li> <li>Lingual or labial frenulum tears, especially in nonambulatory infants </li> <li>Tongue lacerations, especially in nonambulatory infants </li> <li>Bruising or wounds of the buccal mucosa, gums, or palate, especially in nonambulatory infants </li> <li>Missing or fractured teeth with an absent or implausible history </li> <li>Maxillary or mandibular fractures with an absent or implausible history </li> <li>Bruising, lichenification, or scarring at the corners of the mouth from being gagged </li> </ul> </td> </tr> <tr> <td><strong>Burns</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Scalds in children &#60;5 years of age that do not fit an unintentional spill pattern </li> <li>Scalds from hot tap water due to immersion, demonstrating a sharp upper line of demarcation (\"high tide mark\"), affecting both sides of the body symmetrically, or involving the lower extremities and/or perineum </li> <li>Burns that have a sharply demarcated edge in the shape of the burning object (eg, clothing iron, spatulas, spoons, grates, metal hairdryer grids, curling irons, or the metal tops of butane cigarette lighters) </li> <li>Cigarette burns that appear as discreet circular burns 8 to 12 mm in diameter and are deep (eg, third degree burns) </li> </ul> </td> </tr> <tr> <td><strong>Fractures</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Metaphyseal corner fractures </li> <li>Rib fractures </li> <li>Fractures of the sternum, scapula, or spinous processes </li> <li>Long bone fracture in a nonambulatory infant </li> <li>Multiple fractures in various stages of healing </li> <li>Bilateral acute long-bone fractures </li> <li>Vertebral body fractures and subluxations in the absence of a history of high force trauma </li> <li>Digital fractures in children younger than 36 months of age </li> <li>Epiphyseal separations </li> <li>Severe skull fractures in children younger than 18 months of age </li> </ul> </td> </tr> <tr> <td><strong>Serious injury without explanation*</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Subdural hematoma or retinal hemorrhage in a young child, without a significant public trauma such as a fall out a tall building window or a car crash </li> <li>Other intracranial injury without a clear trauma history </li> <li>Abdominal injury (perforation or hematoma of the bowel, pancreas,&nbsp;or bladder; solid organ [eg, liver, spleen, or kidney] hematoma or laceration) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Any major traumatic injury without a plausible explanation is concerning for physical child abuse.</div><div id=\"graphicVersion\">Graphic 109402 Version 2.0</div></div></div>"},"109404":{"type":"graphic_table","displayName":"Sample consent to treat with parent waiver","title":"Sample of a consent to treat an adolescent patient that includes a limited waiver of parental rights","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample of a consent to treat an adolescent patient that includes a limited waiver of parental rights</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"2\"><br /> <span style=\"font-size:1.2em;\"><strong>Oklahoma University (OU) adolescent medicine consent to certain treatment of an adolescent patient and limited waiver of parental rights</strong></span><br /> <sub>&nbsp;</sub></td> </tr> <tr class=\"highlight_gray_text divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Welcome to the OU Children's Physicians Adolescent Medicine Clinic!</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>Our goal is to treat you and your child with respect and provide thorough and complete care. Please let us know if you ever have questions, as we want you to be a participating partner in our adolescent's care. This document is meant to prepare you for your adolescent's visit so that you and your child can have the most productive visit possible. We specifically want to address expectations you may have for: 1) scope of the visit; 2) confidentiality issues; 3) discussion with patient regarding contraception.</p> </td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"subtitle2_left\" colspan=\"2\">Scope</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>As a clinic that treats adolescent patients, we may have policies that differ from those of your other physicians. As adolescents become adults, it is important to help them understand their own health care needs and make sure they are capable of maintaining their health independently. In order to fully evaluate your child as he/she moves towards adulthood, it may be necessary to ask him/her questions about past actions and potential exposures, current behavior, and family/friend dynamics. A physical exam may be necessary. The scope of the physical exam will be discussed with you and your child prior to the exam, so that any questions can be addressed.</p> </td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"subtitle2_left\" colspan=\"2\">Parental rights under Oklahoma law</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Oklahoma law specifically confers the following rights on parents: <ul class=\"decimal_heading\"> <li>The right to make healthcare decisions concerning their children'</li> <li>The right to provide written consent for a provider to treat the child, including, but not limited to performing physical examination or prescribing prescription drugs, or to deny such consent; and</li> <li>The right to access and review all of their children's medical records.</li> </ul> </td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"subtitle2_left\" colspan=\"2\">Confidentiality of medical records</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>Studies have shown that adolescents are more likely to share important health information with providers if the adolescents are offered qualified confidentiality. Qualified confidentiality means that as providers, we will ask to have private time (without the parent present) with the child, and we will ask that the parent agree in writing that the child's confidentiality should be broken only if we have reason to believe that the child is at significant risk of harm. We always encourage our minor patients to discuss with parents/guardians any and all health information that we discuss in private; however, in the event they do not feel comfortable doing so, we believe it is important to provide this opportunity for them to receive health advice from a health care provider rather than unreliable source. In the event that your child discloses information that causes the health care provider to believe your child is at significant risk for injury or death, the health care provider will disclose this information and discuss his/her concerns directly with you.</p> <p>Federal and Oklahoma law allows parents/guardians to have access to all medical records of a minor, except in limited circumstances. In order to improve the health care that our adolescent patients receive, we will ask you to waive your right to access certain portions of your child's records which will be marked \"confidential\" and document your waiver by signing a written consent. Your agreement not to access the records pertaining to your child generated by our providers allows our providers to assure your child that the information your child shares related to their exposure to sexual activity or other risk behaviors, including but not limited to drug and alcohol use, will be maintained in confidence. Research indicates that this assurance of confidentiality improves the health care that adolescents receive. <em>By signing the Limited Waiver of Parental Rights and Consent to Certain Treatment of Adolescent Patient below, you agree that you will not request access to or copies of your child's confidential health information that is designated in a special section of the medical record as \"confidential.\"</em></p> <p>As providers, we value the independent health information provided by parents regarding their children's health. Whenever possible, we prefer that such conversations regarding the child take place with the child present. If that is not possible, we are happy to discuss your child with you separately with the understanding that we will not tell you information that the child has told us in confidence.</p> </td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"subtitle2_left\" colspan=\"2\">Contraception discussions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>The state of Oklahoma has one of the highest pregnancy rates in the country. In an effort to decrease rates of unplanned pregnancies, this clinic provides information regarding preventative contraception as well as medically appropriate hormonal contraception to adolescent patients. It is our normal practice to encourage adolescent patients to discuss decisions regarding contraceptive methods with their parents/guardians. We routinely offer to make ourselves available to help a patient initiate such a discussion with a parent, if the patient or parent requests. However, in the event a patient feels uncomfortable discussing this issue with parents/guardians, we would like to be able to protect the patient against experiencing an unplanned pregnancy or sexually transmitted disease. The risks of all hormonal methods of contraception are significantly less than the health risks of pregnancy. <em>By signing the Limited Waiver of Parental Rights and Consent to Certain Treatment of Adolescent Patient below, you consent to allowing your child to receive information about contraception as well as being provided with hormonal contraception to prevent unplanned pregnancy or to treat other medical conditions, if the patient desires such therapy and the provider determines the therapy is medically appropriate. The provider will advise the patient how to take the medication, the risks and benefits associated with taking the medication, and the potential risks associated with not taking the medication as prescribed.</em></p> </td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"subtitle2_left\" colspan=\"2\">Limited Waiver of Parental Rights and Consent to Certain Treatment of Adolescent Patient</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p><strong>Limited waiver of parental rights to access medical records related to risk behaviors, including but not limited to the prevention of communicable diseases, contraception, sexual activity, and drug/alcohol use</strong></p> <p>As the parent or legal guardian of <sub><strong>___________________________</strong></sub>, a minor, I understand that I have the legal right to access and review all medical records of my child unless otherwise prohibited or provided by law or unless I am the subject of an investigation of a crime committed against my child. <sub><strong>______</strong></sub> <em>(initial here)</em>.</p> <p>I agree that it is in the best interest of my child to have the opportunity to maintain communications with his/her health care providers within the OU Physicians Adolescent Medicine Clinic in confidence. I agree that my child's physician may deem certain medical records related to risk behaviors, including but not limited to prevention of communicable diseases, contraception, sexual activity, and drug/alcohol use, to be confidential and agree that those records shall be marked \"confidential\" within the medical record. I understand that I will not be able to access or request a copy of the confidential medical records without a court order. <sub><strong>______</strong></sub> <em>(initial here)</em>.</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p><strong>Consent to physical examination and discussion outside the parent's presence</strong></p> <p>I understand that I have the legal right to make health care decisions for my child. I further understand that I have the legal right to consent in writing (or to refuse to consent) to any physical examination, procedure, or prescription drug prescribed for my child. <sub><strong>______</strong></sub> <em>(initial here)</em>.</p> <p>I consent to my child's provider having discussions regarding risk behaviors, including but not limited to prevention of communicable diseases, contraception, sexual activity, and drug/alcohol use with my child outside of my presence so that frank and open health care advice regarding these issues can occur between the provider and my child. <sub><strong>______</strong></sub> <em>(initial here)</em>.</p> <p>I consent to my child receiving a physical examination outside of my presence if the provider determines that it is medically indicated for the purposes of evaluating or diagnosing risk behaviors, including but not limited to the prevention of communicable diseases, contraception, sexual activity and drug/alcohol use. <sub><strong>______</strong></sub> <em>(initial here)</em>.</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p><strong>Consent to treatment</strong></p> <p>I understand that at any time upon request, I am entitled to receive a copy of the risks and benefits associated with hormonal birth control, the proper dosage and administration of the medication, and the risks of my child failing to properly take the medication. I consent to my child being provided information about hormonal contraception and receiving hormonal contraception if indicated by the provider. <sub><strong>______</strong></sub> <em>(initial here)</em>.</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p><strong>Revocation</strong></p> <p>I understand I may revoke elements of this Limited Waiver and Consent at any time by notifying staff of the Adolescent Medicine Clinic in writing. I understand any records of treatment or discussions that have already been documented in the medical record as \"confidential\" will remain confidential, and that this revocation will affect only treatment and discussion from the time of my notification forward.</p> </td> </tr> <tr> <td class=\"indent1\"> <p>Signed: <sub><strong>_____________________________</strong></sub></p> </td> <td> <p>Date: <sub><strong>________________________</strong></sub></p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Witnessed: <sub><strong>__________________________</strong></sub></p> </td> <td> <p>Date: <sub><strong>________________________</strong></sub></p> </td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><em>Form created 5/18/16</em></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 109404 Version 1.0</div></div></div>"},"109405":{"type":"graphic_figure","displayName":"PPV and preload","title":"Relationship between pulse pressure variation and preload","html":"<div class=\"graphic\"><div style=\"width: 982px\" class=\"figure\"><div class=\"ttl\">Relationship between pulse pressure variation and preload</div><div class=\"cntnt\"><img style=\"width:962px; height:643px;\" src=\"images/PULM/109405_PPV_and_preload.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulse pressure variation (PPV) is a marker of the position on the Frank-Starling curve, not an indicator of blood volume or a marker of cardiac preload. Increasing preload induces a decrease in PPV (from 2 to 3). PPV is minimal when the heart is operating on the plateau of the Frank-Starling curve (3 and 4). Decreasing preload induces an increase in PPV (from 2 to 1), also increasing contractility (from 4 to 2).</div><div class=\"graphic_reference\">Modified from: Michard F, Lopes MR, Auler JO Jr. Pulse pressure variation: beyond the fluid management of patients with shock. Crit Care 2007; 11:131. Copyright &copy; 2007 BioMed Central Ltd. Reproduced under the terms of the <a href=\"https://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License</a>.</div><div id=\"graphicVersion\">Graphic 109405 Version 1.0</div></div></div>"},"109406":{"type":"graphic_figure","displayName":"PPV calculation","title":"Calculating pulse pressure variation","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Calculating pulse pressure variation</div><div class=\"cntnt\"><img style=\"width:688px; height:660px;\" src=\"images/PULM/109406_PPV_calculation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulse pressure variation (PPV). Pulse pressure is the difference between systolic and diastolic blood pressure. The phases of respiration, denoted by positive (expiration) and negative (inspiration) deflections, reflect those for patients on mechanical ventilation (these would be different if the patient was spontaneously breathing and can vary depending upon the mode of ventilation). PPV can be calculated as follows: PPV = 100 Ã— (PPmax â€“ PPmin) / ([PPmax + PPmin] / 2).</div><div class=\"graphic_footnotes\">PPmax:&nbsp;maximum pulse pressure;&nbsp;PPmin: minimum pulse pressure.</div><div class=\"graphic_reference\">Reproduced from: ProfBondi. Available at: <a href=\"http://commons.wikimedia.org/wiki/File:Pulse_pressure_variation.jpg\" target=\"_blank\">https://commons.wikimedia.org/wiki/File:Pulse_pressure_variation.jpg</a> (accessed on August 10, 2016).</div><div id=\"graphicVersion\">Graphic 109406 Version 2.0</div></div></div>"},"109407":{"type":"graphic_figure","displayName":"Passive leg raising","title":"Passive leg raising maneuver for fluid responsiveness","html":"<div class=\"graphic\"><div style=\"width: 834px\" class=\"figure\"><div class=\"ttl\">Passive leg raising maneuver for fluid responsiveness</div><div class=\"cntnt\"><img style=\"width:814px; height:314px;\" src=\"images/PULM/109407_Passive_leg_raising.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Passive leg raising maneuver. After starting with the head elevated to 45 degrees, rapidly repositioning the patient with legs elevated to 30 to 45 degrees allows autotransfusion of blood from the legs into the thorax. An increase in cardiac output suggests that the patient might be fluid responsive.</div><div class=\"graphic_reference\">Adapted From: Marik PE, Monnet X, Teboul JL. Hemodynamic parameters to guide fluid therapy. Ann Intensive Care 2011; 1:1. Reproduced under the terms of the <A id=creativecommons.org/licenses/by/2.0/ href=\"https://creativecommons.org/licenses/by/2.0/\" target=_blank>Creative Commons Attribution License</A>.</div><div id=\"graphicVersion\">Graphic 109407 Version 1.0</div></div></div>"},"109414":{"type":"graphic_picture","displayName":"Endotracheal tube with stylet","title":"Endotracheal tube with stylet","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Endotracheal tube with stylet</div><div class=\"cntnt\"><img style=\"width:640px; height:328px;\" src=\"images/EM/109414_Endotracheal_tube_w_stylet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The malleable stylet should be straight from the proximal end of the endotracheal tube to the proximal end of the cuff, and bent at no more than a 35 degree angle. The stylet should not extend beyond the end of the endotracheal tube. For further information, refer to UpToDate content on direct laryngoscopy in adults.</div><div class=\"graphic_reference\">Courtesy of Steven Orebaugh, MD and James Snyder, MD.</div><div id=\"graphicVersion\">Graphic 109414 Version 1.0</div></div></div>"},"109415":{"type":"graphic_table","displayName":"CAPOX plus trastuzumab for advanced gastric and GEJ cancer","title":"Capecitabine and oxaliplatin (CAPOX) plus trastuzumab for HER2-overexpressing* advanced gastric and gastroesophageal junction cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Capecitabine and oxaliplatin (CAPOX) plus trastuzumab for HER2-overexpressing* advanced gastric and gastroesophageal junction cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Trastuzumab</td> <td>Loading dose: 8 mg/kg IV</td> <td>Dilute in 250 mL NS<sup>&#182;</sup> and administer over 90 minutes for the loading dose. <strong>Do not</strong> mix with D5W and <strong>do not</strong> infuse as an IV push or bolus.</td> <td>Day 1 (cycle 1)</td> </tr> <tr> <td>Trastuzumab</td> <td>6 mg/kg IV</td> <td>Dilute in 250 mL NS<sup>&#182;</sup> and administer over 30 to 90 minutes. <strong>Do not</strong> mix with D5W and <strong>do not</strong> infuse as an IV push or bolus.</td> <td>Day 1 of every subsequent cycle, starting with cycle 2</td> </tr> <tr> <td>Oxaliplatin<sup>&#916;</sup></td> <td>130 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL D5W<sup>&#182;</sup> and administer over two hours.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Capecitabine<sup>&#9674;</sup></td> <td>1000 mg/m<sup>2</sup> orally per dose</td> <td>Twice daily (total dose 2000 mg/m<sup>2</sup> per day); swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets.<sup>&#167;</sup></td> <td>Days 1 to 14</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin: MODERATE. </li> <li>Oral capecitabine: LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen for oxaliplatin. Most clinicians do not routinely premedicate prior to the first trastuzumab dose. However, patients may be instructed to self-administer acetaminophen or a nonsteroidal anti-inflammatory drug (NSAID) if flu-like symptoms develop within 24 hours of drug administration. </li> <li>Refer to UpToDate topics on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\" and \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin is classified as an irritant, but can cause significant tissue damage (rare); avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia &#60;20%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Lower starting doses of oxaliplatin and capecitabine may be needed for renal impairment. </li> <li>Refer to UpToDate topic on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Counsel patients to avoid exposure to cold during and for approximately 72 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Prolongation of the corrected QT (QTc) interval and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. Pulmonary toxicity is rarely reported with oxaliplatin. </li> <li>Trastuzumab is associated with cardiomyopathy; assess baseline left ventricular ejection fraction (LVEF) prior to therapy and at least every three months during therapy.<sup>[2]</sup> Patients with heart failure, coronary artery disease, myocardial infarction in the prior six months, or baseline LVEF &#60;50% were excluded from the study.<sup>[1]</sup> Trastuzumab may also cause serious pulmonary toxicity and should be used with caution in patients with preexisting pulmonary disease. </li> <li>Refer to UpToDate topics on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\" and \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Obtain CBC with differential and platelet count prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes and liver and renal function every three weeks prior to each new treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess cardiac function every three months during therapy or as clinically indicated. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for mucositis, diarrhea, and palmar-plantar erythrodysesthesias during treatment. </li> <li>Refer to UpToDate topics on \"Oral toxicity associated with chemotherapy\" and \"Cutaneous complications of conventional chemotherapy agents\" and \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>A new cycle of treatment should not start until neutrophils recover to &#62;1500/microL and platelets recover to &#62;100,000/microL. Interrupt capecitabine for any grade 2 or worse hematologic toxicity and delay treatment with both capecitabine and oxaliplatin until complete recovery or improvement to &#8804;grade 1.<sup>[3]</sup> Reduce the capecitabine dose by 25% in subsequent cycles at the first occurrence of a grade 2 or grade 3 toxicity, and by 50% at the second occurrence of a given grade 2 or grade 3 toxicity or at the first occurrence of a grade 4 event. After recovery, reduce oxaliplatin by 25% for any intracycle grade 3 or 4 neutropenia or thrombocytopenia. Discontinue capecitabine and oxaliplatin permanently if, despite dose reduction, hematologic toxicity occurs for the third time at grade 2 or grade 3, or a second time at grade 4. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Withhold oxaliplatin for persisting grade 2 or any grade 3 paresthesias/dysesthesias until recovery.<sup>[1]</sup> The United States Prescribing Information recommends a dose reduction in oxaliplatin to 65 mg/m<sup>2</sup> for persistent grade 2 neurosensory events that do not resolve, and permanent discontinuation for persistent grade 3 neurosensory events.<sup>[4]</sup> </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine and delay oxaliplatin for any grade 2 or worse gastrointestinal toxicity; restart treatment only after complete recovery or improvement to &#8804;grade 1.<sup>[3,5]</sup> After recovery, reduce the dose of oxaliplatin by 25% after the first episode of grade 3 or worse diarrhea or mucositis. Reduce the capecitabine dose by 25% in subsequent cycles at the first occurrence of grade 2 or 3 toxicity, and by 50% at the second occurrence of a given grade 2 or grade 3 toxicity or at the first occurrence of a grade 4 event. Discontinue capecitabine permanently if, despite dose reduction, a given toxicity occurs for the third time at grade 2 or grade 3, or a second time at grade 4.<sup>[3]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Assess LVEF at least every three months during trastuzumab.<sup>[2]</sup> In the original trial, if LVEF decreased by 10 points from baseline and to below 50%, trastuzumab was withheld and a repeat LVEF assessment performed within three weeks.<sup>[1]</sup> If LVEF failed to improve, discontinuation of trastuzumab was suggested. The United States Prescribing Information suggests withholding trastuzumab for at least four weeks for LVEF &#8805;16% decrease from baseline or LVEF below normal limits and &#8805;10% decrease from baseline, and repeat LVEF every four weeks. May resume trastuzumab treatment if LVEF returns to normal limits within four to eight weeks and remains at &#8804;15% decrease from baseline value. Discontinue permanently for persistent (&#62;8 weeks) LVEF decline or for &#62;3 incidents of treatment interruptions for cardiomyopathy.<sup>[2]</sup> Guidelines for managing cardiac dysfunction during therapy with HER2-targeted agents are available. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Discontinue trastuzumab for serious pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. </li> <li>Refer to UpToDate topics on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\" and \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicities (including heptotoxicity)</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine and delay oxaliplatin for any grade 2 or worse other non-neurologic toxicity (except alopecia); restart treatment only after complete recovery or improvement to &#8804;grade 1.<sup>[3]</sup> Reduce the dose of oxaliplatin for subsequent cycles by 25% for drug-related grade 3 toxicity. Reduce the capecitabine dose by 25% in subsequent cycles at the first occurrence of a grade 2 or grade 3 toxicity, and by 50% at the second occurrence of a given grade 2 or grade 3 toxicity or at the first occurrence of a grade 4 event. Discontinue capecitabine permanently if, despite dose reduction, a given toxicity occurs for the third time at grade 2 or grade 3, or a second time at grade 4.<sup>[3]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><strong>Doses of capecitabine omitted for toxicity are not replaced or restored; instead the patient should resume with the next planned treatment cycle.</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">HER2: human epidermal growth factor 2 receptor; IV: intravenous; NS: normal saline; D5W: 5% dextrose in water; ECG: electrocardiogram; CBC: complete blood count; INR: international normalized ratio.<br />* High levels of HER2 overexpression, as determined by either 3+ immunohistochemical staining (IHC) or positive fluorescence in situ hybridization (FISH), are used to select patients for therapy with trastuzumab. Refer to UpToDate topic on \"Systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer\".<br />Â¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Î” Many centers routinely infuse oxaliplatin through a central venous catheter because of local pain with infusion into a peripheral vein.<br /><FONT class=lozenge>â—Š</FONT> No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br />Â§ Extemporaneous compounding of liquid dosage forms has been reported,<SUP>[6]</SUP> but intravenous alternatives may be more appropriate for patients with significant swallowing difficulty.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gong J, et al. BMC Cancer 2016; 16:68.</LI>&#xD;&#xA;<LI>Trastuzumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on May 11, 2016).</LI>&#xD;&#xA;<LI>Nehls O, et al. Br J Cancer 2008; 98:309.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on May 11, 2016).</LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on May 11, 2016).</LI>&#xD;&#xA;<LI>Lam MS. Pharmacotherapy 2011; 31:164.</LI></OL></div><div id=\"graphicVersion\">Graphic 109415 Version 6.0</div></div></div>"},"109416":{"type":"graphic_table","displayName":"FOLFOX plus trastuzumab for metastatic gastric and GEJ cancer","title":"FOLFOX plus trastuzumab chemotherapy for HER2-overexpressing* metastatic gastric and gastroesophageal junction cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">FOLFOX plus trastuzumab chemotherapy for HER2-overexpressing* metastatic gastric and gastroesophageal junction cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 14 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Trastuzumab</td> <td>6 mg/kg IV (loading dose)</td> <td>Dilute in 250 mL NS<sup>&#182;</sup> and administer over 90 minutes for the loading dose. <strong>Do not</strong> mix with D5W and <strong>do not</strong> infuse as an IV push or bolus.</td> <td>Day 1 (cycle 1 only)</td> </tr> <tr> <td>Trastuzumab</td> <td>4 mg/kg IV</td> <td>Dilute in 250 mL NS<sup>&#182;</sup> and administer over 30 minutes. <strong>Do not</strong> mix with D5W and <strong>do not</strong> infuse as an IV push or bolus.</td> <td>Day 1 of every subsequent cycle, starting with cycle 2</td> </tr> <tr> <td>Oxaliplatin<sup>&#916;</sup></td> <td>85 mg/m<sup>2</sup> IV</td> <td>Dilute with 500 mL D5W<sup>&#182;</sup> and administer over two hours. Oxaliplatin and leucovorin can be administered concurrently in separate bags using a Y-connector.</td> <td>Day 1</td> </tr> <tr> <td>Leucovorin<sup>&#9674;</sup></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL D5W<sup>&#182;</sup> and administer over two hours concurrent with oxaliplatin.</td> <td>Day 1</td> </tr> <tr> <td>Fluorouracil (FU)<sup>&#167;</sup></td> <td>400 mg/m<sup>2</sup> IV bolus</td> <td>Slow IV push (over two to five minutes). Administer immediately after leucovorin.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>FU</td> <td>2400 mg/m<sup>2</sup> total dose IV</td> <td>Dilute with 500 to 1000 mL D5W<sup>&#182;</sup> and administer as continuous IV over 46 hours (begin immediately after FU IV bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen for FOLFOX. Most clinicians do not routinely premedicate prior to the first trastuzumab dose. However, patients may be instructed to self-administer acetaminophen or a nonsteroidal anti-inflammatory drug (NSAID) if flu-like symptoms develop within 24 hours of drug administration. </li> <li>Refer to UpToDate topics on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\" and \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin and fluorouracil are classified as irritants, but oxaliplatin (rare) can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia &#60;5%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of oxaliplatin may be needed for severe renal impairment.<sup>[2]</sup> A lower starting dose of FU may be needed for patients with liver impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Counsel patients to avoid exposure to cold during and for approximately 72 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiopulmonary issues</strong></td> <td colspan=\"3\"> <ul> <li>Prolongation of the corrected QT interval (QTc) and ventricular arrhythmias has been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QTc interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. Cases of pulmonary fibrosis are rarely reported with oxaliplatin. </li> <li>Trastuzumab is associated with cardiotoxicity; assess baseline left ventricular ejection fraction (LVEF) prior to therapy and then at least every three months during therapy.<sup>[3]</sup> Patients with heart failure or a baseline LVEF &#60;50% were excluded from the study.<sup>[1]</sup> Trastuzumab may cause serious pulmonary toxicity and should be used with caution in patients with preexisting pulmonary disease. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\". </li> <li>Cardiotoxicity observed with FU includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (especially potassium and magnesium) and liver and renal function every two weeks prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for infusion reactions, especially during the first two courses of trastuzumab. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for mucositis, diarrhea, and palmar-plantar erythrodysesthesias during treatment. </li> <li>Refer to UpToDate topics on \"Oral toxicity associated with chemotherapy\" and \"Cutaneous complications of conventional chemotherapy agents\" and \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess cardiac function as clinically indicated. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment cycle by one week for absolute neutrophil count &#60;1500/microL or platelets &#60;75,000/microL on the day of treatment. If treatment is delayed for two weeks or delayed for one week on two separate occasions, eliminate FU bolus. With the second occurrence, reduce infusional FU by 20% and reduce oxaliplatin dose from 85 to 65 mg/m<sup>2</sup>.<sup>[2]</sup> </li> <li><strong>NOTE:</strong> Severe myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Withhold oxaliplatin for persisting grade 2 or any grade 3 paresthesias/dysesthesias until recovery.<sup>[1]</sup> The United States Prescribing Information recommends a dose reduction in oxaliplatin to 65 mg/m<sup>2</sup> for persistent grade 2 neurosensory events that do not resolve, and permanent discontinuation for persistent grade 3 neurosensory events.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Withhold treatment for grade 2 or worse diarrhea, and restart at a 20% lower dose of all agents after complete resolution. The United States Prescribing Information recommends dose reduction of oxaliplatin to 65 mg/m<sup>2</sup> as well as a reduction of bolus FU and infusional FU after recovery from grade 3 or 4 diarrhea during the prior cycle.<sup>[2]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency.<sup>[4]</sup> Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Assess LVEF at least every three months during trastuzumab.<sup>[3]</sup> The United States Prescribing Information recommends withholding trastuzumab for at least four weeks for LVEF &#8805;16% decrease from baseline or LVEF below normal limits and &#8805;10% decrease from baseline; repeat LVEF assessment every four weeks. May resume trastuzumab treatment if LVEF returns to normal limits within four to eight weeks and remains at &#8804;15% decrease from baseline value. Discontinue permanently for persistent (&#62;8 weeks) LVEF decline or for &#62;3 incidents of treatment interruptions for cardiomyopathy.<sup>[3]</sup> Guidelines for managing cardiac dysfunction during therapy with HER2-targeted agents are available. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Discontinue trastuzumab for serious pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\" and \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">HER2: human epidermal growth factor receptor 2; IV: intravenous; NS: normal saline; D5W: 5% dextrose in water; ECG: electrocardiogram; CBC: complete blood count.<br />* High levels of HER2 overexpression, as determined by either 3+ immunohistochemical staining (IHC) or positive fluorescence in situ hybridization (FISH), are used to select patients for therapy with trastuzumab. Refer to UpToDate topic on \"Systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer\".<br />Â¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Î” Many centers routinely infuse oxaliplatin through a central venous catheter because of local pain with infusion into a peripheral vein.<br /><FONT class=lozenge>â—Š</FONT> Leucovorin dose is given for dl-racemic mixture.<SUP>[5]</SUP> Use half the dose for LEVOleucovorin (l-leucovorin).<br />Â§ No FU dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Soularue E, et al. Bull Cancer 2015; 102:324.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on May 11, 2016).</LI>&#xD;&#xA;<LI>Trastuzumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on May 11, 2016).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on May 11, 2016).</LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on May 11, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 109416 Version 4.0</div></div></div>"},"109423":{"type":"graphic_algorithm","displayName":"Propranolol for complicated infantile hemangiomas","title":"Treatment of complicated infantile hemangiomas* with oral propranolol","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Treatment of complicated infantile hemangiomas* with oral propranolol</div><div class=\"cntnt\"><img style=\"width:712px; height:1024px;\" src=\"images/DERM/109423_Propranolol_compl_hemangims.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; MRI: magnetic resonance imaging; PHACE: posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities; bpm: beats per minute.<br />* Complicated hemangiomas include:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Large hemangiomas at increased risk of scarring or disfigurement</li>&#xD;&#xA;    <li>Life-threatening hemangiomas</li>&#xD;&#xA;    <li>Hemangiomas carrying functional risks</li>&#xD;&#xA;    <li>Ulcerated hemangiomas</li>&#xD;&#xA;</ul>&#xD;&#xA;&para; Postnatal age in weeks minus number of weeks preterm.<br />&Delta; Falsely low or high blood pressure measurements may occur if an inappropriate cuff size is used. In addition, the infant's behavioral state (crying/agitated versus calm/sleeping) can greatly impact blood pressure measurements. Refer to UpToDate topics on measurement of blood pressure in infants and children.<br /><span class=\"lozenge\">&loz;</span> Baseline head/neck MRI with angiography is also preferred in infants with large facial hemangiomas at risk for PHACE prior to initiating propranolol; however, in infants needing urgent treatment, propranolol may be given in the wait for neuroimaging results. Propranolol can be initiated at a lower dose and slowly titrated up to a maximum dose of 1 mg/kg/day.<br />&sect; This is a suggested initial dose; however, the initial dose and titration may vary according to local protocols.<br />&yen; Serious adverse reactions:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Bradycardia (&lt;90 bpm in newborns and infants &le;3 months)</li>&#xD;&#xA;    <li>Hypotension</li>&#xD;&#xA;    <li>Bronchospasm</li>&#xD;&#xA;    <li>Hypoglycemia</li>&#xD;&#xA;</ul>&#xD;&#xA;Refer to UpToDate topics on beta-blocker toxicity.<br />&Dagger; Early signs of hypoglycemia:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Sweating (most important, not masked by beta blockers)</li>&#xD;&#xA;    <li>Jitteriness</li>&#xD;&#xA;    <li>Irritability</li>&#xD;&#xA;    <li>Cyanosis</li>&#xD;&#xA;    <li>Poor feeding</li>&#xD;&#xA;    <li>Hypothermia</li>&#xD;&#xA;    <li>Lethargy</li>&#xD;&#xA;</ul>&#xD;&#xA;Refer to UpToDate topics on hypoglycemia in infancy.</div><div id=\"graphicVersion\">Graphic 109423 Version 1.0</div></div></div>"},"109424":{"type":"graphic_table","displayName":"Definition of MAC values","title":"Definition of minimum alveolar concentration (MAC) values","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of minimum alveolar concentration (MAC) values</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;MAC level</td> <td class=\"subtitle1\">Effect</td> </tr> <tr> <td><strong>0.3 MAC</strong></td> <td><span style=\"color: black;\">MAC<sub>awake</sub> (</span><span style=\"color: black;\">MAC value below this will allow the patient to become conscious)</span></td> </tr> <tr> <td><strong>1 MAC</strong></td> <td>End-tidal concentration of anesthetic agent necessary to prevent movement in response to a surgical stimulus in 50% of patients</td> </tr> <tr> <td><strong>1.5 MAC</strong></td> <td>MAC value where 90% of patients will not move in response to a surgical stimulus</td> </tr> <tr> <td><strong>2.0 MAC</strong></td> <td>MAC-BAR <span style=\"color: black;\">(</span><span style=\"color: black;\">MAC value required to block autonomic responses to a surgical stimulus in 50% of patients)</span></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><SPAN style=\"COLOR: black\">MAC: minimum alveolar concentration; a value of 1.0 MAC is </SPAN>the concentration of an inhalation anesthetic agent in the alveoli required to prevent movement to a surgical stimulus in 50% of patients.</div><div id=\"graphicVersion\">Graphic 109424 Version 2.0</div></div></div>"},"109425":{"type":"graphic_table","displayName":"Evaluation for behavioral sleep problem in children","title":"Clinical evaluation for children with suspected behavioral sleep problem","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical evaluation for children with suspected behavioral sleep problem</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Detailed description of the sleep problem(s)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Type of problem - eg, bedtime resistance, difficulty initiating sleep, and/or nighttime awakenings </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Onset, frequency, and duration </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Child's usual sleep schedule (weekdays and weekends) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Sleeping environment - including presence of siblings, television, or other noise or distraction </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Pre-sleep activities - including exercise, videogames, or other stimulating activities </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Bedtime routine </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Parents' response to the problem and previous treatment attempts </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Potential psychosocial contributors</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Potential triggers at time of onset - eg, change in schedule, stressful family event, or birth of a sibling </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Other psychosocial triggers - eg, marital discord, mental health problems, or medical illness (in parents, child, or other family members) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Child's developmental history, temperament, and any behavioral problems </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Screen time - including time of day </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Potential biologic contributors (may also have psychosocial effects)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Other primary sleep disorders, especially: <ul> <li>Obstructive sleep apnea - symptoms may include frequent snoring, loud snoring, observed pauses in breathing, mouth breathing, or daytime hyperactive, inattentive, or somnolent behavior</li> <li>Restless legs syndrome - symptoms include the urge to move the legs especially in the evening and at rest, leg discomfort, restless sleep, and kicking movements during sleep</li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Child's medical history - especially disorders that may interfere with sleep, such as allergies and atopic dermatitis, seizure disorders, or rheumatologic conditions </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Medications or caffeine - especially stimulants or psychoactive medications </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Family history for insomnia or psychopathology </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Additional focused history for adolescents with insomnia</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Bedtime, sleep onset, and waking time - especially on weekends versus school days </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Access to and use of electronics in bedroom - computer, television, e-readers </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Medications or caffeine - especially stimulants or psychoactive medications; drug and/or alcohol use </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Preferred sleep schedule and if insomnia resolves when sleeping on preferred schedule </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Anxiety about falling or staying asleep and anticipated consequences </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Activities in bed other than sleeping (doing homework, use of social media phone, texting, social games) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Daytime napping (when, how long) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Daytime sleepiness (dozing off at school, doing homework, on car rides) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Dr. Judith Owens.</div><div id=\"graphicVersion\">Graphic 109425 Version 4.0</div></div></div>"},"109426":{"type":"graphic_table","displayName":"Recommended sleep times for children","title":"Recommended sleep times for children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended sleep times for children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age group</td> <td class=\"subtitle1\">Recommended sleep time</td> </tr> <tr> <td>Infants 4 to 12 months</td> <td>12 to 16 hours (including naps)</td> </tr> <tr> <td>Toddlers 1 to 2 years</td> <td>11 to 14 hours (including naps)</td> </tr> <tr> <td>Children 3 to 5 years</td> <td>10 to 13 hours (including naps)</td> </tr> <tr> <td>Children 6 to 12 years</td> <td>9 to 12 hours</td> </tr> <tr> <td>Teens 13 to 18 years</td> <td>8 to 10 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For optimal health, daytime functioning and development, the above sleep times are recommended on a regular basis. These consensus recommendations were made by the American Academy of Sleep Medicine (AASM)<SUP>[1]</SUP> and endorsed by the American Academy of Pediatrics (AAP).<SUP>[2]</SUP></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Paruthi S, Brooks LJ, D'Ambrosio C, et al. Recommended Amount of Sleep for Pediatric Populations: A Consensus Statement of the American Academy of Sleep Medicine. J Clin Sleep Med 2016; 12:785.â€‹</li>&#xD;&#xA;    <li>Recommended Amount of Sleep for Pediatric Populations. Pediatrics 2016; 138.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109426 Version 2.0</div></div></div>"},"109427":{"type":"graphic_algorithm","displayName":"Initial evaluation and treatment of RCC","title":"Initial evaluation and treatment of renal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Initial evaluation and treatment of renal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:626px; height:568px;\" src=\"images/ONC/109427_Initial_eval_treatment_RCC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IVC: inferior vena cava.<br />* Preliminary diagnosis is based upon characteristic findings on imaging studies (computed tomography/magentic resonance imaging [CT/MRI]); tissue diagnosis generally obtained at time of definitive surgery.<br />&para; Chest imaging, additional studies as clinically indicated to look for evidence of metastases.<br />&Delta; Selection of patients should be done with considerable care so that appropriate patients can proceed with systemic therapy; important factors include good performance status, ability to perform adequate debulking, and limited metastatic disease burden. Refer to UpToDate topic on the role of surgery in patients with metastatic renal cell carcinoma.<br /><span class=\"lozenge\">&loz;</span> Partial nephrectomy is the preferred approach to confirm the diagnosis and treat a renal mass &lt;4 cm. However, thermal ablation (cryotherapy, radiofrequency ablation) or active surveillance may be appropriate alternatives for patients who are not surgical candidates. The choice between these approaches is guided by local expertise and patient preference. Refer to UpToDate topic on the diagnostic approach, differential diagnosis, and treatment of a small renal mass.<br />&sect; Based upon factors including patient preference, age, comorbidity.</div><div id=\"graphicVersion\">Graphic 109427 Version 1.0</div></div></div>"},"109428":{"type":"graphic_algorithm","displayName":"Algorithm for the management of claudication","title":"Algorithm for the management of claudication","html":"<div class=\"graphic\"><div style=\"width: 698px\" class=\"figure\"><div class=\"ttl\">Algorithm for the management of claudication</div><div class=\"cntnt\"><img style=\"width:678px; height:1214px;\" src=\"images/SURG/109428_Algorithm_mgmt_claudication.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; MR: magnetic resonance.<br />* Exclude other causes of vascular occlusive disease based upon demographics, risk factors and clinical signs such as embolism (eg, atrial fibrillation), thrombosed arterial aneurysm (eg, palpable popliteal mass), and extrinsic vascular compression (younger age).<br />Â¶ Noninvasive studies include ankle-brachial index, segmental pressures, pulse volume recordings, and exercise testing.<br />Î” Supervised exercise therapy is preferred but not always possible. Unsupervised exercise with monitoring is an acceptable alternative. For patients with predicted limited exercise capability, cilostazol can be initiated concurrently.<br /><FONT class=lozenge>â—Š</FONT> We suggest a therapeutic trial of cilostazol for patients with moderate-to-severe claudication. Naftidrofuryl, which has fewer side effects, can be tried first where available. For patients with contraindications or who do not tolerate cilostazol, pentoxifylline is an alternative. These can be prescribed concurrently with initiation of an exercise program.<br />Â§ CT or MR angiography. For patients with proximal occlusive disease (weak femoral pulse), conventional catheter-based arteriography may be performed initially in anticipation of possible intervention.<br />Â¥ Tibial vessel disease alone is rarely a cause of lifestyle-limiting claudication. Tibial revascularization is rarely indicated for claudication.<br />â€¡ Good candidates for peripheral bypass surgery have favorable anatomy for bypass (target vessel; good runoff; and, ideally, vein conduit), are medically fit, and have an anticipated life expectancy that will allow the patient to benefit from the procedure.<br />â€  Following revascularization, antithrombotic therapy depends upon the nature of revascularization (ie, type of stent, type of bypass conduit); if initiated, cilostazol may be discontinued.</div><div id=\"graphicVersion\">Graphic 109428 Version 1.0</div></div></div>"},"109429":{"type":"graphic_table","displayName":"Differential diagnosis of emergence delirium","title":"Differential diagnosis of emergence delirium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of emergence delirium</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Pain</li> </ul> </td> </tr> <tr> <td> <ul> <li>Hypoxia</li> </ul> </td> </tr> <tr> <td> <ul> <li>Hypotension</li> </ul> </td> </tr> <tr> <td> <ul> <li>Hypocarbia or hypercarbia</li> </ul> </td> </tr> <tr> <td> <ul> <li>Hypothermia</li> </ul> </td> </tr> <tr> <td> <ul> <li>Hypoglycemia</li> </ul> </td> </tr> <tr> <td> <ul> <li>Increased intracranial pressure</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The diagnosis most often confused with ED is pain. The remaining diagnoses shown in this table present with some or all of the features of ED, most notably an altered state of consciousness with disturbance in attention, and disorientation.</div><div class=\"graphic_footnotes\">ED: emergence delirium.</div><div id=\"graphicVersion\">Graphic 109429 Version 2.0</div></div></div>"},"109441":{"type":"graphic_picture","displayName":"Difficult access to airway during robotic thoracoscopic surgery","title":"Difficult access to the airway during robotic-assisted thoracoscopic surgery","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Difficult access to the airway during robotic-assisted thoracoscopic surgery</div><div class=\"cntnt\"><img style=\"width:510px; height:764px;\" src=\"images/ANEST/109441_Diff_airway_robo_thrcic_sur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This picture shows a patient who is about to undergo robotic-assisted thoracoscopic surgery. The patient is in the&nbsp;lateral decubitus position, facing away from the anesthesia machine and other anesthesia equipment.<br />(B) This picture shows the&nbsp;same patient after he has been covered with surgical drapes,&nbsp;with the robotic equipment now \"docked\" into position surrounding the patient's upper body. In these circumstances, the patient's face, airway, and endotracheal tube are nearly inaccessible. </div><div id=\"graphicVersion\">Graphic 109441 Version 1.0</div></div></div>"},"109443":{"type":"graphic_figure","displayName":"Typical electrocardiographic features of hyperkalemia","title":"Typical electrocardiographic features of hyperkalemia","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Typical electrocardiographic features of hyperkalemia</div><div class=\"cntnt\"><img style=\"width:626px; height:514px;\" src=\"images/NEPH/109443_Typcl_EKG_feat_hyperkalemia.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med 2000; 18:721.</div><div id=\"graphicVersion\">Graphic 109443 Version 1.0</div></div></div>"},"109446":{"type":"graphic_picture","displayName":"Necrotic wound eschar","title":"Necrotic wound eschar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrotic wound eschar</div><div class=\"cntnt\"><img style=\"width:188px; height:238px;\" src=\"images/SURG/109446_Necrotic_wound_eschar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrotic eschar at the exit site of an infected&nbsp;Hickman catheter in a neutropenic patient with acute leukemia.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders, MD.</div><div id=\"graphicVersion\">Graphic 109446 Version 1.0</div></div></div>"},"109447":{"type":"graphic_algorithm","displayName":"Hepatotoxicity caused by first-line anti-TB drugs in adults","title":"Approach to hepatotoxicity caused by first-line antituberculous drugs in adults*","html":"<div class=\"graphic\"><div style=\"width: 1042px\" class=\"figure\"><div class=\"ttl\">Approach to hepatotoxicity caused by first-line antituberculous drugs in adults*</div><div class=\"cntnt\"><img style=\"width:1022px; height:972px;\" src=\"images/ID/109447_Hepatotoxicty_anti-TB_adlts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* First-line antituberculous drugs include isoniazid, rifampin, pyrazinamide and ethabutol. Isoniazid, rifampin and pyrazinamide are potentially hepatotoxic; ethambutol is not hepatotoxic.<br />Â¶ Liver function tests include measurement of serum bilirubin, alkaline phosphatase, and hepatocellular enzymes (alanine aminotransferase and aspartate aminotransferase).<br />Î” Alternative causes of elevated liver function tests include alcohol, acetaminophen, viral hepatitis, gallstones, biliary obstruction, and others.<br /><FONT class=lozenge>â—Š</FONT> Signs and symptoms of hepatotoxicity include nausea, vomiting, malaise, low-grade fever, and anorexia. Refer to the UpToDate topic on drug-induced liver injury for further discussion.<br />Â§ The approach to subsequent monitoring depends on clinical circumstances; some favor checking liver function tests weekly until on a stable regimen, then every two to four weeks thereafter.<br />Â¥ There is overlap in the pattern of liver injury caused by rifampin, isoniazid, and pyrazinamide; all individually or in combination may contribute to hepatotoxicity.<br />â€¡ Intervals of treatment interruption warranting resumption of therapy from the beginning vary between initiation and continuation phases; refer to text for further discussion.<br />â€  Refer to UpToDate content on treatment of tuberculosis for further discussion.</div><div class=\"graphic_reference\">References &#xD;&#xA;<OL>&#xD;&#xA;<LI>Curry International Tuberculosis Center and California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition.</LI>&#xD;&#xA;<LI>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016.</LI></OL></div><div id=\"graphicVersion\">Graphic 109447 Version 1.0</div></div></div>"},"109448":{"type":"graphic_picture","displayName":"Ultrasound transducer position anterior elbow long axis","title":"UltrasoundÂ transducer position for examination of the anterior elbow in long axis","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Ultrasound&nbsp;transducer position for examination of the anterior elbow in long axis</div><div class=\"cntnt\"><img style=\"width:501px; height:756px;\" src=\"images/SM/109448_Probe_pos_ant_elbow_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows the position of the ultrasound transducer for obtaining a long axis view of the anterior elbow.</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109448 Version 1.0</div></div></div>"},"109449":{"type":"graphic_diagnosticimage","displayName":"Ultrasound long axis view anterior elbow","title":"Ultrasound long axis view anterior elbow","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">Ultrasound long axis view anterior elbow</div><div class=\"cntnt\"><img style=\"width:721px; height:416px;\" src=\"images/SM/109449_Lng_axs_view_ant_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image&nbsp;above shows&nbsp;a long axis view of the anterior elbow.&nbsp;</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109449 Version 1.0</div></div></div>"},"109450":{"type":"graphic_picture","displayName":"Ultrasound probe position anterior elbow transverse axis","title":"Ultrasound probe position anterior elbow transverse axis","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Ultrasound probe position anterior elbow transverse axis</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/SM/109450_Prbe_pos_ant_elbw_trnsv_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows the position of the ultrasound transducer for obtaining a&nbsp;short axis, or transverse,&nbsp;view of the anterior elbow.</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109450 Version 1.0</div></div></div>"},"109451":{"type":"graphic_diagnosticimage","displayName":"Ultrasound transverse view anterior elbow","title":"Ultrasound transverse view anterior elbow","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">Ultrasound transverse view anterior elbow</div><div class=\"cntnt\"><img style=\"width:721px; height:416px;\" src=\"images/SM/109451_Transv_view_ant_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image&nbsp;shows the anterior elbow in the short (transverse)&nbsp;axis.&nbsp; </div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109451 Version 1.0</div></div></div>"},"109452":{"type":"graphic_picture","displayName":"Ultrasound probe position distal biceps tendon long axis","title":"Ultrasound probe position distal biceps tendon long axis","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Ultrasound probe position distal biceps tendon long axis</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/SM/109452_Probe_pos_distl_biceps_tndn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows proper position of the ultrasound transducer for imaging the distal biceps tendon in its long axis. The probe&nbsp;lies over the anterior elbow distal to the antecubital fossa, while the patient's elbow is extended and forearm is supinated.</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109452 Version 1.0</div></div></div>"},"109453":{"type":"graphic_diagnosticimage","displayName":"Ultrasound long axis distal biceps tendon","title":"Ultrasound long axis distal biceps tendon","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Ultrasound long axis distal biceps tendon</div><div class=\"cntnt\"><img style=\"width:612px; height:540px;\" src=\"images/SM/109453_Lng_axs_distl_biceps_tndn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows the distal bicep tendon in long axis as it travels to its insertion on the radial tuberosity.</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109453 Version 2.0</div></div></div>"},"109454":{"type":"graphic_picture","displayName":"Ultrasound elbow \"snake charmer\" transducer position","title":"Ultrasound elbow \"snake charmer\"Â transducer position","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Ultrasound elbow \"snake charmer\"&nbsp;transducer position</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/SM/109454_Snake_charmer_probe_pos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows the&nbsp;so-called \"snake charmer\"&nbsp;position used to&nbsp;obtain ultrasound images&nbsp;of the elbow, particularly the distal biceps tendon insertion, in the short, or transverse, axis.&nbsp;</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109454 Version 1.0</div></div></div>"},"109455":{"type":"graphic_diagnosticimage","displayName":"Ultrasound snake charmer distal biceps tendon","title":"Ultrasound snake charmer distal biceps tendon","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Ultrasound snake charmer distal biceps tendon</div><div class=\"cntnt\"><img style=\"width:612px; height:540px;\" src=\"images/SM/109455_Snake_chrmr_distl_bcps_tndn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image&nbsp;above shows&nbsp;the distal aspect of the biceps tendon in its &nbsp;long axis. This image is obtained using the \"snake charmer\" positioning. </div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109455 Version 1.0</div></div></div>"},"109456":{"type":"graphic_diagnosticimage","displayName":"Ultrasound brachial artery at anterior elbow","title":"Ultrasound brachial artery at anterior elbow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound brachial artery at anterior elbow</div><div class=\"cntnt\"><img style=\"width:418px; height:490px;\" src=\"images/SM/109456_Brachial_artery_ant_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows the distal biceps tendon in its long axis adjacent to the brachial artery (shown with color Doppler). The dashed arrows outline the borders of the distal biceps tendon at its&nbsp;insertion.</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109456 Version 2.0</div></div></div>"},"109457":{"type":"graphic_figure","displayName":"HLA nomenclature","title":"HLA nomenclature","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">HLA nomenclature</div><div class=\"cntnt\"><img style=\"width:506px; height:378px;\" src=\"images/RHEUM/109457_HLA_nomenclature_PR.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.</div><div class=\"graphic_reference\">This figure is kindly provided by Professor Steven GE Marsh, Anthony Nolan Research Institute, London UK and is taken from the HLA Nomenclature website <A href=\"http://hla.alleles.org/\" target=_blank>http://hla.alleles.org</A>. Figure available at: <A href=\"http://hla.alleles.org/nomenclature/naming.html\" target=_blank>http://hla.alleles.org/nomenclature/naming.html</A> (Accessed on August 16, 2016). Copyright Â© 2010. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109457 Version 1.0</div></div></div>"},"109458":{"type":"graphic_diagnosticimage","displayName":"Ultrasound radial nerve at elbow","title":"Ultrasound radial nerve at elbow","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Ultrasound radial nerve at elbow</div><div class=\"cntnt\"><img style=\"width:483px; height:320px;\" src=\"images/SM/109458_Ultrsnd_radial_nerve_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above is an ultrasound image of the radial tunnel&nbsp;showing the&nbsp;radial nerve in its short axis.</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109458 Version 1.0</div></div></div>"},"109459":{"type":"graphic_figure","displayName":"Gene structure of the human major histocompatibility complex","title":"Gene structure of the human major histocompatibility complex","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Gene structure of the human major histocompatibility complex</div><div class=\"cntnt\"><img style=\"width:562px; height:335px;\" src=\"images/RHEUM/109459_GenestructureofthehumanMHC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chromosome 6 and its cytogenetic bands are shown. The human MHC region, also referred to as the HLA region (pink), is located on the short arm at position p21.3. The classical MHC spans 3.6 megabases (Mb) and includes more than 200 genes. Some MHC class I, II, and III genes are shown schematically.</div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen; TAP: transporter associated with antigen processing; TAPBP: TAP binding protein; LMP: low-molecular-weight protein (proteasome subunit); C4B: complement factor C4B; C4A: complement factor C4A; LTB: lymphotoxin beta; TNF: tumor necrosis factor-alpha; LTA: lymphotoxin alpha; MHC: major histocompatibility complex.</div><div class=\"graphic_reference\">Modified from: Murphy KM, Travers P, Walport R. Antigen presentation to T lymphocytes. In: Janeway's Immunobiology, 7th ed, Murphey KM, Travers P, Walport M (Eds), Garland Science, 2007.</div><div id=\"graphicVersion\">Graphic 109459 Version 2.0</div></div></div>"},"109460":{"type":"graphic_diagnosticimage","displayName":"Ultrasound elbow extensor tendon long axis","title":"Ultrasound elbow extensor tendon long axis","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Ultrasound elbow extensor tendon long axis</div><div class=\"cntnt\"><img style=\"width:713px; height:382px;\" src=\"images/SM/109460_Elbow_extensor_tndn_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image&nbsp;above shows&nbsp;the common extensor tendon and radiocapitellar joint in their long axis.&nbsp;</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109460 Version 1.0</div></div></div>"},"109461":{"type":"graphic_picture","displayName":"Ultrasound transducer position posterior elbow","title":"UltrasoundÂ transducer position for posterior elbow examination","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Ultrasound&nbsp;transducer position for posterior elbow examination</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/SM/109461_Probe_pos_post_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows the position of the ultrasound transducer for examining the posterior elbow. The transducer is oriented in the long axis of the triceps tendon insertion on the olecranon.</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109461 Version 1.0</div></div></div>"},"109462":{"type":"graphic_diagnosticimage","displayName":"Ultrasound ulnar nerve cubital tunnel","title":"Ultrasound ulnar nerve cubital tunnel","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Ultrasound ulnar nerve cubital tunnel</div><div class=\"cntnt\"><img style=\"width:535px; height:235px;\" src=\"images/SM/109462_Ulnar_nerve_cubital_tunnel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above is an ultrasound image of the posterior elbow showing the&nbsp;cubital tunnel and ulnar nerve on the medial wall of the tunnel, as well as the triceps tendon in short axis.</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109462 Version 1.0</div></div></div>"},"109463":{"type":"graphic_diagnosticimage","displayName":"Ultrasound common flexor tendon long axis","title":"Ultrasound common flexor tendon long axis","html":"<div class=\"graphic\"><div style=\"width: 777px\" class=\"figure\"><div class=\"ttl\">Ultrasound common flexor tendon long axis</div><div class=\"cntnt\"><img style=\"width:757px; height:301px;\" src=\"images/SM/109463_Common_flexor_tndn_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image&nbsp;above shows a long axis view of&nbsp;the common flexor tendon&nbsp;at its origin on the&nbsp;medial epicondyle.</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109463 Version 1.0</div></div></div>"},"109464":{"type":"graphic_diagnosticimage","displayName":"Ultrasound elbow ulnar collateral ligament","title":"Ultrasound elbow ulnar collateral ligament","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Ultrasound elbow ulnar collateral ligament</div><div class=\"cntnt\"><img style=\"width:715px; height:524px;\" src=\"images/SM/109464_Elbow_ulnar_clltrl_ligament.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above is an ultrasound image of the ulnar collateral ligament and medial elbow joint in long axis.</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109464 Version 1.0</div></div></div>"},"109466":{"type":"graphic_table","displayName":"Criteria for considering palliative care referral, ESLD","title":"Criteria for considering a palliative care referral in chronic liver disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for considering a palliative care referral in chronic liver disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient characteristics</td> <td class=\"subtitle1\">Social circumstances or issues related to anticipatory bereavement</td> </tr> <tr> <td> <ul> <li>Child-Turcotte-Pugh class B or&nbsp;C </li> <li>MELD score &#8805;14 to 15 </li> <li>No longer a transplant candidate or patient refusal of transplant </li> <li>Complications, such as ascites, bleeding varices, or hepatic encephalopathy, that are difficult to manage or are treatment refractory </li> <li>Severe muscle wasting and cachexia </li> <li>Development of hepatorenal syndrome or renal failure </li> <li>Impaired function in daily activities or dependence on others</li> </ul> </td> <td> <ul> <li>Familial factors including: <ul> <li>Inadequate&nbsp;caregiver support or family discord so that the patient has unmet needs</li> <li>History of intensely dependent relationship(s) </li> <li>Parental concerns regarding care of dependents </li> </ul> </li> <li>Unresolved grief or multiple prior losses </li> <li>Disagreements about goals of care </li> <li>Spiritual/existential crisis </li> <li>Need for coordination of care at multiple sites </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MELD: Model for End Stage Liver Disease.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>NCCN Guidelines: Palliative Care, Version 1.2016. National Comprehensive Cancer Network 2016. </LI>&#xD;&#xA;<LI>Cox-North P, Doorenbos A, Shannon SE, et al. The transition to end-of-life care in end-stage liver disease. J Hosp Palliat Nurs. 2013; 15:209.</LI></OL></div><div id=\"graphicVersion\">Graphic 109466 Version 1.0</div></div></div>"},"109467":{"type":"graphic_table","displayName":"WHO classification of medulloblastoma","title":"World Health Organization (WHO)Â classification of medulloblastoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO)&nbsp;classification of medulloblastoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Medulloblastomas, genetically defined</td> </tr> <tr> <td class=\"indent1\">Medulloblastoma, WNT-activated</td> </tr> <tr> <td class=\"indent1\">Medulloblastoma, SHH-activated and <em>TP53</em>-mutant</td> </tr> <tr> <td class=\"indent1\">Medulloblastoma, SHH-activated and <em>TP53</em>-wildtype</td> </tr> <tr> <td class=\"indent1\">Medulloblastoma, non-WNT/non-SHH</td> </tr> <tr> <td class=\"indent2\">Medulloblastoma, group 3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Medulloblastoma, group 4</td> </tr> <tr> <td class=\"subtitle1_left\">Medulloblastomas, histologically defined</td> </tr> <tr> <td class=\"indent1\">Medulloblastoma, classic</td> </tr> <tr> <td class=\"indent1\">Desmoplastic/nodular medulloblastoma</td> </tr> <tr> <td class=\"indent1\">Medulloblastoma with extensive nodularity</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Large cell/anaplastic medulloblastoma</td> </tr> <tr> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\"><strong>Medulloblastoma, NOS</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WNT: winged; SHH: sonic hedgehog; NOS: not otherwise specified.</div><div class=\"graphic_reference\">Data from: WHO Classification of Tumours of the Central Nervous System (revised 4<SUP>th </SUP>ed), Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC: Lyon 2016.</div><div id=\"graphicVersion\">Graphic 109467 Version 2.0</div></div></div>"},"109468":{"type":"graphic_diagnosticimage","displayName":"Ultrasound elbow medial epicondylosis","title":"Ultrasound elbow medial epicondylosis","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Ultrasound elbow medial epicondylosis</div><div class=\"cntnt\"><img style=\"width:509px; height:246px;\" src=\"images/SM/109468_Elbow_medial_epicondylosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above is an ultrasound image of a pathologic common flexor tendon shown in long axis&nbsp;with thickening and other signs of tendinosis.</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109468 Version 1.0</div></div></div>"},"109469":{"type":"graphic_diagnosticimage","displayName":"Ultrasound distal biceps tendon partial tear","title":"Ultrasound distal biceps tendon partial tear","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Ultrasound distal biceps tendon partial tear</div><div class=\"cntnt\"><img style=\"width:467px; height:362px;\" src=\"images/SM/109469_Distal_bcps_tndn_partl_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above is an ultrasound image of the distal biceps tendon in long axis showing a partial tear (arrow).</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109469 Version 1.0</div></div></div>"},"109472":{"type":"graphic_figure","displayName":"Side-to-side isoperistaltic strictureplasty","title":"Side-to-side isoperistaltic strictureplasty","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Side-to-side isoperistaltic strictureplasty</div><div class=\"cntnt\"><img style=\"width:478px; height:1295px;\" src=\"images/SURG/109472_Side_isoprstltc_strctrplsty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) The mesentery of the intestinal loop is divided at its midpoint, and the small bowel is severed between atraumatic intestinal clamps. The proximal intestinal loop is moved over the distal one in a side-to-side fashion such that stenotic areas of one loop are placed adjacent to dilated areas of the other loop. The two loops are approximated by a layer of interrupted nonabsorbable sutures.<br />(Panel B) A longitudinal enterotomy is performed on both loops, and the intestinal ends are spatulated (tapered) to avoid blind stumps.<br />(Panel C) The enterotomies are closed with an internal (posterior) running, full-thickness absorbable suture that is continued anteriorly and finished as a running Connell suture. This closure is reinforced by another layer of interrupted seromuscular nonabsorbable sutures (not shown).</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DW, Garrett KA. Strictureplasty and small bowel bypass in inflammatory bowel disease. In: Operative Techniques in Surgery, Mulholland MW (Ed), Wolters Kluwer Health, Philadelphia 2015. Copyright &copy; 2015 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 109472 Version 1.0</div></div></div>"},"109473":{"type":"graphic_figure","displayName":"Kono-S anastomosis","title":"Kono-S anastomosis","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Kono-S anastomosis</div><div class=\"cntnt\"><img style=\"width:532px; height:665px;\" src=\"images/SURG/109473_Kono-S_anastomosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform a Kono-S anastomosis, bowel resection is carried out with GIA staplers placed perpendicular to the mesentery (A). The bowel stumps are first reinforced with&nbsp;absorbable sutures, then sutured together to create a common support column, a unique feature of this technique (B). Bowels on both sides of the center support column are then opened longitudinally at the antimesenteric border, starting at 1 cm from the support column (C). The longitudinal incisions are then hand-sewn closed transversely using&nbsp;absorbable sutures in a single-layer manner to complete the anastomosis (D). In the completed anastomosis, the support column is positioned between the anastomosis and the mesentery (E). The potential advantage of the support column is to maintain the diameter and dimension of the anastomosis and prevent distortion or stenosis associated with recurrent strictures, which usually starts from the mesenteric side.</div><div class=\"graphic_reference\">Modified from: Kono T, Ashida T, Ebisawa Y, et al. A new antimesenteric functional end-to-end handsewn anastomosis: surgical prevention of anastomotic recurrence in Crohn's disease. Dis Colon Rectum 2011; 54:586.</div><div id=\"graphicVersion\">Graphic 109473 Version 1.0</div></div></div>"},"109481":{"type":"graphic_table","displayName":"Epidemiologic clues to the diagnosis of lymphadenopathy","title":"Epidemiologic clues to the diagnosis of lymphadenopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidemiologic clues to the diagnosis of lymphadenopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Exposure</td> <td class=\"subtitle1\">Diagnosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cat</li> </ul> </td> <td> <ul> <li>Cat-scratch disease, toxoplasmosis</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Undercooked meat</li> </ul> </td> <td> <ul> <li>Toxoplasmosis</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Tick bite</li> </ul> </td> <td> <ul> <li>Lyme disease, tularemia</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Tuberculosis</li> </ul> </td> <td> <ul> <li>Tuberculous adenitis</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recent blood transfusion or transplant</li> </ul> </td> <td> <ul> <li>Cytomegalovirus, HIV</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>High-risk sexual behavior</li> </ul> </td> <td> <ul> <li>HIV, syphilis, herpes simplex virus, cytomegalovirus, hepatitis B infection</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Intravenous drug use</li> </ul> </td> <td> <ul> <li>HIV, endocarditis, hepatitis B infection</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Occupational</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hunters, trappers</li> </ul> </td> <td> <ul> <li>Tularemia</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Fishermen, fishmongers, slaughterhouse workers</li> </ul> </td> <td> <ul> <li>Erysipeloid</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Travel-related</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Arizona, southern California, New Mexico, western Texas</li> </ul> </td> <td> <ul> <li>Coccidioidomycosis</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Southwestern United States</li> </ul> </td> <td> <ul> <li>Bubonic plague</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Southeastern or central United States</li> </ul> </td> <td> <ul> <li>Histoplasmosis</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Southeast Asia, India, northern Australia</li> </ul> </td> <td> <ul> <li>Scrub typhus</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Central or west Africa</li> </ul> </td> <td> <ul> <li>African trypanosomiasis (sleeping sickness)</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Central or South America</li> </ul> </td> <td> <ul> <li>American trypanosomiasis (Chagas' disease)</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>East Africa, Mediterranean, China, Latin America</li> </ul> </td> <td> <ul> <li>Kala-azar (leishmaniasis)</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Mexico, Peru, Chile, India, Pakistan, Egypt, Indonesia</li> </ul> </td> <td> <ul> <li>Typhoid fever</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Reproduced with permission from: Ferrer R. Lymphadenopathy: differential diagnosis and evaluation. Am Fam Physician 1998; 58:1313. Copyright &copy; 1998 American Academy of Family Physicians. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109481 Version 1.0</div></div></div>"},"109482":{"type":"graphic_table","displayName":"Lymph node groups: Location, lymphatic drainage and selected Ddx","title":"Lymph node groups: Location, lymphatic drainage and selected differential diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lymph node groups: Location, lymphatic drainage and selected differential diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Lymphatic drainage</td> <td class=\"subtitle1\">Causes</td> </tr> <tr> <td>Submandibular</td> <td>Tongue, submaxillary gland, lips and mouth, conjunctivae</td> <td>Infections of head, neck, sinuses, ears, eyes, scalp, pharynx</td> </tr> <tr> <td>Submental</td> <td>Lower lip, floor of mouth, tip of tongue, skin of cheek</td> <td>Mononucleosis syndromes, Epstein-Â­Barr virus, cytomegalovirus, toxoplasmosiss</td> </tr> <tr> <td>Jugular</td> <td>Tongue, tonsil, pinna, parotid</td> <td>Pharyngitis organisms, rubella</td> </tr> <tr> <td>Posterior cervical</td> <td>Scalp and neck, skin of arms and pectorals, thorax, cervical and axillary nodes</td> <td>Tuberculosis, lymphoma, head and neck malignancy</td> </tr> <tr> <td>Suboccipital</td> <td>Scalp and head</td> <td>Local infection</td> </tr> <tr> <td>Postauricular</td> <td>External auditory meatus, pinna, scalp</td> <td>Local infection</td> </tr> <tr> <td>Preauricular</td> <td>Eyelids and conjunctivae, temporal region, pinna</td> <td>External auditory canal</td> </tr> <tr> <td>Right supraclavicular node</td> <td>Mediastinum, lungs, esophagus</td> <td>Lung, retroperitoneal, or gastrointestinal cancer</td> </tr> <tr> <td>Left supraclavicular node</td> <td>Thorax, abdomen via thoracic duct</td> <td>Lymphoma, thoracic or retroperitoneal cancer, bacterial or fungal infection</td> </tr> <tr> <td>Axillary</td> <td>Arm, thoracic wall, breast</td> <td>Infections, catÂ­-scratch disease, lymphoma, breast cancer, silicone implants, brucellosis, melanoma</td> </tr> <tr> <td>Epitrochlear</td> <td>Ulnar aspect of forearm and hand</td> <td>Infections, lymphoma, sarcoidosis, tularemia, secondary syphilis</td> </tr> <tr> <td>Inguinal</td> <td>Penis, scrotum, vulva, vagina, perineum, gluteal region, lower abdominal wall, lower anal canal</td> <td>Infections of the leg or foot, STDs (eg, herpes simplex virus, gonococcal infection, syphilis, chancroid, granuloma inguinale, lymphogranuloma venereum), lymphoma, pelvic malignancy, bubonic plague</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">STDs: sexually transmitted diseases.</div><div class=\"graphic_reference\">Reproduced with permission from: Ferrer R. Lymphadenopathy: differential diagnosis and evaluation. Am Fam Physician 1998; 58:1313. Copyright &copy; 1998 American Academy of Family Physicians. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109482 Version 1.0</div></div></div>"},"109484":{"type":"graphic_figure","displayName":"Distribution of HIV-1 subtypes globally, 2004-2007","title":"Distribution of HIV-1 subtypes globally, 2004-2007","html":"<div class=\"graphic\"><div style=\"width: 1249px\" class=\"figure\"><div class=\"ttl\">Distribution of HIV-1 subtypes globally, 2004-2007</div><div class=\"cntnt\"><img style=\"width:1229px; height:750px;\" src=\"images/ID/109484_Dstrbtn_HIV1_subtyps_global.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the inset labeled global, the number of infections caused by HIV-1 subtypes and recombinants are represented as a proportion of the total number of people living with HIV-1 globally&nbsp;from 2004 to 2007. The relative size of the pie charts associated with each region on the map corresponds to the relative number of people living with HIV in that region. The colors representing the different HIV-1 subtypes are indicated in the superimposed legend.</div><div class=\"graphic_footnotes\">CRF: circulating recombinant forms; URF: unique recombinant forms.</div><div class=\"graphic_reference\">From: Hemelaar J, Gouws E, Ghys PD, et al. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25:679. DOI: <A href=\"http://journals.lww.com/aidsonline/pages/articleviewer.aspx?year=2011&amp;issue=03130&amp;article=00018&amp;type=abstract\" target=_blank>10.1097/QAD.0b013e328342ff93</A>. Copyright Â© 2011 International AIDS Society. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 109484 Version 1.0</div></div></div>"},"109485":{"type":"graphic_table","displayName":"Typical dosing of antiseizure drugs in adults with CKD","title":"Typical maintenance dosing of antiseizure drugs in adults with chronic kidney disease*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical maintenance dosing of antiseizure drugs in adults with chronic kidney disease*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antiseizure drug</td> <td class=\"subtitle1\">GFR &#62;60 mL/minute/1.73 m<sup>2</sup></td> <td class=\"subtitle1\">CKD stage 3<br /> GFR 30 to 59 mL/minute/1.73 m<sup>2</sup></td> <td class=\"subtitle1\">CKD stage 4<br /> GFR 15 to 29 mL/minute/1.73 m<sup>2</sup></td> <td class=\"subtitle1\">CKD stage 5<br /> GFR &#60;15 mL/minute/1.73 m<sup>2</sup></td> <td class=\"subtitle1\">ESRD with dialysis</td> </tr> <tr class=\"divider_bottom\"> <td>Carbamazepine</td> <td>400 to 1600 mg orally per day in two or three divided doses.</td> <td>No adjustment necessary.</td> <td>No adjustment necessary.</td> <td>No adjustment necessary.</td> <td>Usually no adjustment necessary.</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td>Gabapentin<sup>&#182;</sup></td> <td>900 to 3600 mg orally per day in three divided doses.</td> <td>400 to 1400 mg orally per day in two divided doses.</td> <td>200 to 700 mg orally once per day.</td> <td> <p>100 to 300 mg orally once per day.</p> Use with caution.</td> <td>200 to 300 mg supplement after each IHD session<sup>&#182;</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Lacosamide</td> <td>100 to 400 mg orally per day in two divided doses.</td> <td>No adjustment necessary<sup>&#916;</sup>.</td> <td> <p>Gradually titrate from low initial dose.</p> Maximum 300 mg per day in divided doses<sup>&#916;</sup>.</td> <td> <p>Gradually titrate from low initial dose.</p> Maximum 300 mg per day in divided doses<sup>&#916;</sup>.</td> <td>50% of daily dose as supplement after each IHD session<sup>&#916;</sup>.</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td>Lamotrigine</td> <td>Varies due to indication and concomitant antiseizure drugs (eg, without enzyme-inducing drug: 225 to 375 mg orally per day in two divided doses).</td> <td>Use with caution; dose reduction may be needed.</td> <td>Use with caution; dose reduction may be needed.</td> <td>Use with caution; dose reduction may be needed.</td> <td> <p>Give dose after IHD.</p> Consider post-HD supplemental dosing.</td> </tr> <tr class=\"divider_bottom\"> <td>Levetiracetam</td> <td>1000 to 3000 mg orally per day in two divided doses.</td> <td>500 to 1500 mg orally per day in two divided doses.</td> <td>500 to 1000 mg orally per day in two divided doses.</td> <td>500 to 1000 mg orally per day in two divided doses.</td> <td> <p>500 to 1000 mg orally per day.</p> Give 50% of daily dose as post-IHD supplement.</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td>Oxcarbazepine</td> <td>600 to 2400 mg orally per day in two divided doses.</td> <td>No adjustment necessary.</td> <td>Initiate at half of usual daily dose.</td> <td>Initiate at half of usual daily dose.</td> <td>Supplemental dose not needed.</td> </tr> <tr class=\"divider_bottom\"> <td>Phenobarbital</td> <td> <p>120 to 300 mg orally per day in two or three divided doses.</p> Carefully individualize dose according to seizure control and serum concentrations, refer to clinical topic for detail.</td> <td>Use with caution; dose reduction may be needed.</td> <td>Use with caution; dose reduction may be needed.</td> <td>Use with caution; dose reduction may be needed.</td> <td> <p>High-flux dialyzers can likely remove drug; however, findings are variable, and no clear consensus on supplemental dose is available.</p> Consider giving up to 50% of daily dose as supplement after IHD or PD.</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td>Phenytoin</td> <td> <p>300 to 600 mg orally per day in two or three divided doses.</p> Carefully individualize dose according to seizure control and serum concentrations, refer to clinical topic for detail.</td> <td> <p>No change.</p> Oral loading dose usually not given.</td> <td> <p>No change.</p> Oral loading dose usually not given.</td> <td> <p>No change.</p> <p>Oral loading dose usually not given.</p> Protein binding may be decreased; consider assessing free phenytoin levels.</td> <td> <p>No change<sup>&#9674;</sup>.</p> <p>Oral loading dose usually not given.</p> Protein binding may be decreased; consider assessing free phenytoin levels.</td> </tr> <tr class=\"divider_bottom\"> <td>Pregabalin<sup>&#182;</sup></td> <td>150 to 600 mg orally per day in two or three divided doses.</td> <td>75 to 300 mg orally per day in two or three divided doses.</td> <td>25 to 150 mg orally once per day in a single or two divided doses.</td> <td>25 to 75 mg orally once per day.</td> <td>25 to 150 mg supplement after each IHD session<sup>&#182;</sup>.</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td>Topiramate</td> <td>200 to 400 mg orally per day in two divided doses.</td> <td>50% dose reduction.</td> <td>50% dose reduction.</td> <td>50% dose reduction.</td> <td>Give dose after IHD or 50% of daily dose as post-HD supplement.</td> </tr> <tr class=\"divider_bottom\"> <td>Valproic acid (valproate)</td> <td> <p>15 to 60 mg/kg orally per day in two or three divided doses.</p> Standard dose (usual upper limit of weight-based dosing): &#8804;2500 mg per day.</td> <td>No adjustment necessary.</td> <td>No adjustment necessary.</td> <td>No adjustment necessary.</td> <td> <p>Supplementation usually not given.</p> <p>High-flux dialyzers can likely remove drug.</p> Protein binding may be decreased; consider assessing free valproic acid levels.</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>Zonisamide</td> <td>100 to 400 mg orally once per day.</td> <td> <p>No adjustment necessary.</p> Gradually titrate from low initial dose.</td> <td> <p>Unclear.</p> Gradually titrate from low initial dose.</td> <td> <p>Unclear.</p> Gradually titrate from low initial dose.</td> <td> <p>Give dose after IHD.</p> Supplement needed for post-IHD seizures.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Typical adult maintenance dosing in epilepsy (ie, not for status epilepticus or other indications) of oral immediate-release formulations; initial dosing is usually the lowest maintenance dose,&nbsp;which may need to be titrated to improve tolerability and according to seizure control. Details for initiating and adjustment of dose vary by each agent. Refer to the Lexicomp drug monographs and appropriate UpToDate clinical reviews for detailed information on individual agents.</div><div class=\"graphic_footnotes\">GFR: glomerular filtration rate; CKD: chronic kidney disease; ESRD: end-stage renal disease; IHD: intermittent hemodialysis; PD: peritoneal dialysis.<br />* Dose is adjusted according to seizure control. Drug levels may be useful for establishing an individual therapeutic range when the patient is in remission and for guiding dose adjustments (eg, when renal function is changing or there is an alteration in drug formulation or change in regimen involving an interacting medication). Refer to UpToDate clinical reviews of epilepsy treatment.<br />Â¶ Clearance dependent upon kidney function; low protein binding, low volume of distribution (Vd), and cleared efficiently by dialysis. Post-dialysis supplemental dosing is necessary.<br />Î” Patients with CKD who are taking medications that are strong CYP3A4 and CYP2C9 inhibitors may have increased exposure to lacosamide; a further dose reduction may be needed. Specific interactions may be determined by using the Lexi-Interact program included within UpToDate.<br /><FONT class=lozenge>â—Š</FONT> Seizures have been reported in a small number of patients after high-flux IHD. Individualized supplementation may be needed.</div><div class=\"graphic_reference\">Adapted from: Bansal AD, Hill CE, Berns JB. Use of antiepileptic drugs in patients with chronic kidney disease and end stage renal disease. Semin Dial 2015; 28:404.<br />Additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>â€‹Israni R, Kasbekar N, Haynes K, Berns J. Use of antiepileptic drugs in patients with kidney disease. Semin Dial 2006; 19:408.</LI>&#xD;&#xA;<LI>Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 2001; 15:405.</LI>&#xD;&#xA;<LI>AsconapÃ© JJ. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol 2014; 119:417.</LI>&#xD;&#xA;<LI>Diaz A, Deliz B, Benbadis S. The use of newer antiepileptic drugs in patients with renal failure. Expert Rev Neurother 2014; 12:99.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright Â© 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 109485 Version 3.0</div></div></div>"},"109486":{"type":"graphic_table","displayName":"Causes of gynecomastia in children and adolescents","title":"Selected causes of unilateral or bilateral gynecomastia in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected causes of unilateral or bilateral gynecomastia in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Associated clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Physiologic causes</td> </tr> <tr> <td class=\"indent1\">Neonatal</td> <td> <ul> <li>May be associated with galactorrhea; usually resolves spontaneously within the first year of life</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pubertal</td> <td> <ul> <li>Occurs at mid-puberty: during peak height velocity at age 12 to 14 years; pubic hair SMR stage 3 to 4; testicular volume&nbsp;8 to 10 mL </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pathologic causes</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" colspan=\"2\"><strong>Drugs</strong></td> </tr> <tr> <td class=\"indent2\">Exogenous estrogen</td> <td> <ul> <li>Source of exogenous estrogen (eg, combined oral contraceptive pills, topical estrogen cream) </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Other drugs</td> <td> <ul> <li>History of exposure to drug or other substances associated with gynecomastia (refer to UpToDate content on drugs that cause gynecomastia) </li> </ul> </td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" colspan=\"2\"><strong>Hypogonadism</strong></td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Primary (hypergonadotropic)</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Klinefelter syndrome </li> </ul> </td> <td> <ul> <li>Tall, thin body habitus; small firm testes in pubertal-aged males</li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Cryptorchidism </li> </ul> </td> <td> <ul> <li>One or both testes not within the scrotum (or history of testis that is not within the scrotum) </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Defect in testosterone synthesis (eg, 17-ketosteroid reductase deficiency) </li> </ul> </td> <td> <ul> <li>Atypical genitalia; undervirilization </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Acquired primary hypogonadism </li> </ul> </td> <td> <ul> <li>History of testicular insult or injury (eg, surgery, radiation, systemic illness, etc) </li> </ul> </td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Secondary (hypogonadotropic)</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Acquired secondary hypogonadism </li> </ul> </td> <td> <ul> <li>Insult to hypothalamic-pituitary axis (eg, surgery, radiation, trauma, etc) </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Hyperprolactinemia </li> </ul> </td> <td> <ul> <li>Galactorrhea </li> </ul> </td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" colspan=\"2\"><strong>Tumors</strong></td> </tr> <tr> <td class=\"indent2\">Testicular cancer (Leydig- or Sertoli-cell)</td> <td> <ul> <li>Testicular mass; increased risk with history of cryptorchidism (any testicular cancer); increased risk in Peutz-Jeghers syndrome (Sertoli-cell tumors) </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Feminizing adrenal tumor</td> <td> <ul> <li>Abdominal mass </li> </ul> </td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">hCG-producing tumors</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Testicular (germ-cell) </li> </ul> </td> <td> <ul> <li>Testicular mass; increased risk with history of cryptorchidism </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Extragonadal germ cell tumor (eg, mediastinal, retroperitoneal) </li> </ul> </td> <td> <ul> <li>May be detected with chest or abdominal imaging </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Nontrophoblastic hCG-producing tumor </li> </ul> </td> <td> <ul> <li>May be detected with chest or abdominal imaging </li> </ul> </td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" colspan=\"2\"><strong>Other causes</strong></td> </tr> <tr> <td class=\"indent2\">Chronic liver or kidney disease/malnutrition</td> <td> <ul> <li>Underweight; findings associated with chronic liver or kidney disease (eg, hepatomegaly, edema, etc) </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Hyperthyroidism</td> <td> <ul> <li>Goiter, accelerated growth, weight loss, ophthalmopathy, tachycardia, increased appetite, tremor </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Aromatase excess syndrome</td> <td> <ul> <li>Accelerated early linear growth, prepubertal gynecomastia, testicular failure </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Androgen resistance (eg, partial androgen insensitivity)</td> <td> <ul> <li>Atypical genitalia; undervirilization; muscle fasciculations, weakness, and calf hypertrophy (X-linked spinal and bulbar muscular atrophy) </li> </ul> </td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Congenital adrenal hyperplasia</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>11-beta-hydroxylase deficiency </li> </ul> </td> <td> <ul> <li>Premature adrenarche, early puberty, accelerated linear growth, hypertension </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>3-beta-hydroxysteroid dehydrogenase deficiency </li> </ul> </td> <td> <ul> <li>Atypical genitalia, undervirilization </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Late-onset 21-hydroxylase deficiency </li> </ul> </td> <td> <ul> <li>Premature adrenarche with advanced bone age, accelerated linear growth during childhood, acne </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Ovotesticular disorder of sex development (previously \"true hermaphroditism\")</td> <td> <ul> <li>Atypical genitalia (presence of both ovarian follicular and testicular tubular tissue in a single individual); undervirilization </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SMR: sexual maturity rating; hCG: human chorionic gonadotropin.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Braunstein GD. Gynecomastia. N Engl J Med 1993; 328:490.</li>&#xD;&#xA;    <li>Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357:1229.</li>&#xD;&#xA;    <li>Ma NS, Geffner ME. Gynecomastia in prepubertal and pubertal men. Curr Opin Pediatr 2008; 20:465.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109486 Version 1.0</div></div></div>"},"109487":{"type":"graphic_table","displayName":"Hereditary gynecomastia","title":"Selected hereditary causes of gynecomastia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected hereditary causes of gynecomastia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease (gene)</td> <td class=\"subtitle1\">Associated clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Primary hypogonadism</td> </tr> <tr> <td class=\"indent1\">Congenital adrenal hyperplasia</td> <td> <ul> <li>Autosomal recessive inheritance</li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li><a href=\"http://omim.org/entry/201810\" target=\"_blank\">3-beta hydroxysteroid dehydrogenase defect</a> (<em>HSD3B2</em>)</li> </ul> </td> <td> <ul> <li>Hypogonadism (atypical genitalia, undervirilization)</li> <li>Cortisol deficiency (fatigue, nausea, vomiting)</li> <li>Aldosterone deficiency (hypotension, volume depletion, hyperkalemia, metabolic acidosis)</li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li><a href=\"http://omim.org/entry/202110\" target=\"_blank\">17-alpha hydroxylase deficiency</a> (<em>CYP17A1</em>)</li> </ul> </td> <td> <ul> <li>Hypogonadism (atypical genitalia, absence of secondary sexual characteristics)</li> <li>Cortisol deficiency (fatigue, nausea, vomiting)</li> <li>Hypertension</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li><a href=\"http://omim.org/entry/613571\" target=\"_blank\">Cytochrome P450 oxidoreductase deficiency</a> (<em>POR</em>)</li> </ul> </td> <td> <ul> <li>Severe undervirilization</li> <li>Cortisol deficiency (fatigue, nausea, vomiting)</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Secondary hypogonadism</td> </tr> <tr> <td class=\"indent1\">Congenital hypogonadotropic hypogonadism (<em><a href=\"http://omim.org/entry/136350\" target=\"_blank\">FGFR1</a></em>, <em><a href=\"http://omim.org/entry/603286\" target=\"_blank\">KISS1</a></em>, <em><a href=\"http://omim.org/entry/604161\" target=\"_blank\">KISS1R</a></em>, and others)</td> <td> <ul> <li>Autosomal dominant or recessive inheritance</li> <li>Hypogonadotropic hypogonadism</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://omim.org/entry/308700\" target=\"_blank\">Kallmann syndrome 1</a> (<em>KAL1</em>)</td> <td> <ul> <li>X-linked inheritance</li> <li>Hypogonadotropic hypogonadism</li> <li>Anosmia/hyposmia</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Increased aromatase</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/139300\" target=\"_blank\">Aromatase excess syndrome</a> (<em>CYP19A1</em>)</td> <td> <ul> <li>Autosomal dominant inheritance</li> <li>Prepubertal/peripubertal gynecomastia</li> <li>Accelerated early linear growth</li> <li>Testicular failure</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/160980\" target=\"_blank\">Carney complex</a> (<em>PRKAR1A</em>)</td> <td> <ul> <li>Autosomal dominant inheritance</li> <li>Prepubertal/peripubertal gynecomastia</li> <li>Multiple lentigines</li> <li>Atrial and mucocutaneous myxomas</li> <li>Blue nevi</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://omim.org/entry/175200\" target=\"_blank\">Peutz-Jeghers syndrome</a> (<em>STK11</em>)</td> <td> <ul> <li>Autosomal dominant inheritance</li> <li>Prepubertal gynecomastia</li> <li>Mucocutaneous pigmentation</li> <li>Multiple hamartomatous polyps in GI tract</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Androgen receptor defect</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/300068\" target=\"_blank\">Androgen insensitivity syndrome</a> (<em>AR</em>)</td> <td> <ul> <li>X-linked inheritance</li> <li>Atypical genitalia</li> <li>Undervirilization</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/313200\" target=\"_blank\">Spinal and bulbar muscular atrophy</a> (<em>AR</em> [expanded CAG repeats])</td> <td> <ul> <li>X-linked inheritance</li> <li>Atypical genitalia</li> <li>Undervirilization</li> <li>Muscle fasciculations</li> <li>Weakness</li> <li>Calf hypertrophy</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Narula HS, Carlson HE. Gynaecomastia&mdash;pathophysiology, diagnosis and treatment. Nat Rev Endocrinol 2014; 10:684.</div><div id=\"graphicVersion\">Graphic 109487 Version 1.0</div></div></div>"},"109488":{"type":"graphic_table","displayName":"Interpretation labs pediatric gynecomastia","title":"Interpretation of laboratory tests in the evaluation of unilateral or bilateral gynecomastia in phenotypically male children and adolescents*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation of laboratory tests in the evaluation of unilateral or bilateral gynecomastia in phenotypically male children and adolescents*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"12%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"5\">Initial tests</td> <td class=\"subtitle1\" rowspan=\"2\">Additional evaluation/supportive findings</td> <td class=\"subtitle1\" rowspan=\"2\">Potential cause(s)</td> </tr> <tr> <td class=\"subtitle2\">hCG</td> <td class=\"subtitle2\">Estradiol</td> <td class=\"subtitle2\">Testosterone</td> <td class=\"subtitle2\">LH</td> <td class=\"subtitle2\">DHEA</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"2\"><strong>Increased</strong></td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td>Testicular US: Normal</td> <td>Extragonadal germ-cell tumor or hCG-secreting nontrophoblastic neoplasm*</td> </tr> <tr> <td class=\"divider_bottom\">Testicular US: Mass</td> <td class=\"divider_bottom\">Testicular germ cell tumor</td> </tr> <tr> <td class=\"centered divider_bottom\">Normal</td> <td class=\"centered divider_bottom\"><strong>Increased</strong></td> <td class=\"centered divider_bottom\">Normal</td> <td class=\"centered divider_bottom\"><strong>Increased</strong></td> <td class=\"centered divider_bottom\">Normal</td> <td class=\"divider_bottom\">Karyotype</td> <td class=\"divider_bottom\">Possible ovotesticular DSD<sup>&#182;</sup></td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"centered divider_bottom\" rowspan=\"2\"><strong>Increased</strong></td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal or decreased</td> <td class=\"centered divider_bottom\" rowspan=\"2\"><strong>Increased</strong></td> <td>Adrenal imaging: Adrenal mass</td> <td>Adrenal neoplasm</td> </tr> <tr> <td class=\"divider_bottom\">Adrenal imaging: Normal</td> <td class=\"divider_bottom\">Possible CAH<sup>&#182;</sup></td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"centered divider_bottom\" rowspan=\"2\"><strong>Increased</strong></td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal or decreased</td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td> <p>Testicular US: Normal</p> Adrenal imaging: Normal</td> <td>Increased extraglandular aromatase activity (eg, aromatase excess syndrome)</td> </tr> <tr> <td class=\"divider_bottom\">Testicular US: Mass</td> <td class=\"divider_bottom\">Sertoli-cell tumor</td> </tr> <tr> <td class=\"centered divider_bottom\">Normal</td> <td class=\"centered divider_bottom\"><strong>Increased</strong></td> <td class=\"centered divider_bottom\"><strong>Increased</strong></td> <td class=\"centered divider_bottom\">Normal or decreased</td> <td class=\"centered divider_bottom\">Normal</td> <td class=\"divider_bottom\">Testicular US: Mass</td> <td class=\"divider_bottom\">Leydig-cell tumor or Leydig-cell and Sertoli-cell tumor</td> </tr> <t /> <tr> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"centered divider_bottom\" rowspan=\"2\"><strong>Increased</strong></td> <td class=\"centered divider_bottom\" rowspan=\"2\"><strong>Increased</strong></td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td> <p>TSH: Decreased</p> Thyroxine: Increased</td> <td>Hyperthyroidism</td> </tr> <tr> <td class=\"divider_bottom\"> <p>TSH: Normal</p> Thyroxine: Normal</td> <td class=\"divider_bottom\">Androgen resistance (eg, partial androgen insensitivity)</td> </tr> <tr> <td class=\"centered divider_bottom\">Normal</td> <td class=\"centered divider_bottom\">Normal</td> <td class=\"centered divider_bottom\"><strong>Decreased</strong><sup>&#916;</sup></td> <td class=\"centered divider_bottom\"><strong>Increased</strong></td> <td class=\"centered divider_bottom\">Normal</td> <td class=\"divider_bottom\">Refer to UpToDate content on primary hypogonadism in males</td> <td class=\"divider_bottom\">Primary hypogonadism</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"centered divider_bottom\" rowspan=\"2\"><strong>Decreased<sup>&#916;</sup></strong></td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal or decreased<sup>&#916;</sup></td> <td class=\"centered divider_bottom\" rowspan=\"2\">Normal</td> <td>Serum prolactin: Normal</td> <td>Secondary hypogonadism</td> </tr> <tr> <td class=\"divider_bottom\">Serum prolactin: Elevated</td> <td class=\"divider_bottom\">Prolactin-secreting pituitary tumor<sup>&#9674;</sup></td> </tr> <tr> <td class=\"centered\">Normal</td> <td class=\"centered\">Normal</td> <td class=\"centered\">Normal</td> <td class=\"centered\">Normal</td> <td class=\"centered\">Normal</td> <td>NA</td> <td>Pubertal or idiopathic gynecomastia</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Our suggested initial laboratory evaluation for phenotypically male children and adolescents with unilateral or bilateral gynecomastia in whom a potential cause is not identified on history and physical examination includes measurement of early morning hCG, estradiol, LH, testosterone, and DHEA. The reference range for hormones may vary by age, sexual maturity rating, and clinical laboratory. All patients may not fit into the categories in the table above.</div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin; LH: luteinizing hormone; DHEA: dehydroepiandrosterone; US: ultrasonography; CT: computed tomography; MRI: magnetic resonance imaging; TSH: thyroid-stimulating hormone; NA: not applicable; DSD: disorder of sex development; CAH: congenital adrenal hyperplasia.<br />* Further evaluation may include chest radiography and abdominal computed tomography.<br />Â¶ Referral to a pediatric endocrinologist is recommended. Refer to UpToDate content on atypical genitalia and congenital adrenal hyperplasia for more information.<br />Î” Decreased testosterone and decreased LH are normal findings in prepubertal-age boys and not helpful in the evaluation of gynecomastia.<br /><FONT class=lozenge>â—Š</FONT> Further evaluation may include magnetic resonance imaging of the head.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357:1229.</li>&#xD;&#xA;    <li>Ma NS, Geffner ME. Gynecomastia in prepubertal and pubertal men. Curr Opin Pediatr 2008; 20:465.</li>&#xD;&#xA;    <li>Misra M, Sagar P, Friedmann AM, et al. Case records of the Massachusetts General Hospital. Case 12-2016. An 8-Year-Old Boy with an Enlarging Mass in the Right Breast. N Engl J Med 2016; 374:1565.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109488 Version 1.0</div></div></div>"},"109490":{"type":"graphic_table","displayName":"Targeted evaluation of gynecomastia in children and adolescents","title":"Evaluation for pathologic causes of gynecomastia suggested by the history or examination in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation for pathologic causes of gynecomastia suggested by the history or examination in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical findings</td> <td class=\"subtitle1\">Possible cause(s)</td> <td class=\"subtitle1\">Initial targeted evaluation</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Testicular pain</li> <li>Testicular enlargement/mass</li> </ul> </td> <td> <ul> <li>Testicular cancer</li> </ul> </td> <td> <ul> <li>Testicular ultrasonography</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Perioral pigmentation</li> <li>Family history of Peutz-Jeghers syndrome</li> </ul> </td> <td> <ul> <li>Peutz-Jeghers syndrome (increased risk of Sertoli-cell tumor)</li> </ul> </td> <td> <ul> <li>Testicular ultrasonography</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Weight loss</li> <li>Abdominal mass</li> </ul> </td> <td> <ul> <li>Adrenal tumor</li> <li>Extragonadal germ cell tumor</li> <li>hCG-secreting nontrophoblastic neoplasm</li> </ul> </td> <td> <ul> <li>Adrenal imaging</li> <li>Chest imaging</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Increased appetite</li> <li>Goiter</li> <li>Ophthalmopathy</li> <li>Tachycardia</li> <li>Tremor</li> </ul> </td> <td> <ul> <li>Hyperthyroidism</li> </ul> </td> <td> <ul> <li>Free thyroxine (T4), tri-iodothyronine (T3), TSH</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Tall, thin body habitus</li> <li>Long arms and legs</li> <li>Small (&#60;3 cm [1.2 inches] or &#60;5 mL in volume), firm testes (in adolescent or adult)</li> <li>Learning, language, or behavioral difficulties</li> </ul> </td> <td> <ul> <li>Klinefelter syndrome*</li> </ul> </td> <td> <ul> <li>Karyotype</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Galactorrhea</li> </ul> </td> <td> <ul> <li>Hyperprolactinemia</li> </ul> </td> <td> <ul> <li>Serum prolactin</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Undervirilization</li> <li>Atypical genitalia</li> <li>Hypospadias</li> <li>Cryptorchidism</li> <li>Muscle fasciculations, weakness, calf hypertrophy<sup>&#182;</sup></li> </ul> </td> <td> <ul> <li>Primary or secondary hypogonadism</li> <li>Partial androgen insensitivity</li> <li>3 beta-hydroxysteroid dehydrogenase deficiency</li> <li>Ovotesticular disorder of sex development</li> </ul> </td> <td> <ul> <li>Referral to a pediatric endocrinologist is suggested; specialized testing may be necessary</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Anorexia, nausea, vomiting, acholic stools</li> <li>Jaundice, edema, spider angiomata</li> </ul> </td> <td> <ul> <li>Liver disease</li> </ul> </td> <td> <ul> <li>Liver function tests</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Anorexia, nausea, vomiting, edema</li> <li>Changes in urination, hematuria</li> </ul> </td> <td> <ul> <li>Kidney disease</li> </ul> </td> <td> <ul> <li>BUN/creatinine</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Accelerated early linear growth</li> <li>Family history of gynecomastia</li> </ul> </td> <td> <ul> <li>Aromatase excess syndrome</li> </ul> </td> <td> <ul> <li>Molecular genetic testing*</li> </ul> </td> </tr> <tr> <td> <ul> <li>Accelerated early linear growth</li> <li>Premature adrenarche or puberty</li> <li>Hypertension (11-beta hydroxylase deficiency)</li> </ul> </td> <td> <ul> <li>11-beta hydroxylase deficiency</li> <li>Nonclassic (late-onset) 21-hydroxylase deficiency</li> </ul> </td> <td> <ul> <li>Referral to pediatric endocrinologist is suggested; specialized testing may be necessary</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin; TSH: thyroid stimulating hormone; BUN: blood urea nitrogen.<br />* Consultation with a pediatric endocrinologist or geneticist is suggested.<br />&para; Muscle fasciculations, weakness, and calf hypertrophy may indicate X-linked spinal and bulbar muscular atrophy, which is associated with partial androgen insensitivity. Referral to a neurologist is also suggested.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Braunstein GD. Gynecomastia. N Engl J Med 1993; 328:490.</li>&#xD;&#xA;    <li>Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357:1229.</li>&#xD;&#xA;    <li>Ma NS, Geffner ME. Gynecomastia in prepubertal and pubertal men. Curr Opin Pediatr 2008; 20:465.</li>&#xD;&#xA;    <li>Narula HS, Carlson HE. Gynaecomastia--pathophysiology, diagnosis and treatment. Nat Rev Endocrinol 2014; 10:684.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109490 Version 1.0</div></div></div>"},"109491":{"type":"graphic_table","displayName":"Management of treatment interruptions table","title":"Management of treatment interruptions* table","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of treatment interruptions* table</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Time point of interruption</td> <td class=\"subtitle1\">Details of interruption</td> <td class=\"subtitle1\">Approach</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">During intensive phase</td> <td> <ul> <li>Lapse is &#60;14 days in duration </li> </ul> </td> <td> <ul> <li>Continue treatment to complete planned total number of doses (as long as all doses are completed within 3 months) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Lapse is &#8805;14 days in duration </li> </ul> </td> <td> <ul> <li>Restart treatment from the beginning </li> </ul> </td> </tr> <tr> <td rowspan=\"4\">During continuation phase</td> <td> <ul> <li>Received &#8805;80 percent of doses and sputum was AFB smear negative on initial testing </li> </ul> </td> <td> <ul> <li>Further therapy may not be necessary </li> </ul> </td> </tr> <tr> <td> <ul> <li>Received &#8805;80 percent of doses and sputum was AFB smear positive on initial testing </li> </ul> </td> <td> <ul> <li>Continue therapy until all doses are completed </li> </ul> </td> </tr> <tr> <td> <ul> <li>Received &#60;80 percent of doses and accumulative lapse is &#60;3 months in duration </li> </ul> </td> <td> <ul> <li>Continue therapy until all doses are completed (full course), unless consecutive lapse is &#62;2 months </li> <li>If treatment cannot be completed within recommended time frame for regimen, restart therapy from the beginning (ie, restart intensive phase, to be followed by continuation phase)<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Received &#60;80 percent of doses and lapse is &#8805;3 months in duration </li> </ul> </td> <td> <ul> <li>Restart therapy from the beginning, new intensive and continuation phases (ie, restart intensive phase, to be followed by continuation phase) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AFB: acid-fast bacilli.<br />* According to expert opinion, patients who are lost to follow-up (on treatment) and brought back to therapy, with interim treatment interruption, should have sputum resent for AFB smear, culture, and drug susceptibility testing.<br />&para; The recommended time frame for regimen, in tuberculosis control programs in the United States and in several European countries, is to administer all of the specified number of doses for the intensive phase within 3 months and those for the 4-month continuation phase within 6 months, so that the 6-month regimen is completed within 9 months.</div><div class=\"graphic_reference\">Reproduced from: Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63(7):e147-e195, by permission of Oxford University Press on behalf of the Infectious Diseases Society of America. Copyright Â© 2016 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.idsociety.org/\" target=_blank>www.idsociety.org</A>.</div><div id=\"graphicVersion\">Graphic 109491 Version 4.0</div></div></div>"},"109492":{"type":"graphic_table","displayName":"Case definition of Lassa fever (WHO definition)","title":"Case definition of Lassa fever (World Health Organization definition)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Case definition of Lassa fever (World Health Organization definition)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td colspan=\"2\"><strong>Known exposure to a person suspected to have Lassa fever</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Fever &#62;38&#176;C for less than three weeks <strong>PLUS</strong> </li> <li>Absence of signs of local inflammation <strong>AND</strong> </li> <li>Two major signs or one major sign and two minor signs </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\">Major signs</td> <td class=\"subtitle1\">Minor signs</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Bleeding </li> <li>Swollen neck or face </li> <li>Conjunctival or subconjunctival hemorrhage </li> <li>Spontaneous abortion </li> <li>Petechial or hemorrhagic rash </li> <li>New onset of tinnitus or altered hearing </li> <li>Persistent hypotension </li> <li>Absence of clinical response after 48 hours of antimalarial and/or broad-spectrum antibiotic therapy </li> </ul> </td> <td> <ul> <li>Headache </li> <li>Sore throat </li> <li>Vomiting </li> <li>Diffuse abdominal pain </li> <li>Chest or retrosternal pain </li> <li>Cough </li> <li>Diarrhea </li> <li>Generalized myalgia or arthralgias </li> <li>Profuse weakness </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted from Clinical Management of Patients with Viral Haemorrhagic Fever: A Pocket Guide for the front-line health worker, World Health Organization, p. 68, Copyright &copy; 2014. Available from: <a href=\"http://apps.who.int/iris/handle/10665/130883\" target=\"_blank\">http://apps.who.int/iris/handle/10665/130883</a> (accessed on August 18, 2016).</div><div id=\"graphicVersion\">Graphic 109492 Version 1.0</div></div></div>"},"109493":{"type":"graphic_diagnosticimage","displayName":"Widened mediastinum on chest radiography","title":"Widened mediastinum on chest radiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Widened mediastinum on chest radiography</div><div class=\"cntnt\"><img style=\"width:365px; height:294px;\" src=\"images/SURG/109493_Thoracic_aortic_aneurysm_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain chest radiograph shows a widened mediastinum that is due to thoracic aortic aneurysm. The arrows, left and right, show the lateral margin of the ascending and descending aorta, respectively.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 109493 Version 2.0</div></div></div>"},"109494":{"type":"graphic_table","displayName":"Minimum alveolar concentration (MAC) values for 1 MAC","title":"Minimum alveolar concentration (MAC) values for inhalation agents: 1 MAC","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Minimum alveolar concentration (MAC) values for inhalation agents: 1 MAC</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Inhalation anesthetic agent</td> <td class=\"subtitle1\">Minimum alveolar concentration (MAC) value (1 MAC)*</td> </tr> <tr> <td>Nitrous oxide</td> <td class=\"centered\">104</td> </tr> <tr> <td>Desflurane</td> <td class=\"centered\">6.6</td> </tr> <tr> <td>Sevoflurane</td> <td class=\"centered\">1.8</td> </tr> <tr> <td>Isoflurane</td> <td class=\"centered\">1.17</td> </tr> <tr> <td>Halothane</td> <td class=\"centered\">0.75</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The minimum alveolar concentration (MAC) value is the concentration of an inhalation anesthetic agent in the lung alveoli required to prevent movement in response to a surgical stimulus in 50% of patients.</div><div class=\"graphic_footnotes\">* These MAC values are for a 40-year-old person.</div><div id=\"graphicVersion\">Graphic 109494 Version 2.0</div></div></div>"},"109495":{"type":"graphic_table","displayName":"Factors that influence MAC values","title":"Factors that influence minimum alveolar concentration (MAC) values of inhalation anesthetic agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that influence minimum alveolar concentration (MAC) values of inhalation anesthetic agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Factors that increase MAC</td> <td class=\"subtitle1\">Factors that decrease MAC</td> </tr> <tr> <td> <ul> <li>Chronic&nbsp;alcohol use </li> <li>Infancy (highest MAC at 6 months) </li> <li>Hypernatremia </li> <li>Hyperthermia </li> <li>Amphetamines </li> <li>Cocaine </li> <li>Ephedrine </li> </ul> </td> <td> <ul> <li>Acute&nbsp;alcohol use </li> <li>Older age </li> <li>Hyponatremia </li> <li>Hypothermia </li> <li>Anemia (Hgb &#60;5 g/dL) </li> <li>Hypercarbia </li> <li>Hypoxia </li> <li>Metabolic acidosis </li> <li>Pregnancy </li> <li>Nitrous oxide </li> <li>Opioids </li> <li>Benzodiazepines </li> <li>Propofol </li> <li>Alpha<sub>2</sub> agonists </li> <li>Intravenous lidocaine </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Factors that increase or decrease the minimum alveolar concentration (MAC) value, defined as the concentration of an inhalation anesthetic agent in the alveoli required to prevent movement in response to a surgical stimulus in 50 percent of patients.</div><div class=\"graphic_footnotes\">MAC: minimum alveolar concentration; Hgb: hemoglobin.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>McKay RE. Inhaled anesthetics. In: Basics of Anesthesia, 6th ed, Miller RD, Pardo, Jr., MC (Eds), Elsevier, Philadelphia 2011.</li>&#xD;&#xA;    <li>Bartunek AE, Minimum alveolar concentration. In: Faust's Anesthesiology Review, 4th ed, Murray MJ, Harrison BA, Mueller JT, et al (Eds), Elsevier, Philadelphia 2015.</li>&#xD;&#xA;    <li>Miller's Anesthesia, 8th ed, Miller RD, Cohen NH, Eriksson LI, et al (Eds), Elsevier, Philadelphia 2015.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109495 Version 2.0</div></div></div>"},"109497":{"type":"graphic_picture","displayName":"Marfan thumb sign","title":"Marfan thumb sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Marfan thumb sign</div><div class=\"cntnt\"><img style=\"width:176px; height:273px;\" src=\"images/CARD/109497_Marfan_thumb_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thumb sign is positive when the entire distal phalanx of the adducted thumb extends beyond the ulnar border of the palm with or without the assistance of the patient or examiner to achieve maximal adduction. This reflects both longitudinal laxity of the hand and a long thumb.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 The Marfan Foundation. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109497 Version 1.0</div></div></div>"},"109498":{"type":"graphic_picture","displayName":"Marfan wrist sign","title":"Marfan wrist sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Marfan wrist sign</div><div class=\"cntnt\"><img style=\"width:164px; height:273px;\" src=\"images/CARD/109498_Marfan_wrist_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The wrist sign is positive when the tip of the thumb covers the entire fingernail of the fifth finger when wrapped around the contralateral wrist.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 The Marfan Foundation. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109498 Version 1.0</div></div></div>"},"109500":{"type":"graphic_diagnosticimage","displayName":"Axillary block ultrasound","title":"Axillary block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Axillary block ultrasound</div><div class=\"cntnt\"><img style=\"width:756px; height:277px;\" src=\"images/ANEST/109500_Axillary_block_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided axillary block, the needle is introduced perpendicular to the skin and advanced until the tip is next to each nerve. Three to 4 mL of local anesthetic is injected around each nerve. In this graphic, the arrow shows the needle trajectory for the injection near the radial nerve.</div><div class=\"graphic_footnotes\">n.: nerve; m.: muscle; a.: artery.</div><div id=\"graphicVersion\">Graphic 109500 Version 1.0</div></div></div>"},"109502":{"type":"graphic_figure","displayName":"Context-sensitive half time for opioids","title":"Context-sensitive half time for opioids","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Context-sensitive half time for opioids</div><div class=\"cntnt\"><img style=\"width:614px; height:346px;\" src=\"images/ANEST/109502_Cntxt-snstv_hlf_tim_opioids.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Context-sensitive half time, or time in minutes to a 50 percent decrease in effect-site concentration (Ce) after an infusion is stopped.</div><div class=\"graphic_reference\">Reproduced from: Ogura T, Egan TD. Opioid Agonists and Antagonists. In: Pharmacologyand Physiology for Anesthesia: Foundations and Clinical Application, Hemmings HC, Egan TD (Eds), Philadelphia, PA, Elsevier, 2013. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109502 Version 2.0</div></div></div>"},"109503":{"type":"graphic_figure","displayName":"Rapid attainment of steady state with remifentanil","title":"Rapid attainment of steady state with remifentanil","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rapid attainment of steady state with remifentanil</div><div class=\"cntnt\"><img style=\"width:438px; height:346px;\" src=\"images/ANEST/109503_Rpd_stdy_state_remifentanil.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simulation demonstrating plasma concentrations after administration of a bolus dose of remifentanil followed by an infusion, showing the rapid attainment of steady state when a bolus is used.</div><div class=\"graphic_footnotes\">Ce: Effect site concentration.</div><div class=\"graphic_reference\">Reproduced from: Ogura T, Egan TD. Opioid Agonists and Antagonists. In: Pharmacologyand Physiology for Anesthesia: Foundations and Clinical Application, Hemmings HC, Egan TD (Eds), Philadelphia, PA, Elsevier, 2013. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109503 Version 2.0</div></div></div>"},"109504":{"type":"graphic_figure","displayName":"Bolus front-end and back-end pharmacokinetics of opioids","title":"Bolus front-end and back-end pharmacokinetics of opioids","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Bolus front-end and back-end pharmacokinetics of opioids</div><div class=\"cntnt\"><img style=\"width:604px; height:346px;\" src=\"images/ANEST/109504_Bls_f-b-end_phrmckntcs_opds.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percent of peak effect-site concentration (Ce) after bolus dosing of different opioids.</div><div class=\"graphic_reference\">Reproduced from: Ogura T, Egan TD. Opioid Agonists and Antagonists. In: Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application, Hemmings HC, Egan TD (Eds), Philadelphia, PA, Elsevier, 2013. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109504 Version 3.0</div></div></div>"},"109507":{"type":"graphic_figure","displayName":"Contemporary nomogram for salvage RT after prostatectomy","title":"Contemporary nomogram for salvage radiotherapy after prostatectomy","html":"<div class=\"graphic\"><div style=\"width: 854px\" class=\"figure\"><div class=\"ttl\">Contemporary nomogram for salvage radiotherapy after prostatectomy</div><div class=\"cntnt\"><img style=\"width:834px; height:628px;\" src=\"images/ONC/109507_Contemp_nomogram_RT_prsttct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pretreatment nomogram estimating 5- and 10-year rates of freedom from biochemical failure after salvage RT. Concordance index, 0.68. Instructions: locate the patient's Gleason score on the respective axis; draw a straight line up to the Points axis to determine how many points toward disease recurrence the patient receives for the Gleason score; repeat this process for the remaining disease and treatment parameters; sum the points and locate this number on the Total points axis; and draw a straight line down to find the patient's estimated risk of biochemical recurrence.<br />(B) Calibration of the freedom from biochemical failure nomogram.</div><div class=\"graphic_footnotes\">NC: neoadjuvant/concurrent; ADT: androgen deprivation therapy; RT: radiotherapy; PSA: prostate-specific antigen.</div><div class=\"graphic_reference\">From: Tendulkar RD, Agrawal S, Gao T, et al. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol 2016. Reprinted with permission. Copyright &copy; 2016 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109507 Version 1.0</div></div></div>"},"109508":{"type":"graphic_picture","displayName":"Fascia iliaca block probe placement","title":"Fascia iliaca block probe placement","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Fascia iliaca block probe placement</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/ANEST/109508_Fascia_iliaca_block_probe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For an ultrasound-guided fascia iliaca block, the probe is placed transversely to the leg at the junction of the middle and lateral thirds of a line between the anterior superior iliac spine and the pubic tubercle. For further information, refer to UpToDate content on fascia iliaca block.</div><div id=\"graphicVersion\">Graphic 109508 Version 1.0</div></div></div>"},"109509":{"type":"graphic_table","displayName":"Diffuse astrocytic and oligodendroglial tumors","title":"World Health Organization (WHO) classification of diffuse astrocytic and oligodendroglial tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) classification of diffuse astrocytic and oligodendroglial tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor classification</td> <td class=\"subtitle1\">Tumor grade</td> <td class=\"subtitle1\">Defining* or characteristic molecular genetic features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Astrocytic tumors</td> <td class=\"subtitle2_left\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Diffuse astrocytoma, IDH-mutant</td> <td class=\"centered\">II</td> <td class=\"centered\"><em>IDH1/2</em> mutation*, <em>TP53</em> mutation, <em>ATRX</em> mutation</td> </tr> <tr> <td class=\"indent1\">Diffuse astrocytoma, IDH-wildtype</td> <td class=\"centered\">II</td> <td class=\"centered\">No <em>IDH1/2</em> mutation</td> </tr> <tr> <td class=\"indent1\">Anaplastic astrocytoma, IDH-mutant</td> <td class=\"centered\">III</td> <td class=\"centered\"><em>IDH1/2</em> mutation*, <em>TP53</em> mutation, <em>ATRX</em> mutation</td> </tr> <tr> <td class=\"indent1\">Anaplastic astrocytoma, IDH-wildtype</td> <td class=\"centered\">III</td> <td class=\"centered\">No <em>IDH1/2</em> mutation</td> </tr> <tr> <td class=\"indent1\">Glioblastoma, IDH-mutant</td> <td class=\"centered\">IV</td> <td class=\"centered\"><em>IDH1/2</em> mutation*, <em>TP53</em> mutation, <em>ATRX</em> mutation</td> </tr> <tr> <td class=\"indent1\">Glioblastoma, IDH-wildtype</td> <td class=\"centered\">IV</td> <td class=\"centered\">No <em>IDH1/2</em> mutation, <em>TERT</em> promoter mutations</td> </tr> <tr> <td class=\"indent1\">Glioblastoma, NOS</td> <td class=\"centered\">IV</td> <td class=\"centered\">Genetic testing not done or inconclusive</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Midline diffuse glioma, H3 K27M-mutant</td> <td class=\"centered\">IV</td> <td class=\"centered\">H3 K27M mutation*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Oligodendroglial tumors</td> <td class=\"subtitle2_left\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Oligodendroglioma, IDH-mutant and 1p/19q-codeleted</td> <td class=\"centered\">II</td> <td class=\"centered\"><em>IDH1/2</em> mutation*, 1p/19q-codeletion*, no <em>ATRX</em> mutation, <em>TERT</em> promoter mutations</td> </tr> <tr> <td class=\"indent1\">Oligodendroglioma, NOS</td> <td class=\"centered\">II</td> <td class=\"centered\">Genetic testing not done or inconclusive</td> </tr> <tr> <td class=\"indent1\">Oligoastrocytoma, NOS</td> <td class=\"centered\">II</td> <td class=\"centered\">Genetic testing not done or inconclusive</td> </tr> <tr> <td class=\"indent1\">Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted</td> <td class=\"centered\">III</td> <td class=\"centered\"><em>IDH1/2</em> mutation*, 1p/19q-codeletion*, no <em>ATRX</em> mutation, <em>TERT</em> promoter mutations</td> </tr> <tr> <td class=\"indent1\">Anaplastic oligodendroglioma, NOS</td> <td class=\"centered\">III</td> <td class=\"centered\">Genetic testing not done or inconclusive</td> </tr> <tr> <td class=\"indent1\">Anaplastic oligoastrocytoma, NOS</td> <td class=\"centered\">III</td> <td class=\"centered\">Genetic testing not done or inconclusive</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IDH: isocitrate dehydrogenase; NOS: not otherwise specified.<br />* Alterations that define the WHO classification entity are marked by an asterisk.</div><div class=\"graphic_reference\">Data from: WHO classification of tumours of the central nervous system, revised 4<SUP>th</SUP> ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.</div><div id=\"graphicVersion\">Graphic 109509 Version 3.0</div></div></div>"},"109510":{"type":"graphic_diagnosticimage","displayName":"Fascia iliaca block ultrasound","title":"Fascia iliaca block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Fascia iliaca block ultrasound</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/ANEST/109510_Fascia_iliaca_block_ultrsnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided fascia iliaca block, the fascia lata, iliacus muscle, and fascia iliaca are identified. The needle is inserted in-plane, with the tip placed under the fascia iliaca for injection of local anesthetic. The arrow shows the needle trajectory. <br />For further details, refer to UpToDate content on fascia iliaca block.</div><div class=\"graphic_footnotes\">m.: muscle; n.: nerve; a.: artery.</div><div id=\"graphicVersion\">Graphic 109510 Version 1.0</div></div></div>"},"109511":{"type":"graphic_table","displayName":"Other astrocytic tumors","title":"World Health Organization (WHO) classification of other astrocytic tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) classification of other astrocytic tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor classification</td> <td class=\"subtitle1\">Tumor grade</td> </tr> <tr> <td>Pilocytic astrocytoma</td> <td class=\"centered\">I</td> </tr> <tr> <td>Subependymal giant cell astrocytoma</td> <td class=\"centered\">I</td> </tr> <tr> <td>Pleomorphic xanthoastrocytoma</td> <td class=\"centered\">II</td> </tr> <tr> <td>Anaplastic pleomorphic xanthoastrocytoma</td> <td class=\"centered\">III</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: WHO Classification of Tumours of the Central Nervous System, 4th ed., Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.</div><div id=\"graphicVersion\">Graphic 109511 Version 1.0</div></div></div>"},"109512":{"type":"graphic_diagnosticimage","displayName":"Sagittal lumbar plexus block ultrasound","title":"Sagittal lumbar plexus block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 715px\" class=\"figure\"><div class=\"ttl\">Sagittal lumbar plexus block ultrasound</div><div class=\"cntnt\"><img style=\"width:695px; height:756px;\" src=\"images/ANEST/109512_Sagittl_lumbar_plexus_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graphic shows the sagittal view ultrasound image for a lumbar plexus block. The dashed arrow shows the needle trajectory. For further details, refer to UpToDate content on lumbar plexus block.</div><div id=\"graphicVersion\">Graphic 109512 Version 1.0</div></div></div>"},"109513":{"type":"graphic_table","displayName":"Ependymal tumors","title":"World Health Organization (WHO) classification of ependymal tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) classification of ependymal tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor classification</td> <td class=\"subtitle1\">Tumor grade</td> </tr> <tr> <td>Subependymoma</td> <td class=\"centered\">I</td> </tr> <tr> <td>Myxopapillary ependymoma</td> <td class=\"centered\">I</td> </tr> <tr> <td>Ependymoma</td> <td class=\"centered\">II*</td> </tr> <tr> <td>Ependymoma, RELA fusion&#8212;positive</td> <td class=\"centered\">II or III</td> </tr> <tr> <td>Anaplastic ependymoma</td> <td class=\"centered\">III*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Traditionally, classic ependymoma and anaplastic ependymoma are considered to correspond histologically to WHO grades II and III. However, no association between grade and biologic behavior or survival has been definitively established, and the practice of histologically grading ependymoma may soon be supplemented by molecular subtyping approaches.</div><div class=\"graphic_reference\">Data from: WHO Classification of Tumours of the Central Nervous System, Revised 4th ed., Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.</div><div id=\"graphicVersion\">Graphic 109513 Version 3.0</div></div></div>"},"109514":{"type":"graphic_diagnosticimage","displayName":"Obturator block ultrasound","title":"Obturator block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Obturator block ultrasound</div><div class=\"cntnt\"><img style=\"width:543px; height:756px;\" src=\"images/ANEST/109514_Obturator_block_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided obturator nerve block, the pectineus and adductor longus and brevis muscles are visualized.&nbsp;In this view, the anterior branch of the obturator nerve is visualized&nbsp;between the adductor longus and&nbsp;pectineus muscles, and the posterior&nbsp;branch is visualized between the adductor brevis and adductor magnus muscles. The needle is inserted in-plane (dashed arrows) or out-of-plane (solid arrows), to place the tip in each of the two intermuscular fascial planes. For further details, refer to UpToDate content on obturator nerve block.</div><div class=\"graphic_footnotes\">IP: in-plane; OP: out-of-plane; m.: muscle; n.: nerve.</div><div id=\"graphicVersion\">Graphic 109514 Version 1.0</div></div></div>"},"109515":{"type":"graphic_table","displayName":"Choroid plexus tumors","title":"World Health Organization (WHO) classification of choroid plexus tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) classification of choroid plexus tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor classification</td> <td class=\"subtitle1\">Tumor grade</td> </tr> <tr> <td>Choroid plexus papilloma</td> <td class=\"centered\">I</td> </tr> <tr> <td>Atypical choroid plexus papilloma</td> <td class=\"centered\">II</td> </tr> <tr> <td>Choroid plexus carcinoma</td> <td class=\"centered\">III</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: WHO Classification of Tumours of the Central Nervous System, 4th ed., Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.</div><div id=\"graphicVersion\">Graphic 109515 Version 1.0</div></div></div>"},"109516":{"type":"graphic_diagnosticimage","displayName":"Sciatic transgluteal block ultrasound","title":"Sciatic transgluteal block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Sciatic transgluteal block ultrasound</div><div class=\"cntnt\"><img style=\"width:756px; height:730px;\" src=\"images/ANEST/109516_Sciaticsubglutealblock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For sciatic block using a posterior approach, the needle is inserted in-plane, with the tip of the needle adjacent to the nerve. The arrow in this graphic shows the needle path. For further details, refer to UpToDate&nbsp;content on lower extremity nerve blocks.</div><div class=\"graphic_footnotes\">m.: muscle; n.: nerve.</div><div id=\"graphicVersion\">Graphic 109516 Version 2.0</div></div></div>"},"109517":{"type":"graphic_table","displayName":"Neuronal and mixed neuronal-glial tumors","title":"World Health Organization (WHO) classification of neuronal and mixed neuronal-glial tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) classification of neuronal and mixed neuronal-glial tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor classification</td> <td class=\"subtitle1\">Tumor grade</td> </tr> <tr> <td>Dysembryoplastic neuroepithelial tumor</td> <td class=\"centered\">I</td> </tr> <tr> <td>Gangliocytoma</td> <td class=\"centered\">I</td> </tr> <tr> <td>Ganglioglioma</td> <td class=\"centered\">I</td> </tr> <tr> <td>Anaplastic ganglioglioma</td> <td class=\"centered\">III</td> </tr> <tr> <td>Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease)</td> <td class=\"centered\">I</td> </tr> <tr> <td>Desmoplastic infantile astrocytoma and ganglioglioma</td> <td class=\"centered\">I</td> </tr> <tr> <td>Papillary glioneuronal tumor</td> <td class=\"centered\">I</td> </tr> <tr> <td>Rosette-forming glioneuronal tumor</td> <td class=\"centered\">I</td> </tr> <tr> <td>Diffuse leptomeningeal glioneuronal tumor</td> <td class=\"centered\">Not yet assigned</td> </tr> <tr> <td>Central neurocytoma</td> <td class=\"centered\">II</td> </tr> <tr> <td>Extraventricular neurocytoma</td> <td class=\"centered\">II</td> </tr> <tr> <td>Cerebellar liponeurocytoma</td> <td class=\"centered\">II</td> </tr> <tr> <td>Paraganglioma</td> <td class=\"centered\">I</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: WHO Classification of Tumours of the Central Nervous System, 4th ed., Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.</div><div id=\"graphicVersion\">Graphic 109517 Version 1.0</div></div></div>"},"109518":{"type":"graphic_diagnosticimage","displayName":"Popliteal block ultrasound","title":"Popliteal block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Popliteal block ultrasound</div><div class=\"cntnt\"><img style=\"width:756px; height:632px;\" src=\"images/ANEST/109518_Post_popliteal_block_ultrsd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Under ultrasound guidance, a popliteal nerve block can be performed from posterior or lateral needle approaches. In this graphic, the dashed arrows show the needle path using an in-plane needle orientation. For further details, refer to UpToDate&nbsp;content on lower extremity nerve blocks.</div><div class=\"graphic_footnotes\">IP: in-plane; OP: out-of-plane; n.: nerve; a.: artery; v.: vein.</div><div id=\"graphicVersion\">Graphic 109518 Version 1.0</div></div></div>"},"109519":{"type":"graphic_diagnosticimage","displayName":"Cephalad posterior popliteal block ultrasound","title":"Cephalad posterior popliteal block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Cephalad posterior popliteal block ultrasound</div><div class=\"cntnt\"><img style=\"width:756px; height:649px;\" src=\"images/ANEST/109519_Cephalad_post_popliteal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Popliteal view midway up posterior leg with merging of posterior tibial and common peroneal nerves into sciatic bundle.</div><div class=\"graphic_footnotes\">n.: nerve.</div><div id=\"graphicVersion\">Graphic 109519 Version 1.0</div></div></div>"},"109520":{"type":"graphic_diagnosticimage","displayName":"Adductor canal block ultrasound","title":"Adductor canal block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 775px\" class=\"figure\"><div class=\"ttl\">Adductor canal block ultrasound</div><div class=\"cntnt\"><img style=\"width:755px; height:626px;\" src=\"images/ANEST/109520_Adductor_canal_block_ultrsd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the adductor canal block of the saphenous nerve, the nerve is visualized adjacent to the femoral artery. The needle is inserted in-plane to the transducer, and the tip is placed deep to the sartorius muscle, at the lateral border of the artery. The arrow in this graphic shows the needle trajectory. For further details, refer to UpToDate content on lower extremity nerve blocks.</div><div id=\"graphicVersion\">Graphic 109520 Version 1.0</div></div></div>"},"109523":{"type":"graphic_diagnosticimage","displayName":"Ultrasound elbow common extensor tendon","title":"Ultrasound of common extensor tendon origin at elbow","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Ultrasound of common extensor tendon origin at elbow</div><div class=\"cntnt\"><img style=\"width:510px; height:269px;\" src=\"images/SM/109523_Ultrsnd_cmmn_extensor_tndn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above is an ultrasound image of a pathologic common extensor tendon shown in long axis&nbsp;with signs of&nbsp;tendinosis and a tear.</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109523 Version 1.0</div></div></div>"},"109524":{"type":"graphic_diagnosticimage","displayName":"Ultrasound medial elbow torn ulnar collateral ligament","title":"Ultrasound medial elbow with torn ulnar collateral ligament","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Ultrasound medial elbow with torn ulnar collateral ligament</div><div class=\"cntnt\"><img style=\"width:510px; height:266px;\" src=\"images/SM/109524_Mdl_elbw_ulnr_clltrl_lgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above is an ultrasound image of the medial elbow in long axis showing a torn proximal ulnar collateral ligament with joint space widening and air bubbles seen within the joint.</div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109524 Version 1.0</div></div></div>"},"109525":{"type":"graphic_algorithm","displayName":"Empiric treatment VAP","title":"Empiric treatment of ventilator-associated pneumonia in patients with normal renal function","html":"<div class=\"graphic\"><div style=\"width: 1242px\" class=\"figure\"><div class=\"ttl\">Empiric treatment of ventilator-associated pneumonia in patients with normal renal function</div><div class=\"cntnt\"><img style=\"width:1222px; height:804px;\" src=\"images/ID/109525_Empiric_treatment_VAP_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IDSA/ATS: Infectious Diseases Society of America/American Thoracic Society; HAP: hospital-acquired pneumonia; VAP: ventilator-associated pneumonia; ICU: intensive care unit; MDR: multidrug-resistant; IV: intravenous; ARDS: acute respiratory distress syndrome; MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>.<br />* Among these agents, we generally prefer piperacillin-tazobactam or cefepime because they are more likely to have activity against gram-negative bacilli than levofloxacin. The IDSA/ATS guidelines also include imipenem and meropenem as options, but we generally reserve these agents for patients with a high likelihood of infection with extended-spectrum beta-lactamase (ESBL)-producing gram-negative bacilli.<br />Â¶ We favor prolonged infusions of broad-spectrum beta-lactams for empiric and targeted therapy of gram-negative bacilli in critically ill patients as well as in patients with infections caused by gram-negative bacilli that have elevated but susceptible minimum inhibitory concentrations to the chosen agent. Refer to the related UpToDate table and topic review on prolonged infusions of beta-lactams for dosing information. The dosing information provided above represents traditional intermittent dosing (eg, administered over 30 minutes).<br />Î” Among these agents, we generally prefer piperacillin-tazobactam, cefepime, or ceftazidime because they are more likely to have activity against gram-negative bacilli than the fluoroquinolones or aztreonam. The IDSA/ATS guidelines also include imipenem and meropenem as options, but we generally reserve these agents for patients with a high likelihood of infection with ESBL-producing gram-negative bacilli.<br /><FONT class=lozenge>â—Š</FONT> The combination of vancomycin and piperacillin-tazobactam has been associated with acute kidney injury. In patients who require an anti-MRSA agent and an antipseudomonal beta-lactam, options include using a beta-lactam other than piperacillin-tazobactam (eg, cefepime or ceftazidime) or, if piperacillin-tazobactam is favored, using linezolid instead of vancomycin.<br />Â§ Telavancin (10 mg/kg IV every 24 hours) is an alternative agent when neither linezolid nor vancomycin can be used, but there are several boxed warnings that must be considered before choosing it. Boxed warnings include information about risk of acute kidney injury, increased mortality in patients with pre-existing acute renal failure, and concerns about safety in fetuses when used during pregnancy. Refer to the UpToDate topic review on treatment of HAP and VAP for additional details.<br />Â¥ Monitoring drug concentrations and adjustment of doses and/or intervals are required. Refer to the UpToDate topic reviews and tables on dosing of vancomycin and aminoglycosides for details about the approach to initial dosing (including the appropriate body weight to use in dosing calculations, renal function assessment, and monitoring).<br />â€¡ The IDSA/ATS guidelines recommend either an antipseudomonal fluoroquinolone or an aminoglycoside for the second agent for gram-negative bacilli, but we generally prefer an aminoglycoside over a fluoroquinolone if there is not concern for <EM>Legionella,</EM> as aminoglycosides are more likely to have in vitro activity against gram-negative bacilli in those with risk factors for resistance. In contrast, the guidelines state that aminoglycosides should be avoided if alternative agents with adequate gram-negative activity are available.<br />â€  The IDSA/ATS guidelines include the polymyxins (polymyxin B and colistin) as options for the second agent for gram-negative bacilli. Polymyxins are used rarely given their significant nephrotoxicity and should be avoided if alternative agents with adequate activity against gram-negative bacilli are available. When they are required, an infectious disease physician and/or pharmacist with expertise using these agents should be consulted.<br />** We typically discontinue the aminoglycoside after one or two days, especially in patients who have improved clinically and in whom the pathogen (if identified) is susceptible to the beta-lactam.<br />Â¶Â¶ In the absence of other options, it is acceptable to use aztreonam as a second agent for gram-negative bacilli with another beta-lactam because it has different targets within the bacterial cell wall.<br />Î”Î” We use aztreonam infrequently since rates of resistance among gram-negative bacilli are typically higher than to the other beta-lactams options.</div><div class=\"graphic_reference\">Reference: Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61.</div><div id=\"graphicVersion\">Graphic 109525 Version 3.0</div></div></div>"},"109526":{"type":"graphic_algorithm","displayName":"Empiric treatment HAP","title":"Empiric treatment of hospital-acquired pneumonia (not ventilator-associated pneumonia) in patients with normal renal function","html":"<div class=\"graphic\"><div style=\"width: 1246px\" class=\"figure\"><div class=\"ttl\">Empiric treatment of hospital-acquired pneumonia (not ventilator-associated pneumonia) in patients with normal renal function</div><div class=\"cntnt\"><img style=\"width:1226px; height:816px;\" src=\"images/ID/109526_Empiric_treatment_HAP_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IDSA/ATS: Infectious Diseases Society of America/American Thoracic Society; HAP: hospital-acquired pneumonia; VAP: ventilator-associated pneumonia; MDR: multidrug resistant; IV: intravenous; MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>.<br />* Among these agents, we generally prefer piperacillin-tazobactam or cefepime because they are more likely to have activity against gram-negative bacilli than levofloxacin. The IDSA/ATS guidelines also include imipenem and meropenem as options, but we generally reserve these agents for patients with a high likelihood of infection with ESBL-producing gram-negative bacilli.<br />Â¶ We favor prolonged infusions of broad-spectrum beta-lactams for empiric and targeted therapy of gram-negative bacilli in critically ill patients as well as in patients with infections caused by gram-negative bacilli that have elevated but susceptible minimum inhibitory concentrations to the chosen agent. Refer to the related UpToDate table and topic review on prolonged infusions of beta-lactams for dosing information. The dosing information provided above represents traditional intermittent dosing (eg, administered over 30 minutes).<br />Î” Among these agents, we generally prefer piperacillin-tazobactam, cefepime, or ceftazidime because they are more likely to have activity against gram-negative bacilli than the fluoroquinolones or aztreonam. The IDSA/ATS guidelines also include imipenem and meropenem as options, but we generally reserve these agents for patients with a high likelihood of infection with extended-spectrum beta-lactamase (ESBL)-producing gram-negative bacilli.<br /><FONT class=lozenge>â—Š</FONT> The combination of vancomycin and piperacillin-tazobactam has been associated with acute kidney injury. In patients who require an anti-MRSA agent and an antipseudomonal beta-lactam, options include using a beta-lactam other than piperacillin-tazobactam (eg, cefepime or ceftazidime) or, if piperacillin-tazobactam is favored, using linezolid instead of vancomycin.<br />Â§ Telavancin (10 mg/kg IV every 24 hours) is an alternative agent when neither linezolid nor vancomycin can be used, but there are several boxed warnings that must be considered before choosing it. Boxed warnings include information about risk of acute kidney injury, increased mortality in patients with pre-existing acute renal failure, and concerns about safety in fetuses when used during pregnancy. Refer to the UpToDate topic review on treatment of HAP and VAP for additional details.<br />Â¥ Monitoring drug concentrations and adjustment of doses and/or intervals are required. Refer to the UpToDate topic reviews and tables on dosing of vancomycin and aminoglycosides for details about the approach to initial dosing (including the appropriate body weight to use in dosing calculations, renal function assessment, and monitoring).<br />â€¡ We use aztreonam infrequently since rates of resistance among gram-negative bacilli are typically higher than to the other beta-lactams options.<br />â€  The IDSA/ATS guidelines recommend either an antipseudomonal fluoroquinolone or an aminoglycoside for the second agent for gram-negative bacilli, but we generally prefer an aminoglycoside over a fluoroquinolone if there is not concern for <EM>Legionella,</EM> as aminoglycosides are more likely to have in vitro activity against gram-negative bacilli in those with risk factors for resistance. In contrast, the guidelines state that aminoglycosides should be avoided if alternative agents with adequate gram-negative activity are available.<br />** We typically discontinue the aminoglycoside after one or two days, especially in patients who have improved clinically and in whom the pathogen (if identified) is susceptible to the beta-lactam.<br />Â¶Â¶ In the absence of other options, it is acceptable to use aztreonam as a second agent for gram-negative bacilli with another beta-lactam because it has different targets within the bacterial cell wall.</div><div class=\"graphic_reference\">Reference: Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61.</div><div id=\"graphicVersion\">Graphic 109526 Version 3.0</div></div></div>"},"109528":{"type":"graphic_picture","displayName":"Netherton syndrome newborn","title":"Netherton syndrome","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Netherton syndrome</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109528_Netherton_syndrome_newborn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythroderma and scaling in a neonate with Netherton syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109528 Version 1.0</div></div></div>"},"109530":{"type":"graphic_table","displayName":"VAP MDR risk factors","title":"Risk factors for multidrug-resistant ventilator-associated pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for multidrug-resistant ventilator-associated pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Risk factors for MDR pathogens:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>IV antibiotic use within the previous 90 days </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Septic shock at the time of VAP </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>ARDS preceding VAP </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>&#8805;5 days of hospitalization prior to the occurrence of VAP </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Acute renal replacement therapy prior to VAP onset </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Risk factors for MDR <em>Pseudomonas</em> and other gram-negative bacilli:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Treatment in an ICU in which &#62;10 percent of gram-negative isolates are resistant to an agent being considered for monotherapy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Treatment in an ICU in which local antimicrobial susceptibility rates are not known </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Risk factors for MRSA:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Treatment in a unit in which &#62;10 to 20 percent of <em>Staphylococcus aureus</em> isolates are methicillin resistant </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Treatment in a unit in which the prevalence of MRSA is not known </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MDR: multidrug resistant; IV: intravenous; VAP: ventilator-associated pneumonia; ARDS: acute respiratory distress syndrome; ICU: intensive care unit; MRSA: methicillin-resistant <EM>S. aureus</EM>.</div><div class=\"graphic_reference\">Adapted from: Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61.</div><div id=\"graphicVersion\">Graphic 109530 Version 1.0</div></div></div>"},"109531":{"type":"graphic_table","displayName":"HAP MDR and mortality risk factors","title":"Risk factors for MDR pathogens and/or increased mortality in patients with hospital-acquired pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for MDR pathogens and/or increased mortality in patients with hospital-acquired pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Risk factors for increased mortality:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Ventilatory support for HAP </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Septic shock </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Risk factor for MDR <em>Pseudomonas</em>, other gram-negative bacilli, and MRSA:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>IV antibiotics within the past 90 days </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Risk factors for MDR <em>Pseudomonas</em> and other gram-negative bacilli:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Structural lung disease (bronchiectasis or cystic fibrosis) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>A respiratory specimen Gram stain with numerous and predominant gram-negative bacilli </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Risk factors for MRSA:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Treatment in a unit in which &#62;20 percent of <em>Staphylococcus aureus</em> isolates are methicillin resistant </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Treatment in a unit in which the prevalence of MRSA is not known </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MDR: multidrug resistant; HAP: hospital-acquired pneumonia; MRSA: methicillin-resistant <EM innerHtml>S. aureus</EM>; IV: intravenous.</div><div class=\"graphic_reference\">Adapted from: Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61.</div><div id=\"graphicVersion\">Graphic 109531 Version 1.0</div></div></div>"},"109535":{"type":"graphic_table","displayName":"Prognosis in ESLD according to MELD score","title":"Prognosis in end stage liver disease according to Model for End Stage Liver Disease (MELD) score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognosis in end stage liver disease according to Model for End Stage Liver Disease (MELD) score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">MELD score</td> <td class=\"subtitle1\">Predicted three-month survival</td> <td class=\"subtitle1\">Predicted six-month survival</td> <td class=\"subtitle1\">Predicted 12-month survival</td> <td class=\"subtitle1\">Predicted 24-month survival</td> </tr> <tr> <td class=\"centered\">0 to 9</td> <td class=\"centered\">98%</td> <td class=\"centered\">98%</td> <td class=\"centered\">93%</td> <td class=\"centered\">90%</td> </tr> <tr> <td class=\"centered\">10 to 19</td> <td class=\"centered\">94%</td> <td class=\"centered\">92%</td> <td class=\"centered\">86%</td> <td class=\"centered\">80%</td> </tr> <tr> <td class=\"centered\">20 to 29</td> <td class=\"centered\">80%</td> <td class=\"centered\">78%</td> <td class=\"centered\">71%</td> <td class=\"centered\">66%</td> </tr> <tr> <td class=\"centered\">30 to 39</td> <td class=\"centered\">47%</td> <td class=\"centered\">40%</td> <td class=\"centered\">37%</td> <td class=\"centered\">33%</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 109535 Version 1.0</div></div></div>"},"109536":{"type":"graphic_movie","displayName":"Bioprosthetic aortic valve degeneration","title":"Bioprosthetic aortic valve with degenerative changes","html":"<div class=\"graphic normal\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Bioprosthetic aortic valve with degenerative changes</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/109536_Aorticbprsthtcdgnrtnvid.mp4\" style=\"width:592px;height:432px\"></div><img style=\"width:877px; height:601px;\" src=\"images/CARD/109536_Aorticbprsthtcdgnrtnimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical appearance of bioprosthetic aortic valve with degenerative changes. The posterior cusp appears thickened and has increased echodensity, suggestive of calcification rather than thrombosis. Note the comparatively normal appearance of the anterior cusp.</div><div id=\"graphicVersion\">Graphic 109536 Version 1.0</div></div></div>"},"109537":{"type":"graphic_movie","displayName":"Color Doppler of bioprosthetic aortic valve degeneration","title":"Color Doppler of bioprosthetic aortic valve withÂ degenerative changes","html":"<div class=\"graphic normal\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Color Doppler of bioprosthetic aortic valve with&nbsp;degenerative changes</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/109537_Clrartcbprsthtdgnrtnvid.mp4\" style=\"width:592px;height:400px\"></div><img style=\"width:892px; height:569px;\" src=\"images/CARD/109537_Clrartcbprsthtdgnrtnimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Significant obstruction to flow&nbsp;through the degenerated bioprosthetic&nbsp;aortic valve is demonstrated by aliased color Doppler signal.</div><div id=\"graphicVersion\">Graphic 109537 Version 1.0</div></div></div>"},"109538":{"type":"graphic_picture","displayName":"Scarlatiniform rash 2","title":"Scarlatiniform rash","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Scarlatiniform rash</div><div class=\"cntnt\"><img style=\"width:756px; height:501px;\" src=\"images/PEDS/109538_Scarlatiniform_rash2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scarlet fever rash on the volar surface of the forearm. The scarlet fever rash first appears as tiny red bumps on the chest and abdomen that may spread all over the body. Looking like a sunburn, it feels like a rough piece of sandpaper, and lasts about two to five days.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Public Health Image Library (<a href=\"https://phil.cdc.gov/phil/details.asp\" target=\"_blank\">https://phil.cdc.gov/phil/details.asp</a>).</div><div id=\"graphicVersion\">Graphic 109538 Version 2.0</div></div></div>"},"109541":{"type":"graphic_table","displayName":"Scripts for adoption communication","title":"Sample \"scripts\" for communicating about adoption","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample \"scripts\" for communicating about adoption</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Question/situation</td> <td class=\"subtitle1\">Sample response</td> </tr> <tr class=\"divider_bottom\"> <td>Questions about birth mother</td> <td>\"Your birth mother chose adoption for you because she felt unprepared to raise a child*, any child, at that time. She probably thinks about you and wonders about how you are doing.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Questions about birth father</td> <td>\"Your birth father may have been overwhelmed by the situation and thought he was not entitled to be more involved. He probably thinks about you and wonders about how you are doing.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Questions about birth parents who had challenges (eg, drug abuse, domestic violence, etc)</td> <td>\"Your parents needed help, but were not getting the help that they needed. As a result, they needed someone else to care for their child.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Personal/intrusive questions from outsiders</td> <td>\"I prefer not to discuss the details of my child's history because I think it should be his or her choice at an older age as to what information will be shared and with whom.\"</td> </tr> <tr> <td>Child is teased about being adopted</td> <td>\"Yeah, I'm adopted, so what? So was __________<sup>&#182;</sup>!\"</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Reasons for feeling unprepared include illness or lack of money, maturity, or resources.<br />&para; Depending upon the child's circumstances, the blank can be filled in with: President Clinton, President Ford, Steve Jobs, John Lennon, Nelson Mandela, Babe Ruth, Maya Angelou, Faith Hill, Eleanor Roosevelt.</div><div class=\"graphic_reference\">Adapted from: Albers Prock, L. Adoption. In: The Zuckerman Parker Handbook of Developmental and Behavioral Pediatrics for Primary Care, 3rd ed, Augustyn M, Zuckerman B, Caronna EB (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.415.</div><div id=\"graphicVersion\">Graphic 109541 Version 1.0</div></div></div>"},"109543":{"type":"graphic_movie","displayName":"Mitral bioprosthetic thrombosis before and after anticoagulation","title":"Mitral bioprosthetic valve thrombosis before and after anticoagulant therapy","html":"<div class=\"graphic normal\"><div style=\"width: 868px\" class=\"figure\"><div class=\"ttl\">Mitral bioprosthetic valve thrombosis before and after anticoagulant therapy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/109543_MBTpriorpostantiglntvid.mp4\" style=\"width:848px;height:336px\"></div><img style=\"width:784px; height:306px;\" src=\"images/CARD/109543_MBTpriorpostantiglntimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The transesophageal echocardiographic image and movie on the left demonstrate a typical appearance of bioprosthetic valve thrombosis, with soft echodense material deposited on the downstream surface of the mitral valve, inside the cusp body. The thrombus impedes leaflet motion and may thus induce prosthetic valve stenosis; prosthetic valve regurgitation may also be induced.<br />(B) The transesophageal echocardiographic image and movie on the right were obtain after four weeks of vitamin K antagonist (warfarin) therapy. There is near resolution of thrombus with only minute amounts of echodense material adjacent to the prosthetic posts. Mitral bioprosthetic leaflet mobility is now normal.</div><div id=\"graphicVersion\">Graphic 109543 Version 1.0</div></div></div>"},"109545":{"type":"graphic_table","displayName":"Situations for DOT","title":"Priority situations for use of directly observed therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Priority situations for use of directly observed therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patients with the following conditions/circumstances:<sup>[1-6]</sup></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Positive sputum smears </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Delayed culture conversion (sputum obtained at/after completion of intensive-phase therapy is culture positive) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Treatment failure </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Relapse </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Drug resistance </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Homelessness </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Current or prior substance abuse </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Use of intermittent dosing </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>HIV infection </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Previous nonadherence to therapy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Children and adolescents </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Mental, emotional, or physical disability (ie, cognitive deficits such as dementia; neurological deficits; medically fragile patients; or patients with blindness or severe loss of vision) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Resident at correctional or long-term care facility </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Previous treatment for active or latent tuberculosis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Managing tuberculosis patients and improving adherence. CDC, Atlanta, GA 2014.</LI>&#xD;&#xA;<LI>Burman WJ, Cohn DL, Rietmeijer CA, et al. Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. Chest 1997; 111:1168.</LI>&#xD;&#xA;<LI>Moonan PK, Quitugua TN, Pogoda JM, et al. Does directly observed therapy (DOT) reduce drug resistant tuberculosis? BMC Public Health 2011; 11:19.</LI>&#xD;&#xA;<LI>Kim S, Crittenden K. Treatment completion among TB patients returned to the community from a large urban jail. J Community Health 2007; 32:135.</LI>&#xD;&#xA;<LI>Ehman M, Shaw T, Cass A, et al. Developing and using performance measures based on surveillance data for program improvement in tuberculosis control. J Public Health Manag Pract 2013; 19:E29.</LI>&#xD;&#xA;<LI>Mitruka K, Winston CA, Navin TR. Predictors of failure in timely tuberculosis treatment completion, United States. Int J Tuberc Lung Dis 2012; 16:1075.</LI></OL>Reproduced from: Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63(7):e147-e195, by permission of Oxford University Press on behalf of the Infectious Diseases Society of America. Copyright Â© 2016 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.idsociety.org/\" target=_blank>www.idsociety.org</A>.</div><div id=\"graphicVersion\">Graphic 109545 Version 3.0</div></div></div>"},"109546":{"type":"graphic_table","displayName":"Modified FOLFIRINOX for metastatic pancreatic cancer","title":"Modified FOLFIRINOX chemotherapy for metastatic pancreatic cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified FOLFIRINOX chemotherapy for metastatic pancreatic cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 14 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Oxaliplatin*</td> <td>85 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL 5% dextrose in water (D5W)<sup>&#182;</sup> and administer over two hours (prior to leucovorin).</td> <td>Day 1</td> </tr> <tr> <td>Leucovorin<sup>&#916;</sup></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (NS) or D5W<sup>&#182;</sup> and administer over two hours (after oxaliplatin).</td> <td>Day 1</td> </tr> <tr> <td>Irinotecan<sup>&#9674;</sup></td> <td>150 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL NS or D5W<sup>&#182;</sup> and administer over 90 minutes. Administer concurrent with the last 90 minutes of leucovorin infusion, in separate bags, using a Y-line connection.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Fluorouracil (FU)</td> <td>2400 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 to 1000 mL 0.9% NS or D5W<sup>&#182;</sup> and administer as a continuous IV infusion over 46 hours. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose diluted in 100 to 150 mL NS.<sup>&#182;</sup></td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (greater than 90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Although infusion reactions have been reported with oxaliplatin, there is no recommended standard premedication for this regimen. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin and fluorouracil are irritants, but oxaliplatin can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not warranted. However, given the risk of grade 3 or 4 neutropenia (46%<sup>[1]</sup>), primary prophylaxis with G-CSF is used at many institutions. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of oxaliplatin and irinotecan may be needed for severe renal insufficiency.<sup>[2,3]</sup> A lower starting dose of irinotecan and FU may be needed for patients with hepatic impairment.<sup>[3,4]</sup> </li> <li><strong>NOTE:</strong> We do not recommend administration of FOLFIRINOX unless serum bilirubin is normal. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion.<sup>[2]</sup> Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. </li> <li>Cardiotoxicity observed with FU includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Electrolytes (especially potassium and magnesium) and liver and renal function prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Irinotecan is associated with early and late diarrhea, both of which may be severe.<sup>[2]</sup> For patients who develop abdominal cramping and/or diarrhea within 24 hours of receiving irinotecan, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide for late diarrhea. Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) should be provided as needed. </li> <li>Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Do not retreat unless neutrophil count is &#8805;1500/microL and platelets are &#8805;75,000/microL. The following dose reduction guidelines for hematologic toxicity are recommended; several of these are based upon recommendations in the original FOLFIRINOX protocol.<sup>[5]</sup> </li> <li><strong>Neutropenia</strong> <ul> <li>If day 1 treatment delayed for granulocytes &#60;1500/microL or febrile neutropenia or grade 4 neutropenia &#62;7 days: Reduce irinotecan dose to 120 mg/m<sup>2</sup>. For second occurrence: Reduce oxaliplatin dose to 60 mg/m<sup>2</sup>. If nonrecovery after a two-week delay, or if there is a third occurrence of granulocytes &#60;1500/microL on day 1, discontinue treatment. For grade 4 neutropenia &#62;7 days <strong>during</strong> treatment or febrile neutropenia, reduce oxaliplatin dose to 60 mg/m<sup>2</sup> and the infusional FU dose to 75% of the original dose. For the second occurrence, reduce dose of irinotecan to 120 mg/m<sup>2</sup> and the dose of infusional FU an additional 25%. Discontinue treatment for third occurrence. </li> </ul> </li> <li><strong>Thrombocytopenia</strong> <ul> <li>If day 1 treatment delayed for platelet count &#60;75,000/microL, reduce oxaliplatin dose to 60 mg/m<sup>2</sup> and reduce the continuous infusion FU to 75% of original doses. For second occurrence, reduce irinotecan dose to 120 mg/m<sup>2</sup>. If nonrecovery after a two-week delay, or if there is a third occurrence of platelets &#60;75,000/microL, discontinue treatment. For grade 3 or 4 thrombocytopenia <strong>during</strong> treatment, reduce oxaliplatin dose to 60 mg/m<sup>2</sup> and the infusional FU dose to 75% of the original dose. For the second occurrence, reduce dose of irinotecan to 120 mg/m<sup>2</sup> and the dose of infusional FU an additional 25%. Discontinue treatment for third occurrence. </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Do not retreat with FOLFIRINOX until resolution of diarrhea for at least 24 hours without antidiarrheal medication. For diarrhea grade 3 or 4, or diarrhea with fever and/or grade 3 or 4 neutropenia, reduce irinotecan dose to 120 mg/m<sup>2</sup>. For second occurrence, reduce the oxaliplatin dose to 60 mg/m<sup>2</sup> and the continuous FU dose to 75% of original dose. Discontinue treatment for third occurrence. </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents.\" </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Mucositis or hand-foot syndrome</strong></td> <td colspan=\"3\"> <ul> <li>For grade 3 to 4 toxicity, reduce dose of infusional FU by 25%. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Any other toxicity &#8805;grade 2, except anemia and alopecia, can justify dose reduction if medically indicated. For persistent grade 3 paresthesias/dysesthesias or transient grade 2 symptoms lasting &#62;7 days, decrease oxaliplatin dose by 25%.<sup>[2]</sup> Discontinue oxaliplatin for grade 4 or persistent grade 3 paresthesia/dysesthesia. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony-stimulating factors; ECG: electrocardiogram; CBC: complete blood count.<br />* Many centers routinely infuse oxaliplatin via central venous line because of local pain with infusion into a peripheral vein.<br />Â¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Î” Leucovorin dose is given for d,l-racemic mixture.<SUP>[6]</SUP> Use half the dose for LEVOleucovorin (l-leucovorin).<br /><FONT class=lozenge>â—Š</FONT> A lower initial dose of irinotecan may be considered for patients with poor performance status, prior pelvic or abdominal radiotherapy, or increased bilirubin levels.<SUP>[3]</SUP> Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Ueno M, et al. J Clin Oncol 34, 2016 (suppl; abstr 4111). Abstract presented at the 2016 annual meeting of the American Society of Clinical Oncology (http://meetinglibrary.asco.org/content/167038-176).</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 22, 2016).</LI>&#xD;&#xA;<LI>Irinotecan hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 22, 2016).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 22, 2016).</LI>&#xD;&#xA;<LI>Conroy T, et al. N Engl J Med 2011; 364:1817.</LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 22, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 109546 Version 3.0</div></div></div>"},"109547":{"type":"graphic_table","displayName":"ASO and ADB streptococcal antibody titers (US data)","title":"Upper limit of normal (80<SUP>th</SUP> centile) values for serum streptococcal antibody titers in children in the United States<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Upper limit of normal (80<SUP>th</SUP> centile) values for serum streptococcal antibody titers in children in the United States<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age (years)</td> <td class=\"subtitle1\" colspan=\"2\">Upper limit of normal (international units/mL)</td> </tr> <tr> <td class=\"subtitle2\">ASO titer</td> <td class=\"subtitle2\">ADB titer</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">160</td> <td class=\"centered\">240</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">120</td> <td class=\"centered\">60</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">240</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">160</td> <td class=\"centered\">320</td> </tr> <tr> <td class=\"centered\">6</td> <td class=\"centered\">240</td> <td class=\"centered\">480</td> </tr> <tr> <td class=\"centered\">7</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">640</td> </tr> <tr> <td class=\"centered\">8</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">9</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">10</td> <td class=\"centered\">320</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">11</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">800</td> </tr> <tr> <td class=\"centered\">12</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">480</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ASO: anti-streptolysin O; ADB: anti-deoxyribonuclease B.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kaplan EL, Rothermel CD, Johnson DR. Antistreptolysin O and anti-deoxyribonuclease B titers: Normal values for children ages 2 to 12 in the United States. Pediatrics 1998; 101:86.</li>&#xD;&#xA;</ol>&#xD;&#xA;European Journal of Clinical Microbiology &amp; Infectious Diseases, ASO titer or not? When to use streptococcal serology: A guide for clinicians, Vol. 34, 2015, p. 845, Parks T, Smeesters PR, Curtis N, Steer AC, with permission of Springer.</div><div id=\"graphicVersion\">Graphic 109547 Version 3.0</div></div></div>"},"109548":{"type":"graphic_table","displayName":"ASO and ADB streptococcal antibody titers (endemic regions)","title":"Upper limit of normal (80<SUP>th</SUP> centile) for serum streptococcal antibody titers in children and adults in tropical settings where group A <EM>Streptococcus</EM> disease is endemic","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Upper limit of normal (80<SUP>th</SUP> centile) for serum streptococcal antibody titers in children and adults in tropical settings where group A <EM>Streptococcus</EM> disease is endemic</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age group (years)</td> <td class=\"subtitle1\" colspan=\"2\">Upper limit of normal (international units/mL)</td> </tr> <tr> <td class=\"subtitle2\">ASO titer</td> <td class=\"subtitle2\">ADB titer</td> </tr> <tr> <td class=\"centered\">1 to 4</td> <td class=\"centered\">170</td> <td class=\"centered\">366</td> </tr> <tr> <td class=\"centered\">5 to 14</td> <td class=\"centered\">276</td> <td class=\"centered\">499</td> </tr> <tr> <td class=\"centered\">15 to 24</td> <td class=\"centered\">238</td> <td class=\"centered\">473</td> </tr> <tr> <td class=\"centered\">25 to 34</td> <td class=\"centered\">177</td> <td class=\"centered\">390</td> </tr> <tr> <td class=\"centered\">&#8805;35</td> <td class=\"centered\">127</td> <td class=\"centered\">265</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ASO: anti-streptolysin O; ADB: anti-deoxyribonuclease B.</div><div class=\"graphic_reference\">Adapted with permission from: Steer AC, Vidmar S, Ritika R, et al. Normal ranges of streptococcal antibody titers are similar whether streptococci are endemic to the setting or not. Clin Vaccine Immunol 2009; 16:172. Copyright &copy; 2009 American Society for Microbiology.</div><div id=\"graphicVersion\">Graphic 109548 Version 1.0</div></div></div>"},"109549":{"type":"graphic_table","displayName":"MMC and capecitabine with RT locally advanced anal carcinoma","title":"Mitomycin and capecitabine with concurrent radiation therapy for locally advanced anal carcinoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mitomycin and capecitabine with concurrent radiation therapy for locally advanced anal carcinoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 6.5 weeks (chemoradiotherapy). </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Mitomycin</td> <td>10 mg/m<sup>2</sup> (maximum 15 mg*) IV</td> <td>Infuse as slow IV push (over 5 to 10 minutes).</td> <td>Day 1<sup>&#182;</sup></td> </tr> <tr> <td>Capecitabine<sup>&#916;</sup></td> <td>825 mg/m<sup>2</sup> per dose by mouth</td> <td>Twice daily (total dose 1650 mg/m<sup>2</sup> per day) on radiation days; swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets.<sup>&#9674;</sup></td> <td>Days 1 through completion of radiotherapy (do not give with boost fractions)</td> </tr> <tr class=\"divider_bottom\"> <td>Radiotherapy<sup>&#167;</sup></td> <td>59.4 Gy primary tumor; elective 45 to 49.5 Gy to pelvic and inguinal lymph nodes</td> <td> <p>Three dimensional CF-RT: 25 fractions (45 Gy) followed by three weeks rest then 8 to 11 additional fractions (1.8 Gy per boost) based on clinical/radiographic assessment (week 5).</p> IMRT: 33 fractions (59.4 Gy) followed by a boost of three fractions (1.8 Gy each), if needed, based on clinical/radiographic assessment (week 5).</td> <td>Five days per week beginning week 1 and continuing through at least week 6</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>Mitomycin: LOW. </li> <li>Capecitabine: LOW. </li> <li>Refer to UpToDate topics on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\" and \"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated. G-CSF should be used with caution, if at all, with chemoradiotherapy. </li> <li>Refer to UpToDate topic on \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Mitomycin is a potent vesicant and can cause ulceration, necrosis, cellulitis, and tissue sloughing; avoid extravasation.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Lower initial doses of mitomycin may be needed in patients with renal insufficiency. A lower starting dose of capecitabine may be needed for patients with moderate renal impairment.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential and platelet count prior to treatment and weekly for at least eight weeks after starting treatment. Thrombocytopenia with or without neutropenia may occur anytime within eight weeks, with an average time of four weeks.<sup>[2]</sup> Recovery occurs within 10 weeks; however, myelosuppression is cumulative and counts may not recover in about 25% of cases. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (including serum creatinine) and liver function tests prior to starting treatment then weekly during chemoradiotherapy. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for signs and symptoms of localized dermatological toxicity and for changes in urinary and bowel habits during and after radiation therapy. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea, stomatitis, and cutaneous toxicity (palmar-plantar erythrodysesthesias) during treatment. </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topics on \"Enterotoxicity of chemotherapeutic agents\" and \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for signs and symptoms of mitomycin-associated acute lung injury. </li> <li>Refer to UpToDate topic on \"Mitomycin-C pulmonary toxicity\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for signs and symptoms of drug-induced thrombotic microangiopathy (TMA), which usually involves microangiopathic hemolytic anemia, thrombocytopenia, and irreversible renal failure. Other symptoms such as pulmonary edema, neurologic deficits, and hypertension may be present. TMA is usually associated with cumulative doses &#8805;50 mg/m<sup>2</sup>. Discontinue mitomycin immediately and permanently. </li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>This regimen should not be initiated unless white blood cells are &#8805;4000/microL, neutrophils are &#8805;1500/microL, and platelets are &#8805;100,000/microL.<sup>[2,3]</sup> At some institutions, the mitomycin dose is repeated on day 29, as was used in Radiation Therapy Oncology Group (RTOG) 98-11.<sup>[4]</sup> The day 29 mitomycin dose should be reduced to 7.5 mg/m<sup>2</sup> if the nadir white blood cell count (WBC) is &#60;2400/microL but &#62;1000/microL, or if the nadir platelet count is &#62;50,000/microL but &#60;85,000/microL. If the nadir WBC is &#60;1000/microL or the nadir platelet count is &#60;50,000/microL, the day 29 dose of mitomycin is reduced to 5 mg/m<sup>2</sup>. If the day 28 WBC is &#60;2400/microL or platelet count &#60;85,000/microL, we delay the start of the second cycle of therapy by one week. Reduce subsequent mitomycin doses if leukocyte nadir is &#60;3000/microL or platelet nadir is &#60;75,000/microL. The authors of this study do not state specific chemotherapy dose adjustment parameters for toxicity observed; however, other studies of capecitabine chemoradiotherapy<sup>[5,6]</sup>, and the United States Prescribing Information<sup>[3]</sup>, suggest withholding capecitabine for grade 3 or 4 hematologic toxicity, and that capecitabine be restarted after at least seven days or when recovered to &#8804;grade 1. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nonhematologic toxicity (including hepatotoxicity)</strong></td> <td colspan=\"3\"> <ul> <li>The authors of this study do not specify chemotherapy dose adjustments for nonhematologic toxicity; however, other studies of capecitabine-based chemoradiotherapy<sup>[5,6]</sup> recommend interrupting capecitabine for &#8805;grade 2 nonhematologic toxicity (except alopecia) that is likely related to capecitabine until it decreases to &#8804;grade 1 for the first incidence.<sup>[5,6]</sup> Decrease subsequent capecitabine dose by 25% for &#8805;grade 3 nonhematologic toxicity or recurrent grade 2 toxicity (except alopecia).<sup>[5,6]</sup> </li> <li><strong>The United States Prescribing Information for capecitabine provides the following guidelines for capecitabine dose modification:</strong><sup>[3]</sup> <ul> <li>Grade 2: For the first, second, and third occurrence, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment (first occurrence, no dosage adjustment; second occurrence, 75% of the starting dose; third occurrence, 50% of the starting dose).<sup>[3]</sup> For the fourth occurrence of a grade 2 toxicity, discontinue capecitabine therapy. </li> <li>Grade 3: For the first and second occurrence, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment at a reduced dose (first occurrence, 75% of the starting dose; second occurrence, 50% of the starting dose). For the third occurrence of a grade 3 toxicity, discontinue capecitabine therapy. </li> <li>Grade 4: Discontinue capecitabine therapy. Alternatively, hold capecitabine therapy, and begin next treatment at 50% of the starting dose when toxicity resolves to grade 1 or less; discontinue treatment for first recurrence of grade 4 toxicity. </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Mitomycin should be discontinued for any signs or symptoms of acute lung injury.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>TMA, also sometimes called thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS) has been associated with mitomycin. Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP. </li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><strong>Omitted capecitabine doses for toxicity are not replaced or restored.</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; Gy: gray; CF-RT: conformal radiotherapy; IMRT: intensity-modulated radiotherapy; G-CSF: granulocyte colony stimulating factor; CBC: complete blood count; INR: international normalized ratio; ULN: upper limit normal; RT: radiation therapy.<br />* At other institutions, the mitomycin dose is capped at 20 mg total dose.<br />Â¶ At some institutions, the mitomycin dose is repeated on day 29, as was used in RTOG 98-11.<SUP>[4]</SUP><br />Î” No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br /><FONT class=lozenge>â—Š</FONT> Extemporaneous compounding of liquid dosage forms has been recommended, but IV therapies may be more appropriate for patients with significant swallowing difficulty.<br />Â§ The original trial administered three-dimensional chemoradiotherapy with conventional fractionation RT prior to March 2006 and then received integrated boost IMRT thereafter.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Meulendijks D, et al. Br J Cancer 2014; 111:1726.</LI>&#xD;&#xA;<LI>Mitomycin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on April 6, 2016).</LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on April 6, 2016).</LI>&#xD;&#xA;<LI>Flam J, et al. J Clin Oncol 1996; 14:2527.</LI>&#xD;&#xA;<LI>Thind G, et al. Radiation Oncology 2014; 9:124.</LI>&#xD;&#xA;<LI>Deenen M, et al. Int J Radiation Oncol Biol Phys 2013; 85:e201.</LI></OL></div><div id=\"graphicVersion\">Graphic 109549 Version 5.0</div></div></div>"},"109553":{"type":"graphic_table","displayName":"Primary palliative care assessment of patients with ESLD","title":"Primary palliative care assessment of patients with end-stage liver disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Primary palliative care assessment of patients with end-stage liver disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Understanding of illness/prognosis and treatment options</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Does the patient/family/surrogate understand the current illness, their prognosis for quantity and quality of life, expected disease trajectory/uncertainty about disease trajectory, and treatment options?</td> </tr> <tr> <td class=\"subtitle1_left\">Symptom management</td> </tr> <tr> <td class=\"indent1\">Does the patient have uncontrolled/distressing symptoms? In particular, does the patient have any of the following?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Ascites, recurrent variceal bleeding, encephalopathy, pruritus, dyspnea </li> <li>Pain </li> <li>Fatigue and sleep disturbance </li> <li>Distressing psychological symptoms (depression, anxiety) </li> <li>Constitutional symptoms (anorexia, weight loss) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Social/spiritual assessment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Are there significant social or spiritual concerns affecting daily life?</td> </tr> <tr> <td class=\"subtitle1_left\">Decision-making</td> </tr> <tr> <td class=\"indent1\">Is cognitive function adequate for individual decision-making?</td> </tr> <tr> <td class=\"indent1\">Is the patient comfortable making health care decisions? Or, does the patient rely on family members, friends, or health care professionals to make decisions?</td> </tr> <tr> <td class=\"indent1\">Has the patient identified a surrogate decision-maker and talked with this person about their goals and values?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Would the patient/family/surrogate like help with treatment decision-making?</td> </tr> <tr> <td class=\"subtitle1_left\">Identification of patient-centered goals of care</td> </tr> <tr> <td class=\"indent1\">What are the goals for care, as identified by the patient/family/surrogate?</td> </tr> <tr> <td class=\"indent1\">Are treatment options matched to informed patient-centered goals?</td> </tr> <tr> <td class=\"indent1\">Has the patient participated in an advance care planning process?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Has the patient completed an advance care planning document?</td> </tr> <tr> <td class=\"subtitle1_left\">Coping with life-threatening illness</td> </tr> <tr> <td class=\"indent1\">How is the patient coping with their illness?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">How are the family/family caregivers coping with the illness?</td> </tr> <tr> <td class=\"subtitle1_left\">Coordination of care</td> </tr> <tr> <td class=\"indent1\">Are there barriers to safe and sustainable transitions from one setting to another (eg, transportation to appointments)?</td> </tr> <tr> <td class=\"indent1\">Are systems in place to enable good communication between multiple providers?</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 109553 Version 1.0</div></div></div>"},"109563":{"type":"graphic_table","displayName":"Adjusted prevalence of dialysis in the US population","title":"Adjusted* prevalence (per million) of dialysis in the US population and distribution (%) of age, diabetes, sex, race, and ethnicity among prevalent dialysis patients by ESRD Network in 2013","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjusted* prevalence (per million) of dialysis in the US population and distribution (%) of age, diabetes, sex, race, and ethnicity among prevalent dialysis patients by ESRD Network in 2013</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"5%\"></colgroup><colgroup span=\"7\" width=\"10%\"></colgroup><colgroup span=\"5\" width=\"5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Network</td> <td class=\"subtitle1\" rowspan=\"2\">States in network</td> <td class=\"subtitle1\" rowspan=\"2\">Prevalence per million</td> <td class=\"subtitle1\" rowspan=\"2\">Total number of prevalent dialysis cases</td> <td class=\"subtitle1\" rowspan=\"2\">Percent of prevalent dialysis cases</td> <td class=\"subtitle1\" rowspan=\"2\">Mean age</td> <td class=\"subtitle1\" rowspan=\"2\">Diabetic (%)</td> <td class=\"subtitle1\" rowspan=\"2\">Male (%)</td> <td class=\"subtitle1\" colspan=\"4\">Race</td> <td class=\"subtitle1\">Ethnicity</td> </tr> <tr> <td class=\"subtitle2\">White (%)</td> <td class=\"subtitle2\">Black/African American (%)</td> <td class=\"subtitle2\">Native American (%)</td> <td class=\"subtitle2\">Asian (%)</td> <td class=\"subtitle2\">Hispanic (%)</td> </tr> <tr> <td class=\"centered\">16</td> <td>Alaska, Idaho, Montana, Oregon, Washington</td> <td class=\"centered\">944</td> <td class=\"centered\">13,373</td> <td class=\"centered\">2.9</td> <td class=\"centered\">56.5</td> <td class=\"centered\">43.1</td> <td class=\"centered\">57.1</td> <td class=\"centered\">79.1</td> <td class=\"centered\">8.4</td> <td class=\"centered\">3.2</td> <td class=\"centered\">9.1</td> <td class=\"centered\">11.2</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">1</td> <td>Connecticut, Massachusetts, Maine, New Hampshire, Rhode Island, Vermont</td> <td class=\"centered\">982</td> <td class=\"centered\">14,042</td> <td class=\"centered\">3.0</td> <td class=\"centered\">59.2</td> <td class=\"centered\">39.9</td> <td class=\"centered\">58.2</td> <td class=\"centered\">75.3</td> <td class=\"centered\">20.6</td> <td class=\"centered\">0.2</td> <td class=\"centered\">3.5</td> <td class=\"centered\">12.0</td> </tr> <tr> <td class=\"centered\">15</td> <td>Arizona, Colorado, Nevada, New Mexico, Utah, Wyoming</td> <td class=\"centered\">1095</td> <td class=\"centered\">22,233</td> <td class=\"centered\">4.7</td> <td class=\"centered\">56.6</td> <td class=\"centered\">50.6</td> <td class=\"centered\">57.3</td> <td class=\"centered\">73.8</td> <td class=\"centered\">10.1</td> <td class=\"centered\">11.5</td> <td class=\"centered\">4.5</td> <td class=\"centered\">31.0</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">12</td> <td>Iowa, Kansas, Missouri, Nebraska</td> <td class=\"centered\">1128</td> <td class=\"centered\">15,683</td> <td class=\"centered\">3.3</td> <td class=\"centered\">57.7</td> <td class=\"centered\">40.7</td> <td class=\"centered\">56.4</td> <td class=\"centered\">68.7</td> <td class=\"centered\">29.0</td> <td class=\"centered\">0.6</td> <td class=\"centered\">1.6</td> <td class=\"centered\">5.8</td> </tr> <tr> <td class=\"centered\">11</td> <td>Michigan, Minnesota, North Dakota, South Dakota, Wisconsin</td> <td class=\"centered\">1188</td> <td class=\"centered\">27,191</td> <td class=\"centered\">5.8</td> <td class=\"centered\">58.0</td> <td class=\"centered\">40.9</td> <td class=\"centered\">56.7</td> <td class=\"centered\">63.0</td> <td class=\"centered\">31.0</td> <td class=\"centered\">2.8</td> <td class=\"centered\">3.1</td> <td class=\"centered\">4.7</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">9</td> <td>Indiana, Kentucky, Ohio</td> <td class=\"centered\">1415</td> <td class=\"centered\">32,196</td> <td class=\"centered\">6.9</td> <td class=\"centered\">57.6</td> <td class=\"centered\">43.7</td> <td class=\"centered\">56.2</td> <td class=\"centered\">66.3</td> <td class=\"centered\">32.6</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.9</td> <td class=\"centered\">2.9</td> </tr> <tr> <td class=\"centered\">4</td> <td>Delaware, Pennsylvania</td> <td class=\"centered\">1420</td> <td class=\"centered\">19,325</td> <td class=\"centered\">4.1</td> <td class=\"centered\">58.6</td> <td class=\"centered\">40.5</td> <td class=\"centered\">57.7</td> <td class=\"centered\">63.4</td> <td class=\"centered\">34.7</td> <td class=\"centered\">0.1</td> <td class=\"centered\">1.7</td> <td class=\"centered\">5.2</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">7</td> <td>Florida</td> <td class=\"centered\">1434</td> <td class=\"centered\">28,218</td> <td class=\"centered\">6.0</td> <td class=\"centered\">57.9</td> <td class=\"centered\">39.8</td> <td class=\"centered\">57.6</td> <td class=\"centered\">57.3</td> <td class=\"centered\">40.1</td> <td class=\"centered\">0.2</td> <td class=\"centered\">2.2</td> <td class=\"centered\">17.6</td> </tr> <tr> <td class=\"centered\">2</td> <td>New York</td> <td class=\"centered\">1485</td> <td class=\"centered\">29,272</td> <td class=\"centered\">6.2</td> <td class=\"centered\">58.1</td> <td class=\"centered\">40.7</td> <td class=\"centered\">57.5</td> <td class=\"centered\">53.4</td> <td class=\"centered\">38.1</td> <td class=\"centered\">0.4</td> <td class=\"centered\">7.1</td> <td class=\"centered\">16.4</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">10</td> <td>Illinois</td> <td class=\"centered\">1555</td> <td class=\"centered\">19,987</td> <td class=\"centered\">4.3</td> <td class=\"centered\">57.5</td> <td class=\"centered\">38.8</td> <td class=\"centered\">56.2</td> <td class=\"centered\">56.9</td> <td class=\"centered\">39.3</td> <td class=\"centered\">0.0</td> <td class=\"centered\">3.5</td> <td class=\"centered\">14.8</td> </tr> <tr> <td class=\"centered\">5</td> <td>Maryland, District of Columbia, Virginia, West Virginia</td> <td class=\"centered\">1588</td> <td class=\"centered\">26,760</td> <td class=\"centered\">5.7</td> <td class=\"centered\">56.6</td> <td class=\"centered\">38.1</td> <td class=\"centered\">56.0</td> <td class=\"centered\">39.2</td> <td class=\"centered\">57.3</td> <td class=\"centered\">0.1</td> <td class=\"centered\">3.3</td> <td class=\"centered\">4.1</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">17</td> <td>Northern California, Hawaii, Guam, American Samoa</td> <td class=\"centered\">1607</td> <td class=\"centered\">26,043</td> <td class=\"centered\">5.6</td> <td class=\"centered\">57.0</td> <td class=\"centered\">49.3</td> <td class=\"centered\">55.6</td> <td class=\"centered\">51.7</td> <td class=\"centered\">14.1</td> <td class=\"centered\">0.6</td> <td class=\"centered\">33.1</td> <td class=\"centered\">25.0</td> </tr> <tr> <td class=\"centered\">13</td> <td>Arkansas, Louisiana, Oklahoma</td> <td class=\"centered\">1620</td> <td class=\"centered\">18,543</td> <td class=\"centered\">4.0</td> <td class=\"centered\">55.0</td> <td class=\"centered\">42.3</td> <td class=\"centered\">53.8</td> <td class=\"centered\">43.4</td> <td class=\"centered\">51.4</td> <td class=\"centered\">3.8</td> <td class=\"centered\">1.3</td> <td class=\"centered\">3.9</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">14</td> <td>Texas</td> <td class=\"centered\">1656</td> <td class=\"centered\">44,189</td> <td class=\"centered\">9.4</td> <td class=\"centered\">55.2</td> <td class=\"centered\">52.8</td> <td class=\"centered\">54.8</td> <td class=\"centered\">68.9</td> <td class=\"centered\">28.5</td> <td class=\"centered\">0.1</td> <td class=\"centered\">2.4</td> <td class=\"centered\">45.2</td> </tr> <tr> <td class=\"centered\">18</td> <td>Southern California</td> <td class=\"centered\">1672</td> <td class=\"centered\">40,522</td> <td class=\"centered\">8.7</td> <td class=\"centered\">57.0</td> <td class=\"centered\">48.8</td> <td class=\"centered\">57.9</td> <td class=\"centered\">70.9</td> <td class=\"centered\">14.7</td> <td class=\"centered\">0.3</td> <td class=\"centered\">13.8</td> <td class=\"centered\">48.1</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">3</td> <td>New Jersey, Puerto Rico</td> <td class=\"centered\">1674</td> <td class=\"centered\">19,203</td> <td class=\"centered\">4.1</td> <td class=\"centered\">58.7</td> <td class=\"centered\">46.7</td> <td class=\"centered\">59.2</td> <td class=\"centered\">64.3</td> <td class=\"centered\">30.9</td> <td class=\"centered\">0.0</td> <td class=\"centered\">3.6</td> <td class=\"centered\">38.2</td> </tr> <tr> <td class=\"centered\">6</td> <td>North Carolina, South Carolina, Georgia</td> <td class=\"centered\">1780</td> <td class=\"centered\">44,475</td> <td class=\"centered\">9.5</td> <td class=\"centered\">54.8</td> <td class=\"centered\">39.3</td> <td class=\"centered\">54.5</td> <td class=\"centered\">32.5</td> <td class=\"centered\">65.7</td> <td class=\"centered\">0.5</td> <td class=\"centered\">1.3</td> <td class=\"centered\">3.0</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"centered\">8</td> <td>Alabama, Mississippi, Tennessee</td> <td class=\"centered\">1855</td> <td class=\"centered\">26,114</td> <td class=\"centered\">5.6</td> <td class=\"centered\">55.1</td> <td class=\"centered\">40.5</td> <td class=\"centered\">54.2</td> <td class=\"centered\">38.2</td> <td class=\"centered\">60.6</td> <td class=\"centered\">0.3</td> <td class=\"centered\">0.8</td> <td class=\"centered\">1.3</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>All</strong></td> <td class=\"centered\"><strong>1425</strong></td> <td class=\"centered\"><strong>468,386</strong></td> <td class=\"centered\"><strong>100.0</strong></td> <td class=\"centered\"><strong>56.9</strong></td> <td class=\"centered\"><strong>43.6</strong></td> <td class=\"centered\"><strong>56.3</strong></td> <td class=\"centered\"><strong>57.8</strong></td> <td class=\"centered\"><strong>35.2</strong></td> <td class=\"centered\"><strong>1.2</strong></td> <td class=\"centered\"><strong>5.5</strong></td> <td class=\"centered\"><strong>17.9</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ESRD: end-stage renal disease.<br />* Adjusted for age, sex, and race. The standard population was the US population in 2011. Listed from lowest to highest prevalence per million.</div><div class=\"graphic_reference\">Reproduced from: United States Renal Data System. 2015 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2015. The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.</div><div id=\"graphicVersion\">Graphic 109563 Version 1.0</div></div></div>"},"109572":{"type":"graphic_picture","displayName":"Netherton syndrome hair","title":"Netherton syndrome","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Netherton syndrome</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109572_Netherton_syndrome_hair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sparse, lusterless, and short hair in a patient with Netherton syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109572 Version 1.0</div></div></div>"},"109576":{"type":"graphic_picture","displayName":"Hemochromatosis biopsy","title":"Hemochromatosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Hemochromatosis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109576_Hemochromatosis_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Periportal hepatocytes contain both fine and coarse iron granules. On H&amp;E stain, these iron granules appear brown.</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin.</div><div id=\"graphicVersion\">Graphic 109576 Version 1.0</div></div></div>"},"109577":{"type":"graphic_picture","displayName":"Hemochromatosis Prussian blue biopsy","title":"Hemochromatosis (Perls' Prussian blue iron stain)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Hemochromatosis (Perls' Prussian blue iron stain)</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109577_Hemochromatosis_Pruss_bpsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The special stain shows moderate iron deposition as highlighted by the blue-colored granules present. Note that there is a decreasing gradient from periportal hepatocytes (arrows) to centrilobular hepatocytes.</div><div id=\"graphicVersion\">Graphic 109577 Version 1.0</div></div></div>"},"109578":{"type":"graphic_picture","displayName":"Hemochromatosis Prussian blue biopsy 2","title":"Hemochromatosis (Perls' Prussian blue iron stain)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Hemochromatosis (Perls' Prussian blue iron stain)</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109578_Hemochromatosis_Pruss_bpsy2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As hemochromatosis progresses, the iron accumulation becomes diffused and the iron granules become coarser, as in this photomicrograph where iron granules are present throughout the lobule.</div><div id=\"graphicVersion\">Graphic 109578 Version 1.0</div></div></div>"},"109579":{"type":"graphic_picture","displayName":"Hemochromatosis sarcoidosis Prussian blue biopsy","title":"Hemochromatosis and sarcoidosis (Perls' Prussian blue iron stain)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Hemochromatosis and sarcoidosis (Perls' Prussian blue iron stain)</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109579_Hmchrmtss_srcdss_Pruss_bpsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view showing blue-stained, fine to coarse iron granules present in hepatocytes.</div><div id=\"graphicVersion\">Graphic 109579 Version 1.0</div></div></div>"},"109580":{"type":"graphic_picture","displayName":"Hemochromatosis and sarcoidosis Prussian blue biopsy","title":"Hemochromatosis and sarcoidosis after two years of phlebotomy (Perls' Prussian blue iron stain)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Hemochromatosis and sarcoidosis after two years of phlebotomy (Perls' Prussian blue iron stain)</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109580_Hmchrmtss_srcdss_phlebotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy from a patient with hemochromatosis and sarcoidosis after two years after having undergone regular phlebotomy. The liver biopsy still shows mild patchy iron deposition.</div><div id=\"graphicVersion\">Graphic 109580 Version 1.0</div></div></div>"},"109581":{"type":"graphic_picture","displayName":"Alcoholic steatohepatitis biopsy","title":"Alcoholic steatohepatitis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Alcoholic steatohepatitis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109581_Alchlc_steatohepatitis_bpsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several hepatocytes are ballooned and contain hyaline deposits (Mallory-Denk hyalines). Arrows point to neutrophils surrounding individual ballooned hepatocytes, termed neutrophilic satellitosis.</div><div id=\"graphicVersion\">Graphic 109581 Version 1.0</div></div></div>"},"109582":{"type":"graphic_picture","displayName":"NASH biopsy","title":"Nonalcoholic steatohepatitis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Nonalcoholic steatohepatitis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109582_NASH_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power magnification of a liver biopsy demonstrating steatosis, ballooned hepatocytes (arrows) along with mild chronic inflammatory infiltrates (thick arrow). A poorly formed Mallory-Denk hyaline is also present (dashed arrow).</div><div id=\"graphicVersion\">Graphic 109582 Version 1.0</div></div></div>"},"109583":{"type":"graphic_picture","displayName":"Miliary TB liver biopsy","title":"Miliary tuberculosis with caseating granulomas","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Miliary tuberculosis with caseating granulomas</div><div class=\"cntnt\"><img style=\"width:756px; height:461px;\" src=\"images/GAST/109583_Miliary_TB_liver_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photomicrograph shows a caseating granuloma, which is surrounded by fibroblasts and histiocytes (arrows). There is no normal parenchyma present in this picture.</div><div id=\"graphicVersion\">Graphic 109583 Version 1.0</div></div></div>"},"109584":{"type":"graphic_picture","displayName":"Miliary TB caseating granulomas liver biopsy","title":"Miliary tuberculosis with caseating granulomas","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Miliary tuberculosis with caseating granulomas</div><div class=\"cntnt\"><img style=\"width:756px; height:568px;\" src=\"images/GAST/109584_MiliaryTB_cstng_granulomas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A granuloma with central necrosis (marked by asterisk). The granuloma is made up of epithelioid histiocytes (marked by arrows) that are arranged in a palisaded manner.</div><div id=\"graphicVersion\">Graphic 109584 Version 1.0</div></div></div>"},"109585":{"type":"graphic_picture","displayName":"Miliary TB granulomas liver biopsy","title":"Miliary tuberculosis with granulomas","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Miliary tuberculosis with granulomas</div><div class=\"cntnt\"><img style=\"width:756px; height:539px;\" src=\"images/GAST/109585_MiliaryTB_granulom_lvr_bpsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">H&amp;E stain of a medium-sized granuloma (arrow) accompanied by inflammatory cells.</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin.</div><div id=\"graphicVersion\">Graphic 109585 Version 1.0</div></div></div>"},"109586":{"type":"graphic_picture","displayName":"Miliary TB liver biopsy Ziehl-Neelsen stain","title":"Miliary tuberculosis with granulomas","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Miliary tuberculosis with granulomas</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109586_MiliaryTB_lvr_Ziehl-Neelsen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ziehl-Neelsen stain showing two acid-fast bacilli (AFB) within a granuloma (arrow). Finding acid-fast bacilli (AFB+) organisms is unusual in <em>Mycobacterium tuberculosis</em> because overall the organisms are few in number and may not be present in the section examined. Negative AFB stain does not necessarily rule out a mycobacterial infection.</div><div id=\"graphicVersion\">Graphic 109586 Version 1.0</div></div></div>"},"109587":{"type":"graphic_picture","displayName":"HCC liver biopsy","title":"Hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109587_HCC_liver_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy showing conventional features of hepatocellular carcinoma (left side of picture). The cells have eosinophilic cytoplasm and are arranged in broad trabeculae (four to five cells per plate). Each trabeculum is lined by endothelial cells.</div><div id=\"graphicVersion\">Graphic 109587 Version 1.0</div></div></div>"},"109588":{"type":"graphic_picture","displayName":"PBC 71-year-old woman","title":"Primary biliary cholangitis (primary biliary cirrhosis) in a 71-year-old woman","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis (primary biliary cirrhosis) in a 71-year-old woman</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109588_PBC_71-year-old_woman.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A liver biopsy showing a florid-duct lesion characterized by a damaged bile duct (arrow) that has an irregular shape and destroyed basement membrane located near the center of an enlarged inflamed portal tract. The inflammatory cells consist of histiocytes and lymphocytes that create a granulomatous reaction around the bile duct. This florid-duct lesion is virtually diagnostic of primary biliary cholangitis.</div><div id=\"graphicVersion\">Graphic 109588 Version 1.0</div></div></div>"},"109589":{"type":"graphic_picture","displayName":"PBC stage II biopsy","title":"Primary biliary cholangitis (primary biliary cirrhosis), stage II, in a 45-year-old man with pruritus","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis (primary biliary cirrhosis), stage II, in a 45-year-old man with pruritus</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109589_PBC_stage_II_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The liver biopsy shows a florid-duct lesion. A damaged bile duct (thick arrow) is surrounded by an infiltrate of lymphocytes, histiocytes, some plasma cells, and occasional eosinophils. Destruction of the basement membrane is apparent as shown by an irregular contour of the bile duct lumen and intraepithelial lymphocytes (arrows).</div><div id=\"graphicVersion\">Graphic 109589 Version 1.0</div></div></div>"},"109590":{"type":"graphic_picture","displayName":"PBC stage I biopsy","title":"Primary biliary cholangitis (primary biliary cirrhosis), stage I, in a 64-year-old-woman","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis (primary biliary cirrhosis), stage I, in a 64-year-old-woman</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109590_PBC_stage_I_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A florid-duct lesion is shown. The arrow points to a slightly damaged bile duct. The inflammatory cells surrounding this duct are a mixture of lymphocytes, plasma cells, histiocytes, and eosinophils. Note the presence of intraepithelial lymphocytes.</div><div id=\"graphicVersion\">Graphic 109590 Version 1.0</div></div></div>"},"109592":{"type":"graphic_picture","displayName":"PBC stage IV biopsy","title":"Primary biliary cholangitis (primary biliary cirrhosis), stage IV","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis (primary biliary cirrhosis), stage IV</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109592_PBC_stage_IV_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biliary-type cirrhosis with hypocellular fibrous septa surrounding a cirrhotic nodule (thin arrows). There are no bile ducts present (a finding indicative of ductopenia) and the regenerative nodule shows severe cholestasis (thick arrows).</div><div id=\"graphicVersion\">Graphic 109592 Version 1.0</div></div></div>"},"109594":{"type":"graphic_picture","displayName":"PSC biopsy","title":"Primary sclerosing cholangitis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109594_PSC_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early changes in primary sclerosing cholangitis. Layers of fibrous tissue are deposited around a bile duct (arrows). Note that the hepatic arteriole to the left of the duct has a thick muscular wall.</div><div id=\"graphicVersion\">Graphic 109594 Version 1.0</div></div></div>"},"109595":{"type":"graphic_picture","displayName":"PSC stage II biopsy","title":"Primary sclerosing cholangitis, stage II","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis, stage II</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109595_PSC_stage_II_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A bile duct (arrow) with periductal fibrosis. The lining epithelium shows mucinous metaplasia as shown by the finely vacuolated cytoplasm of the epithelial cells lining the duct. The thick arrow indicates an atrophic bile duct that is almost totally replaced by fibrous tissue, on its way to becoming a bile duct scar.</div><div id=\"graphicVersion\">Graphic 109595 Version 1.0</div></div></div>"},"109596":{"type":"graphic_picture","displayName":"Wilson disease biopsy","title":"Wilson disease","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Wilson disease</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/109596_Wilson_disease_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The liver is uniformly micronodular, as seen in this picture. Within the cirrhotic nodules, the hepatocytes are ballooned. Patients are often cirrhotic at presentation, as in this case.</div><div id=\"graphicVersion\">Graphic 109596 Version 1.0</div></div></div>"},"109597":{"type":"graphic_picture","displayName":"A1AT deficiency liver biopsy","title":"Alpha-1-antitrypsin deficiency","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Alpha-1-antitrypsin deficiency</div><div class=\"cntnt\"><img style=\"width:756px; height:566px;\" src=\"images/GAST/109597_A1AT_deficiency_livr_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunohistochemical stain of a liver biopsy using peroxidase-anti-peroxidase reaction for alpha-1-antitrypsin shows dark brown intracytoplasmic inclusions (arrows) as well as lightly brown-stained cytoplasm of hepatocytes throughout the parenchyma, indicative of retained material due to the alpha-1-antitrypsin being formed by hepatocytes which cannot then be secreted out of the cell.</div><div id=\"graphicVersion\">Graphic 109597 Version 1.0</div></div></div>"},"109598":{"type":"graphic_picture","displayName":"Liver schistosome ovum biopsy","title":"29-year-old woman with recurrent bleeding from esophageal varices","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">29-year-old woman with recurrent bleeding from esophageal varices</div><div class=\"cntnt\"><img style=\"width:756px; height:490px;\" src=\"images/GAST/109598_Liver_schistosome_ovum_bpsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver biopsy shows a granuloma surrounding a schistosome ovum at the center. The trapped eggs are the cause of the granulomatous reaction. Portal hypertension develops when many portal vein branches are involved, and, eventually, irregular bands of fibrosis develop (pipestem cirrhosis).</div><div id=\"graphicVersion\">Graphic 109598 Version 1.0</div></div></div>"},"109599":{"type":"graphic_picture","displayName":"Erythropoietic protoporphyria liver biopsy","title":"60-year-old man with jaundice and weight loss","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">60-year-old man with jaundice and weight loss</div><div class=\"cntnt\"><img style=\"width:756px; height:546px;\" src=\"images/GAST/109599_Erythropoietc_prtprphyr_lvr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The liver shows cirrhosis with portal chronic inflammation and brisk interface hepatitis in a patient with erythropoietic protoporphyria.</div><div id=\"graphicVersion\">Graphic 109599 Version 1.0</div></div></div>"},"109600":{"type":"graphic_algorithm","displayName":"An approach to the patient with visual hallucinations","title":"An approach to the evaluation of a patient with visual hallucinations","html":"<div class=\"graphic\"><div style=\"width: 860px\" class=\"figure\"><div class=\"ttl\">An approach to the evaluation of a patient with visual hallucinations</div><div class=\"cntnt\"><img style=\"width:840px; height:550px;\" src=\"images/NEURO/109600_Patient_visual_hallucinatns.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EEG: electroencephalogram.</div><div id=\"graphicVersion\">Graphic 109600 Version 2.0</div></div></div>"},"109609":{"type":"graphic_table","displayName":"Types of endoleak","title":"Types of endoleak","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of endoleak</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of endoleak</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td colspan=\"2\"><strong>Type I</strong></td> </tr> <tr> <td class=\"indent1\">Ia</td> <td>Inadequate seal at proximal end of endograft</td> </tr> <tr> <td class=\"indent1\">Ib</td> <td>Inadequate seal at distal end of endograft</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ic</td> <td>Inadequate seal at iliac occluder plug</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Type II</strong></td> <td>Backflow of blood from aortic collaterals into the aneurysm sac</td> </tr> <tr> <td><strong>Type III</strong></td> <td>Flow from visceral vessel (lumbar, IMA, accessory, renal hypogastric) without attachment site connection</td> </tr> <tr> <td class=\"indent1\">IIIa: component disconnection</td> <td>Flow from module disconnection</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">IIIb: stent fabric disturbance</td> <td>Flow from fabric disruption (minor: &#60;2 mm; major: &#8805;2 mm)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Type IV</strong></td> <td>Flow from porous fabric (&#60;30 days after graft placement)</td> </tr> <tr> <td><strong>Endoleak of undefined origin (Type V)</strong></td> <td>Flow visualized but source unidentified</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IMA: inferior mesenteric artery.</div><div class=\"graphic_reference\">Reproduced from: Chaikof EL, Blankensteijn JD, Harris PL, et al. Reporting standards for endovascular aortic aneurysm repair. J Vasc Surg 2002; 35:1048. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109609 Version 1.0</div></div></div>"},"109610":{"type":"graphic_algorithm","displayName":"Algorithm for the management of endoleak after EVAR","title":"Algorithm for the management of endoleak after EVAR","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Algorithm for the management of endoleak after EVAR</div><div class=\"cntnt\"><img style=\"width:557px; height:649px;\" src=\"images/SURG/109610_Alg_mgmt_endoleak_aftr_EVAR.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EVAR: endovascular aortic repair; IMA: inferior mesenteric artery; CT: computed tomography; MR: magnetic resonance.<br />* Endograft surveillance using CT or MR angiography or duplex ultrasound is typically at one month, six months, and annually after endograft placement.<br />&para; Vascular imaging using a different modality for indeterminate endoleak. For type II endoleak, selection is based on modality most likely to demonstrate the source of flow into the aneurysm sac.<br />&Delta; For types I or III endoleak, endovascular repair involves reballooning stent-graft fixation sites or deployment of graft extensions. For type II endoleak, successful translumbar or transarterial embolization of vessels feeding the aneurysm sac will resolve the endoleak. For type IV endoleak, relining with a new endograft may be necessary.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Chaikof EL, Blankensteijn JD, Harris PL, et al. Reporting standards for endovascular aortic aneurysm repair. J Vasc Surg 2002; 35:1048.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109610 Version 1.0</div></div></div>"},"109612":{"type":"graphic_diagnosticimage","displayName":"Transarterial embolization of type II endoleak","title":"Transarterial embolization of type II endoleak","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Transarterial embolization of type II endoleak</div><div class=\"cntnt\"><img style=\"width:766px; height:621px;\" src=\"images/SURG/109612_Transart_embo_typeII_endolk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transarterial embolization.<br />(A) A 6F sheath has been placed in the internal iliac artery, and a 5F selective catheter is used to image the endoleak.<br />(B) A microcatheter is guided over a microwire (coaxial system) toward the lumbar artery origin.<br />(C) Microcoils are used, and there is no residual endoleak.<br />(D) Six months later, the endoleak persists and the abdominal aortic aneurysm is expanding; more feeders are identified (arrow).<br />(E) The microcatheter is again used to reach the abdominal aortic aneurysm sac.<br />(F) Nidus and branches are coiled, and endoleak resolves.</div><div class=\"graphic_reference\">Reproduced from: Avgerinos ED, Chaer RA, Makaroun MS. Type II endoleaks. J Vasc Surg 2014; 60:1386. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109612 Version 2.0</div></div></div>"},"109613":{"type":"graphic_diagnosticimage","displayName":"Translumbar embolization for type II endoleak","title":"Translumbar embolization for type II endoleak","html":"<div class=\"graphic\"><div style=\"width: 696px\" class=\"figure\"><div class=\"ttl\">Translumbar embolization for type II endoleak</div><div class=\"cntnt\"><img style=\"width:676px; height:766px;\" src=\"images/SURG/109613_Translum_embo_typeII_endolk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Translumbar embolization.<br />(A) With the patient in the prone position, access has been obtained through the left paraspinal approach, and a 6F 30-cm sheath has been introduced into the abdominal aortic aneurysm sac.<br />(B) A \"sacogram\" is obtained that reveals the endoleak.<br />(C) A 5F catheter is used to guide embolization.<br />(D) The nidus is embolized with multiple coils.</div><div class=\"graphic_reference\">Reproduced from: Avgerinos ED, Chaer RA, Makaroun MS. Type II endoleaks. J Vasc Surg 2014; 60:1386. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109613 Version 3.0</div></div></div>"},"109614":{"type":"graphic_table","displayName":"Fetal imaging findings in Zika virus infection","title":"Fetal imaging findings in 17 confirmed and 28 presumed Zika virus infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fetal imaging findings in 17 confirmed and 28 presumed Zika virus infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Abnormality</td> <td class=\"subtitle1\">Number of confirmed infections at prenatal and/or postnatal imaging</td> <td class=\"subtitle1\">Number of presumed infections with microcephaly and calcifications on CT images or postnatal MR images</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Parenchymal volume loss</td> <td>17 (100)</td> <td>28 (100)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent1\">Mild to moderate</td> <td>6 (35)</td> <td>17 (61)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Severe</td> <td>12 (70)</td> <td>11 (39)</td> <td>&ndash;</td> </tr> <tr> <td>Cortical abnormalities</td> <td>16 (94)</td> <td>28 (100)</td> <td>Fifteen subjects were categorized as having both polymicrogyria and irregular areas of sulci and/or gyri not otherwise specified.</td> </tr> <tr> <td class=\"indent1\">Lissencephaly</td> <td>2 (12)</td> <td>6 (21)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent1\">Polymicrogyria or pachygyria</td> <td>11 (65)</td> <td>14 (50)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Irregular areas of sulci and/or gyri not otherwise specified</td> <td>5 (29)</td> <td>21 (75)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td>Corpus callosum abnormalities</td> <td>16 (94)</td> <td>22 (78)</td> <td>CT findings of agenesis and/or dysgenesis of the corpus callosum were frequently difficult owing to relatively large fornices and some anterior corpus callosum being present, but pronounced colpocephaly without visualization of the body of the corpus callosum was used for this diagnosis at CT. At MR imaging and US, direct visualization of the corpus callosum was used for diagnosis.</td> </tr> <tr> <td>Ventriculomegaly</td> <td>16 (94)</td> <td>27 (96)</td> <td>It can be difficult to characterize ventriculomegaly as mild or moderate, since the occipital horns were often dilated out of proportion to the frontal horns owing to parieto-occipital gray and white matter loss. Asymmetrical venticulomegaly was observed in 6 of 17 and 5 of 28 of the confirmed and presumed infections, respectively.</td> </tr> <tr> <td class=\"indent1\">Mild</td> <td>4 (24)</td> <td>5 (18)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent1\">Moderate</td> <td>7 (41)</td> <td>9 (32)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent1\">Severe</td> <td>5 (29)</td> <td>13 (46)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Septations in occipital horns</td> <td>5 (29)</td> <td>3 (11)</td> <td>&ndash;</td> </tr> <tr> <td>Cerebellum abnormalities</td> <td>14 (82)</td> <td>21 (75)</td> <td>Twelve subjects had abnormalities of cerebellar hemispheres and vermis.</td> </tr> <tr> <td class=\"indent1\">Hemisphere hypoplasia or maldevelopment</td> <td>14 (82)</td> <td>11 (39)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vermis hypoplasia</td> <td>10 (59)</td> <td>19 (68)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td>Brainstem hypoplasia and/or atrophy</td> <td>12 (70)</td> <td>6 (21)</td> <td>The high percentage in the confirmed infections reflects that these are predominantly prenatally diagnosed infections compared with the presumed infections, which has many neonates with only postnatal images. Prenatal imaging includes sagittal fetal MR imaging, which allows for better visualization of the brainstem compared with axial postnatal CT.</td> </tr> <tr> <td>Calcifications</td> <td>17 (100)</td> <td>28 (100)</td> <td>This was an inclusion criterion for the presumed infection cohort.</td> </tr> <tr> <td class=\"indent1\">Periventricular</td> <td>11 (65)</td> <td>4 (14)</td> <td>All instances with periventricular calcifications had the periventricular calcifications in areas of parenchymal thinning.</td> </tr> <tr> <td class=\"indent1\">Cortical</td> <td>4 (24)</td> <td>4 (14)</td> <td>At times, a layered appearance can be seen with cortical, gray, and white matter.</td> </tr> <tr> <td class=\"indent1\">Gray matter-white matter junction</td> <td>15 (88)</td> <td>28 (100)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent1\">Basal ganglia and/or thalamus</td> <td>11 (65)</td> <td>18 (64)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent1\">Brainstem</td> <td>3 (18)</td> <td>4 (14)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent1\">Cerebellum</td> <td>1 (6)</td> <td>1 (4)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Soft tissues of the neck</td> <td>0</td> <td>1 (4)</td> <td>&ndash;</td> </tr> <tr> <td>Heterogeneous material, some of which could be thrombus in the region of the confluence of sinuses</td> <td>9 (53)</td> <td>8 (28)</td> <td>At unenhanced CT, it is helpful to compare material in the confluence of the sinuses region to the basilar artery to determine if the attenuating and/or heterogeneous material is due to thrombus rather than dehydration and hemoconcentration effect.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Numbers in parentheses are percentages.</div><div class=\"graphic_footnotes\">CT: computed tomography; MR: magnetic resonance; US: ultrasound.</div><div class=\"graphic_reference\">Reproduced with permission from: Soares de Oliveira-Szejnfeld P, Levine D, Suely de Oliveira Melo A, et al. Congenital brain abnormalities and Zika virus: What the radiologist can expect to see prenatally and postnatally. Radiology 2016. DOI: 10.1148/radiol.2016161584. Published Online August 23, 2016. Copyright &copy; RSNA.</div><div id=\"graphicVersion\">Graphic 109614 Version 2.0</div></div></div>"},"109616":{"type":"graphic_algorithm","displayName":"Evaluation of secondary amenorrhea","title":"Evaluation of secondary amenorrhea","html":"<div class=\"graphic\"><div style=\"width: 940px\" class=\"figure\"><div class=\"ttl\">Evaluation of secondary amenorrhea</div><div class=\"cntnt\"><img style=\"width:920px; height:1054px;\" src=\"images/ENDO/109616_Eval_secondary_amenorrhea.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm offers a stepwise approach to the evaluation of secondary amenorrhea. For further details, refer to additional content on the causes, evaluation, and treatment of secondary amenorrhea.</div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin; BMI: body mass index; FSH: follicle-stimulating hormone; E2: estradiol; TSH: thyroid-stimulating hormone; PRL: prolactin; T: testosterone; MRI: magnetic resonance imaging; PCOS: polycystic ovary syndrome.<br />* Many clinicians also measure serum 17-hydroxyprogesterone at the initial visit to rule out nonclassic 21-hydroxylase deficiency. Some also measure serum dehydroepiandrosterone sulfate (DHEAS).<br />&para; Mild hyperprolactinemia can sometimes be seen with hypothyroidism. Euthyroidism should be confirmed before performing MRI.<br />&Delta; Pituitary MRI not required in those with clear explanation for their hypogonadotropic amenorrhea, eg, eating disorder, excessive exercise, celiac disease, or type 1 diabetes mellitus.</div><div id=\"graphicVersion\">Graphic 109616 Version 2.0</div></div></div>"},"109617":{"type":"graphic_algorithm","displayName":"Algorithm management Mobitz I second degree AV block in adults","title":"Algorithm management Mobitz I second degree AV block in adults","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Algorithm management Mobitz I second degree AV block in adults</div><div class=\"cntnt\"><img style=\"width:592px; height:778px;\" src=\"images/CARD/109617_MobitzI_sec_deg_AV_adlts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AV: atrioventricular; ECG: electrocardiogram; CHB: complete heart block; BP: blood pressure; HF: heart failure; IV: intravenous; PPM: permanent pacemaker.<br />* The initial dose of atropine is 0.5 mg IV. This dose may be repeated every three to five minutes to a total dose of 3 mg.<br />&para; While transcutaneous pacing may be initially successful in stabilizing the patient, it may not be consistently reliable. Central venous access should be considered in the event that urgent transvenous pacing is required.<br />&Delta; Dopamine IV infusion typically begins at a dose of 3 mcg/kg/minute and can be titrated up to 20 mcg/kg/minute if needed for heart rate and blood pressure augmentation.<br /><span class=\"lozenge\">&loz;</span> Dobutamine IV infusion typically begins at a dose of 5 mcg/kg/minute and can be titrated up to 20 mcg/kg/minute if needed for heart rate and blood pressure augmentation.</div><div id=\"graphicVersion\">Graphic 109617 Version 1.0</div></div></div>"},"109619":{"type":"graphic_algorithm","displayName":"Algorithm management Mobitz II second degree AV block in adults","title":"Algorithm management Mobitz II second degree AV block in adults","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Algorithm management Mobitz II second degree AV block in adults</div><div class=\"cntnt\"><img style=\"width:510px; height:728px;\" src=\"images/CARD/109619_MobitzII_sec_dg_AV_adlts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AV: atrioventricular; ECG: electrocardiogram; CHB: complete heart block; BP: blood pressure; HF: heart failure; IV: intravenous; PPM: permanent pacemaker.<br />* The initial dose of atropine is 0.5 mg IV. This dose may be repeated every three to five minutes to a total dose of 3 mg.<br />&para; While transcutaneous pacing may be initially successful in stabilizing the patient, it may not be consistently reliable. Central venous access should be considered in the event that urgent transvenous pacing is required.<br />&Delta; Dopamine IV infusion typically begins at a dose of 3 mcg/kg/minute and can be titrated up to 20 mcg/kg/minute if needed for heart rate and blood pressure augmentation.<br /><span class=\"lozenge\">&loz;</span> Dobutamine IV infusion typically begins at a dose of 5 mcg/kg/minute and can be titrated up to 20 mcg/kg/minute if needed for heart rate and blood pressure augmentation.</div><div id=\"graphicVersion\">Graphic 109619 Version 1.0</div></div></div>"},"109621":{"type":"graphic_figure","displayName":"Venn diagram TTTS, IUGR, TAPS","title":"Venn diagram TTTS, IUGR, TAPS","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Venn diagram TTTS, IUGR, TAPS</div><div class=\"cntnt\"><img style=\"width:466px; height:450px;\" src=\"images/OBGYN/109621_Venn_diagram_TTTS_IUGR_TAPS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TTTS: twin-twin transfusion syndrome; sIUGR: selective intrauterine growth restriction; TAPS: twin anemia polycythemia sequence.</div><div id=\"graphicVersion\">Graphic 109621 Version 1.0</div></div></div>"},"109622":{"type":"graphic_picture","displayName":"Lichen amyloidosis on extremity","title":"Lichen amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Lichen amyloidosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109622_Lichen_amyloidosis_extremty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dome-shaped papules coalescing into a rippled plaque.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109622 Version 1.0</div></div></div>"},"109623":{"type":"graphic_picture","displayName":"Lichen amyloidosis on arm","title":"Lichen amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Lichen amyloidosis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/109623_Lichen_amyloidosis_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous hyperpigmented, dome-shaped papules on arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109623 Version 1.0</div></div></div>"},"109624":{"type":"graphic_picture","displayName":"Lichen amyloidosis on extremity 2","title":"Lichen amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Lichen amyloidosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109624_Lchn_amyloidosis_extremity2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hyperpigmented papules on the extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109624 Version 1.0</div></div></div>"},"109625":{"type":"graphic_picture","displayName":"Nodular amyloidosis","title":"Nodular amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Nodular amyloidosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109625_Nodular_amyloidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Waxy plaques on the feet in a patient with nodular amyloidosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109625 Version 1.0</div></div></div>"},"109626":{"type":"graphic_picture","displayName":"Nodular amyloidosis on chin","title":"Nodular amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Nodular amyloidosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109626_Nodular_amyloidosis_chin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Waxy nodule on the chin.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109626 Version 1.0</div></div></div>"},"109632":{"type":"graphic_picture","displayName":"Lamellar ichthyosis newborn","title":"Lamellar ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Lamellar ichthyosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109632_Lamellar_ichthyosis_newborn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Newborn with lamellar ichthyosis presenting with thick plate-like scales on a mildly erythrodermic skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109632 Version 1.0</div></div></div>"},"109634":{"type":"graphic_picture","displayName":"Nonbullous congenital ichthyosiform erythroderma","title":"Nonbullous congenital ichthyosiform erythroderma","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Nonbullous congenital ichthyosiform erythroderma</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/109634_Nnblls_cngntl_ichthysfrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythroderma with fine white scales in a newborn with nonbullous congenital ichthyosiform erythroderma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109634 Version 1.0</div></div></div>"},"109638":{"type":"graphic_figure","displayName":"Hypoxemia HPS","title":"Mechanisms of hypoxemia in hepatopulmonary syndrome","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Mechanisms of hypoxemia in hepatopulmonary syndrome</div><div class=\"cntnt\"><img style=\"width:540px; height:679px;\" src=\"images/PULM/109638_Hypoxemia_HPS.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from:<br /><OL>&#xD;&#xA;<LI>â€‹RodrÃ­guez-Roisin R, Krowka MJ. Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N Engl J Med 2008; 358:2378.</LI>&#xD;&#xA;<LI>Tumgor G. Cirrhosis and hepatopulmonary syndrome. World J Gastroenterol 2014; 20:2586.</LI></OL></div><div id=\"graphicVersion\">Graphic 109638 Version 1.0</div></div></div>"},"109644":{"type":"graphic_table","displayName":"Diagnostic criteria for pancreatitis in children","title":"Diagnostic criteria for pancreatitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for pancreatitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Entity</td> <td class=\"subtitle1\">Clinical definition</td> </tr> <tr class=\"divider_bottom\"> <td>Acute pancreatitis</td> <td>Requires at least 2 of the following 3 criteria: <ul class=\"decimal_heading\"> <li>Abdominal pain suggestive of or compatible with acute pancreatitis (ie, abdominal pain of acute onset, especially in the epigastric region) </li> <li>Serum amylase and/or lipase activity at least 3 times greater than the upper limit of normal </li> <li>Imaging findings characteristic of or compatible with acute pancreatitis (eg, using U/S, CECT, EUS, MRI/MRCP) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Pediatric onset</td> <td>First episode of acute pancreatitis occurring before the patient's 19th birthday</td> </tr> <tr class=\"divider_bottom\"> <td>Acute recurrent pancreatitis</td> <td>Requires at least 2 distinct episodes of acute pancreatitis (each as defined above), along with: <ul class=\"decimal_heading\"> <li>Complete resolution of pain (&#8805;1-month pain-free interval between the diagnoses of acute pancreatitis) </li> </ul> <strong>or</strong> <ul class=\"decimal_heading\"> <li>Complete normalization of serum pancreatic enzyme levels (amylase and lipase) before the subsequent episode of acute pancreatitis is diagnosed, along with complete resolution of pain symptoms, irrespective of a specific time interval between acute pancreatitis episodes </li> </ul> </td> </tr> <tr> <td>Chronic pancreatitis</td> <td>Requires <strong>either</strong> at least 1 of the following 3 criteria: <ul class=\"decimal_heading\"> <li>Abdominal pain consistent with pancreatic origin and imaging findings suggestive of chronic pancreatic damage* </li> <li>Evidence of exocrine pancreatic insufficiency<sup>&#182;</sup> and suggestive pancreatic imaging findings* </li> <li>Evidence of endocrine pancreatic insufficiency<sup>&#916;</sup> and suggestive pancreatic imaging findings* </li> </ul> <strong>or</strong> <ul class=\"decimal_heading\"> <li>Surgical or pancreatic biopsy specimen demonstrating histopathologic features compatible with chronic pancreatitis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">U/S: transabdominal ultrasonography; CECT: contrast-enhanced computerized tomography; EUS: endoscopic ultrasonography; MRI: magnetic resonance imaging; MRCP: magnetic resonance cholangiopancreatography; ERCP: endoscopic retrograde cholangio-pancreatography.<br />* Suggestive imaging findings of chronic pancreatitis/chronic pancreatic damage including: Ductal changes (irregular contour of the main pancreatic duct or its radicles; intraductal filling defects; calculi, stricture, or dilation) and parenchymal changes (generalized or focal enlargement, irregular contour [accentuated lobular architecture], cavities, calcifications, heterogeneous echotexture). Imaging modalities may include CECT, MRI/ MRCP, ERCP; U/S; EUS (in which at least five EUS features [as defined by the Rosemont classification<SUP>[1]</SUP>] must be fulfilled).<br />Â¶ Exocrine pancreatic insufficiency to be diagnosed via fecal elastase-1 monoclonal assay &lt;100 micrograms/g stool (two separate samples done one month apart); or coefficient of dietary fat absorption &lt;90% on a 72-hour fecal fat collection. Neither test should be performed during an acute pancreatitis episode because the results may be temporarily low. Children with classic cystic fibrosis, exhibiting early-onset pancreatic insufficiency without earlier evidence of any meaningful pancreas sufficiency, typically should not be diagnosed as having chronic pancreatitis. They do not have chronic abdominal pain and pancreatic imaging findings described in the chronic pancreatitis criteria.<br />Î” Endocrine pancreatic insufficiency to be diagnosed via 2006 World Health Organization criteria for the diagnosis of diabetes mellitus: Fasting glucose â‰¥7.0 mmol/L (126 mg/dL) or plasma glucose â‰¥11.1 mmol/L (200 mg/dL) two hours after glucose load 1.75 g/kg children (to maximum 75-g glucose load).<SUP>[2]</SUP></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Catalano MF, Sahai A, Levy M, et al. EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. Gastrointest Endosc 2009;69:1251.</li>&#xD;&#xA;    <li>Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(suppl 1):S5.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Morinville VD, Husain SZ, Bai H, et al. Definitions of pediatric pancreatitis and survey of present clinical practices. J Pediatr Gastroenterol Nutr 2012; 55:261. DOI: <a href=\"http://journals.lww.com/jpgn/pages/articleviewer.aspx?year=2012&amp;issue=09000&amp;article=00006&amp;type=abstract\" target=\"_blank\">10.1097/MPG.0b013e31824f1516</a>. Copyright &copy; 2012 ESPGHN and NASPGHN. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 109644 Version 1.0</div></div></div>"},"109645":{"type":"graphic_table","displayName":"Left ventricular dysfunction associated with chemotherapy drugs","title":"Incidence of LV dysfunction with chemotherapy drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of LV dysfunction with chemotherapy drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Chemotherapy agents</td> <td class=\"subtitle1\">Incidence of heart failure&nbsp;(%)</td> <td class=\"subtitle1\">Incidence of&nbsp;decline in LVEF (%)&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Anthracyclines (cumulative dose)</td> <td class=\"subtitle2_left\">&nbsp;</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\" colspan=\"2\">Doxorubicin (Adriamycin)</td> <td class=\"indent1 highlight_gray_text\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">&nbsp;100</td> <td>&nbsp;0</td> <td>&nbsp;0.5</td> </tr> <tr> <td class=\"indent2\">&nbsp;150 mg/m<sup>2</sup></td> <td>&nbsp;0.2</td> <td>&nbsp;7</td> </tr> <tr> <td class=\"indent2\">&nbsp;300 mg/m<sup>2</sup></td> <td>&nbsp;0.6</td> <td>&nbsp;16</td> </tr> <tr> <td class=\"indent2\">400 mg/m<sup>2</sup></td> <td>3 to 5</td> <td>&nbsp;32</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent2\">550 mg/m<sup>2</sup></td> <td>7 to 26</td> <td>&nbsp;65</td> </tr> <tr> <td class=\"indent2\">700 mg/m<sup>2</sup></td> <td>18 to 48</td> <td>&nbsp;86</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Idarubicin (&#62;90 mg/m<sup>2</sup>)</td> <td>5 to 18</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Epirubicin (&#62;900 mg/m<sup>2</sup>)</td> <td>0.9 to 11.4</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Mitoxanthone (&#62;120 mg/m<sup>2</sup>)</td> <td>2.6</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Liposomal anthracyclines (&#62;900 mg/m<sup>2</sup>)</td> <td>2</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LVEF: left ventricular ejection fraction. Decline in LVEF is defined as a decline in absolute value of at least 20 percent in LVEF from baseline, a decline in absolute value of at least 10 percent in LVEF from baseline and to below the institution's lower limit of normal, a postbaseline decline in absolute value of at least 5 percet in LVEF below the institution's lower limit of normal, or the occurrence of heart failure.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Zamorano JL, Lancellotti P, Rodriguez MuÃ±oz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37:2768.</LI>&#xD;&#xA;<LI>Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003; 97:2869.</LI></OL></div><div id=\"graphicVersion\">Graphic 109645 Version 1.0</div></div></div>"},"109646":{"type":"graphic_figure","displayName":"Pathology of diffuse neuroendocrine hyperplasia","title":"Spectrum of pathology in diffuse neuroendocrine hyperplasia (DPNECH)","html":"<div class=\"graphic\"><div style=\"width: 700px\" class=\"figure\"><div class=\"ttl\">Spectrum of pathology in diffuse neuroendocrine hyperplasia (DPNECH)</div><div class=\"cntnt\"><img style=\"width:680px; height:768px;\" src=\"images/ONC/109646_Pathology_DPNECH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Multiple carcinoid tumorlets. Each is &le;5 mm (by definition).<br />(B) Higher power of carcinoid tumorlet. On this field alone one could not distinguish between ordinary carcinoid (&gt;5 mm) or a tumorlet. This is based on size alone.<br />(C) Obliterative bronchiolitis is present in some cases. The arrows highlight submucosal fibrosis resulting in partial obliteration. The lower arrow tip is on the smooth muscle of the bronchiole, and the space between the arrows is filled with collagen.<br />(D) Chromogranin immunoperoxidase stain of bronchiole (compare to normal shown in panel E). Note the clusters of positive cells indicating hyperplasia of neuroendocrine cells.<br />(E) Chromogranin immunoperoxidase stain of bronchiole (compare to DPNECH shown in panel D). In a normal bronchiole, there are very few positive neuroendocrine cells.</div><div class=\"graphic_reference\">Courtesy of Henry D. Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 109646 Version 1.0</div></div></div>"},"109647":{"type":"graphic_table","displayName":"Adenocarcinoma subtypes","title":"Adenocarcinoma subtypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adenocarcinoma subtypes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Preinvasive glandular proliferations</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Atypical adenomatous hyperplasia</td> <td>Proliferation of atypical pneumocytes or Clara cells along alveolar walls, with cytology that falls short of carcinoma and is &#8804;5 mm.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Adenocarcinoma in situ (AIS)</td> <td>Malignant epithelial cells growing along intact alveolar walls (lepidic pattern) with no evidence of invasion, measuring &#8804;3 cm.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Invasive adenocarcinoma subtypes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Minimally invasive</td> <td>Lepidic growth present in the majority of the tumor, but with &#8804;5 mm of invasion. Tumors are generally &#8804;3 cm.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lepidic</td> <td>Lepidic growth present in the majority of the tumor, but with at least one focus of invasion that is &#62;5 mm.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Acinar</td> <td>Tumors cells form gland-like spaces (acini), sometimes with cribriform architecture. Typically associated with desmoplastic stromal response.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Papillary</td> <td>Tumor cells coat papillae with central fibrovascular core.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Micropapillary</td> <td>Tumor cells coat papillae but do <strong>NOT</strong> have a fibrovascular core. Tumor cells seem to float in alveolar spaces.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Solid</td> <td>Tumors lack recognizable glandular features or papillae. The cells grow in solid-appearing sheets. Mucin generally present with special stains. Also, typically express pneumocytic differentiation by immunoperoxidase studies, eg, TTF-1.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Invasive mucinous</td> <td>Tumor cells have goblet cell morphology or columnar cells with abundant mucin. Many of the cells grow along intact alveolar septae, but will also show areas of invasion. Most of these tumors were formerly known as mucinous bronchioloalveolar carcinomas.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Colloid</td> <td>Malignant cells are associated with abundant extracellular mucin. Tumor cells may be hard to find and may also be found floating in the mucin.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fetal</td> <td>The overall low appearance of the tumor resembles fetal lung. The tumors resemble endometrioid adenocarcinoma.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Enteric</td> <td>The tumors resemble those arising in the colorectum. Central necrosis is typically present in the tumor cell nests.</td> </tr> <tr> <td class=\"indent1\">Signet ring and clear cell features</td> <td>Both of these patterns may be seen as components of other tumor types, most commonly solid forms and are no longer considered as stand-alone diagnoses.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TTF-1: thyroid transcription factor-1.</div><div id=\"graphicVersion\">Graphic 109647 Version 1.0</div></div></div>"},"109651":{"type":"graphic_table","displayName":"RCTs of axillary lymph node management in early breast cancer","title":"Randomized trials of axillary lymph node management in early breast cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Randomized trials of axillary lymph node management in early breast cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"10%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study name</td> <td class=\"subtitle1\">Study population</td> <td class=\"subtitle1\">Mean follow-up</td> <td class=\"subtitle1\" colspan=\"2\">Comparison</td> <td class=\"subtitle1\">Primary outcome</td> <td class=\"subtitle1\">Additional outcomes</td> <td class=\"subtitle1\">Morbidity</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">RCTs comparing SLNB with ALND</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">NSABP B32 (2010)<sup>[1,2]</sup></td> <td>5611 women with mostly &#60;4 cm invasive breast cancer</td> <td>96 months</td> <td>SLNB + ALND</td> <td>SLNB alone (if negative)</td> <td>OS: no difference</td> <td> <p>DFS: no difference</p> Axillary recurrence: no difference</td> <td>ALND caused fewer shoulder abduction deficits, less arm volume difference (lymphedema), and less patient-reported arm numbness or tingling throughout a three-year follow-up period.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">ALMANAC (2006)<sup>[3]</sup></td> <td>1031 women with clinically node-negative breast cancer</td> <td>12 months</td> <td>ALND</td> <td> <p>SLNB alone (if negative)</p> SLNB + ALND or axillary RT (if positive)</td> <td>Arm/shoulder morbidity and Quality of Life (QOL)</td> <td>&nbsp;</td> <td> <p>SLNB causes less lymphedema and sensory loss than ALND (relative risk 0.37 and 0.37).</p> <p>Drain use, length of hospital stay, and time to normal activity were all lower in SLNB group.</p> Patient-recorded QOL and arm functioning scores were better in SLNB group.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Veronesi (2010)<sup>[4,5]</sup></td> <td>516 women with &#60;2 cm breast cancer</td> <td>102 months</td> <td>SLNB + ALND</td> <td>SLNB alone (if negative)</td> <td>DFS: no difference</td> <td> <p>OS: no difference</p> Breast cancer related events or death: no difference</td> <td>NR</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cambridge/East Anglia study group (2005)<sup>[6]</sup></td> <td>298 patients with &#60;3 cm breast cancer</td> <td>12 months</td> <td>ALND</td> <td>SLNB alone (if negative)</td> <td>Postoperative morbidity</td> <td>&nbsp;</td> <td> <p>SLNB caused a reduction in postoperative arm swelling, subjective lymphedema, seroma formation, numbness, loss of sensitivity to light touch and pinprick, and paresthesia.</p> <p>SLNB was associated with less impairment in shoulder mobility.</p> Scores reflecting QOL and psychological morbidity were better in SLNB group.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">RACS/SNAC (2004)<sup>[7]</sup></td> <td>1088 women with clinically node-negative breast cancer</td> <td>36 months</td> <td>ALND</td> <td>SLNB alone (if negative)</td> <td>Upper limb volume, symptoms, and function</td> <td>&nbsp;</td> <td> <p>Upper limb volume increased in both groups over first two years but was less likely to stay increased in SLNB group after the first month.</p> <p>Reduction in upper limb movement was greater in ALND group up to six months but similar between groups from one to three years.</p> Subjective ratings of upper limb swelling, symptoms, dysfunction, and disability over three years were worse in ALND group.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sentinella/GIVOM (2008)<sup>[8]</sup></td> <td>697 women with &#60;3 cm breast cancer</td> <td>56 months</td> <td>ALND</td> <td>SLNB alone (if negative)</td> <td>DFS: no difference</td> <td>OS: no difference</td> <td>SLNB group had less lymphedema, restriction of shoulder mobility, and numbness.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Canavese (2009)<sup>[9]</sup></td> <td>225 patients with &#60;3 cm primary invasive cancer clinically node-negative</td> <td>66 months</td> <td>ALND</td> <td>SLNB alone (if negative)</td> <td> <p>OS: no difference</p> Axillary recurrence: none in SLNB group</td> <td>DFS: no difference</td> <td>NR</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">RCTs comparing ALND with no further axillary treatment for patients with positive sentinel nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Z0011 (2011)<sup>[10]</sup></td> <td> <p>856 women with T1-2 breast cancer, and 1-2 metastatic nodes by SLNB</p> All underwent lumpectomy and whole-breast irradiation</td> <td> <p>76 months<sup>[10]</sup></p> 111 months<sup>[11]</sup> </td> <td>ALND</td> <td>No further axillary treatment</td> <td>OS: no difference<sup>[10]</sup></td> <td> <p>DFS: no difference<sup>[10,11]</sup></p> <p>Nodal recurrence: no difference<sup>[11]</sup></p> Local regional recurrence: no difference<sup>[11]</sup></td> <td> <p>Wound infections, axillary seromas, and paresthesias were more common in ALND group.<sup>[10]</sup></p> Lymphedema was more common by self-reporting and by arm circumference measurement in ALND group.<sup>[10]</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">IBCSG 23-01 (2013)<sup>[12]</sup></td> <td>931 women with &#60;5 cm breast cancer and 1 or more micrometastatic sentinel nodes</td> <td>60 months</td> <td>ALND</td> <td>No further axillary treatment</td> <td>DFS: no difference</td> <td> <p>OS: no difference</p> Breast cancer events: no difference</td> <td>ALND caused more lymphedema, sensory neuropathy, and motor neuropathy than the no further treatment group.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">RCT comparing ALND with axillary radiotherapy for patients with positive sentinel nodes</td> </tr> <tr> <td class=\"indent1\">AMAROS (2014)<sup>[13]</sup></td> <td> <p>4805 patients randomized, 1425 patients had positive sentinel node(s)</p> 744 assigned to ALND, 681 to axillary radiotherapy</td> <td>73 months</td> <td>ALND</td> <td>Axillary radiation</td> <td>Axillary recurrence: 0.43 percent ALND versus 1.19 percent axillary radiation</td> <td> <p>OS: no difference</p> DFS: no difference</td> <td>ALND caused more lymphedema at one, three, and five years.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RCT: randomized controlled trial; SLNB: sentinel lymph node biopsy; ALND: axillary lymph node dissection; OS: overall survival; DFS: disease-free survival; NR: not reported.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Krag DN, Anderson SJ, JulianTB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010; 11:927.</li>&#xD;&#xA;    <li>Ashikaga, T, Krag, DN, Land, SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010; 102:111.</li>&#xD;&#xA;    <li>Mansel, RE, Fallowfield, L, Kissin, M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599.</li>&#xD;&#xA;    <li>Veronesi, U, Viale, G, Paganelli, G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010; 251:595.</li>&#xD;&#xA;    <li>Veronesi, U, Paganelli, G, Viale, G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006; 7:983.</li>&#xD;&#xA;    <li>Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005; 23:4312.</li>&#xD;&#xA;    <li>Wetzig N, Gill PG, Zannino D, et al. Sentinel lymph node based management or routine axillary clearance? Three-year outcomes of the RACS sentinel node biopsy versus axillary clearance (SNAC) 1 trial. Ann Surg Oncol 2015; 22:17.</li>&#xD;&#xA;    <li>Zavagno G, De Salvo GL, Scalco G, et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 2008; 247:207.</li>&#xD;&#xA;    <li>Canavese G, Catturich A, Vecchio C, et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol 2009; 20:1001.</li>&#xD;&#xA;    <li>Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305:569.</li>&#xD;&#xA;    <li>Giuliano AE, Ballman K, McCall L, et al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg 2016; 264:413.</li>&#xD;&#xA;    <li>Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013; 14:297.</li>&#xD;&#xA;    <li>Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15:1303.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109651 Version 2.0</div></div></div>"},"109654":{"type":"graphic_algorithm","displayName":"Normal bleeding and AUB","title":"Normal and abnormal uterine bleeding patterns in reproductive-age women","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Normal and abnormal uterine bleeding patterns in reproductive-age women</div><div class=\"cntnt\"><img style=\"width:762px; height:320px;\" src=\"images/OBGYN/109654_NormalbleedingandAUB.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HMB: heavy menstrual bleeding.</div><div class=\"graphic_reference\">Reproduced with permission from Malcom G Munro, MD, FRCS(c), FACOG.</div><div id=\"graphicVersion\">Graphic 109654 Version 1.0</div></div></div>"},"109655":{"type":"graphic_table","displayName":"FIGO AUB worksheet","title":"FIGO uterine bleeding symptom worksheet","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">FIGO uterine bleeding symptom worksheet</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"30%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Normal</td> <td class=\"subtitle2 highlight_green_text\" style=\"font-size: 1.2em;border-color: #000;\">Abnormal</td> <td class=\"subtitle1\"><span class=\"primarybox_left\" style=\"float: none; padding-left: 0.1em; padding-right:0.1em;\">âœ“</span></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Frequency</strong></td> <td class=\"highlight_green_text\" colspan=\"2\">Absent (no periods or bleeding) = amenorrhea</td> <td class=\"highlight_green_text\" style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"highlight_green_text\" colspan=\"2\">Frequent (&#60;24 days)</td> <td class=\"highlight_green_text\" style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\">Normal (24 to 38 days)</td> <td style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_green_text\" colspan=\"2\">Infrequent (&#62;38 days)</td> <td class=\"highlight_green_text\" style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Duration</strong></td> <td class=\"highlight_green_text\" colspan=\"2\">Prolonged (&#62;8 days)</td> <td class=\"highlight_green_text\" style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Normal (&#8804;8 days)</td> <td style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Regularity</strong></td> <td colspan=\"2\">Regular variation (cycle length variation is &#177;4 days)</td> <td style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_green_text\" colspan=\"2\">Irregular (cycle length variation is &#62;&#177;4 days)</td> <td class=\"highlight_green_text\" style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Flow volume</strong></td> <td class=\"highlight_green_text\" colspan=\"2\">Heavy</td> <td class=\"highlight_green_text\" style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\">Normal</td> <td style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_green_text\" colspan=\"2\">Light</td> <td class=\"highlight_green_text\" style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Intermenstrual bleeding (IMB)</strong><br /> (bleeding between cyclically regular onset of menses)</td> <td colspan=\"2\">None</td> <td style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"highlight_green_text\" colspan=\"2\">Random</td> <td class=\"highlight_green_text\" style=\"text-align: center;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"divider_bottom highlight_green_text\" rowspan=\"3\">Cyclic (predictable)</td> <td class=\"highlight_green_text\">Early cycle</td> <td class=\"highlight_green_text\" style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"highlight_green_text\">Mid cycle</td> <td class=\"highlight_green_text\" style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_green_text\">Late cycle</td> <td class=\"highlight_green_text\" style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td rowspan=\"3\"><strong>Unscheduled bleeding on hormone medication</strong><br /> (eg, birth control pills, rings, or patches)</td> <td colspan=\"2\">Not applicable (not on hormone medication)</td> <td style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\">None (on hormone medication)</td> <td style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"highlight_green_text\" colspan=\"2\">Present</td> <td class=\"highlight_green_text\" style=\"text-align: center; padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FIGO: International Federation of Gynecology and Obstetrics.</div><div class=\"graphic_reference\">Reproduced with permission from Malcom G Munro, MD, FRCS(c), FACOG.</div><div id=\"graphicVersion\">Graphic 109655 Version 1.0</div></div></div>"},"109656":{"type":"graphic_figure","displayName":"Frequency of menses","title":"Frequency of menses","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Frequency of menses</div><div class=\"cntnt\"><img style=\"width:622px; height:630px;\" src=\"images/OBGYN/109656_Frequencyofmenses.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal frequency of onset of menstrual periods is from 24 to 38 days, based on large databases and using the 5<SUP>th</SUP> to the 95<SUP>th</SUP> percentiles. The top panel demonstrates an individual with a 27-day cycle that is \"normal\"; the middle panel is a cycle length of 44 days, outside the normal range (infrequent); the bottom panel depicts a cycle length of 22 days, and is therefore defined as being \"frequent.\"</div><div class=\"graphic_reference\">Reproduced with permission from Malcom G Munro, MD, FRCS(c), FACOG.</div><div id=\"graphicVersion\">Graphic 109656 Version 1.0</div></div></div>"},"109657":{"type":"graphic_figure","displayName":"Regularity of menses","title":"Regularity of menses","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Regularity of menses</div><div class=\"cntnt\"><img style=\"width:618px; height:442px;\" src=\"images/OBGYN/109657_Regularityofmenses.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Regular and irregular frequency of mesnses. \"Regular\" means \"cyclically predictable\" and generally reflects the presence of consistently predictable ovulation, typically about 14 days prior to the onset of menses. The top panel depicts a 65-day interval where the first cycle length is 29 days and the second is&nbsp;31 days, with each menstrual period lasting five days and&nbsp;day 2 having the heaviest volume.&nbsp;This variation of 2 days is well within the definition of regularity: cycle length from first day of one period to the next is fairly consistent, with each cycle length within 4 days of the others.&nbsp;The bottom panel demonstrates and irregular cycle, with the first cycle with a length&nbsp;of 13 days and a second cycle of 39 days. This variation in cycle length is outside the normal range for any age and suggests that the patient is not ovulating regularly or not ovulating at all. Note the variable&nbsp;duration and flow of the menses, also consistent with some ovulatory disorders, but not necessary for defining \"irregular\" onset of menses.</div><div class=\"graphic_reference\">Reproduced with permission from Malcom G Munro, MD, FRCS(c), FACOG.</div><div id=\"graphicVersion\">Graphic 109657 Version 1.0</div></div></div>"},"109658":{"type":"graphic_figure","displayName":"Duration of menses","title":"Duration of menses","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Duration of menses</div><div class=\"cntnt\"><img style=\"width:620px; height:226px;\" src=\"images/OBGYN/109658_Durationofmenses.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The panel above demonstrates the two definitions of duration of menses. When a menstrual period is present and lasts up to 8 days, it is considered \"normal,\" while if it is in excess of 8 days, regardless of volume, as depicted in the center and right cluster, it is deemed \"prolonged.\"</div><div class=\"graphic_reference\">Reproduced with permission from Malcom G Munro, MD, FRCS(c), FACOG.</div><div id=\"graphicVersion\">Graphic 109658 Version 1.0</div></div></div>"},"109659":{"type":"graphic_figure","displayName":"Volume of menses","title":"Volume of menses","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Volume of menses</div><div class=\"cntnt\"><img style=\"width:644px; height:298px;\" src=\"images/OBGYN/109659_Volumeofmenses.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The volume of a menstrual period comprises the total amount of red cells, serum, transudate, and tissue discharged from the uterus. The menstrual volume can be quantified with research&nbsp;laboratory techniques, but for clinical purposes, the patient's perception of volume is of primary importance. Each of the clusters in the above panel represents a menstrual period. The first cluster would likely reflect the patient's perception of \"normal\" volume with a normal period length of 7 days. The second cluster reflects increased volume, primarily because of prolongation of the duration of the period â€“ there is no increase in flow rate per day. The third cluster depicts increased volume, but&nbsp;with a period of normal duration with increase in daily flow rate responsible for the increased volume. The fourth&nbsp;cluster demonstrates a period with both increased duration and increased flow rate contributing to the increase in perceived volume. </div><div class=\"graphic_reference\">Reproduced with permission from Malcom G Munro, MD, FRCS(c), FACOG.</div><div id=\"graphicVersion\">Graphic 109659 Version 1.0</div></div></div>"},"109660":{"type":"graphic_figure","displayName":"Intermenstrual bleeding","title":"Intermenstrual bleeding","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Intermenstrual bleeding</div><div class=\"cntnt\"><img style=\"width:622px; height:240px;\" src=\"images/OBGYN/109660_Intermenstrualbleeding.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This depicts an&nbsp;individual with intermenstrual bleeding. She has three periods in this interval â€“ the first period starts day 1, the next period starts 29 days later, and the next 30 days after that. The lighter intermenstrual bleeding is depicted as being on day 13 of the first cycle, and on day 25 of the second. This type of random bleeding is typically seen with a focal lesion or inflammation, including:&nbsp;cervicitis, cervical or endometrial polyp, or cervical cancer.</div><div class=\"graphic_reference\">Reproduced with permission from Malcom G Munro, MD, FRCS(c), FACOG.</div><div id=\"graphicVersion\">Graphic 109660 Version 1.0</div></div></div>"},"109661":{"type":"graphic_table","displayName":"Female genital tract bleeding","title":"Causes of female genital tract bleeding in reproductive-age women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of female genital tract bleeding in reproductive-age women</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Pregnancy</strong></td> </tr> <tr> <td colspan=\"2\"><strong>Uterus</strong></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Polyps</td> <td>Endometrial</td> </tr> <tr> <td>Endocervical</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Adenomyosis</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Leiomyomas</td> <td>Submucous</td> </tr> <tr> <td>Other (no contact with endometrium)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Malignancy and hyperplasia</td> <td>EIN</td> </tr> <tr> <td>Endometrial adenocarcinoma</td> </tr> <tr> <td>Sarcoma</td> </tr> <tr> <td>Endocervical malignancy</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Coagulopathy</td> <td>Von Willebrand disease</td> </tr> <tr> <td>Other coagulopathies, congenital and acquired</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Ovulatory disorders</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Endometrial disorders</td> <td>Disorders of local hemostasis</td> </tr> <tr> <td>Endometritis</td> </tr> <tr> <td>Other</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Iatrogenic</td> <td>Anticoagulants</td> </tr> <tr> <td>Gonadal steroid drugs or drugs that effect normal gonadal steroid production or function</td> </tr> <tr> <td>Devices (intrauterine systems)</td> </tr> <tr> <td>Other</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Not otherwise classified</td> <td>Arteriovenous and other vascular malformations</td> </tr> <tr> <td>Cesarean section scar bleeding</td> </tr> <tr> <td>Endometriosis</td> </tr> <tr> <td class=\"divider_bottom\">Other</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Exocervix</strong></td> <td>Cervicitis, acute and chronic</td> </tr> <tr> <td>Polyps</td> </tr> <tr> <td class=\"divider_bottom\">Malignancy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Vagina</strong></td> <td>Trauma</td> </tr> <tr> <td>Neoplasia</td> </tr> <tr> <td class=\"divider_bottom\">Other</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Vulva</strong></td> <td>Trauma</td> </tr> <tr> <td>Neoplasia</td> </tr> <tr> <td>Infection</td> </tr> <tr> <td class=\"divider_bottom\">Other</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EIN: endometrial epithelial neoplasia.</div><div class=\"graphic_reference\">Reproduced with permission from Malcom G Munro, MD, FRCS(c), FACOG.</div><div id=\"graphicVersion\">Graphic 109661 Version 1.0</div></div></div>"},"109662":{"type":"graphic_table","displayName":"PALM-COEIN AUB worksheet","title":"Chronic abnormal uterine bleeding evaluation: PALM-COEIN worksheet","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronic abnormal uterine bleeding evaluation: PALM-COEIN worksheet</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"3\" width=\"5%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"highlight_gray_text\" style=\"text-align: right;\" colspan=\"2\"><strong>Name:</strong></td> <td class=\"highlight_gray_text subtitle2_left\" colspan=\"6\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\" style=\"text-align: right;\" colspan=\"2\"><strong>Date:</strong></td> <td class=\"highlight_gray_text subtitle2_left\" colspan=\"6\">&nbsp;</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2\">PALM-COEIN category</td> <td class=\"subtitle2\">Not assessed</td> <td class=\"subtitle2\">Absent</td> <td class=\"subtitle2\">Present</td> <td class=\"subtitle2\">Diagnostic method</td> <td class=\"subtitle2\"><span class=\"primarybox_left\" style=\"float: none; padding-bottom: 0.1em; padding-top: 0.1em; padding-left: 0.2em; padding-right:0.1em;\">âœ“</span></td> <td class=\"subtitle2\">Date</td> <td class=\"subtitle2\">Comment</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Polyps</strong></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"6\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"6\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"6\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td>Vaginal ultrasound</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Vaginal ultrasound with contrast</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hysteroscopy</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hysterosalpingogram</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>MRI</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Histopathology</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Adenomyosis</strong></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"4\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"4\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"4\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td>Vaginal ultrasound</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hysteroscopy</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>MRI</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Histopathology</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\"><strong>Leiomyoma</strong></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"7\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"7\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"7\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td>Vaginal ultrasound</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Vaginal ultrasound with contrast</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hysteroscopy</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hysterosalpingogram</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Laparoscopy</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>MRI</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Histopathology</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Malignancy and hyperplasia</strong></td> <td class=\"centered\" style=\"padding-top:0.6em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.6em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.6em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td>Endometrial biopsy</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Coagulopathy</strong></td> <td class=\"centered\" style=\"padding-top:0.6em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.6em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.6em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td>Laboratory</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Ovulatory disorders</strong></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"4\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"4\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"4\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td>History</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Basal body temperature</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Serum progesterone</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Other</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Endometrial disorders</strong></td> <td class=\"centered\" style=\"padding-top:0.6em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.6em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.6em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td>History</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Iatrogenic</strong></td> <td class=\"centered\" style=\"padding-top:0.6em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.6em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.6em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td>History</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\"><strong>Not otherwise classified</strong></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"7\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"7\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered divider_bottom\" style=\"padding-top:0.6em;\" rowspan=\"7\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td>Vaginal ultrasound</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Vaginal ultrasound with contrast</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hysteroscopy</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hysterosalpingogram</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Laparoscopy</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>MRI</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Biopsy</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Notes:</strong></td> <td colspan=\"7\">&nbsp;<br /> &nbsp;<br /> &nbsp;<br /> &nbsp;<br /> &nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from Malcom G Munro, MD, FRCS(c), FACOG.</div><div id=\"graphicVersion\">Graphic 109662 Version 1.0</div></div></div>"},"109665":{"type":"graphic_table","displayName":"DPYD and TYMS mutations associated with increased risk","title":"<EM>DPYD</EM> and <EM>TYMS</EM> mutations associated with increased risk of fluoropyrimidine toxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\"><EM>DPYD</EM> and <EM>TYMS</EM> mutations associated with increased risk of fluoropyrimidine toxicity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"2\" width=\"17.5%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Alternative names</td> <td class=\"subtitle1\">Allele</td> <td class=\"subtitle1\">Predicted consequence in patients receiving FU</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\"><em>DPYD</em> variants</td> </tr> <tr> <td class=\"indent1\"><em>DPYD</em>*13</td> <td class=\"centered\">c.1679T&#62;G (rs55886062)</td> <td class=\"centered\">&ndash;</td> <td> <ul> <li>Decreased DPD activity </li> <li>Increased toxicity risk </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><em>DPYD</em>*2A</td> <td class=\"centered\">c.1905+1G&#62;A (rs3918290)</td> <td class=\"centered\">&ndash;</td> <td> <ul> <li>Abolished DPD activity (homozygotes) </li> <li>Greatly increased toxicity risk </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>DPYD</em>*9B</td> <td class=\"centered\">c.2846A&#62;T (rs67376798)</td> <td class=\"centered\">&ndash;</td> <td> <ul> <li>Decreased DPD activity </li> <li>Increased toxicity risk </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\"><em>TYMS</em> variants</td> </tr> <tr> <td class=\"indent1\">3'-UTR <ul class=\"decimal_heading\"> <li>6 bp deletion (TTAAAG) (rs34489327; historically rs16430) </li> </ul> </td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">Deletion</td> <td> <ul> <li>Decreased TYMS expression </li> <li>Increased FU responsiveness </li> <li>Increased risk of toxicity </li> </ul> </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">5'-TSER <ul class=\"decimal_heading\"> <li>28 bp VNTR (2R; 3R) (rs45445694) </li> <li>G&#62;C SNP in 2<sup>nd</sup> repeat of 3R allele (3RC) (rs34743033) </li> </ul> </td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">2R</td> <td>2R/2R or 2R/3RC: <ul class=\"decimal_heading\"> <li>Decreased TYMS expression </li> <li>Increased FU responsiveness </li> <li>Increased risk of toxicity </li> </ul> </td> </tr> <tr> <td class=\"centered\">&ndash;</td> <td class=\"centered\">3RC</td> <td>3RC/3RC or 2R/3RC: <ul class=\"decimal_heading\"> <li>Decreased TYMS expression </li> <li>Increased FU responsiveness </li> <li>Increased risk of toxicity </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DPYD: gene for dihydropyrimidine dehydrogenase; TYMS: gene for thymidylate synthetase; FU: fluorouracil; DPD: dihydropyrimidine dehydrogenase; UTR: untranslated region; bp: base pair; TSER: promoter enhancer region of TYMS; VNTR: variable number of 28 base&nbsp;bp tandem repeats; SNP: single-nucleotide polymorphism.</div><div class=\"graphic_reference\">Modified from: ARUP Laboratories Test Directory, available at <a href=\"http://ltd.aruplab.com/Tests/Pub/2007228\" target=\"_blank\">http://ltd.aruplab.com/Tests/Pub/2007228</a>. Copyright &copy; 2016 ARUP Laboratories. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 109665 Version 1.0</div></div></div>"},"109668":{"type":"graphic_figure","displayName":"Prevalence of systemic lupus in subtypes of cutaneous lupus","title":"Coprevalent systemic lupus erythematosus by cutaneous lupus subtype","html":"<div class=\"graphic\"><div style=\"width: 790px\" class=\"figure\"><div class=\"ttl\">Coprevalent systemic lupus erythematosus by cutaneous lupus subtype</div><div class=\"cntnt\"><img style=\"width:770px; height:522px;\" src=\"images/DERM/109668_Systmc_lps_subtype_ctns_lps.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circle size roughly reflects the relative prevalence of the subtypes of cutaneous lupus erythematosus.</div><div class=\"graphic_footnotes\">SCLE: subacute cutaneous lupus erythematosus; ACLE: acute cutaneous lupus erythematosus; LE: lupus erythematosus; DLE: discoid lupus erythematosus; SLE: systemic lupus erythematosus.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Watanabe T, Tsuchida T. Classification of lupus erythematosus based upon cutaneous manifestations. Dermatological, systemic and laboratory findings in 191 patients. Dermatology 1995; 190:277.</li>&#xD;&#xA;    <li>Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 2005; 4:253.</li>&#xD;&#xA;    <li>Chong BF, Song J, Olsen NJ. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol 2012; 166:29.</li>&#xD;&#xA;    <li>Watanabe T, Tsuchida T. Lupus erythematosus profundus: a cutaneous marker for a distinct clinical subset? Br J Dermatol 1996; 134:123.</li>&#xD;&#xA;    <li>Maize JC Jr, Costner M. Tumid lupus erythematosus: a form of lupus erythematosus. Arch Dermatol 2010; 146:451.</li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted from: Gr&ouml;nhagen CM, Nyberg F. Cutaneous lupus erythematosus: An update. Indian Dermatol Online J 2014; 5:7.</div><div id=\"graphicVersion\">Graphic 109668 Version 1.0</div></div></div>"},"109669":{"type":"graphic_picture","displayName":"Seborrheic keratosis superficial 2","title":"Seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109669_Seborrheic_keratosis_spfcl2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial seborrheic keratosis presenting as a well-demarcated, slightly elevated plaque with a dull appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109669 Version 1.0</div></div></div>"},"109670":{"type":"graphic_diagnosticimage","displayName":"Ultrasound middle phalanx fracture","title":"Ultrasound middle phalanx fracture","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Ultrasound middle phalanx fracture</div><div class=\"cntnt\"><img style=\"width:766px; height:533px;\" src=\"images/SM/109670_Ultrsnd_middle_phalanx_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A fracture of the middle phalanx is shown above in an ultrasound image (A) and a plain radiograph (B).&nbsp;The yellow box in the photograph (C) shows the position of the ultrasound transducer needed to obtain the ultrasound image. </div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109670 Version 1.0</div></div></div>"},"109671":{"type":"graphic_diagnosticimage","displayName":"Ultrasound distal phalanx avulsion fracture","title":"Ultrasound distal phalanx avulsion fracture","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">Ultrasound distal phalanx avulsion fracture</div><div class=\"cntnt\"><img style=\"width:646px; height:281px;\" src=\"images/SM/109671_Ultrsd_distl_phalanx_avulsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The images above show an avulsion fracture of the distal phalanx on plain radiograph (B) and ultrasound (A). In the photograph of the hand, the yellow box shows the position of the ultrasound transducer to obtain the adjacent ultrasound image.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109671 Version 1.0</div></div></div>"},"109672":{"type":"graphic_diagnosticimage","displayName":"Ultrasound scapholunate ligament","title":"Ultrasound scapholunate ligament","html":"<div class=\"graphic\"><div style=\"width: 672px\" class=\"figure\"><div class=\"ttl\">Ultrasound scapholunate ligament</div><div class=\"cntnt\"><img style=\"width:652px; height:624px;\" src=\"images/SM/109672_US_scapholunate_ligament.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;ultrasound image above (A)&nbsp;shows the scapholunate ligament and its surrounding structures. The yellow&nbsp;box in the photograph (B)&nbsp;shows&nbsp;the position of the ultrasound transducer necessary to obtain this view.</div><div class=\"graphic_footnotes\">ECRB: extensor carpi radialis brevis tendon; IV: fourth compartment of extensor tendons.<br />* Dorsal&nbsp;aspect of&nbsp;scapholunate ligament.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109672 Version 1.0</div></div></div>"},"109673":{"type":"graphic_diagnosticimage","displayName":"Ultrasound wrist TFCC short and long axis","title":"Ultrasound wrist TFCC short and long axis","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Ultrasound wrist TFCC short and long axis</div><div class=\"cntnt\"><img style=\"width:766px; height:401px;\" src=\"images/SM/109673_Wrist_TFCC_short_long_axis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound images above show the region of the triangular fibrocartilage complex in both the transverse (or short axis) view (A), and the longitudinal (or long axis) view (B). The position of the transducer to obtain the transverse view is shown in photograph D, while the position needed for to obtain the longitudinal image is shown in photograph C.</div><div class=\"graphic_footnotes\">TFCC: triangular fibrocartilage complex; ECU: extensor carpi ulnaris tendon.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109673 Version 1.0</div></div></div>"},"109674":{"type":"graphic_diagnosticimage","displayName":"Ultrasound de Quervain tenosynovitis","title":"Ultrasound de Quervain tenosynovitis","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Ultrasound de Quervain tenosynovitis</div><div class=\"cntnt\"><img style=\"width:766px; height:338px;\" src=\"images/SM/109674_Ultrsd_Quervain_tenosynovts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above (B) shows a patient with de Quervain's tenosynovitis being treated with an injection under ultrasound guidance. In the corresponding ultrasound image (A), the tip of the needle can be seen entering the fluid-filled tendon sheath. </div><div class=\"graphic_footnotes\">* Fluid within the tendon sheath.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109674 Version 1.0</div></div></div>"},"109675":{"type":"graphic_diagnosticimage","displayName":"Ultrasound proximal carpal tunnel","title":"Ultrasound proximal carpal tunnel","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Ultrasound proximal carpal tunnel</div><div class=\"cntnt\"><img style=\"width:766px; height:340px;\" src=\"images/SM/109675_Ultrsd_proximl_carpal_tnnl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above (A)&nbsp;shows&nbsp;a relatively proximal view of the carpal tunnel. The photograph (B)&nbsp;shows the position of the ultrasound&nbsp;transducer needed to obtain this view.</div><div class=\"graphic_footnotes\">FCR: flexor carpi radialis tendon; FPL: flexor pollicis longus tendon.<br />* Median nerve.<br />&para; Ulnar artery.<br />&Delta; Flexor digitorum superficialis tendons.<br /><span class=\"lozenge\">&loz;</span> Flexor digitorum profundus tendons.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109675 Version 1.0</div></div></div>"},"109676":{"type":"graphic_diagnosticimage","displayName":"Ultrasound distal carpal tunnel","title":"Ultrasound distal carpal tunnel","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Ultrasound distal carpal tunnel</div><div class=\"cntnt\"><img style=\"width:766px; height:333px;\" src=\"images/SM/109676_US_distal_carpal_tunnel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture&nbsp;A shows a detailed ultrasound image of the distal carpal tunnel, while picture B shows the position of the ultrasound transducer needed to obtain this image.</div><div class=\"graphic_footnotes\">FPL: flexor pollicis longus.<br />* Median nerve.<br />&para; Ulnar artery.<br />&Delta; Flexor digitorum superficialis tendons.<br /><span class=\"lozenge\">&loz;</span> Flexor digitorum profundus tendons.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109676 Version 1.0</div></div></div>"},"109677":{"type":"graphic_diagnosticimage","displayName":"Ultrasound carpal tunnel detail","title":"Ultrasound carpal tunnel detail","html":"<div class=\"graphic\"><div style=\"width: 685px\" class=\"figure\"><div class=\"ttl\">Ultrasound carpal tunnel detail</div><div class=\"cntnt\"><img style=\"width:665px; height:493px;\" src=\"images/SM/109677_Ultrsd_carpal_tunnel_close.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows a close-up, detailed view of the carpal tunnel and the structures within it.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109677 Version 1.0</div></div></div>"},"109678":{"type":"graphic_diagnosticimage","displayName":"Ultrasound carpal tunnel enlarged median nerve","title":"Ultrasound carpal tunnel enlarged median nerve","html":"<div class=\"graphic\"><div style=\"width: 689px\" class=\"figure\"><div class=\"ttl\">Ultrasound carpal tunnel enlarged median nerve</div><div class=\"cntnt\"><img style=\"width:669px; height:494px;\" src=\"images/SM/109678_Carpal_tnnl_enlrgd_median_n.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows a detailed, transverse view of the carpal tunnel region, including an enlarged median nerve. </div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109678 Version 1.0</div></div></div>"},"109679":{"type":"graphic_diagnosticimage","displayName":"Ultrasound Guyon's canal and ulnar nerve","title":"Ultrasound Guyon's canal and ulnar nerve","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Ultrasound Guyon's canal and ulnar nerve</div><div class=\"cntnt\"><img style=\"width:766px; height:311px;\" src=\"images/SM/109679_Guyon_canal_ulnar_nerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image of Guyon's canal above (A) is obtained with the transducer placed as shown in the accompanying photograph (B). </div><div class=\"graphic_footnotes\">* Ulnar nerve.<br />&Delta; Ulnar artery.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109679 Version 1.0</div></div></div>"},"109680":{"type":"graphic_table","displayName":"Pharmacokinetics of oral immunosuppressive drugs in adults","title":"Pharmacokinetics of orally administered immunosuppressive drugs in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetics of orally administered immunosuppressive drugs in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug (US brand name)</td> <td class=\"subtitle1\">Oral bioavailability</td> <td class=\"subtitle1\">Effect of food on absorption</td> <td class=\"subtitle1\">Metabolism and clearance*</td> <td class=\"subtitle1\">Enzyme/transporter inhibition*</td> <td class=\"subtitle1\">Half-life in hours (range)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Antimetabolites</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mycophenolate mofetil (MMF, CellCept)</td> <td>80.7% (renal transplant patients)<br /> 94% (healthy volunteers)</td> <td> <ul> <li>High-fat meal: &#8595;Cmax by 40%; AUC is unchanged </li> <li>Should be taken on an empty stomach or at a consistent time each day in relation to meals to improve GI tolerability </li> <li>Giving total daily dose in three or four equally divided doses may improve GI tolerability </li> </ul> </td> <td>Rapidly hydrolyzed to its active metabolite mycophenolic acid (MPA), which is further metabolized by UGT to the inactive metabolite mycophenolic acid glucuronide (MPAG), which is excreted primarily via urine; MPA undergoes enterohepatic recirculation, and secondary increases in MPA levels are seen 6 to 12 hours after a dose of MMF</td> <td>None known</td> <td> <p>17.9 (11.4 to 24.4)<sup>&#182;</sup> (MPA)</p> MPAG can accumulate in renal failure</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mycophenolate sodium, enteric coated (Myfortic)<sup>&#916;</sup></td> <td>72% (renal transplant patients)</td> <td> <ul> <li>High-fat meal: &#8595;Cmax by 33%; AUC is unchanged </li> <li>Should be taken on an empty stomach </li> </ul> </td> <td>Rapidly hydrolyzed to the active metabolite mycophenolic acid (MPA), which is further metabolized by UGT to the inactive metabolite mycophenolic acid glucuronide (MPAG), which is excreted primarily via urine; MPA undergoes enterohepatic recirculation, and secondary increases in MPA levels are seen 6 to 8 hours after a dose of mycophenolate sodium</td> <td>None known</td> <td> <p>12 (8 to 16) (MPA)</p> MPAG can accumulate in renal failure</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Calcineurin inhibitors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cyclosporine non-modified (Sandimmune)</td> <td>Generally poor and unpredictable: <ul class=\"decimal_heading\"> <li>10 to 89% (renal transplant patients) </li> <li>&#60;10% (liver transplant patients) </li> </ul> </td> <td> <ul> <li>High-fat meal: &#8593;(highly variable) </li> <li>Should be taken at a consistent time each day in relation to meals </li> </ul> </td> <td rowspan=\"2\"> <p>Metabolized by CYP3A4 to reduced activity and inactive metabolites (eg, M1, M9, M4N) cleared fecally via bile</p> Substrate of P-gp</td> <td rowspan=\"2\">Inhibitor of P-gp</td> <td> <p>19 (10 to 27)</p> Prolonged in hepatic impairment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cyclosporine modified (microemulsion) (Neoral)</td> <td>23 to 50% better absorbed than non-modified formulation in renal and liver transplant patients, respectively</td> <td> <ul> <li>High-fat meal: &#8595;Cmax by 33% and &#8595;AUC by 13% </li> <li>Should be taken at a consistent time each day in relation to meals </li> </ul> </td> <td> <p>8.4 (5 to 18)</p> Prolonged in hepatic impairment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tacrolimus immediate-release capsule (Prograf)</td> <td>7 to 32%</td> <td> <ul> <li>High-fat meal: &#8595;Cmax by 77% and &#8595;AUC by 37% </li> <li>High-carbohydrate meal: &#8595;Cmax by 65% and &#8595;AUC by 28% </li> <li>Should be taken on an empty stomach </li> </ul> </td> <td rowspan=\"3\"> <p>Metabolized by CYP3A4/5 to active (eg, 13-O-demethyl) and inactive metabolites cleared fecally via bile</p> Substrate of P-gp</td> <td rowspan=\"3\">May be an inhibitor of P-gp; supportive data are limited to in-vitro effects (ie, clinical effect is unknown)<br /> </td> <td> <p>12 (2 to 36)</p> Prolonged in severe hepatic impairment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tacrolimus extended-release capsule (Astagraf XL)</td> <td>12 to 19%</td> <td> <ul> <li>High-fat meal: &#8595;Cmax by 77% and &#8595;AUC by 25% </li> <li>Should be taken preferably on an empty stomach at least 1 hour before a meal or at least 2 hours after a meal </li> </ul> </td> <td> <p>38 (35 to 41)</p> Prolonged in severe hepatic impairment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tacrolimus extended-release tablet (Envarsus XR)</td> <td>50% better absorbed than immediate-release capsule</td> <td> <ul> <li>High-fat meal: &#8595;Cmax by 22% and &#8595;AUC by 55% </li> <li>Evening administration: &#8595;AUC by 15% </li> <li>Should be taken on an empty stomach </li> </ul> </td> <td> <p>31 (23 to 39)</p> Prolonged in severe hepatic impairment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">mTOR inhibitors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Everolimus (Zortress)</td> <td>30%</td> <td> <ul> <li>High-fat meal: &#8595;Cmax by 60%; &#8595;AUC by 16% </li> <li>Should be taken at a consistent time each day in relation to meals </li> </ul> </td> <td> <p>Metabolized by CYP3A4 to six weakly active metabolites that are excreted primarily via feces</p> Substrate of P-gp</td> <td>None known</td> <td> <p>30 (19 to 41)</p> Prolonged in hepatic impairment</td> </tr> <tr> <td class=\"indent1\">Sirolimus (Rapamune)</td> <td>18% (tablet)<br /> 14% (oral solution)</td> <td> <ul> <li>High-fat meal: &#8593;AUC by 23 to 35% </li> <li>Should be taken at a consistent time each day in relation to meals </li> </ul> </td> <td> <p>Metabolized by CYP3A4 to seven metabolites (some have weak activity) that are excreted primarily via feces</p> Substrate of P-gp</td> <td>None known</td> <td> <p>62 (46 to 78)</p> Prolonged in hepatic impairment</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Careful therapeutic drug monitoring (TDM) of systemic calcineurin inhibitors and mTOR inhibitors is essential due to the narrow margin between adequate immunosuppression and toxicity. Blood concentration monitoring is necessary for any change in formulation (including switch between generics or brands) and between methods of administration (eg, oral, sublingual, intravenous) to determine the need for dose alteration. Refer to accompanying text.</div><div class=\"graphic_footnotes\">MMF: mycophenolate mofetil; Cmax: maximum concentration; AUC: area under the 24-hour serum concentration x time plot; GI: gastrointestinal; MPA: mycophenolic acid (active form of mycophenolate); UGT: uridine diphosphate (UDP) glucuronosyltransferase; MPAG: mycophenolic acid glucuronide (inactive metabolite of mycophenolic acid); CYP3A4: cytochrome P450 3A4; P-gp: P-glycoprotein efflux membrane transporters (multi-drug efflux pump); mTOR inhibitors: mammalian (mechanistic) target of rapamycin inhibitors.<br />* Data provided on drug metabolism are included to assess the potential for drug interactions. Only strong or moderate effects are listed. Specific drug interactions may be determined by use of Lexi-Interact, the drug interactions tool included with UpToDate.<br />Â¶ Standard deviation 6.5 hours per US manufacturer.<br />Î” To convert from mycophenolate mofetil (MMF, CellCept) 1000 mg every 12 hours, switch to mycophenolate sodium enteric coated (Myfortic) 720 mg every 12 hours.</div><div class=\"graphic_reference\">Prepared with data from Lexicomp Online. Copyright Â© 1978-2018 Lexicomp, Inc. All Rights Reserved with additional data from US prescribing information available at <A href=\"https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm\" target=_blank>https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</A>.</div><div id=\"graphicVersion\">Graphic 109680 Version 4.0</div></div></div>"},"109687":{"type":"graphic_picture","displayName":"Melanoma of the penis","title":"Melanoma of the penis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Melanoma of the penis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/ONC/109687_Melanoma_of_the_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Curtis A Pettaway, MD.</div><div id=\"graphicVersion\">Graphic 109687 Version 2.0</div></div></div>"},"109689":{"type":"graphic_algorithm","displayName":"CDC congenital Zika evaluation algorithm","title":"Approach to initial evaluation and follow-up of the infant born to a mother with possible Zika virus exposure during pregnancy*<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">Approach to initial evaluation and follow-up of the infant born to a mother with possible Zika virus exposure during pregnancy*<SUP>[1,2]</SUP></div><div class=\"cntnt\"><img style=\"width:784px; height:665px;\" src=\"images/PEDS/109689_CDCcongentlZikaevalalgo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended for use in conjunction with additional UpToDate content. Refer to UpToDate topics on Zika virus infection in pregnancy and congenital Zika virus infection in the newborn for detailed discussion of the approach to evaluating newborns with suspected congenital Zika virus infection.</div><div class=\"graphic_footnotes\">CZS: congenital Zika syndrome; ABR: auditory brainstem response; CBC: complete blood count; LFTs: liver function tests; OFC: occipitofrontal circumference; rRT-PCR: real-time reverse transcription-polymerase chain reaction; IgM: immunoglobulin M; ELISA: enzyme-linked immunosorbent assay; RNA: ribonucleic acid; CSF: cerebrospinal fluid.<br />* This includes infants born to mothers with laboratory evidence of Zika virus infection during pregnancy and infants with findings suggestive of congenital Zika virus infection in the setting of a maternal epidemiologic link (eg, residence in or recent travel to an area where mosquito-borne transmission of Zika virus infection has been reported or unprotected sexual contact with a person with recent Zika virus exposure). Refer to UpToDate topic on Zika virus infection in pregnancy for additional details.<br />Â¶ The initial clinical evaluation can be completed before hospital discharge or as an outpatient, taking into account hospital capabilities and needs of the family. Transfer to a facility with access to pediatric subspecialty care typically is not necessary unless there is an urgent clinical need (eg, refractory seizures, respiratory failure). For severely affected infants who are receiving palliative care, providers and families may choose to forego some of these consultations and evaluations. Refer to UpToDate topic on congenital Zika virus infection for additional details.<br />Î” Zika virus testing in the infant includes serum and urine Zika virus rRT-PCR testing and serum Zika virus IgM ELISA. If CSF is obtained for other studies, rRT-PCR testing for Zika virus RNA and Zika virus IgM should be performed on CSF. <SPAN style=\"COLOR: black\">The initial samples should be collected from the infant within the first few days after birth if possible. </SPAN><SPAN style=\"COLOR: black\">Testing is positive if the rRT-PCR is positive in any of the samples collected at birth</SPAN>. Negative rRT-PCR with positive IgM (including \"positive,\" \"presumptive positive,\" \"possible positive,\" or \"equivocal\") indicates probable congenital Zika virus infection. If both rRT-PCR and IgM testing are negative, congenital Zika virus infection is unlikely. Negative Zika virus testing should prompt a thorough evaluation for other causes of microcephaly or other findings, if present. Refer to UpToDate topic on congenital Zika virus infection for further details.<br /><FONT class=lozenge>â—Š</FONT> Evaluation for other causes of congenital anomalies is based on the specific findings and may include testing for other congenital infections and/or testing for genetic causes of microcephaly. For further details, refer to separate UpToDate content on congenital (TORCH) infections and evaluation of microcephaly.<br />Â§ Laboratory evidence of maternal Zika virus infection includes positive rRT-PCR in any clinical specimen or positive Zika virus IgM with confirmatory neutralizing antibody titers. Refer to UpToDate content on Zika virus infection in pregnancy for further details.<br />Â¥ Infants with confirmed or probable Zika virus infection who pass the initial newborn hearing screen using only otoacoustic emissions methodology should have automated ABR performed by age 1 month.<br />â€¡ Additional outpatient follow-up is based on the clinical findings. For severely affected infants who are receiving palliative care, providers and families may choose to forego some of these consultations and evaluations.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Russell K, Oliver SE, Lewis L, et al. Update: Interim Guidance for the Evaluation and Management of Infants with Possible Congenital Zika Virus Infection - United States, August 2016. MMWR Morb Mortal Wkly Rep 2016; 65:870.</LI>&#xD;&#xA;<LI>Adebanjo T, Godfred-Cato S, Viens L, et al. Update: Interim Guidance for the Diagnosis, Evaluation, and Management of Infants with Possible Congenital Zika Virus Infection - United States, October 2017. MMWR Morb Mortal Wkly Rep 2017; 66:1089.</LI></OL></div><div id=\"graphicVersion\">Graphic 109689 Version 5.0</div></div></div>"},"109690":{"type":"graphic_picture","displayName":"Congenital Zika syndrome","title":"Newborn with congenital Zika syndrome","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Newborn with congenital Zika syndrome</div><div class=\"cntnt\"><img style=\"width:724px; height:528px;\" src=\"images/PEDS/109690_Congenital_Zika_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Newborn infant congenitally infected with Zika virus. Clinical features of congenital Zika syndrome include microcephaly, facial disproportion, hypertonia/spasticity, hyperreflexia, seizures,&nbsp;irritability, arthrogryposis, club feet, ocular abnormalities, and hearing loss.</div><div class=\"graphic_reference\">Reproduced with permission from: Miranda-Filho Dde B, Martelli CM, Ximenes RA, et al. Initial Description of the Presumed Congenital Zika Syndrome. Am J Public Health 2016; 106(4):598-600. Copyright &copy; 2016 American Public Health Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109690 Version 2.0</div></div></div>"},"109691":{"type":"graphic_diagnosticimage","displayName":"CT scan congenital Zika","title":"CT scan of the brain of a newborn with congenital Zika syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of the brain of a newborn with congenital Zika syndrome</div><div class=\"cntnt\"><img style=\"width:379px; height:453px;\" src=\"images/PEDS/109691_CT_scan_congenital_Zika.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT image of a newborn congenitally infected with Zika virus showing microcephaly, cortical malformation, and brain calcification. Many small dystrophic calcifications are noted in the junction between cortical and subcortical white matter (arrows). There is also noticeable reduction of the brain parenchyma thickness.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">From: de Fatima Vasco Aragao M, van der Linden V, Brainer-Lima AM, et al. Clinical features and neuroimaging (CT and MRI) findings in presumed Zika virus related congenital infection and microcephaly: retrospective case series study. BMJ 2016; 353:i1901. Reproduced with permission from BMJ Publishing Group Ltd. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 109691 Version 1.0</div></div></div>"},"109692":{"type":"graphic_diagnosticimage","displayName":"MRI congenital Zika","title":"MRI of the brain of a newborn with congenital Zika syndrome","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">MRI of the brain of a newborn with congenital Zika syndrome</div><div class=\"cntnt\"><img style=\"width:764px; height:431px;\" src=\"images/PEDS/109692_MRI_congenital_Zika.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI of a newborn congenitally infected with Zika virus with associated severe microcephaly. Sagittal T1 weighted image (A) shows profound craniofacial disproportion, noticeably hypogenetic corpus callosum (short white arrow), and brainstem (long white arrow), hypoplasia of the cerebellum (short black arrow), and enlargement of the cisterna magna (long black arrow). Axial T2 weighted image (B) shows severe ventriculomegaly, mainly at the posterior horn and ventricular atrium (short white arrows). Note the bulging walls of the ventricle, the upward dilated third ventricle (black arrow), and enlargement of the subarachnoid space (long white arrows).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">From: de Fatima Vasco Aragao M, van der Linden V, Brainer-Lima AM, et al. Clinical features and neuroimaging (CT and MRI) findings in presumed Zika virus related congenital infection and microcephaly: retrospective case series study. BMJ 2016; 353:i1901. Reproduced with permission from BMJ Publishing Group Ltd. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 109692 Version 1.0</div></div></div>"},"109693":{"type":"graphic_table","displayName":"AIHA drugs","title":"Drugs associated with autoimmune hemolytic anemia and/or a positive direct antiglobulin (Coombs) test","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs associated with autoimmune hemolytic anemia and/or a positive direct antiglobulin (Coombs) test</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Antibiotics</td> </tr> <tr> <td class=\"indent1\">Amoxicillin</td> <td>Amphotericin B</td> <td>Ampicillin</td> </tr> <tr> <td class=\"indent1\">Cefazolin</td> <td>Cefotaxime</td> <td>Cefotetan</td> </tr> <tr> <td class=\"indent1\">Cefoxitin</td> <td>Ceftazidime</td> <td>Ceftizoxime</td> </tr> <tr> <td class=\"indent1\">Ceftriaxone</td> <td>Cefuroxime</td> <td>Cephalexin</td> </tr> <tr> <td class=\"indent1\">Cephalothin</td> <td>Chloramphenicol</td> <td>Ciprofloxacin</td> </tr> <tr> <td class=\"indent1\">Erythromycin</td> <td>Isoniazid</td> <td>Levofloxacin</td> </tr> <tr> <td class=\"indent1\">Mefloquine</td> <td>Nafcillin</td> <td>P-aminosalicylic acid</td> </tr> <tr> <td class=\"indent1\">Penicillin</td> <td>Piperacillin</td> <td>Pyrimethamine</td> </tr> <tr> <td class=\"indent1\">Quinidine</td> <td>Quinine</td> <td>Rifampin</td> </tr> <tr> <td class=\"indent1\">Stibophen</td> <td>Streptomycin</td> <td>Teicoplanin</td> </tr> <tr> <td class=\"indent1\">Temafloxacin</td> <td>Tetracycline</td> <td>Ticarcillin</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trimethoprim/sulfamethoxazole</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Nonsteroidal anti-inflammatory drugs and analgesic/antipyretics</td> </tr> <tr> <td class=\"indent1\">Acetaminophen</td> <td>Aspirin</td> <td>Azapropazone</td> </tr> <tr> <td class=\"indent1\">Diclofenac</td> <td>Dipyrone</td> <td>Ibuprofen</td> </tr> <tr> <td class=\"indent1\">Methadone (positive DAT only)</td> <td>Naproxen</td> <td>Phenacetin</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sulfasalazine</td> <td>Sulindac</td> <td>Tolmetin</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Anti-cancer drugs</td> </tr> <tr> <td class=\"indent1\">Carboplatin</td> <td>Cisplatin</td> <td>Fluorouracil</td> </tr> <tr> <td class=\"indent1\">9-hydroxymethyl-ellipticinium</td> <td>Imatinib</td> <td>Methotrexate</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Oxaliplatin</td> <td>Pemetrexed</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Other</td> </tr> <tr> <td class=\"indent1\">Antazoline</td> <td>Buthiazide</td> <td>Carbimazole</td> </tr> <tr> <td class=\"indent1\">Catechin</td> <td>Chlorinated hydrocarbon insecticides</td> <td>Chlorpromazine</td> </tr> <tr> <td class=\"indent1\">Chlorpropamide</td> <td>Cyclofenil</td> <td>Cyclosporin</td> </tr> <tr> <td class=\"indent1\">Diethylstilbestrol</td> <td>Furosemide (positive DAT only)</td> <td>Hydrochlorothiazide</td> </tr> <tr> <td class=\"indent1\">Insulin</td> <td>Methadone (positive DAT only)</td> <td>Methotrexate</td> </tr> <tr> <td class=\"indent1\">Nomifensine</td> <td>Probenecid</td> <td>Puerarin (Chinese herb)</td> </tr> <tr> <td class=\"indent1\">Quinidine</td> <td>Quinine</td> <td>Ranitidine</td> </tr> <tr> <td class=\"indent1\">Tolbutamide</td> <td>Triamterene</td> <td>Trimellitic anhydride (used in dyes, resins)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Only drugs with more than one case report of drug-induced AIHA are listed. Drugs that belong in two classes are listed under both. Refer to UpToDate for further information about patient evaluation and management.</div><div class=\"graphic_footnotes\">AIHA: autoimmune hemolytic anemia; DAT: direct antiglobulin (Coombs) test.</div><div class=\"graphic_reference\">Adapted from: Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology 2014; 30:66.</div><div id=\"graphicVersion\">Graphic 109693 Version 1.0</div></div></div>"},"109694":{"type":"graphic_figure","displayName":"Cognitive-behavioral model of hoarding disorder symptoms","title":"Cognitive-behavioral model of hoarding disorder symptoms","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cognitive-behavioral model of hoarding disorder symptoms</div><div class=\"cntnt\"><img style=\"width:446px; height:468px;\" src=\"images/PSYCH/109694_Hoarding_disorder_symptoms.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Wheaton MG. Understanding and treating hoarding disorder: A review of cognitive-behavioral models and treatment. J Obsessive Compuls Relat Disord 2016; 9:43. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109694 Version 1.0</div></div></div>"},"109697":{"type":"graphic_picture","displayName":"Infected tattoo","title":"Infected tattoo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infected tattoo</div><div class=\"cntnt\"><img style=\"width:293px; height:756px;\" src=\"images/PEDS/109697_Infected_tattoo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustular rash caused by <em>Mycobacterium haemophilum</em> confined to the tattooed region of the forearm. Photograph taken in October 2009, two months after tattooing.</div><div class=\"graphic_reference\">Reproduced from: Kay MK, Perti TR, Duchin JS. Tattoo-associated Mycobacterium haemophilum skin infection in immunocompetent adult, 2009. Emerg Infect Dis 2011; 17:1734.</div><div id=\"graphicVersion\">Graphic 109697 Version 1.0</div></div></div>"},"109701":{"type":"graphic_picture","displayName":"Tattoo machine","title":"Tattoo machine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tattoo machine</div><div class=\"cntnt\"><img style=\"width:427px; height:530px;\" src=\"images/PEDS/109701_Tattoo_machine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tattoo artist inserts a set of one to seven needles into the tip of the machine. The needle(s) are dipped in tattoo ink and then pressed to the skin. When turned on, the armature bar moves the needle(s) up and down rapidly to apply the ink under the skin. </div><div id=\"graphicVersion\">Graphic 109701 Version 1.0</div></div></div>"},"109702":{"type":"graphic_table","displayName":"Screening questions to identify augmentation","title":"Screening questions to identify augmentation in patients on dopaminergic therapy for RLS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening questions to identify augmentation in patients on dopaminergic therapy for RLS</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Do RLS symptoms appear earlier than when the drug was first started? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Are higher doses of the drug now needed, or do you need to take the drug earlier in the day to control symptoms? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Has the intensity of symptoms worsened since starting the drug? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Have symptoms spread to other body parts (eg, arms) since starting the drug? </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RLS: restless legs syndrome.</div><div class=\"graphic_reference\">Data from: Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: A combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 2016; 21:1.</div><div id=\"graphicVersion\">Graphic 109702 Version 2.0</div></div></div>"},"109703":{"type":"graphic_diagnosticimage","displayName":"Arterial wall edema in giant cell (temporal) arteritis","title":"Arterial wall edema in giant cell (temporal) arteritis","html":"<div class=\"graphic\"><div style=\"width: 790px\" class=\"figure\"><div class=\"ttl\">Arterial wall edema in giant cell (temporal) arteritis</div><div class=\"cntnt\"><img style=\"width:770px; height:546px;\" src=\"images/RHEUM/109703_Arterial_wall_edema_GCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound showing circumferential dark areas about the vascular lumens of the common superficial temporal artery and its parietal branch (\"halo signs\") in a patient with giant cell (temporal) arteritis. The halo sign results from hypoechogenicity of the vessel wall, attributed to mural edema.</div><div class=\"graphic_reference\">Courtesy of William Docken, MD.</div><div id=\"graphicVersion\">Graphic 109703 Version 2.0</div></div></div>"},"109704":{"type":"graphic_diagnosticimage","displayName":"Duplex of left mid-subclavian artery in giant cell arteritis","title":"Duplex of left mid-subclavian artery in giant cell (temporal)Â arteritis","html":"<div class=\"graphic\"><div style=\"width: 687px\" class=\"figure\"><div class=\"ttl\">Duplex of left mid-subclavian artery in giant cell (temporal)&nbsp;arteritis</div><div class=\"cntnt\"><img style=\"width:667px; height:618px;\" src=\"images/RHEUM/109704_Duplex_left_mid_subclav_GCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Halo sign at the mid-subclavian artery in a patient with biopsy-proven giant cell (temporal) arteritis, indicating large vessel involvement.</div><div class=\"graphic_reference\">Courtesy of William Docken, MD.</div><div id=\"graphicVersion\">Graphic 109704 Version 2.0</div></div></div>"},"109705":{"type":"graphic_picture","displayName":"GCA temporal artery stains","title":"GCA temporal artery stains","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">GCA temporal artery stains</div><div class=\"cntnt\"><img style=\"width:512px; height:766px;\" src=\"images/RHEUM/109705_GCA_temporal_artery_stains.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) GCA, temporal artery: H&amp;E stain.<br />(B) Same artery: elastin stain showing marked disruption of the internal elastic lamina, only a small fragment of which remains intact.</div><div class=\"graphic_footnotes\">GCA: giant cell (temporal)&nbsp;arteritis; H&amp;E: hematoxylin and eosin.</div><div class=\"graphic_reference\">Courtesy of William Docken, MD.</div><div id=\"graphicVersion\">Graphic 109705 Version 3.0</div></div></div>"},"109708":{"type":"graphic_algorithm","displayName":"Approach to cervical radiculopathy","title":"Approach to acute cervical radiculopathy","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Approach to acute cervical radiculopathy</div><div class=\"cntnt\"><img style=\"width:710px; height:781px;\" src=\"images/NEURO/109708_Apprch_cervical_radiculopat.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs; MRI: magnetic resonance imaging; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 109708 Version 1.0</div></div></div>"},"109709":{"type":"graphic_picture","displayName":"Arm position for wrist ultrasound with patient supine","title":"Arm position for wrist ultrasound with patient supine","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Arm position for wrist ultrasound with patient supine</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/SM/109709_Arm_pos_wrist_US_supine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound examination of the wrist can be performed with the patient sitting or supine. Supine positioning is demonstrated in the photograph above. </div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109709 Version 1.0</div></div></div>"},"109710":{"type":"graphic_picture","displayName":"Arm position for wrist ultrasound exam with patient seated","title":"Arm position for wrist ultrasound exam with patient seated","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Arm position for wrist ultrasound exam with patient seated</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/SM/109710_Arm_pos_wrist_US_seated.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound examination of the wrist can be performed with the patient seated and their forearm resting on an examination table, as pictured above. </div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109710 Version 1.0</div></div></div>"},"109711":{"type":"graphic_diagnosticimage","displayName":"Ultrasound sixth extensor compartment wrist long axis","title":"Ultrasound sixth extensor compartment wrist long axis","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Ultrasound sixth extensor compartment wrist long axis</div><div class=\"cntnt\"><img style=\"width:766px; height:766px;\" src=\"images/SM/109711_US_sixth_ext_wrist_lng_axis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A above is an ultrasound image of the ulnar aspect of the wrist in long axis. The rectangular outline in the bottom photograph&nbsp;(B) shows where the ultrasound transducer is placed to obtain this image.</div><div class=\"graphic_footnotes\">ECU: extensor carpi ulnaris tendon.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109711 Version 1.0</div></div></div>"},"109712":{"type":"graphic_diagnosticimage","displayName":"Ultrasound first metacarpal joint normal UCL","title":"Ultrasound first metacarpal joint normal UCL","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Ultrasound first metacarpal joint normal UCL</div><div class=\"cntnt\"><img style=\"width:522px; height:638px;\" src=\"images/SM/109712_US_frst_mtcrpl_jnt_norm_UCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image, obtained by placing the transducer in the position shown above, shows a normal ulnar collateral ligament of the thumb.</div><div class=\"graphic_footnotes\">UCL: ulnar collateral ligament.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109712 Version 1.0</div></div></div>"},"109713":{"type":"graphic_diagnosticimage","displayName":"Ultrasound first metacarpal joint torn UCL","title":"Ultrasound first metacarpal joint torn UCL","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Ultrasound first metacarpal joint torn UCL</div><div class=\"cntnt\"><img style=\"width:488px; height:584px;\" src=\"images/SM/109713_US_frst_mtcrpl_jnt_torn_UCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows the disrupted ligament fibers of a torn ulnar collateral ligament of the thumb (A). The photograph (B) shows the position of the ultrasound transducer necessary to obtain this image.</div><div class=\"graphic_footnotes\">UCL: ulnar collateral ligament.<br />* Disrupted UCL fibers.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 109713 Version 1.0</div></div></div>"},"109715":{"type":"graphic_algorithm","displayName":"Treatment of patients with asymptomatic LV dysfunction","title":"Indications for neurohormonal blockade and implantable cardioverter-defibrillator use in patients with left ventricular systolic dysfunction without heart failure*","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Indications for neurohormonal blockade and implantable cardioverter-defibrillator use in patients with left ventricular systolic dysfunction without heart failure*</div><div class=\"cntnt\"><img style=\"width:708px; height:572px;\" src=\"images/CARD/109715_Blckd_ICD_ptnts_LV_dysfnctn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LVEF: left ventricular ejection fraction; ACE: angiotensin converting enzyme; ARB: angiotensin II receptor blocker; VT: ventricular tachycardia; ICD: implantable cardioverter-defibrillator.<br />* Left ventricular systolic dysfunction is defined here to include globally or focally depresed left ventricular systolic function with or without depressed LVEF. Refer to UpToDate content on diagnosis of asymptomatic left ventricular systolic dysfunction.<br />&para; Evidence of prior myocardial infarction includes a prior documented event and/or test findings diagnostic of prior myocardial infarction. Refer to UpToDate content on diagnosis of myocardial infarction.<br />&Delta; For patients with an indication for ACE inhibitor who have a cough caused by ACE inhibitor or angioedema, an angiotensin II receptor blocker is suggested as an alternative.<br /><span class=\"lozenge\">&loz;</span> The recommendation for ACE inhibitor post MI is strong in patients with LVEF &le;40 percent, diabetes mellitus, or stable chronic kidney disease and weak for patients without these risk factors.<br />&sect; Refer to UpToDate content on the diagnosis and management of heart failure.</div><div id=\"graphicVersion\">Graphic 109715 Version 1.0</div></div></div>"},"109717":{"type":"graphic_diagnosticimage","displayName":"Apical LV thrombus","title":"Apical left ventricular thrombus","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Apical left ventricular thrombus</div><div class=\"cntnt\"><img style=\"width:656px; height:454px;\" src=\"images/CARD/109717_Apical_LV_thrombus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 109717 Version 1.0</div></div></div>"},"109718":{"type":"graphic_movie","displayName":"Apical LV thrombus TTE","title":"Transesophageal echocardiography of apical LV thrombus","html":"<div class=\"graphic normal\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiography of apical LV thrombus</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/109718_ApicalLVthrombusTTEvid.mp4\" style=\"width:636px;height:448px\"></div><img style=\"width:653px; height:462px;\" src=\"images/CARD/109718_ApicalLVthrombusTTEimg.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 109718 Version 1.0</div></div></div>"},"109720":{"type":"graphic_table","displayName":"Definition of high-risk SMM","title":"Definition of high-risk smoldering multiple myeloma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of high-risk smoldering multiple myeloma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Clonal BMPCs &#8805;10% and any one or more of the following:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Serum M protein &#8805;30 g/L </li> <li>IgA SMM </li> <li>Immunoparesis with reduction of 2 uninvolved immunoglobulin isotypes </li> <li>Serum involved/uninvolved FLC ratio &#8805;8 (but &#60;100) </li> <li>Progressive increase in M protein level (evolving type of SMM; increase in serum M protein by &#8805;25% on 2 successive evaluations within a 6-month period) </li> <li>Clonal BMPCs 50 to 60% </li> <li>Abnormal PC immunophenotype (&#8805;95% of BMPCs are clonal) and reduction of &#8805;1 uninvolved immunoglobulin isotypes </li> <li>t(4;14) or del(17p) or 1q gain </li> <li>Increased circulating PCs </li> <li>MRI with diffuse abnormalities or 1 focal lesion </li> <li>PET-CT with focal lesion with increased uptake without underlying osteolytic bone destruction </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The term smoldering multiple myeloma&nbsp;(SMM) excludes patients without end-organ damage who meet the revised definition of multiple myeloma; namely, those with clonal bone marrow plasma cells â‰¥60% or serum free light chain&nbsp;(FLC) ratio â‰¥100 (plus measurable involved FLC level â‰¥100 mg/L), or &gt;1 focal lesion on MRI scan. The risk factors listed are not meant to be indications for therapy; they are variables associated with a high risk of progression of SMM and identify patients who need close follow-up and consideration for clinical trials.</div><div class=\"graphic_footnotes\">BMPC: bone marrow plasma cells; PET-CT: positron emission tomography with computed tomography.</div><div class=\"graphic_reference\">This research was originally published in Blood. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood 2015; 125:3069. Copyright &copy; 2015 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 109720 Version 1.0</div></div></div>"},"109721":{"type":"graphic_table","displayName":"Cytogenetically defined risk-based classification of SMM","title":"Cytogenetically defined risk-based classification of smoldering multiple myeloma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytogenetically defined risk-based classification of smoldering multiple myeloma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk</td> <td class=\"subtitle1\">Cytogenetic finding</td> </tr> <tr> <td>High</td> <td> <p>t(4;14)</p> <p>del(17p)</p> 1q gain</td> </tr> <tr> <td>Intermediate</td> <td>Trisomies without IgH translocation</td> </tr> <tr> <td>Standard</td> <td> <p>Other IgH translocations including t(11;14), t(14;16), and t(14;20)</p> <p>Presence of trisomies and IgH translocation, except t(4;14)</p> Monosomy13/del(13q)</td> </tr> <tr> <td>Low</td> <td>No abnormalities (normal or insufficient)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgH: immunoglobulin heavy chain.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013; 27:1738.</LI></OL>This research was originally published in Blood. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood 2015; 125:3069. Copyright Â© 2015 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 109721 Version 1.0</div></div></div>"},"109722":{"type":"graphic_diagnosticimage","displayName":"Follow-up of type II endoleak repair","title":"Follow-up of type II endoleak repair","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Follow-up of type II endoleak repair</div><div class=\"cntnt\"><img style=\"width:764px; height:896px;\" src=\"images/SURG/109722_TypeII_endoleak_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Despite the presence of a type II endoleak, the aneurysm sac can shrink and may show late spontaneous resolution.<br /><br />(A) Type II endoleak at year 1.<br />(B) Persistent type II endoleak at year 2 with sac shrinkage.<br />(C) No endoleak, and aneurysm continues to shrink at year 3.</div><div class=\"graphic_reference\">Reproduced from: Avgerinos ED, Chaer RA, Makaroun MS. Type II endoleaks. J Vasc Surg 2014; 60:1386. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109722 Version 1.0</div></div></div>"},"109723":{"type":"graphic_algorithm","displayName":"Thymectomy for myasthenia gravis","title":"Evaluation for thymectomy in patients with myasthenia gravis","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Evaluation for thymectomy in patients with myasthenia gravis</div><div class=\"cntnt\"><img style=\"width:612px; height:374px;\" src=\"images/NEURO/109723_Thymectmy_myasthenia_gravis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The optimal timing for thymectomy in those without thymoma is not established. All patients having thymectomy should have a preoperative anesthesia consultation.</div><div class=\"graphic_footnotes\">AChR: acetylcholine receptor; MG: myasthenia gravis; MuSK: muscle-specific receptor tyrosine kinase.<br />* Refer to UpToDate topics that review symptomatic treatments (anticholinesterase agents), chronic immunotherapies (glucocorticoids and other immunosuppressive drugs), and rapid immunotherapies (plasma exchange and intravenous immune globulin) for MG.<br />Â¶ Preoperative biopsy is necessary if the anterior mediastinal lesion is not well circumscribed (signs of local infiltration) or if the patient has systemic symptoms that suggest another diagnosis.<br />Î” For patients with significant preoperative respiratory or bulbar symptoms, treatment with plasmapheresis or intravenous immune globulin is warranted prior to surgery.</div><div id=\"graphicVersion\">Graphic 109723 Version 1.0</div></div></div>"},"109726":{"type":"graphic_algorithm","displayName":"HPS diagnosis algorithm","title":"Diagnostic algorithm for hepatopulmonary syndrome","html":"<div class=\"graphic\"><div style=\"width: 768px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for hepatopulmonary syndrome</div><div class=\"cntnt\"><img style=\"width:748px; height:716px;\" src=\"images/PULM/109726_HPS_diagnosis_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HPS: hepatopulmonary syndrome; SpO<SUB>2</SUB>: peripheral arterial oxygen saturation; ABG: arterial blood gas analysis; A-a gradient: Alveolar-arterial gradient; PaO<SUB>2</SUB>: partial arterial pressure of oxygen.<br />* Suspected HPS â€“ HPS should be suspected in patients with chronic liver disease and/or portal hypertension. HPS is rare in patients with acute liver disease. All patients who undergo evaluation for liver transplant should be evaluated for HPS. Common manifestations include dyspnea, platypnea, orthodeoxia, and spider nevi.<br />Â¶ Some patients may have low grade shunt in the absence of hypoxemia which warrants continued monitoring in the event of progression to HPS.<br />Î” Some clinicians additionally perform lying and standing oximetry and ABGs which, when positive, can indicate the presence of a shunt.<br /><FONT class=lozenge>â—Š</FONT> Contrast echocardiography typically involves the intravenous administration of agitated saline, followed by imaging with transthoracic echocardiography. Visualization of microbubbles in the left atrium within three to six cardiac cycles after their appearance in the right atrium usually indicates an intrapulmonary shunt and provides strong evidence in favor of the presence of intrapulmonary vascular shunts consistent with HPS. Other forms of shunt assessment are rarely needed (refer to UTD text for details).<br />Â§ It is prudent to exclude contributing etiologies (eg, cardiac failure, intrinsic lung disease, pulmonary arteriovenous malformations; refer to UTD text for details).</div><div id=\"graphicVersion\">Graphic 109726 Version 1.0</div></div></div>"},"109728":{"type":"graphic_table","displayName":"Types of prophylaxis","title":"Types of prophylaxis for patients with hemophilia A or B","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of prophylaxis for patients with hemophilia A or B</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of treatment</td> <td class=\"subtitle1\">Definition</td> </tr> <tr class=\"divider_bottom\"> <td>Episodic (on demand) treatment</td> <td>Replacement factor given at the time of bleeding</td> </tr> <tr> <td>Continuous (regular) prophylaxis</td> <td>Replacement factor given to prevent bleeding for at least 45 of 52 weeks (85%) of a year</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Primary prophylaxis </li> </ul> </td> <td>Continuous prophylaxis started before age three years and before the second large joint bleed</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Secondary prophylaxis </li> </ul> </td> <td>Continuous prophylaxis started after two or more large joint bleeds but before the onset of chronic arthropathy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Tertiary prophylaxis </li> </ul> </td> <td>Continuous prophylaxis started after the onset of arthropathy to prevent further damage</td> </tr> <tr> <td>Intermittent (periodic) prophylaxis</td> <td>Replacement factor given to prevent bleeding for short periods of time such as during and after surgery</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Replacement factor includes plasma-derived or recombinant factor concentrates. Refer to UpToDate for indications and details of factor administration and additional therapies for patients with hemophilia.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19:e1.</li>&#xD;&#xA;    <li>Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: Communication from the SSC of the ISTH. J Thromb Haemost 2014; 12:1935.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109728 Version 1.0</div></div></div>"},"109735":{"type":"graphic_figure","displayName":"Anatomy of the voltage-gated sodium channel","title":"Anatomy of the voltage-gated sodium channel","html":"<div class=\"graphic\"><div style=\"width: 798px\" class=\"figure\"><div class=\"ttl\">Anatomy of the voltage-gated sodium channel</div><div class=\"cntnt\"><img style=\"width:778px; height:352px;\" src=\"images/NEURO/109735_Vltg-gtd_sodium_chnnl_anato.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sodium channel alpha (D1-D4)&nbsp;and beta (Î²)&nbsp;subunits are transmembrane proteins. The four homologous domains of the alpha subunit (D1-D4)&nbsp;are represented in different colors. The transmembrane segments associate in the membrane to form a sodium-permeable pore lined by the re-entrant S5â€“S6 pore-loop segments (inset).</div><div class=\"graphic_reference\">Republished with permission of the American Society for Clinical Investigation, from Meisler MH, Kearney JA. Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest 2005; 115:2011; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 109735 Version 2.0</div></div></div>"},"109736":{"type":"graphic_figure","displayName":"Camptocormia","title":"Camptocormia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Camptocormia</div><div class=\"cntnt\"><img style=\"width:395px; height:575px;\" src=\"images/NEURO/109736_Camptocormia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe anterior flexion of the thoracolumbar spine, known as camptocormia or bent spine syndrome.</div><div id=\"graphicVersion\">Graphic 109736 Version 1.0</div></div></div>"},"109737":{"type":"graphic_figure","displayName":"Antecollis","title":"Antecollis","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Antecollis</div><div class=\"cntnt\"><img style=\"width:472px; height:376px;\" src=\"images/NEURO/109737_Antecollis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Excessive forward flexion of the neck, known as antecollis.</div><div id=\"graphicVersion\">Graphic 109737 Version 1.0</div></div></div>"},"109738":{"type":"graphic_figure","displayName":"Pisa syndrome","title":"Pisa syndrome","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Pisa syndrome</div><div class=\"cntnt\"><img style=\"width:457px; height:706px;\" src=\"images/NEURO/109738_Pisa_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral flexion of the trunk, head, and neck, known as Pisa syndrome.</div><div id=\"graphicVersion\">Graphic 109738 Version 1.0</div></div></div>"},"109740":{"type":"graphic_algorithm","displayName":"Risk stratification and initial management of hyperkalemia","title":"Overview of the risk stratification and initial management of patients presenting with hyperkalemia","html":"<div class=\"graphic\"><div style=\"width: 816px\" class=\"figure\"><div class=\"ttl\">Overview of the risk stratification and initial management of patients presenting with hyperkalemia</div><div class=\"cntnt\"><img style=\"width:796px; height:800px;\" src=\"images/NEPH/109740_Risk_intl_mgmt_hyperkalemia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ESRD: end-stage renal disease; ACE: angiotensin-converting enzyme; CKD: chronic kidney disease; RAS: renin-angiotensin system; NSAIDs: nonsteroidal anti-inflammatory drugs.<br />* Cardiac manifestations of hyperkalemia are discussed in detail in the topic on clinical manifestations of hyperkalemia.<br />&para; Details of therapy are presented in the topic on treatment of hyperkalemia.</div><div id=\"graphicVersion\">Graphic 109740 Version 1.0</div></div></div>"},"109743":{"type":"graphic_table","displayName":"Endometrial hyperplasia classific interobserv variability","title":"Endometrial Hyperplasia: Pathologist inter-observer variability for WHO and EIN classification systems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endometrial Hyperplasia: Pathologist inter-observer variability for WHO and EIN classification systems</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"5\" width=\"10%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">WHO</td> <td class=\"subtitle1\" colspan=\"5\">Correlation coefficients (&#954;)</td> <td class=\"subtitle1\" rowspan=\"2\">Comments</td> </tr> <tr> <td class=\"subtitle2\">Benign</td> <td class=\"subtitle2\">Simple</td> <td class=\"subtitle2\">Complex</td> <td class=\"subtitle2\">Atypia</td> <td class=\"subtitle2\">Carcinoma</td> </tr> <tr> <td>Allison, 2008<sup>[1]</sup><br /> (n = 2147) </td> <td class=\"centered\">0.76</td> <td class=\"centered\">0.16</td> <td class=\"centered\">0.21</td> <td class=\"centered\">0.35</td> <td class=\"centered\">0.55</td> <td>Three academic gynecologic pathologists; blinded to diagnosis of mixture of all specimen types in population-based study of all specimens; correlation improved with increased tissue volume.</td> </tr> <tr> <td>Zaino, 2006<sup>[2]</sup><br /> (n = 302) </td> <td class=\"centered\">0.48</td> <td class=\"centered\">0.38</td> <td class=\"centered\">0.38</td> <td class=\"centered\">0.28</td> <td class=\"centered\">0.51</td> <td>Three academic gynecologic pathologists; not blinded to diagnosis by outside referring center; initial diagnosis of atypical endometrial hyperplasia.</td> </tr> <tr> <td>Kendall, 1998<sup>[3]</sup><br /> (n = 100)</td> <td class=\"centered\">0.86<br /> (n = 25)</td> <td class=\"centered\">0.60<br /> (n = 25)</td> <td class=\"centered\">0.60<br /> (n = 25)</td> <td class=\"centered\">0.47<br /> (n = 25)</td> <td class=\"centered\">0.83<br /> (n = 25)</td> <td>Five academic pathologists; cancer center; specimens selected based on adequate tissue and representative specimen.</td> </tr> <tr> <td>Ordi, 2014<sup>[4]</sup><br /> (n = 196)</td> <td class=\"centered\">0.51</td> <td class=\"centered\">0.22</td> <td class=\"centered\">0.22</td> <td class=\"centered\">0.30</td> <td class=\"centered\">0.47</td> <td>Three academic pathologists; unblinded; cases initially diagnosed as low-grade endometrioid lesions.</td> </tr> <tr> <td>Skov, 1997<sup>[5]</sup><br /> (n = 198)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">0.21 to 0.25</td> <td class=\"centered\">0.07 to 0.15</td> <td class=\"centered\">0.42 to 0.59</td> <td class=\"centered\">&ndash;</td> <td>Six general pathologists with six years' experience; case series.</td> </tr> <tr class=\"divider_bottom\"> <td>Izadi-Mood, 2009<sup>[6]</sup><br /> (n = 100)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">0.74<br /> (n = 25)</td> <td class=\"centered\">0.34<br /> (n = 25)</td> <td class=\"centered\">0.35<br /> (n = 25)</td> <td class=\"centered\">0.64<br /> (n = 25)</td> <td>Five pathologists of varying experience; representative specimens selected; no normal proliferative specimens included; blinded review.</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">EIN system</td> <td class=\"subtitle1\" colspan=\"5\">Correlation coefficients (&#954;)</td> <td class=\"subtitle1\" rowspan=\"2\">Comments</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Benign</td> <td class=\"subtitle2\" colspan=\"2\">EIN</td> <td class=\"subtitle2\">Carcinoma</td> </tr> <tr> <td>Baak, 2001<sup>[7]</sup><br /> (n = 66)</td> <td class=\"centered\" colspan=\"2\">0.64</td> <td class=\"centered\" colspan=\"2\">0.47</td> <td class=\"centered\">0.64</td> <td>Twenty academic pathologists; cancer centers; specimens selected based on adequate tissue and representative specimen.</td> </tr> <tr> <td>Ordi, 2014<sup>[8]</sup><br /> (n = 196)</td> <td class=\"centered\" colspan=\"2\">0.35</td> <td class=\"centered\" colspan=\"2\">0.27</td> <td class=\"centered\">0.52</td> <td>Three academic pathologists; cases initially diagnosed as low-grade endometrioid lesions.</td> </tr> <tr> <td>Hecht, 2005<sup>[9]</sup><br /> (n = 97)</td> <td class=\"centered\" colspan=\"2\">0.54 to 0.62</td> <td class=\"centered\" colspan=\"2\">0.54 to 0.62</td> <td class=\"centered\">0.54 to 0.62</td> <td>Three academic pathologists, sequential endometrial biopsies; did not distinguish correlation coefficient for each diagnostic type.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO: World Health Organization 1994 classification system; EIN: endometrial intraepithelial neoplasia classification system.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Allison KH, Reed SD, Voigt LF, et al. Diagnosing endometrial hyperplasia: why is it so difficult to agree? Am J Surg Pathol 2008; 32:691.</li>&#xD;&#xA;    <li>Zaino RJ, Kauderer J, Trimble CL, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006; 106:804.</li>&#xD;&#xA;    <li>Kendall BS, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998; 22:1012.</li>&#xD;&#xA;    <li>Ordi J, Bergeron C, Hardisson D, et al. Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification. Histopathology 2014; 64:284.</li>&#xD;&#xA;    <li>Skov BG, Broholm H, Engel U, et al. Comparison of the reproducibility of the WHO classifications of 1975 and 1994 of endometrial hyperplasia. Int J Gynecol Pathol 1997; 16:33.</li>&#xD;&#xA;    <li>Izadi-Mood N, Khaniki M, Irvanloo G, et al. Determining the inter- and intraobserver reproducibility of the diagnosis of endometrial hyperplasia subgroups and well-differentiated endometrioid carcinoma in endometrial curettage specimens. Arch Iran Med 2009; 12:377.</li>&#xD;&#xA;    <li>Baak JP, &Oslash;rbo A, van Diest PJ, et al. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am J Surg Pathol 2001; 25:930.</li>&#xD;&#xA;    <li>Ordi J, Bergeron C, Hardisson D, et al. Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification. Histopathology 2014; 64:284.</li>&#xD;&#xA;    <li>Hecht JL, Ince TA, Baak JP, et al. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol 2005; 18:324.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109743 Version 1.0</div></div></div>"},"109751":{"type":"graphic_algorithm","displayName":"Pediatric gynecomastia with increased or decreased testosterone","title":"Additional evaluation of increased or decreased testosterone in children and adolescents with gynecomastia","html":"<div class=\"graphic\"><div style=\"width: 670px\" class=\"figure\"><div class=\"ttl\">Additional evaluation of increased or decreased testosterone in children and adolescents with gynecomastia</div><div class=\"cntnt\"><img style=\"width:650px; height:416px;\" src=\"images/PEDS/109751_Ped_gynecomastia_testostero.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Our suggested initial laboratory evaluation for phenotypically male children and adolescents with unilateral or bilateral gynecomastia in whom a potential cause is not identified during the initial history and physical examination includes measurement of early morning hCG, estradiol, LH, testosterone, and DHEA. The reference range for hormones may vary by age, sexual maturity rating, and clinical laboratory. All patients may not fit into the categories in the algorithm above. Refer to UpToDate content on gynecomastia in children and adolescents for information about interpretation of other laboratory results and combinations.</div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin; DHEA: dehydroepiandrosterone; LH: luteinizing hormone; TSH: thyroid stimulating hormone.<br />* Decreased testosterone and LH are normal findings in prepubertal males and are not helpful in the evaluation of gynecomastia.<br />&para; Referral to a pediatric endocrinologist is recommended. Refer to UpToDate content on gynecomastia in children and adolescents for additional information.<br />&Delta; Referral to a pediatric oncologist is recommended. Refer to UpToDate content on gynecomastia in children and adolescents for additional information.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357:1229.</li>&#xD;&#xA;    <li>Ma NS, Geffner ME. Gynecomastia in prepubertal and pubertal men. Curr Opin Pediatr 2008; 20:465.</li>&#xD;&#xA;    <li>Misra M, Sagar P, Friedmann AM, et al. Case records of the Massachusetts General Hospital. Case 12-2016. An 8-year-old boy with an enlarging mass in the right breast. N Engl J Med 2016; 374:1565.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109751 Version 1.0</div></div></div>"},"109752":{"type":"graphic_algorithm","displayName":"Pediatric gynecomastia with increased estradiol","title":"Additional evaluation of increased estradiol in phenotypically male children and adolescents with gynecomastia","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Additional evaluation of increased estradiol in phenotypically male children and adolescents with gynecomastia</div><div class=\"cntnt\"><img style=\"width:578px; height:482px;\" src=\"images/PEDS/109752_Ped_gynecomastia_estradiol.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Our suggested initial laboratory evaluation for phenotypically male children and adolescents with unilateral or bilateral gynecomastia in whom a potential cause is not identified on history and physical examination includes measurement of early morning hCG, estradiol, LH, testosterone, and DHEA. The reference range for hormones may vary by age, sexual maturity rating, and clinical laboratory. All patients may not fit into the categories in the algorithm above. Refer to UpToDate content on gynecomastia in children and adolescents for information about interpretation of other laboratory results and combinations.</div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin; DHEA: dehydroepiandrosterone; LH: luteinizing hormone; US: ultrasonography; DSD: disorder of sex development; CAH: congenital adrenal hyperplasia.<br />* Referral to a pediatric oncologist and/or pediatric urologist (for testicular tumors) is recommended. Refer to UpToDate content on gynecomastia in children and adolescents for additional information.<br />&para; Referral to a pediatric endocrinologist is recommended. Refer to UpToDate content on gynecomastia in children and adolescents for additional information.<br />&Delta; Measured with initial laboratory studies.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357:1229.</li>&#xD;&#xA;    <li>Ma NS, Geffner ME. Gynecomastia in prepubertal and pubertal men. Curr Opin Pediatr 2008; 20:465.</li>&#xD;&#xA;    <li>Misra M, Sagar P, Friedmann AM, et al. Case records of the Massachusetts General Hospital. Case 12-2016. An 8-year-old boy with an enlarging mass in the right breast. N Engl J Med 2016; 374:1565.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109752 Version 1.0</div></div></div>"},"109753":{"type":"graphic_algorithm","displayName":"Diagnosis and treatment of erythema induratum","title":"Initial management of erythema induratum","html":"<div class=\"graphic\"><div style=\"width: 762px\" class=\"figure\"><div class=\"ttl\">Initial management of erythema induratum</div><div class=\"cntnt\"><img style=\"width:742px; height:602px;\" src=\"images/DERM/109753_Dx_trtmnt_erythema_induratm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EI: erythema induratum; TB: tuberculosis.<br />* Evaluation for TB includes: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Tuberculin skin test or interferon-gamma release assay</LI>&#xD;&#xA;<LI>Review of systems</LI>&#xD;&#xA;<LI>Chest radiograph</LI></UL>â€‹Â¶ Basic evaluation includes: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Complete blood count</LI>&#xD;&#xA;<LI>Erythrocyte sedimentation rate</LI>&#xD;&#xA;<LI>Liver function tests</LI>&#xD;&#xA;<LI>Hepatitis C virus serology</LI>&#xD;&#xA;<LI>Additional testing as indicated based upon review of systems</LI></UL>Î” Symptom-directed therapy includes nonsteroidal anti-inflammatory drugs, rest, elevation, and compression.</div><div id=\"graphicVersion\">Graphic 109753 Version 1.0</div></div></div>"},"109760":{"type":"graphic_figure","displayName":"Hypotension and diagnostic utility of pulse pressure","title":"Hypotension and diagnostic utility of pulse pressure","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Hypotension and diagnostic utility of pulse pressure</div><div class=\"cntnt\"><img style=\"width:608px; height:404px;\" src=\"images/ANEST/109760_Hypotnsn_dx_utl_pulse_prssr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Caution in interpretation of pulse pressure values is warranted if technical factors that may introduce error are suspected. For example, the waveform is affected by the damping coefficient (a measure of how quickly an oscillating system comes to rest). A system with a high damping coefficient (eg, compliant tubing) absorbs mechanical energy to cause a diminution in the transmitted waveform mimicking a small pulse pressure. With under-damping, the waveform may appear to have a large pulse pressure.</div><div class=\"graphic_footnotes\">PP: pulse pressure; DBP: diastolic blood pressure; AV: arteriovenous.</div><div id=\"graphicVersion\">Graphic 109760 Version 2.0</div></div></div>"},"109761":{"type":"graphic_figure","displayName":"Effect of volume status on systolic pressure variation (SPV)","title":"Effect of volume status on systolic pressure variation (SPV)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Effect of volume status on systolic pressure variation (SPV)</div><div class=\"cntnt\"><img style=\"width:756px; height:386px;\" src=\"images/ANEST/109761_Effect_vol_status_SPV_edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">The physiological basis of systolic pressure variation (SPV) reflects the&nbsp;effect of&nbsp;venous return&nbsp;on the Frank-Starling curve. Mechanical ventilation moves the Frank-Starling from its expiratory position (red dashed curve) to its inspiratory position (solid blue curve). The three points on the venous return (cardiac output) curve represent normovolemia, mild hypovolemia, and severe hypovolemia during expiration and inspiration. In normovolemia, there is no significant reduction in venous return&nbsp;or cardiac output with mechanical ventilation; this would translate to minimal volume responsiveness and minimal systolic pressure variation. In contrast, in severe hypovolemia, there is a large reduction in venous return and cardiac output with mechanical ventilation, reflected as significant SPV.</SPAN></div><div class=\"graphic_footnotes\">VR: venous return.</div><div id=\"graphicVersion\">Graphic 109761 Version 2.0</div></div></div>"},"109762":{"type":"graphic_movie","displayName":"New regional wall motion abnormalities","title":"New regional wall motion abnormalities","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">New regional wall motion abnormalities</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/109762_Wallmotionvid.mp4\" style=\"width:608px;height:416px\"></div><img style=\"width:720px; height:470px;\" src=\"images/ANEST/109762_Wallmotionimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left ventricle seen in a transgastric mid-papillary short-axis view demonstrating discrete wall motion abnormalities suggestive of myocardial ischemia. Compromised oxygen delivery in the circumflex and left anterior descending coronary arteries visually manifests as akinesis of the anterolateral, inferoseptal, and inferior walls, as well as hypokinesis of the anterior wall.</div><div id=\"graphicVersion\">Graphic 109762 Version 2.0</div></div></div>"},"109763":{"type":"graphic_movie","displayName":"Septal bounce","title":"Septal bounce","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Septal bounce</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/109763_Septalbouncevid.mp4\" style=\"width:608px;height:432px\"></div><img style=\"width:720px; height:518px;\" src=\"images/ANEST/109763_Septalbounceimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paradoxical septal motion (or septal bounce) is frequently seen in the period immediately following&nbsp;cardiopulmonary bypass&nbsp;if ventricular epicardial pacing is employed. This can be distinguished from septal dyskinesis by (1) thickening of the myocardium despite the motion of the endocardium and (2) normal septal movement if ventricular pacing is paused.&nbsp;This assumes an underlying rhythm with AV conduction.</div><div class=\"graphic_footnotes\">IVS: Interventricular septum; AV: atrioventricular.</div><div id=\"graphicVersion\">Graphic 109763 Version 1.0</div></div></div>"},"109803":{"type":"graphic_table","displayName":"Rapid ultrasound in shock (RUSH) findings","title":"Rapid ultrasound in shock (RUSH) findings in the perioperative setting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid ultrasound in shock (RUSH) findings in the perioperative setting</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">RUSH assessment</td> <td class=\"subtitle1\">Hypovolemic shock</td> <td class=\"subtitle1\">Cardiogenic shock</td> <td class=\"subtitle1\">Obstructive shock</td> <td class=\"subtitle1\">Distributive shock</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pump</strong></td> <td> <ul> <li>Hyperdynamic <span style=\"color: black;\">LV</span><span style=\"color: black;\">&nbsp;</span> </li> <li>Empty/small heart </li> </ul> </td> <td> <ul> <li><span style=\"color: black;\">Hypo</span><span style=\"color: black;\">dynamic LV </span></li> <li>Full/large heart </li> </ul> </td> <td> <ul> <li>Pericardial effusion </li> <li>RV enlargement </li> <li>Hyperdynamic LV </li> </ul> </td> <td> <ul> <li><span style=\"color: black;\">Hyperdynamic LV</span> </li> <li>Empty/small heart </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Tank</strong></td> <td> <ul> <li>Flat IVC and IJ </li> <li>Peritoneal or pleural fluid (source of volume loss) </li> </ul> </td> <td> <ul> <li>Distended IVC and IJ </li> <li>B lines (edema) </li> <li>Pleural or peritoneal fluid </li> </ul> </td> <td> <ul> <li>Distended IVC and IJ </li> <li>Absent lung sliding, A lines (pneumothorax) </li> </ul> </td> <td> <ul> <li>Flat IVC and IJ </li> <li>Peritoneal or pleural fluid (source of sepsis) </li> </ul> </td> </tr> <tr> <td><strong>Pipes</strong></td> <td> <ul> <li><span style=\"color: black;\">May be abnormal (eg, aneurysm, aortic dissection) </span></li> </ul> </td> <td> <ul> <li>Normal </li> </ul> </td> <td> <ul> <li><span style=\"color: black;\">May be abnormal (eg, DVT)</span> </li> </ul> </td> <td> <ul> <li>Normal </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><P class=MsoNormal style=\"MARGIN: 0in 0in 0pt\"><FONT size=3><FONT face=Calibri>A lines: Horizontal hyperechoic reflections spaced at the interval of the distance of the probe to the pleura.<?xml:namespace prefix = \"o\" ns = \"urn:schemas-microsoft-com:office:office\" /><o:p></o:p></FONT></FONT></P>&#xD;&#xA;<P class=MsoNormal style=\"MARGIN: 0in 0in 0pt\"><FONT size=3><FONT face=Calibri>B lines: Narrow vertical hyperechoic reflections that arise at the pleural line and extend to the bottom of the ultrasound screen.<o:p></o:p></FONT></FONT></P>&#xD;&#xA;<P class=MsoNormal style=\"MARGIN: 0in 0in 0pt\"><FONT size=3 face=Calibri>Absent lung sliding: Lack of pleural sliding that can be seen in 2D mode or M mode on bedside ultrasound.</FONT><o:p></o:p></div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; IVC: inferior vena cava; IJ: internal jugular vein; DVT: deep vein thrombosis.</div><div class=\"graphic_reference\">Reproduced from: Perera P, Mailhot T, Riley D, Mandavia D. The RUSH Exam 2012: Rapid ultrasound in shock in the evaluation of the critically ill patient. Ultrasound Clin 2012; 7:255. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109803 Version 1.0</div></div></div>"},"109805":{"type":"graphic_table","displayName":"TNM descriptors 8th edition TNM lung classification","title":"T, N, and M descriptors for the eighth edition of TNM classification for lung cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">T, N, and M descriptors for the eighth edition of TNM classification for lung cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">T: Primary tumor</td> </tr> <tr> <td class=\"indent1\">Tx</td> <td colspan=\"3\">Primary tumor cannot be assessed or tumor proven by presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma in situ</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor &#8804;3 cm in greatest dimension surrounded by lung or visceral pleura without bronchoscopic evidence of invasion more proximal than the lobar bronchus (ie, not in the main bronchus)*</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent2\"><strong>T1a(mi)</strong></td> <td colspan=\"3\"><strong>Minimally invasive adenocarcinoma</strong><sup>&#182;</sup></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent2\"><strong>T1a</strong></td> <td colspan=\"3\"><strong>Tumor &#8804;1 cm in greatest dimension</strong>*</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent2\"><strong>T1b</strong></td> <td colspan=\"3\"><strong>Tumor &#62;1 cm but &#8804;2 cm in greatest dimension</strong>*</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent2\"><strong>T1c</strong></td> <td colspan=\"3\"><strong>Tumor &#62;2 cm but &#8804;3 cm in greatest dimension</strong>*</td> </tr> <tr> <td class=\"indent1\"><strong>T2</strong></td> <td colspan=\"3\">Tumor &#62;3 cm <strong>but &#8804;5 cm</strong> or tumor with any of the following features:<sup>&#916;</sup> <ul class=\"decimal_heading\"> <li><strong>Involves main bronchus regardless of distance from the carina but without involvement of the carina</strong> </li> <li>Invades visceral pleura </li> <li><strong>Associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"><strong>T2a</strong></td> <td colspan=\"3\"><strong>Tumor &#62;3 cm but &#8804;4 cm in greatest dimension</strong></td> </tr> <tr> <td class=\"indent2\"><strong>T2b</strong></td> <td colspan=\"3\"><strong>Tumor &#62;4 cm but &#8804;5 cm in greatest dimension</strong></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\"><strong>T3</strong></td> <td colspan=\"3\"><strong>Tumor &#62;5 cm but &#8804;7 cm in greatest dimension</strong> or associated with separate tumor nodule(s) in the same lobe as the primary tumor or directly invades any of the following structures: chest wall (including the parietal pleura and superior sulcus tumors), phrenic nerve, parietal pericardium</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>T4</strong></td> <td colspan=\"3\"><strong>Tumor &#62;7 cm in greatest dimension</strong> or associated with separate tumor nodule(s) in a different ipsilateral lobe than that of the primary tumor or invades any of the following structures: <strong>diaphragm</strong>, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, and carina</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">N: Regional lymph node involvement</td> </tr> <tr> <td class=\"indent1\">Nx</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">N2</td> <td colspan=\"3\">Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N3</td> <td colspan=\"3\">Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">M: Distant metastasis</td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis present</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent2\">M1a</td> <td colspan=\"3\">Separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodule(s) or malignant pleural or pericardial effusion<sup>&#9674;</sup></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent2\"><strong>M1b</strong></td> <td colspan=\"3\"><strong>Single extrathoracic metastasis</strong><sup>&#167;</sup></td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td class=\"indent2\"><strong>M1c</strong></td> <td colspan=\"3\"><strong>Multiple extrathoracic metastases in one or more organs</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Stage groupings</td> </tr> <tr> <td class=\"indent1\">Occult carcinoma</td> <td>TX</td> <td>N0</td> <td>M0</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Stage 0</td> <td>Tis</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"><strong>Stage IA1</strong></td> <td><strong>T1a(mi)</strong></td> <td><strong>N0</strong></td> <td><strong>M0</strong></td> </tr> <tr> <td><strong>T1a</strong></td> <td><strong>N0</strong></td> <td><strong>M0</strong></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\"><strong>Stage IA2</strong></td> <td><strong>T1b</strong></td> <td><strong>N0</strong></td> <td><strong>M0</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Stage IA3</strong></td> <td><strong>T1c</strong></td> <td><strong>N0</strong></td> <td><strong>M0</strong></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Stage IB</td> <td>T2a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\">Stage IIA</td> <td>T2b</td> <td>N0</td> <td>M0</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\" rowspan=\"4\">Stage IIB</td> <td><strong>T1a to c</strong></td> <td><strong>N1</strong></td> <td><strong>M0</strong></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td><strong>T2a</strong></td> <td><strong>N1</strong></td> <td><strong>M0</strong></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>T2b</td> <td>N1</td> <td>M0</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>T3</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Stage IIIA</td> <td><strong>T1a to c</strong></td> <td><strong>N2</strong></td> <td><strong>M0</strong></td> </tr> <tr> <td>T2a to b</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T4</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T4</td> <td>N1</td> <td>M0</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\" rowspan=\"4\">Stage IIIB</td> <td><strong>T1a to c</strong></td> <td><strong>N3</strong></td> <td><strong>M0</strong></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>T2a to b</td> <td>N3</td> <td>M0</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td><strong>T3</strong></td> <td><strong>N2</strong></td> <td><strong>M0</strong></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>T4</td> <td>N2</td> <td>M0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"><strong>Stage IIIC</strong></td> <td><strong>T3</strong></td> <td><strong>N3</strong></td> <td><strong>M0</strong></td> </tr> <tr> <td><strong>T4</strong></td> <td><strong>N3</strong></td> <td><strong>M0</strong></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\" rowspan=\"2\"><strong>Stage IVA</strong></td> <td><strong>Any T</strong></td> <td><strong>Any N</strong></td> <td><strong>M1a</strong></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td><strong>Any T</strong></td> <td><strong>Any N</strong></td> <td><strong>M1b</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Stage IVB</strong></td> <td><strong>Any T</strong></td> <td><strong>Any N</strong></td> <td><strong>M1c</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Changes to the seventh edition are in bold.</div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; Tis: carcinoma in situ; T1a(mi): minimally invasive adenocarcinoma.<br />* The uncommon superficial spreading tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.<br />&para; Solitary adenocarcinoma, &le;3 cm with a predominately lepidic pattern and &le;5 mm invasion in any one focus.<br />&Delta; T2 tumors with these features are classified as T2a if &le;4 cm in greatest dimension or if size cannot be determined, and T2b if &gt;4 cm but &le;5 cm in greatest dimension.<br /><span class=\"lozenge\">&loz;</span> Most pleural (pericardial) effusions with lung cancer are due to tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor and the fluid is nonbloody and not an exudate. When these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor.<br />&sect; This includes involvement of a single distant (nonregional) lymph node.</div><div class=\"graphic_reference\">Reproduced from: Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:39. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109805 Version 1.0</div></div></div>"},"109806":{"type":"graphic_table","displayName":"7th edition descriptors, T and M categories and 8th edition","title":"Descriptors and T and M categories of the eighth edition with seventh edition for comparison*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Descriptors and T and M categories of the eighth edition with seventh edition for comparison*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"centered highlight_gray_text\" style=\"font-size: 1.2em; vertical-align: middle; border-bottom: black 3px solid;\" rowspan=\"3\"><strong>Descriptor in 7th edition</strong></td> <td class=\"centered highlight_gray_text\" style=\"font-size: 1.2em; vertical-align: middle; border-bottom: black 3px solid;\" rowspan=\"3\"><strong>Descriptor in 8th edition</strong></td> <td class=\"centered highlight_gray_text\" style=\"font-size: 1.2em; vertical-align: middle; border-bottom: black 3px solid;\" colspan=\"4\"><strong>N categories: 8th edition</strong> (7th edition)</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"4\">Overall stage</td> </tr> <tr> <td class=\"subtitle3\">N0</td> <td class=\"subtitle3\">N1</td> <td class=\"subtitle3\">N2</td> <td class=\"subtitle3\">N3</td> </tr> <tr> <td>T1 &#8804;1 cm</td> <td>T1a</td> <td><strong>IA1</strong> (IA)</td> <td><strong>IIB</strong> (IIA)</td> <td>IIIA</td> <td>IIIB</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>T1 &#62;1 to 2 cm</td> <td>T1b</td> <td><strong>IA2</strong> (IA)</td> <td><strong>IIB </strong>(IIA)</td> <td>IIIA</td> <td>IIIB</td> </tr> <tr> <td>T1 &#62;2 to 3 cm</td> <td>T1c</td> <td><strong>IA3</strong> (IA)</td> <td><strong>IIB</strong> (IIA)</td> <td>IIIA</td> <td>IIIB</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>T2 &#62;3 to 4 cm</td> <td>T2a</td> <td>IB</td> <td><strong>IIB</strong> (IIA)</td> <td>IIIA</td> <td>IIIB</td> </tr> <tr> <td>T2 &#62;4 to 5 cm</td> <td>T2b</td> <td><strong>IIA</strong> (IB)</td> <td><strong>IIB</strong> (IIA)</td> <td>IIIA</td> <td>IIIB</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>T2 &#62;5 to 7 cm</td> <td>T3</td> <td><strong>IIB</strong> (IIA)</td> <td><strong>IIIA</strong> (IIB)</td> <td><strong>IIIB</strong> (IIIA)</td> <td><strong>IIIC</strong> (IIIB)</td> </tr> <tr> <td>T3 structures</td> <td>T3</td> <td>IIB</td> <td>IIIA</td> <td><strong>IIIB</strong> (IIIA)</td> <td><strong>IIIC</strong> (IIIB)</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>T3 &#62;7 cm</td> <td>T4</td> <td><strong>IIIA</strong> (IIB)</td> <td>IIIA</td> <td><strong>IIIB</strong> (IIIA)</td> <td><strong>IIIC</strong> (IIIB)</td> </tr> <tr> <td>T3 diaphragm</td> <td>T4</td> <td><strong>IIIA</strong> (IIB)</td> <td>IIIA</td> <td><strong>IIIB</strong> (IIIA)</td> <td><strong>IIIC</strong> (IIIB)</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>T3 endobronchial: location/atelectasis 3 to 4 cm</td> <td>T2a</td> <td><strong>IB</strong> (IIB)</td> <td><strong>IIB</strong> (IIIA)</td> <td>IIIA</td> <td>IIIB</td> </tr> <tr> <td>T3 endobronchial: location/atelectasis 4 to 5 cm</td> <td>T2b</td> <td><strong>IIA</strong> (IIB)</td> <td><strong>IIB</strong> (IIIA)</td> <td>IIIA</td> <td>IIIB</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>T4</td> <td>T4</td> <td>IIIA</td> <td>IIIA</td> <td>IIIB</td> <td><strong>IIIC</strong> (IIIB)</td> </tr> <tr> <td>M1a</td> <td>M1a</td> <td><strong>IVA</strong> (IV)</td> <td><strong>IVA</strong> (IV)</td> <td><strong>IVA</strong> (IV)</td> <td><strong>IVA</strong> (IV)</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>M1b single lesion</td> <td>M1b</td> <td><strong>IVA</strong> (IV)</td> <td><strong>IVA</strong> (IV)</td> <td><strong>IVA</strong> (IV)</td> <td><strong>IVA</strong> (IV)</td> </tr> <tr> <td>M1c multiple lesions</td> <td>M1c</td> <td><strong>IVB</strong> (IV)</td> <td><strong>IVB</strong> (IV)</td> <td><strong>IVB</strong> (IV)</td> <td><strong>IVB</strong> (IV)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Where there is a change, the resultant stage groupings for the eighth edition are in bold, and the stage in the seventh edition is given in parenthesis.</div><div class=\"graphic_reference\">Original figure modified for this publication. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:39. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109806 Version 3.0</div></div></div>"},"109808":{"type":"graphic_table","displayName":"Secondary perforating dermatoses","title":"Secondary perforating dermatoses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secondary perforating dermatoses</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Material \"eliminated\" through the epidermis</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Endogenous substances</strong></td> <td>Chondrodermatitis nodularis helicis</td> <td>Altered collagen</td> </tr> <tr> <td>Perforating pseudoxanthoma elasticum</td> <td>Elastic fibers</td> </tr> <tr> <td>Cutaneous perforating calcinosis</td> <td>Calcium</td> </tr> <tr> <td>Gouty tophi</td> <td>Sodium urate crystals</td> </tr> <tr class=\"divider_bottom\"> <td>Papular mucinosis</td> <td>Mucin</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Granulomas</strong></td> <td>Exogenous foreign body granuloma</td> <td>Foreign body material (ie, silica or wood splinters)</td> </tr> <tr> <td>Perforating granuloma annulare</td> <td>Necrobiotic material</td> </tr> <tr> <td>Necrobiosis lipoidica</td> <td>Degenerated collagen</td> </tr> <tr class=\"divider_bottom\"> <td>Rheumatoid nodule</td> <td>Fibrinoid necrosis</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\"><strong>Infectious diseases</strong></td> <td>Chromoblastomycosis</td> <td>Causative organism</td> </tr> <tr> <td>Leprosy</td> <td>Causative organism</td> </tr> <tr> <td>Schistosomiasis</td> <td>Causative organism</td> </tr> <tr> <td>Tuberculosis</td> <td>Causative organism</td> </tr> <tr> <td>Blastomycosis</td> <td>Causative organism</td> </tr> <tr> <td>Leishmaniasis</td> <td>Causative organism</td> </tr> <tr class=\"divider_bottom\"> <td>Aspergillosis</td> <td>Causative organism</td> </tr> <tr> <td rowspan=\"3\"><strong>Tumor cells</strong></td> <td>Nevus sebaceous</td> <td>Hair follicles from the undifferentiated cells</td> </tr> <tr> <td>Pilomatricoma</td> <td>Calcified shadow cells</td> </tr> <tr> <td>Keratoacanthoma</td> <td>Eosinophilic keratin</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Karpouzis A, Giatromanolaki A, Sivridis E, Kouskoukis C. Acquired reactive perforating collagenosis: current status. J Dermatol 2010; 37;585.</div><div id=\"graphicVersion\">Graphic 109808 Version 1.0</div></div></div>"},"109809":{"type":"graphic_table","displayName":"Systemic diseases and acquired perforating dermatoses","title":"Systemic diseases associated with acquired perforating dermatoses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic diseases associated with acquired perforating dermatoses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Diabetes mellitus<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Chronic renal insufficiency<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Carcinoma </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul style=\"list-style-type: disc;\"> <li>Liver<sup>[2]</sup>, prostate<sup>[3]</sup>, Hodgkin's disease<sup>[4]</sup>, colon carcinoma<sup>[5]</sup>, leukemia<sup>[6]</sup>, nasopharyngeal carcinoma<sup>[7]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Endocrine disease<sup>[8,9]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul style=\"list-style-type: disc;\"> <li>Thyroid dysfunction </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul style=\"list-style-type: disc;\"> <li>Hyperparathyroidism </li> </ul> </td> </tr> <tr> <td> <ul> <li>Primary sclerosing cholangitis<sup>[10]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Acquired immunodeficiency syndrome (AIDS)<sup>[11]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Pulmonary aspergillosis<sup>[12]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Autoimmune disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul style=\"list-style-type: disc;\"> <li>Systemic lupus erythematosus<sup>[13]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul style=\"list-style-type: disc;\"> <li>Dermatomyositis<sup>[14]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Scabies<sup>[15-17]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Poland syndrome<sup>[18]</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kim SW, Kim MS, Lee JH, et al. A clinicopathologic study of thirty cases of acquired perforating dermatosis in Korea. Ann Dermatol 2014; 26:162.</li>&#xD;&#xA;    <li>Lee YS, Vijayasingam S, Tan YO, Wong ST. Acquired perforating dermatosis associated with recurrent hepatocellular carcinoma. Int J Dermatol 1996; 35:743.</li>&#xD;&#xA;    <li>Boeck K, Mempel M, Hein R, Ring J. Acquired perforating collagenosis in a patient with carcinoma of the prostate. Acta Derm Venereol 1997; 77:486.</li>&#xD;&#xA;    <li>Pedragosa R, Knobel HJ, Huguet P, et al. Reactive perforating collagenosis in Hodgkin's disease. Am J Dermatopathol 1987; 9:41.</li>&#xD;&#xA;    <li>Ruiz Villaverde R, Martin Sanchez MC, Blasco Melguizo J, Naranjo Sintes R. Reactive perforating collagenosis and colon carcinoma. Rev Clin Esp 2002; 202:298.</li>&#xD;&#xA;    <li>Karpouzis A, Tsatalas C, Sivridis E, et al. Acquired reactive perforating collagenosis associated with myelodysplastic syndrome evolving to acute myelogenous leukaemia. Australas J Dermatol 2004; 45:78.</li>&#xD;&#xA;    <li>Karpouzis A, Koukourakis MI, Sivridis E. Acquired reactive perforating collagenosis associated with nasopharynx carcinoma. J Eur Acad Dermatol Venereol 2004; 18 (Suppl. 1):62 (PS108).</li>&#xD;&#xA;    <li>Fatani MI, Al-Ghamdi YM, Al-Afif KA, et al. Acquired reactive perforating collagenosis associated with sick euthyroid syndrome. Saudi Med J 2002; 23:1408.</li>&#xD;&#xA;    <li>Faver IR, Daoud MS, Su WP. Acquired reactive perforating collagenosis. Report of six cases and review of the literature. J Am Acad Dermatol 1994; 30:575.</li>&#xD;&#xA;    <li>Skiba G, Milkiewicz P, Mutimer D, et al. Successful treatment of acquired perforating dermatosis with rifampicin in an Asian patient with sclerosing cholangitis. Liver 1999; 19:160.</li>&#xD;&#xA;    <li>Bank DE, Cohen PR, Kohn SR. Reactive perforating collagenosis in a setting of double disaster: acquired immunodeficiency syndrome and end-stage renal disease. J Am Acad Dermatol 1989; 21:371.</li>&#xD;&#xA;    <li>Kim JH, Kang WH. Acquired reactive perforating collagenosis in a diabetic patient with pulmonary aspergillosis. Cutis 2000; 66:425.</li>&#xD;&#xA;    <li>Ohashi T, Yamamoto T. Acquired reactive perforating collagenosis associated with systemic lupus erythematosus. J Dermatol 2016; 43:1097.</li>&#xD;&#xA;    <li>Amano H, Nagai Y, Kishi C, Ishikawa O. Acquired reactive perforating collagenosis in dermatomyositis. J Dermatol 2011; 38:1199.</li>&#xD;&#xA;    <li>Kurschat P, Kroger A, Scharffeter-Kochanek Y, Hunzelmann N. Acquired reactive perforating collagenosis triggered by scabies infection. Acta Derm Venereol 2000; 80:384.</li>&#xD;&#xA;    <li>Brinkmeier T, Herbst RA, Frosch PJ. Reactive perforating collagenosis associated with scabies in a diabetic. J Eur Acad Dermatol Venereol 2004; 18:588.</li>&#xD;&#xA;    <li>Hinrichs W, Breuckmann F, Altmeyer P, Kreuter A. Acquired perforating dermatosis: a report on 4 cases associated with scabies infection. J Am Acad Dermatol 2004; 51:665.</li>&#xD;&#xA;    <li>Fistarol SK, Itin PH. Acquired perforating dermatosis in a patient with Poland syndrome. Dermatology 2003; 207:390.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109809 Version 2.0</div></div></div>"},"109810":{"type":"graphic_table","displayName":"Medications associated with acquired perforating dermatoses","title":"Medications associated with acquired perforating dermatoses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications associated with acquired perforating dermatoses</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td>Tumor necrosis factor inhibitors<sup>[1]</sup></td> </tr> <tr> <td>Sirolimus<sup>[2]</sup></td> </tr> <tr> <td>Lenalidomide<sup>[3]</sup></td> </tr> <tr> <td>Indinavir<sup>[4]</sup></td> </tr> <tr> <td>Bevacizumab<sup>[5]</sup></td> </tr> <tr> <td>Sorafenib<sup>[6,7]</sup></td> </tr> <tr> <td>Nilotinib<sup>[8]</sup></td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gilaberte Y, Coscojuela C, Vazquez C, et al. Perforating folliculitis associated with tumor necrosis factor-alpha inhibitors administered for rheumatoid arthritis. Br J Dermatol 2007; 156:368.</li>&#xD;&#xA;    <li>L&uuml;bbe J, Sorg O, Mal&eacute; PJ, et al. Sirolimus-induced inflammatory papules with acquired reactive perforating collagenosis. Dermatology 2008; 216:239.</li>&#xD;&#xA;    <li>Kuiper EM, Kardaun SH. Late onset perforating folliculitis induced by lenalidomide: a case report. Br J Dermatol 2015; 173:618.</li>&#xD;&#xA;    <li>Calista D, Morri M. Acquired reactive perforating collagenosis induced by indinavir in 2 patients with HIV disease. Eur J Dermatol 2008; 18:84.</li>&#xD;&#xA;    <li>Vano-Galvan S, Moreno C, Medina J, et al. Perforating dermatosis in a patient receiving Bevacizumab. J Eur Acad Dermatol Venereol 2009; 23:972.</li>&#xD;&#xA;    <li>Batalla A, Menendez L, Blay P, Curto JR. Delayed onset perforating folliculitis associated with sorafenib. Australas J Dermatol 2014; 55:233.</li>&#xD;&#xA;    <li>Wolber C, Udvardi A, Tatzreiter G, et al. Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib. J Dtsch Dermatol Ges 2009; 7:449.</li>&#xD;&#xA;    <li>Llamas-Velasco M, Steegmann JL, Carrascosa R, et al. Perforating folliculitis in a patient treated with nilotinib: A further evidence of C-kit involvement. Am J Dermatopathol 2014; 36:592.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109810 Version 1.0</div></div></div>"},"109811":{"type":"graphic_algorithm","displayName":"Evaluation narrow QRS complex tachycardias in unstable patients","title":"Algorithm for the evaluation of narrow QRS complex tachycardias in unstable patients","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for the evaluation of narrow QRS complex tachycardias in unstable patients</div><div class=\"cntnt\"><img style=\"width:402px; height:438px;\" src=\"images/CARD/109811_Eval_narrw_QRS_unstable_pts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AVNRT: atrioventricular nodal reentrant tachycardia; AVRT: atrioventricular reentrant tachycardia (due to an accessory pathway); IV: intravenous; SANRT: sinoatrial nodal reentrant tachycardia.</div><div id=\"graphicVersion\">Graphic 109811 Version 1.0</div></div></div>"},"109814":{"type":"graphic_algorithm","displayName":"Diagnosis of esophageal injury","title":"Diagnosis of esophageal injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagnosis of esophageal injury</div><div class=\"cntnt\"><img style=\"width:442px; height:681px;\" src=\"images/SURG/109814_Diagnosis_esophageal_injury.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; IV: intravenous.<br />* Any of the following: dysphagia, neck/back pain, neck swelling, subcutaneous emphysema.<br />&para; Trauma exploration (eg, neck, chest, abdomen) to identify and manage hemorrhage.<br />&Delta; The nature of the repair or drainage depends on the level of the esophagus that is injured (ie, cervical, thoracic, abdominal).<br /><span class=\"lozenge\">&loz;</span> Signs of esophageal or tracheal injury on CT include paraesophageal air, paraesophageal fluid, subcutaneous emphysema, and missile trajectory passing through the esophageal or tracheal region.</div><div id=\"graphicVersion\">Graphic 109814 Version 1.0</div></div></div>"},"109834":{"type":"graphic_table","displayName":"NIDA quick screen","title":"National Institute on Drug Abuse quick screen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">National Institute on Drug Abuse quick screen</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"5\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" style=\"border-bottom-width: 3px;\">In the past year*, how often have you used the following:</td> <td class=\"subtitle1\">Never</td> <td class=\"subtitle1\">Once or twice</td> <td class=\"subtitle1\">Monthly</td> <td class=\"subtitle1\">Weekly</td> <td class=\"subtitle1\">Daily or almost daily</td> </tr> <tr> <td> <ol> <li>Alcohol, four or more drinks a day </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <ol start=\"2\"> <li>Tobacco products </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <ol start=\"3\"> <li>Prescription drugs for non-medical reasons </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <ol start=\"4\"> <li>Illegal drugs </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For pregnant women, ask about substance use since the woman became pregnant.</div><div class=\"graphic_reference\">Modified from: National Institute on Drug Abuse (NIDA). The NIDA Quick Screen. Available at: <a href=\"https://www.drugabuse.gov/sites/default/files/pdf/nmassist.pdf\" target=\"_blank\">https://www.drugabuse.gov/sites/default/files/pdf/nmassist.pdf</a> (Accessed on September 21, 2016).</div><div id=\"graphicVersion\">Graphic 109834 Version 1.0</div></div></div>"},"109835":{"type":"graphic_table","displayName":"Incontinentia pigmenti clinicopathologic stages","title":"Clinical and histopathologic stages of incontinentia pigmenti","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and histopathologic stages of incontinentia pigmenti</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Clinical skin changes</td> <td class=\"subtitle1\">Stage onset</td> <td class=\"subtitle1\">Histopathologic&nbsp;skin findings</td> <td class=\"subtitle1\">Differential diagnosis</td> </tr> <tr> <td><strong>Stage 1</strong><br /> Vesiculobullous stage</td> <td>Erythema and blistering</td> <td>Within the first few weeks of life; generally disappears by age 18 months</td> <td>Eosinophilic spongiosis and intraepidermal vesicle containing eosinophils. Many apoptotic keratinocytes in the epidermis.</td> <td> <ul> <li>Dermatoses with blistering in early infancy such as different types of epidermolysis bullosa and bullous bacterial infection </li> <li>Herpes simplex </li> <li>Varicella/herpes zoster </li> </ul> </td> </tr> <tr> <td><strong>Stage 2</strong><br /> Verrucous stage</td> <td>Hypertrophic rash</td> <td>Within the first few months of life; usually lasts for a few months</td> <td>Papillomatosis, hyperkeratosis, and acanthosis of the epidermis. Many apoptotic cells in the epidermis forming squamous eddies. Major melanin incontinence.</td> <td> <ul> <li>Verruca vulgaris (simple warts) </li> <li>Nevus verrucosus </li> <li>Molluscum contagiosum </li> <li>X-linked dominant chondrodysplasia punctata </li> <li>Linear epidermal nevus </li> </ul> </td> </tr> <tr> <td><strong>Stage 3</strong><br /> Hyperpigmented stage</td> <td>Hyperpigmentation</td> <td>Usually begins as stage 2 starts to resolve; persists into adulthood</td> <td>Marked melanin incontinence with numerous melanophages in the dermis. No more epidermal hyperplasia. Scattered apoptotic cells in the epidermis.</td> <td> <ul> <li>Hypomelanosis of Ito </li> <li>Naegeli syndrome </li> <li>Pigment mosaicism </li> </ul> </td> </tr> <tr> <td><strong>Stage 4</strong><br /> Atrophic/hypopigmented stage</td> <td>Hypopigmentation and alopecia</td> <td>The hyperpigmentation usually begins to fade in the teens and early twenties; does not occur in all patients</td> <td>An atrophic epidermis; massive reduction of melanin in the basal layer; the persistence of apoptotic bodies in the epidermis or papillary dermis; the complete absence of pilosebaceous units and eccrine glands.</td> <td> <ul> <li>Vitiligo with localized alopecia </li> <li>Different types of ectodermal dysplasia </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: MiniÄ‡ S, Trpinac D, ObradoviÄ‡ M. Incontinentia pigmenti diagnostic criteria update. Clin Genet 2014; 85:536. DOI: <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/cge.12223/abstract\" target=_blank>10.1111/cge.12223</A>. Copyright Â© 2016 John Wiley &amp; Sons A/S. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 109835 Version 2.0</div></div></div>"},"109836":{"type":"graphic_algorithm","displayName":"WHO classification of diffuse gliomas","title":"World Health Organization (WHO) classification of diffuse gliomas","html":"<div class=\"graphic\"><div style=\"width: 998px\" class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) classification of diffuse gliomas</div><div class=\"cntnt\"><img style=\"width:978px; height:290px;\" src=\"images/NEURO/109836_Diffuse_gliomas.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IDH: isocitrate dehydrogenase; ATRX: alpha-thalassemia/mental retardation syndrome X-linked; NOS: not otherwise specified.<br />* Characteristic, but not required for diagnosis.</div><div class=\"graphic_reference\">Algorithm courtesy of David Louis, MD.</div><div id=\"graphicVersion\">Graphic 109836 Version 2.0</div></div></div>"},"109837":{"type":"graphic_table","displayName":"Comparison of prenatal genetic testing methods","title":"Comparison of prenatal genetic testing methods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of prenatal genetic testing methods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Goal&nbsp;</td> <td class=\"subtitle1\">Karyotype</td> <td class=\"subtitle1\">CMA without SNPs</td> <td class=\"subtitle1\">CMA with SNPs</td> <td class=\"subtitle1\">Single gene sequencing test</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Test can be performed on \"direct prep\" and does not require cell culture</strong></td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Test can&nbsp;detect point mutation(s) for a single gene disorder</strong></td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Test can detect balanced structural rearrangement</strong><br /> (eg, balanced translocation or balanced inversion, ring chromosome with no loss of genomic material)</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Test can detect unbalanced structural rearrangement</strong><br /> (eg, unbalanced translocation, ring chromosome with loss of some material)</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Test can detect copy gains/losses larger than 3 to 10 Mb, including whole chromosome aneuploidy</strong></td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Test can detect copy gains/losses smaller than 3 to 10 Mb</strong><br /> (microdeletion and microduplication syndromes)</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Test can detect isochromosomes</strong></td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Test can detect low-level mosaicism (approximately 10 to 15% mosaicism)&nbsp;for chromosome imbalance</strong></td> <td class=\"centered\">Yes</td> <td class=\"centered\">No*&nbsp;</td> <td class=\"centered\">Yes<sup>&#182;</sup></td> <td class=\"centered\">No</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Test can detect triploidy</strong></td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Test can identify origin of small-marker chromosome</strong></td> <td class=\"centered\">No<sup>&#916;</sup></td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td><strong>Test can detect uniparental disomy due to isodisomy</strong><br /> (NOTE: At least half of all uniparental disomy cases are heterodisomy and would not be detected)</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: There are overgeneralizations here; certain sequencing approaches such as whole genome sequencing can detect mosaicism, isodisomy, and even copy number changes. It is not a widespread clinical test yet.</div><div class=\"graphic_footnotes\">CMA: chromosomal microarray; SNP: single nucleotide polymorphism; Mb: megabase.<br /><br />* CMA without SNPs can detect mosaicism in the range of approximately 30% or higher.<br />Â¶ CMA with SNPs performs as well or better than a conventional karyotype. The sensitivity of detection may vary depending on the density of SNP probe coverage.<br />Î” Karyotype can identify the presence of a small marker chromosome, but typically cannot determine which chromosome is involved.</div><div id=\"graphicVersion\">Graphic 109837 Version 1.0</div></div></div>"},"109838":{"type":"graphic_table","displayName":"FVIII products","title":"Selected available factor VIII products for patients with hemophilia A","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected available factor VIII products for patients with hemophilia A</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Product name</td> <td class=\"subtitle1\">Half-life (hours)*</td> <td class=\"subtitle1\">Characteristics</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Standard half-life products</td> </tr> <tr> <td class=\"indent1\">Advate</td> <td>9 to 12</td> <td>Recombinant</td> </tr> <tr> <td class=\"indent1\">Helixate FS/Kogenate FS</td> <td>11 to 15</td> <td>Recombinant</td> </tr> <tr> <td class=\"indent1\">Hemofil M</td> <td>15</td> <td>Plasma-derived; mAb-purified</td> </tr> <tr> <td class=\"indent1\">Koate (previously called Koate DVI)</td> <td>16</td> <td>Plasma-derived;&nbsp;chromatography purified</td> </tr> <tr> <td class=\"indent1\">Kovaltry</td> <td>12 to 14</td> <td>Recombinant</td> </tr> <tr> <td class=\"indent1\">Monoclate-P</td> <td>18</td> <td>Plasma-derived; mAb-purified</td> </tr> <tr> <td class=\"indent1\">Novoeight</td> <td>8 to 12</td> <td>Recombinant</td> </tr> <tr> <td class=\"indent1\">Nuwiq</td> <td>12 to 17</td> <td>Recombinant</td> </tr> <tr> <td class=\"indent1\">Recombinate</td> <td>15<sup>&#182;</sup></td> <td>Recombinant</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Xyntha</td> <td>8 to 11</td> <td>Recombinant</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Longer lasting products</td> </tr> <tr> <td class=\"indent1\">Adynovate</td> <td>13 to 16</td> <td>Recombinant; PEGylated</td> </tr> <tr> <td class=\"indent1\">Afstyla</td> <td>10 to 14</td> <td>Recombinant; single chain</td> </tr> <tr> <td class=\"indent1\">Eloctate</td> <td>13 to 20</td> <td>Recombinant; Fc fusion</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table is intended as a guide for rapid identification of the product the patient is using and its characteristics and should not be used to select a product or calculate dosing. Refer to prescribing information in the product insert and to&nbsp;UpToDate for the use of factor replacement in patients with hemophilia. The plasma-derived products listed here are ultra-high purity (mAb purified) or high purity (chromatography purified).</div><div class=\"graphic_footnotes\">FS: formulated with sucrose; mAb: monoclonal antibody.<br />* Half-lives are approximate. Half-lives are generally shorter for children than adults when assessed in pharmacokinetic studies. The half-life of factor VIII products without modifications to extend half-life is considered to be approximately 12 hours. The half-life should be determined for the individual patient. Refer to product information and institutional guidelines for additional dosing and monitoring information.<br />Â¶ Adults only.</div><div id=\"graphicVersion\">Graphic 109838 Version 3.0</div></div></div>"},"109839":{"type":"graphic_table","displayName":"FIX products","title":"Selected available factor IX products for patients with hemophilia B","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected available factor IX products for patients with hemophilia B</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Product name</td> <td class=\"subtitle1\">Half-life (hours)*</td> <td class=\"subtitle1\">Characteristics</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Standard half-life products</td> </tr> <tr> <td class=\"indent1\">AlphaNine SD</td> <td>18<sup>&#182;</sup></td> <td>Plasma-derived; solvent/detergent treated</td> </tr> <tr> <td class=\"indent1\">BeneFIX</td> <td>16 to 19</td> <td>Recombinant</td> </tr> <tr> <td class=\"indent1\">Ixinity</td> <td>24<sup>&#916;</sup></td> <td>Recombinant</td> </tr> <tr> <td class=\"indent1\">Mononine</td> <td>23<sup>&#182;</sup></td> <td>Plasma-derived; mAb purified</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rixubis</td> <td>23 to 26</td> <td>Recombinant</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Longer-lasting products</td> </tr> <tr> <td class=\"indent1\">Alprolix</td> <td>54 to 90</td> <td>Recombinant; Fc fusion</td> </tr> <tr> <td class=\"indent1\">Idelvion</td> <td>104<sup>&#182;</sup></td> <td>Recombinant; albumin fusion</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table is intended as a guide for rapid identification of the product the patient is using and its characteristics. Refer to the product information and to&nbsp;UpToDate for the use of factor replacement in patients with hemophilia.</div><div class=\"graphic_footnotes\">SD: solvent/detergent treated; mAb: monoclonal antibody.<br />* Half-lives are <STRONG innerHtml>approximate</STRONG>. Half-lives are generally shorter for children than adults when assessed in pharmacokinetic studies. The half-life of factor IX products without modifications to extend half-life is considered to be approximately 24 hours. The half-life should be determined for the individual patient. Refer to product information and institutional guidelines for additional dosing and monitoring information.<br />Â¶ Adults only.<br />Î” 12 years and older.</div><div id=\"graphicVersion\">Graphic 109839 Version 3.0</div></div></div>"},"109841":{"type":"graphic_table","displayName":"Sports in hemophilia","title":"Selected sports in hemophilia, high and low impact","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected sports in hemophilia, high and low impact</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Low impact sports</td> <td class=\"subtitle1\">Moderate impact sports</td> <td class=\"subtitle1\">High impact sports</td> </tr> <tr> <td class=\"centered\">Aquatics</td> <td class=\"centered\">Aerobics</td> <td class=\"centered\">BMX racing</td> </tr> <tr> <td class=\"centered\">Fishing</td> <td class=\"centered\">Basketball</td> <td class=\"centered\">Boxing</td> </tr> <tr> <td class=\"centered\">Frisbee</td> <td class=\"centered\">Horseback riding</td> <td class=\"centered\">Football (American)</td> </tr> <tr> <td class=\"centered\">Golf</td> <td class=\"centered\">Racquetball or tennis</td> <td class=\"centered\">Lacrosse</td> </tr> <tr> <td class=\"centered\">Hiking</td> <td class=\"centered\">Running/jogging</td> <td class=\"centered\">Rodeo</td> </tr> <tr> <td class=\"centered\">Walking</td> <td class=\"centered\">Soccer (world football)</td> <td class=\"centered\">Rugby</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table includes selected examples and should not take the place of clinician judgment regarding sports that are likely to cause injury or bleeding in individual patients. Refer to UpToDate for more information about hemophilia and sports participation.</div><div class=\"graphic_footnotes\">BMX: bicycle motocross, a type of off-road sport cycling and stunt riding.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI><A spellcheck=true href=\"https://www.hemophilia.org/sites/default/files/document/files/Playing-It-Safe.pdf\" target=_blank>https://www.hemophilia.org/sites/default/files/document/files/Playing-It-Safe.pdf</A>.</LI></OL></div><div id=\"graphicVersion\">Graphic 109841 Version 2.0</div></div></div>"},"109848":{"type":"graphic_table","displayName":"Dengue hemodynamic assessment","title":"Dengue hemodynamic assessment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dengue hemodynamic assessment</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Stable circulation</td> <td class=\"subtitle1\">Shock (DHF Grade III)*<sup>&#182;</sup></td> <td class=\"subtitle1\">Prolonged/profound shock (DHF Grade IV)*<sup>&#182;</sup></td> </tr> <tr> <td><strong>Heart rate</strong></td> <td>Normal</td> <td>Tachycardia</td> <td>Severe tachycardia or bradycardia</td> </tr> <tr> <td><strong>Blood pressure</strong></td> <td>Normal</td> <td> <p>Normal systolic pressure but rising diastolic pressure (narrowing pulse pressure<sup>&#916;</sup>)</p> Postural hypotension</td> <td>Severe hypotension or undetectable blood pressure</td> </tr> <tr> <td><strong>Respiratory rate</strong></td> <td>Normal</td> <td>Tachypnea</td> <td>Hyperpnea or Kussmaul respirations</td> </tr> <tr> <td><strong>Urine output</strong></td> <td>Normal</td> <td>Reducing trend</td> <td>Oliguria or anuria</td> </tr> <tr> <td><strong>Consciousness level</strong></td> <td>Clear, lucid</td> <td>Clear, lucid</td> <td>Restless, combative</td> </tr> <tr> <td><strong>Capillary refill</strong></td> <td>Brisk (&#8804;2 seconds)</td> <td>Prolonged (&#62;2 seconds)</td> <td>Very prolonged</td> </tr> <tr> <td><strong>Extremities</strong></td> <td>Warm, pink</td> <td>Cool</td> <td>Cold, clammy, mottled skin</td> </tr> <tr> <td><strong>Peripheral pulse volume</strong></td> <td>Good volume</td> <td>Weak, thready</td> <td>Feeble or absent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DHF: dengue hemorrhagic fever.<br />* The&nbsp;World Health Organization&nbsp;has established the following grading system for severity of dengue hemorrhagic fever: &#xD;&#xA;<UL>&#xD;&#xA;<LI>DHF Grade I â€“ Fever, hemorrhagic manifestation (positive tourniquet test), and evidence of plasma leakage.</LI>&#xD;&#xA;<LI>DHF Grade II â€“ DHF Grade I plus spontaneous bleeding.</LI>&#xD;&#xA;<LI>DHF Grade III â€“ DHF Grade I or DHF Grade II plus narrowing pulse pressure or hypotension.</LI>&#xD;&#xA;<LI>DHF Grade IV â€“ DHF Grade III plus profound shock with undetectable blood pressure and pulse.</LI></UL>Dengue shock syndrome consists of DHF Grade III and DHF Grade IV.<br />Â¶ Shock due to plasma leakage often presents with a narrow pulse pressure or elevated diastolic pressure with preserved systolic pressure, whereas shock due to bleeding often presents with hypotension or low systolic pressure. Other causes of shock must also be considered (such as hypoglycemia, excessive vomiting, or bacterial coinfection).<br />Î” Pulse pressure is systolic pressure minus diastolic pressure.</div><div class=\"graphic_reference\">Modified from: Centers for Disease Control and Prevention. Dengue case management. Available at: <a href=\"http://www.cdc.gov/dengue/resources/dengue-clinician-guide_508.pdf\" target=\"_blank\">http://www.cdc.gov/dengue/resources/dengue-clinician-guide_508.pdf</a> (Accessed on September 15, 2016).</div><div id=\"graphicVersion\">Graphic 109848 Version 2.0</div></div></div>"},"109849":{"type":"graphic_algorithm","displayName":"Dengue plasma leak","title":"An approach to inpatient management of dengue infection with plasma leakage in the absence of shock (WHO DHF Grades I and II)*<sup>Â¶</sup>","html":"<div class=\"graphic\"><div style=\"width: 1066px\" class=\"figure\"><div class=\"ttl\">An approach to inpatient management of dengue infection with plasma leakage in the absence of shock (WHO DHF Grades I and II)*<sup>&para;</sup></div><div class=\"cntnt\"><img style=\"width:1046px; height:922px;\" src=\"images/ID/109849_Dengue_plasma_leak.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WHO: World Health Organization; DHF: dengue hemorrhagic fever.<br />* The WHO has established a grading for severity of dengue hemorrhagic fever: &#xD;&#xA;<UL>&#xD;&#xA;<LI>DHF Grade I â€“ Fever, hemorrhagic manifestation (positive tourniquet test), and evidence of plasma leakage.</LI>&#xD;&#xA;<LI>DHF Grade II â€“ DHF Grade I plus spontaneous bleeding.</LI>&#xD;&#xA;<LI>DHF Grade III â€“ DHF Grade I or DHF Grade II plus circulatory failure.</LI>&#xD;&#xA;<LI>DHF Grade IV â€“ DHF Grade III plus profound shock with undetectable blood pressure and pulse.</LI></UL>Dengue shock syndrome consists of DHF Grade III and DHF Grade IV. Shock refers to normal systolic pressure but rising diastolic pressure with narrowing pulse pressure.<br />Â¶ Inpatient management is warranted for high-risk patients (infants, pregnant women, older adults, obese, diabetes, renal failure, neurologic signs), patients with significant bleeding, patients with leukopenia (white blood cell count â‰¤5000 cells/mcL), patients with thrombocytopenia (platelet count â‰¤10,000 cells/mcL), and patients with warning signs of severe dengue (as defined in Box D above).<br />Î” Criteria for clinical stability include blood pressure rising or normalized, heart rate decreasing, pulse pressure widening, respiratory rate decreasing, or skin warm with turgor intact.<br /><FONT class=lozenge>â—Š</FONT> Criteria for clinical instability include blood pressure decreasing, heart rate increasing, pulse pressure narrowing, respiratory rate increasing, or skin cool and clammy with diminished turgor.<br />Â§ No other colloid formulations (such as albumin) should be used for management of dengue. If 10% dextran 40 in normal saline is not available, crystalloid should be used.<br />Â¥ The patient's clinical status (including vital signs, urine output, and hematocrit) should be evaluated prior to each infusion rate adjustment.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>World Health Organization. Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever. WHO, New Delhi 2011.</li>&#xD;&#xA;    <li>World Health Organization. Dengue: Guidelines for diagnosis, treatment, prevention and control. WHO, Geneva 2009.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109849 Version 1.0</div></div></div>"},"109850":{"type":"graphic_algorithm","displayName":"Dengue profound shock","title":"An approach to management of dengue infection in the setting of profound or prolonged shock (WHO DHF Grade IV)*<sup>Â¶</sup>","html":"<div class=\"graphic\"><div style=\"width: 880px\" class=\"figure\"><div class=\"ttl\">An approach to management of dengue infection in the setting of profound or prolonged shock (WHO DHF Grade IV)*<sup>&para;</sup></div><div class=\"cntnt\"><img style=\"width:860px; height:732px;\" src=\"images/ID/109850_Dengue_profound_shock.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WHO: World Health Organization; DHF: dengue hemorrhagic fever.<br />* The WHO has established a grading for severity of dengue hemorrhagic fever &#xD;&#xA;<UL>&#xD;&#xA;<LI>DHF Grade I â€“ Fever, hemorrhagic manifestation (positive tourniquet test), and evidence of plasma leakage.</LI>&#xD;&#xA;<LI>DHF Grade II â€“ DHF Grade I plus spontaneous bleeding.</LI>&#xD;&#xA;<LI>DHF Grade III â€“ DHF Grade I or DHF Grade II plus circulatory failure.</LI>&#xD;&#xA;<LI>DHF Grade IV â€“ DHF Grade III plus profound shock with undetectable blood pressure and pulse.</LI></UL>Dengue shock syndrome consists of DHF Grade III and DHF Grade IV.<br />Â¶ Shock refers to normal systolic pressure but rising diastolic pressure with narrowing pulse pressure. Profound shock refers to hypotension and narrow pulse pressure (systolic minus diastolic pressure â‰¤20 mmHg).<br />Î” Intravenous crystalloid solutions include normal saline or Ringer's lactate. Colloid solution includes blood products or 10% dextran 40 in normal saline; no other colloid formulations (such as albumin) should be used for management of dengue, and dextran should not be used for initial resuscitation. If 10% dextran 40 in normal saline is not available, crystalloid should be used.<br /><FONT class=lozenge>â—Š</FONT> Criteria for clinical improvement include blood pressure rising or normalized, heart rate decreasing, pulse pressure widening, respiratory rate decreasing, skin warm with turgor intact, or sensorium clear.<br />Â§ The patient's clinical status (including vital signs, urine output, and hematocrit) should be evaluated prior to each infusion rate adjustment.<br />Â¥ Criteria for lack of clinical improvement include blood pressure decreasing, heart rate increasing, pulse pressure narrowing, respiratory rate increasing, skin cool and clammy with diminished turgor, mental confusion, or restlessness.<br />â€¡ Additional interventions include dialysis or plasmapheresis; the clinical approach depends on locally available resources and clinical expertise.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>World Health Organization. Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever. WHO, New Delhi 2011.</li>&#xD;&#xA;    <li>World Health Organization. Dengue: Guidelines for diagnosis, treatment, prevention and control. WHO, Geneva 2009.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109850 Version 1.0</div></div></div>"},"109851":{"type":"graphic_algorithm","displayName":"Dengue shock","title":"An approach to management of dengue infection in the setting of shock, narrowed pulse pressure, or hypotension (WHO DHF Grade III)*<sup>Â¶</sup>","html":"<div class=\"graphic\"><div style=\"width: 956px\" class=\"figure\"><div class=\"ttl\">An approach to management of dengue infection in the setting of shock, narrowed pulse pressure, or hypotension (WHO DHF Grade III)*<sup>&para;</sup></div><div class=\"cntnt\"><img style=\"width:936px; height:630px;\" src=\"images/ID/109851_Dengue_shock.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WHO: World Health Organization; DHF: dengue hemorrhagic fever.<br />* The WHO has established a grading for severity of dengue hemorrhagic fever:&#xD;&#xA;<ul>&#xD;&#xA;    <li>DHF Grade I &ndash; Fever, hemorrhagic manifestation (positive tourniquet test), and evidence of plasma leakage.</li>&#xD;&#xA;    <li>DHF Grade II &ndash; DHF Grade I plus spontaneous bleeding.</li>&#xD;&#xA;    <li>DHF Grade III &ndash; DHF Grade I or DHF Grade II plus circulatory failure.</li>&#xD;&#xA;    <li>DHF Grade IV &ndash; DHF Grade III plus profound shock with undetectable blood pressure and pulse.</li>&#xD;&#xA;</ul>&#xD;&#xA;Dengue shock syndrome consists of DHF Grade III and DHF Grade IV.<br />&para; Shock refers to normal systolic pressure but rising diastolic pressure with narrowing pulse pressure. Profound shock refers to hypotension and narrow pulse pressure (systolic minus diastolic pressure &le;20 mmHg).<br />&Delta; Criteria for clinical improvement include blood pressure rising or normalized, heart rate decreasing, pulse pressure widening, respiratory rate decreasing, skin warm with turgor intact, or sensorium clear.<br /><span class=\"lozenge\">&loz;</span> Criteria for lack of clinical improvement include blood pressure decreasing, heart rate increasing, pulse pressure narrowing, respiratory rate increasing, skin cool and clammy with diminished turgor, mental confusion, or restlessness.<br />&sect; No other colloid formulations (such as albumin) should be used for management of dengue. If 10% dextran 40 in normal saline is not available, crystalloid should be used.<br />&yen; The patient's clinical status (including vital signs, urine output, and hematocrit) should be evaluated prior to each infusion rate adjustment.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>World Health Organization. Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever. WHO, New Delhi 2011.</li>&#xD;&#xA;    <li>World Health Organization. Dengue: Guidelines for diagnosis, treatment, prevention and control. WHO, Geneva 2009.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109851 Version 1.0</div></div></div>"},"109857":{"type":"graphic_picture","displayName":"Anatomic layers of the temple","title":"Anatomic layers of the temple","html":"<div class=\"graphic\"><div style=\"width: 681px\" class=\"figure\"><div class=\"ttl\">Anatomic layers of the temple</div><div class=\"cntnt\"><img style=\"width:661px; height:756px;\" src=\"images/DERM/109857_Anatomic_layers_temple.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Layers of the temple: I, skin; II, subcutaneous tissue; III, TPF (superficial temporal fascia); FP: fat pad; V, deep temporal fascia; VI, temporalis muscle.</div><div class=\"graphic_reference\">From: Sykes JM, Cotofana S, Trevidic P, et al. Upper Face: Clinical Anatomy and Regional Approaches with Injectable Fillers. Plast Reconstr Surg 2015; 136:204S. DOI: <A href=\"http://journals.lww.com/plasreconsurg/pages/articleviewer.aspx?year=2015&amp;issue=11001&amp;article=00030&amp;type=abstract\" target=_blank>10.1097/PRS.0000000000001830</A>. Copyright Â© 2015 International American Society of Plastic Surgeons, Inc. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 109857 Version 1.0</div></div></div>"},"109858":{"type":"graphic_picture","displayName":"Supraorbital nerve and retro-orbicularis oculi fat pad","title":"Supraorbital nerve and retro-orbicularis oculi fat pad","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Supraorbital nerve and retro-orbicularis oculi fat pad</div><div class=\"cntnt\"><img style=\"width:756px; height:529px;\" src=\"images/DERM/109858_Sprrbtl_nrv_retrrbclrs_ocli.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left-sided cadaver dissection shown in a subgaleal dissection plane with the thick arrow pointing to the supraorbital nerve and the arrowhead pointing to the retro-orbicularis oculi fat pad. The safe zone for injection of autologous fat of fillers is lateral to the supraorbital neurovascular bundle.</div><div class=\"graphic_reference\">From: Sykes JM, Cotofana S, Trevidic P, et al. Upper Face: Clinical Anatomy and Regional Approaches with Injectable Fillers. Plast Reconstr Surg 2015; 136:204S. DOI: <A href=\"http://journals.lww.com/plasreconsurg/pages/articleviewer.aspx?year=2015&amp;issue=11001&amp;article=00030&amp;type=abstract\" target=_blank>10.1097/PRS.0000000000001830</A>. Copyright Â© 2015 International American Society of Plastic Surgeons, Inc. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 109858 Version 1.0</div></div></div>"},"109859":{"type":"graphic_picture","displayName":"Facial artery and branches","title":"Facial artery and branches","html":"<div class=\"graphic\"><div style=\"width: 700px\" class=\"figure\"><div class=\"ttl\">Facial artery and branches</div><div class=\"cntnt\"><img style=\"width:680px; height:643px;\" src=\"images/DERM/109859_Facial_artery_branches.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The facial artery and branches: inferior lip artery, superior lip artery, and angular artery.</div><div class=\"graphic_reference\">From: Braz A, Humphrey S, Weinkle S, et al. Lower Face: Clinical Anatomy and Regional Approaches with Injectable Fillers. Plast Reconstr Surg 2015; 136:235S. DOI: <A href=\"http://journals.lww.com/plasreconsurg/Citation/2015/11001/Lower_Face___Clinical_Anatomy_and_Regional.32.aspx\" target=_blank>10.1097/PRS.0000000000001836</A>. Copyright Â© 2015 International American Society of Plastic Surgeons, Inc. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 109859 Version 1.0</div></div></div>"},"109860":{"type":"graphic_picture","displayName":"Facial artery with branches and facial vein","title":"Facial artery with branches and facial vein","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Facial artery with branches and facial vein</div><div class=\"cntnt\"><img style=\"width:725px; height:521px;\" src=\"images/DERM/109860_Facl_artry_brnchs_facl_vein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The facial artery with branches: inferior lip artery and&nbsp;superior lip artery. The facial vein is more lateral and in a deeper position than the artery. The facial vein can be seen inside of the deep fat compartment of the midface.</div><div class=\"graphic_reference\">From: Braz A, Humphrey S, Weinkle S, et al. Lower Face: Clinical Anatomy and Regional Approaches with Injectable Fillers. Plast Reconstr Surg 2015; 136:235S. DOI: <A href=\"http://journals.lww.com/plasreconsurg/Citation/2015/11001/Lower_Face___Clinical_Anatomy_and_Regional.32.aspx\" target=_blank>10.1097/PRS.0000000000001836</A>. Copyright Â© 2015 International American Society of Plastic Surgeons, Inc. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 109860 Version 1.0</div></div></div>"},"109861":{"type":"graphic_picture","displayName":"Infraorbital region deep fat compartment","title":"Infraorbital region deep fat compartment","html":"<div class=\"graphic\"><div style=\"width: 977px\" class=\"figure\"><div class=\"ttl\">Infraorbital region deep fat compartment</div><div class=\"cntnt\"><img style=\"width:957px; height:404px;\" src=\"images/DERM/109861_Infrrbtl_regn_fat_cmprtmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">View onto the right and left infraorbital region of layer&nbsp;four (deep to the OOM) in a female (A) and male (B) fresh-frozen specimen.<br />(A) The PZ and the DLCF are circled. The arrowhead indicates the zygomaticus major muscle with its broadly based fibrous origin. This long attachment represents the lateral-inferior boundary of the DLCF. The facial vein is marked by the arrows and represents the medial-inferior boundary of the DLCF. The OOM is flipped toward the nose to expose the BB where this muscle attaches on the orbital rim.<br />(B) Dyer has been injected into the PZ (red and blue) and into the DLCF (green). Note that the injection was performed with constant contact to the bone during application in all&nbsp;three locations. The red and blue areas correspond to the MS and to the LS. The arrowhead indicates zygomaticus major muscle with its broadly based fibrous origin; BB area after sharp removal of the OOM from its attachment on the orbital rim. The asterisk marks the levator labii superioris alaeque nasi muscle. The arrows point to the facial vein.</div><div class=\"graphic_footnotes\">OOM: orbicularis oculi muscle; PZ: prezygomatic space; DLCF: lateral part of the deep medial cheek fat; BB: bare bone; MS: medial suborbicularis oculi fat; LS: lateral suborbicularis oculi fat.</div><div class=\"graphic_reference\">From: Cotofana S, Schenck TL, Trevidic P, et al. Midface: Clinical anatomy and regional approaches with injectable fillers. Plast Reconstr Surg 2015; 136:219S. DOI: <A href=\"http://journals.lww.com/plasreconsurg/pages/articleviewer.aspx?year=2015&amp;issue=11001&amp;article=00031&amp;type=abstract\" target=_blank>10.1097/PRS.0000000000001837</A>. Copyright Â© 2015 International American Society of Plastic Surgeons, Inc. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 109861 Version 1.0</div></div></div>"},"109862":{"type":"graphic_table","displayName":"Cutaneous lymphomas WHO 2016 classification","title":"Classification of primary cutaneous lymphomas according to the 2016 revision of the WHO classification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of primary cutaneous lymphomas according to the 2016 revision of the WHO classification</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Revised WHO classification 2016</td> <td class=\"subtitle1\">Frequency (%)*</td> <td class=\"subtitle1\">Five-year DSS (%)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\"><strong>Cutaneous T cell and NK cell lymphomas</strong></td> </tr> <tr> <td class=\"indent1\">Mycosis fungoides</td> <td>39</td> <td>89</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Mycosis fungoides variants and subtypes</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Folliculotropic mycosis fungoides </li> </ul> </td> <td>5</td> <td>79</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pagetoid reticulosis </li> </ul> </td> <td>&#60;1</td> <td>100</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Granulomatous slack skin </li> </ul> </td> <td>&#60;1</td> <td>100</td> </tr> <tr> <td class=\"indent1\">S&#233;zary syndrome</td> <td>2</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Adult T cell leukemia/lymphoma</td> <td>&#60;1</td> <td>NDA</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Primary cutaneous CD30+ lymphoproliferative disorders</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Primary cutaneous anaplastic large cell lymphoma </li> </ul> </td> <td>10</td> <td>95</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Lymphomatoid papulosis </li> </ul> </td> <td>15</td> <td>100</td> </tr> <tr> <td class=\"indent1\">Subcutaneous panniculitis-like T cell lymphoma</td> <td>1</td> <td>87</td> </tr> <tr> <td class=\"indent1\">Extranodal NK/T cell lymphoma, nasal type</td> <td>&#60;1</td> <td>NR</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Primary cutaneous peripheral T cell lymphoma, rare subtypes</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Primary cutaneous gamma-delta T cell lymphoma </li> </ul> </td> <td>&#60;1</td> <td>NR</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma (provisional) </li> </ul> </td> <td>&#60;1</td> <td>12</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Primary cutaneous CD4+ small/medium-sized pleomorphic T cell lymphoproliferative disorder (provisional) </li> </ul> </td> <td>3</td> <td>100</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Primary cutaneous acral CD8+ T cell lymphoma (provisional) </li> </ul> </td> <td>&#60;1</td> <td>100</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Primary cutaneous peripheral T cell lymphoma, not otherwise specified</td> <td>2</td> <td>15</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\"><strong>Cutaneous B cell lymphomas</strong></td> </tr> <tr> <td class=\"indent1\">Primary cutaneous marginal zone B cell lymphoma<sup>&#182;</sup></td> <td>7</td> <td>99</td> </tr> <tr> <td class=\"indent1\">Primary cutaneous follicle center lymphoma</td> <td>12</td> <td>95</td> </tr> <tr> <td class=\"indent1\">Primary cutaneous diffuse large B cell lymphoma, leg type</td> <td>4</td> <td>52</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO: World Health Organization; DSS: disease-specific survival; NK: natural killer; NDA: no data available; NR: not reached.<br />* Relative frequency and disease-specific five-year-survival.<br />&para; In the 2016 revised WHO classification, primary cutaneous marginal zone lymphoma is included in the broad category of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue.</div><div class=\"graphic_reference\">This research was originally published in Blood. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768. Copyright &copy; 2005 American Society of Hematology.<br />Updated with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109862 Version 1.0</div></div></div>"},"109868":{"type":"graphic_table","displayName":"Hemodynamic goals in left-sided cardiogenic shock","title":"Hemodynamic goals in left-sided cardiogenic shock","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemodynamic goals in left-sided cardiogenic shock</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"5\" width=\"12%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of shock</td> <td class=\"subtitle1\">Preload</td> <td class=\"subtitle1\">Afterload</td> <td class=\"subtitle1\">Rate</td> <td class=\"subtitle1\">Rhythm</td> <td class=\"subtitle1\">Contractility</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>LV myopathy with systolic dysfunction</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8595;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8595;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8593;</td> <td class=\"centered\">Sinus</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8593;</td> <td>Dobutamine, milrinone, or a combination are ideal agents, unless severe active ischemia is present.</td> </tr> <tr> <td>Acute mitral regurgitation</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8595;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8595;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8593;&#8593;</td> <td class=\"centered\">Sinus</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8593;</td> <td>Dobutamine, milrinone, or a combination are supportive ideal agents. IABP to be considered. Address the cause of the MR as soon as possible.</td> </tr> <tr> <td>Acute aortic regurgitation</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8595;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8595;&#8595;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8593;&#8593;</td> <td class=\"centered\">Sinus</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8593;</td> <td>Dobutamine, milrinone, or a combination are ideal agents until the cause of the AR can be addressed.</td> </tr> <tr> <td>Aortic stenosis (AS)</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8592;&#8594;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8592;&#8594;</td> <td class=\"centered\">70 to 90</td> <td class=\"centered\">Sinus</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8592;&#8594;</td> <td>Patients with critical AS do not tolerate tachycardia or bradycardia. Typically afterload reduction is not tolerated, although may be useful in end-stage disease with dilated LV.</td> </tr> <tr> <td>Hypertrophic cardiomyopathy</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8593;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8593;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8595;</td> <td class=\"centered\">Sinus</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8595;</td> <td>Inotropes are contraindicated. Fluid and phyenylephrine are the first line agents.</td> </tr> <tr> <td colspan=\"7\">Diastolic dysfunction</td> </tr> <tr> <td class=\"indent1\">Mild, relaxation abnormality</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8592;&#8594;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8592;&#8594;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8595;</td> <td class=\"centered\">Sinus</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8592;&#8594;</td> <td>Typically E/A ratio &#60;1 and LV diastolic filling can be augmented by a slow HR.</td> </tr> <tr> <td class=\"indent1\">Severe</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8595;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8592;&#8594;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8593;&#8593;</td> <td class=\"centered\">Sinus</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8592;&#8594;</td> <td>Typically E/A ratio &#62;2 and severe LV stiffness limits filling. Stroke volume is fixed and CO is therefore rate dependent. Consider temporary atrial pacing if possible.</td> </tr> <tr> <td class=\"indent1\">Moderate, pseudo-normalization</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8595;</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8592;&#8594;</td> <td class=\"centered\">?</td> <td class=\"centered\">Sinus</td> <td class=\"centered\" style=\"font-size: 1.5em; vertical-align: top;\">&#8592;&#8594;</td> <td>Some cases of pseudo-normalization behave more like restrictive physiology and require higher HR, whereas others behave more like a relaxation abnormality.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LV: left ventricle/left ventricular; IABP: intra-aortic balloon pump; MR: mitral regurgitation; AR: aortic regurgitation; CO: carbon monoxide; HR: heart rate; E: early mitral inflow velocity; A: late mitral inflow velocity resulting from atrial contraction.</div><div id=\"graphicVersion\">Graphic 109868 Version 1.0</div></div></div>"},"109869":{"type":"graphic_figure","displayName":"Celiac artery compression anatomy","title":"Celiac artery compression anatomy","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Celiac artery compression anatomy</div><div class=\"cntnt\"><img style=\"width:508px; height:366px;\" src=\"images/SURG/109869_Celiac_artery_compression.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The median arcuate ligament is a fibrous arch that traverses the aorta and bridges the crura of the diaphragm. The celiac axis branches from the abdominal aorta, normally below the median arcuate ligament. A higher or lower origin of the celiac axis may be prone to compression.</div><div class=\"graphic_reference\">Modified from: Kim EN, Lamb K, Relles D, et al. Median arcuate ligament syndromeâ€”Review of this rare disease. JAMA Surg 2016; 151:471.</div><div id=\"graphicVersion\">Graphic 109869 Version 1.0</div></div></div>"},"109870":{"type":"graphic_algorithm","displayName":"Algorithm for celiac artery compression syndrome","title":"Algorithm for celiac artery compression syndrome","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Algorithm for celiac artery compression syndrome</div><div class=\"cntnt\"><img style=\"width:571px; height:766px;\" src=\"images/SURG/109870_Celiac_artry_cmprssn_syndrm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; MR: magnetic resonance; SMA: superior mesenteric artery.<br />* Patient should not otherwise have clinical features of chronic mesenteric ischemia due to peripheral artery disease (ie, smoking, claudication).<br />Â¶ Cross-sectional CT or MR, or CT or MR angiography. For patients with clear-cut intestinal angina, duplex ultrasound is an alternative initial study to evaluate for celiac artery stenosis.<br />Î” Without an identifiable intraluminal cause for stenosis (eg, atherosclerosis, embolism) and without concomitant intraluminal SMA stenosis.<br /><FONT class=lozenge>â—Š</FONT> The diagnosis can be confirmed by either positive findings on catheter-based arteriography that includes lateral views or by a combination of anatomic findings on CT or MR angiography combined with appropriate respiratory variations on duplex ultrasound.<br />Â§ Open surgical or minimally invasive robotic-assisted or laparoscopic surgery.<br />Â¥ Intraoperative duplex ultrasound or arteriography.<br />â€¡ Ensure that release is complete prior to angioplasty/stenting.</div><div id=\"graphicVersion\">Graphic 109870 Version 1.0</div></div></div>"},"109871":{"type":"graphic_figure","displayName":"Right-sided cardiogenic shock","title":"Right-sided cardiogenic shock","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Right-sided cardiogenic shock</div><div class=\"cntnt\"><img style=\"width:506px; height:286px;\" src=\"images/ANEST/109871_Right-sided_cardiogenc_shck.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MAP: mean arterial pressure; CVP: central venous pressure; CO: cardiac output; SBP: systolic blood pressure.</div><div class=\"graphic_reference\">Reproduced from: Hrymak A, Strumpher J, Jacobsohn E. Acute RV failure in ICU: Assessment and management. Can J Cardiol 2016. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109871 Version 1.0</div></div></div>"},"109872":{"type":"graphic_table","displayName":"Effects of vasoactive agents in right-sided cardiogenic shock","title":"Effects of vasoactive agents in right-sided cardiogenic shock","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effects of vasoactive agents in right-sided cardiogenic shock</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"6\" width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Inotropic agent</td> <td class=\"subtitle1\">RV inotropy</td> <td class=\"subtitle1\">PVR</td> <td class=\"subtitle1\">PVR with sPA vasodilator</td> <td class=\"subtitle1\">SVR</td> <td class=\"subtitle1\">TSG</td> <td class=\"subtitle1\">CO</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Alpha-agonist (eg, phenylephrine)</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8592;&#8594;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;&#8593;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;&#8593;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8592;&#8594;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</td> <td>Indicated only as bolus dose treatment of acute hypotension, while the typical RV-support regime is prepared.</td> </tr> <tr class=\"divider_bottom\"> <td>Vasopressin (VP)</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8592;&#8594;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8592;&#8594;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;&#8593;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle; white-space: nowrap;\">&#8592;&#8594;/&#8593;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle; white-space: nowrap;\">&#8592;&#8594;/&#8593;</td> <td>Ideal pressor agent in right-sided shock due to minimal effect on PVR. The increased LV pressure pushes the septum back to the R, increases RCA blood flow.</td> </tr> <tr class=\"divider_bottom\"> <td>Phosphodiesterase inhibitors (PDE<sub>3</sub>I) (eg, milrinone)</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;&#8593;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;<br /> &#8595;</td> <td>Good inotrope but potentially dangerous decrease in SBP and TSG. MUST start with VP \"ready to go\".</td> </tr> <tr class=\"divider_bottom\"> <td>Beta-1,2 agonists (eg, dopamine, dobutamine)</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;&#8593;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;<br /> &#8595;</td> <td>Good inotrope and less effect on SVR, SBP, and TSG at lower doses. Also have VP \"ready to go\".</td> </tr> <tr class=\"divider_bottom\"> <td>Calcium sensitizers (eg, levosimendan)</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;&#8593;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</td> <td>Similar risk to PDE<sub>3</sub>I with regards to SVR; there is limited experience in acute right-sided shock.</td> </tr> <tr> <td>Combination of inotropes + vasopressin</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;&#8593;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;&#8595;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle; white-space: nowrap;\">&#8592;&#8594;/&#8593;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8592;&#8594;</td> <td class=\"centered\" style=\"font-size: 2em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</td> <td>Combination of lower dose PDE<sub>3</sub>I and Beta-1,2 agonists have additive effects, but less profound decrease in SVR. Adding VP mitigates SVR with minimal effect on PVR.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RV: right ventricle; PVR: pulmonary vascular resistance; sPA: selective pulmonary artery vasodilator (eg, inhaled nitric oxide [NO], inhaled milrinone, inhaled prostanoid, sublingual sildenafil, or combinations of sPA vasodilators); SVR: systemic vascular resistance; TSG: transseptal pressure gradient; CO: cardiac output; VP: vasopressin; LV: left ventricle; RCA: right coronary artery; PDE<SUB>3</SUB>I: phosphodiesterase inhibitor; SBP: systolic blood pressure.</div><div id=\"graphicVersion\">Graphic 109872 Version 1.0</div></div></div>"},"109873":{"type":"graphic_form","displayName":"Request for collection of blood for serum tryptase","title":"Request for collection of blood for serum tryptase","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Request for collection of blood for serum tryptase</div><div class=\"cntnt\"><img style=\"width:614px; height:465px;\" src=\"images/ALLRG/109873_Request_blood_serum_tryptas.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 109873 Version 1.0</div></div></div>"},"109875":{"type":"graphic_picture","displayName":"Transanal endoscopic operation (TEO)","title":"Transanal endoscopic operation","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Transanal endoscopic operation</div><div class=\"cntnt\"><img style=\"width:756px; height:553px;\" src=\"images/SURG/109875_Transanal_endoscopic_op_TEO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transanal endoscopic operation (TEO) proctoscope is similar in design to the transanal endoscopic microsurgery (TEM) scope and consists of the beveled proctoscope itself; a sealing faceplate; and attachments for insufflation, suction, and instrument ports.</div><div class=\"graphic_reference\">&copy; 2016 Photo Courtesy of KARL STORZ Endoscopy-America, Inc.</div><div id=\"graphicVersion\">Graphic 109875 Version 1.0</div></div></div>"},"109876":{"type":"graphic_figure","displayName":"Transanal minimally invasive surgery (TAMIS)","title":"Transanal minimally invasive surgery","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Transanal minimally invasive surgery</div><div class=\"cntnt\"><img style=\"width:565px; height:756px;\" src=\"images/SURG/109876_Transanl_min_invasive_srgry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transanal minimally invasive surgery (TAMIS) platform consisting of a&nbsp;single incisional laparoscopic surgery (SILS)&nbsp;port and laparoscopic instruments.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright Â© 2016 Applied Medical Resources. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109876 Version 1.0</div></div></div>"},"109877":{"type":"graphic_table","displayName":"Transanal endoscopic surgery (TES) for T1N0 rectal cancer","title":"Transanal endoscopic surgery (TES) for T1N0 rectal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Transanal endoscopic surgery (TES) for T1N0 rectal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Series</td> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\">Platform</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Recurrence<br /> (percent)</td> <td class=\"subtitle1\">Follow-up<br /> (mean months)</td> </tr> <tr> <td>Winde<sup>[1]</sup></td> <td class=\"centered\">1996</td> <td class=\"centered\">TEM</td> <td class=\"centered\">24</td> <td class=\"centered\">4.1</td> <td class=\"centered\">40.9</td> </tr> <tr> <td>Heintz<sup>[2]</sup></td> <td class=\"centered\">1998</td> <td class=\"centered\">TEM</td> <td class=\"centered\">44</td> <td class=\"centered\">4.5</td> <td class=\"centered\">52</td> </tr> <tr> <td>Lee<sup>[3]</sup></td> <td class=\"centered\">2003</td> <td class=\"centered\">TEM</td> <td class=\"centered\">25</td> <td class=\"centered\">4.1</td> <td class=\"centered\">31</td> </tr> <tr> <td>Floyd<sup>[4]</sup></td> <td class=\"centered\">2006</td> <td class=\"centered\">TEM</td> <td class=\"centered\">53</td> <td class=\"centered\">7.5</td> <td class=\"centered\">34.1</td> </tr> <tr> <td>Ganai<sup>[5]</sup></td> <td class=\"centered\">2006</td> <td class=\"centered\">TEM</td> <td class=\"centered\">21</td> <td class=\"centered\">19</td> <td class=\"centered\">43</td> </tr> <tr> <td>Bretagnol<sup>[6]</sup></td> <td class=\"centered\">2007</td> <td class=\"centered\">TEM</td> <td class=\"centered\">31</td> <td class=\"centered\">9.7</td> <td class=\"centered\">34</td> </tr> <tr> <td>Baatrup<sup>[7]</sup></td> <td class=\"centered\">2009</td> <td class=\"centered\">TEM</td> <td class=\"centered\">72</td> <td class=\"centered\">13</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Jeong<sup>[8]</sup></td> <td class=\"centered\">2009</td> <td class=\"centered\">TEM</td> <td class=\"centered\">17</td> <td class=\"centered\">0</td> <td class=\"centered\">37</td> </tr> <tr> <td>Allaix<sup>[9]</sup></td> <td class=\"centered\">2009</td> <td class=\"centered\">TEM</td> <td class=\"centered\">38</td> <td class=\"centered\">0</td> <td class=\"centered\">60</td> </tr> <tr> <td>De Graaf<sup>[10]</sup></td> <td class=\"centered\">2009</td> <td class=\"centered\">TEM</td> <td class=\"centered\">80</td> <td class=\"centered\">24</td> <td class=\"centered\">42</td> </tr> <tr> <td>Palma<sup>[11]</sup></td> <td class=\"centered\">2009</td> <td class=\"centered\">TEM</td> <td class=\"centered\">34</td> <td class=\"centered\">5.9</td> <td class=\"centered\">86.5</td> </tr> <tr> <td>Tsai<sup>[12]</sup></td> <td class=\"centered\">2010</td> <td class=\"centered\">TEM</td> <td class=\"centered\">51</td> <td class=\"centered\">9.8</td> <td class=\"centered\">53.9</td> </tr> <tr> <td>Doornebosch<sup>[13]</sup></td> <td class=\"centered\">2010</td> <td class=\"centered\">TEM</td> <td class=\"centered\">88</td> <td class=\"centered\">20.5</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Steinhagen<sup>[14]</sup></td> <td class=\"centered\">2011</td> <td class=\"centered\">TEM</td> <td class=\"centered\">12</td> <td class=\"centered\">0</td> <td class=\"centered\">33</td> </tr> <tr> <td>Ramirez<sup>[15]</sup></td> <td class=\"centered\">2011</td> <td class=\"centered\">TEM</td> <td class=\"centered\">53</td> <td class=\"centered\">7.5</td> <td class=\"centered\">71</td> </tr> <tr> <td>Lezoche<sup>[16]</sup></td> <td class=\"centered\">2011</td> <td class=\"centered\">TEM</td> <td class=\"centered\">51</td> <td class=\"centered\">0</td> <td class=\"centered\">97</td> </tr> <tr> <td>Stipa<sup>[17]</sup></td> <td class=\"centered\">2012</td> <td class=\"centered\">TEM</td> <td class=\"centered\">86</td> <td class=\"centered\">11.6</td> <td class=\"centered\">85</td> </tr> <tr> <td>Albert<sup>[18]</sup></td> <td class=\"centered\">2013</td> <td class=\"centered\">TAMIS</td> <td class=\"centered\">16</td> <td class=\"centered\">6.3</td> <td class=\"centered\">20.9</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Outcomes of transanal endoscopic surgery (TES) for T1N0 rectal cancer in various studies are presented in this table.</div><div class=\"graphic_footnotes\">TEM: transanal endoscopic microsurgery; TAMIS: transanal minimally invasive surgery.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>â€‹Winde G, Nottberg H, Keller R, et al. Surgical cure for early rectal carcinomas (T1). transanal endoscopic microsurgery vs. anterior resection. Dis Colon Rectum 1996; 39:969.</LI>&#xD;&#xA;<LI>Heintz A, Morschel M, Junginger T. Comparison of results after transanal endoscopic microsurgery and radical resection for T1 carcinoma of the rectum. Surg Endosc 1998; 12:1145.</LI>&#xD;&#xA;<LI>Lee W, Lee D, Choi S, Chun H. Transanal endoscopic microsurgery and radical surgery for T1 and T2 rectal cancer. Surg Endosc 2003; 17:1283.</LI>&#xD;&#xA;<LI>Floyd ND, Saclarides TJ. Transanal endoscopic microsurgical resection of pT1 rectal tumors. Dis Colon Rectum 2006; 49:164.</LI>&#xD;&#xA;<LI>Ganai S, Kanumuri P, Rao RS, Alexander AI. Local recurrence after transanal endoscopic microsurgery for rectal polyps and early cancers. Ann Surg Oncol 2006; 13:547.</LI>&#xD;&#xA;<LI>Bretagnol F, Merrie A, George B, et al. Local excision of rectal tumours by transanal endoscopic microsurgery. Br J Surg 2007; 94:627.</LI>&#xD;&#xA;<LI>Baatrup G, Breum B, Qvist N, et al. Transanal endoscopic microsurgery in 143 consecutive patients with rectal adenocarcinoma: Results from a Danish multicenter study. Colorectal Dis 2009; 11:270.</LI>&#xD;&#xA;<LI>Jeong WK, Park JW, Choi HS, et al. Transanal endoscopic microsurgery for rectal tumors: Experience at Korea's national cancer center. Surg Endosc 2009; 23:2575.</LI>&#xD;&#xA;<LI>Allaix ME, Arezzo A, Caldart M, et al. Transanal endoscopic microsurgery for rectal neoplasms: Experience of 300 consecutive cases. Dis Colon Rectum 2009; 52:1831.</LI>&#xD;&#xA;<LI>De Graaf EJ, Doornebosch PG, Tollenaar RA, et al. Transanal endoscopic microsurgery versus total mesorectal excision of T1 rectal adenocarcinomas with curative intention. Eur J Surg Oncol 2009; 35:1280.</LI>&#xD;&#xA;<LI>Palma P, Horisberger K, Joos A, et al. Local excision of early rectal cancer: Is transanal endoscopic microsurgery an alternative to radical surgery? Rev Esp Enferm Dig 2009; 101:172.</LI>&#xD;&#xA;<LI>Tsai BM, Finne CO, Nordenstam JF, et al. Transanal endoscopic microsurgery resection of rectal tumors: Outcomes and recommendations. Dis Colon Rectum 2010; 53:16.</LI>&#xD;&#xA;<LI>Doornebosch PG, Ferenschild FT, de Wilt JH, et al. Treatment of recurrence after transanal endoscopic microsurgery (TEM) for T1 rectal cancer. Dis Colon Rectum 2010; 53:1234.</LI>&#xD;&#xA;<LI>Steinhagen E, Chang G, Guillem JG. Initial experience with transanal endoscopic microsurgery: The need for understanding the limitations. J Gastrointest Surg 2011; 15:958.</LI>&#xD;&#xA;<LI>Ramirez JM, Aguilella V, Valencia J, et al. Transanal endoscopic microsurgery for rectal cancer. long-term oncologic results. Int J Colorectal Dis 2011; 26:437.</LI>&#xD;&#xA;<LI>Lezoche G, Guerrieri M, Baldarelli M, et al. Transanal endoscopic microsurgery for 135 patients with small nonadvanced low rectal cancer (iT1-iT2, iN0): Short- and long-term results. Surg Endosc 2011; 25:1222.</LI>&#xD;&#xA;<LI>Stipa F, Giaccaglia V, Burza A. Management and outcome of local recurrence following transanal endoscopic microsurgery for rectal cancer. Dis Colon Rectum 2012; 55:262.</LI>&#xD;&#xA;<LI>Albert MR, Atallah SB, deBeche-Adams TC, et al. Transanal minimally invasive surgery (TAMIS) for local excision of benign neoplasms and early-stage rectal cancer: Efficacy and outcomes in the first 50 patients. Dis Colon Rectum 2013; 56:301.</LI></OL>Reproduced with permission from: Thompson EV, Bleier JI. Transanal minimally invasive surgery. Clin Colon Rectal Surg 2017; 30:112. Copyright Â© Georg Thieme Verlag KG.</div><div id=\"graphicVersion\">Graphic 109877 Version 1.0</div></div></div>"},"109878":{"type":"graphic_table","displayName":"Transanal endoscopic surgery (TES) for T2N0 rectal cancer","title":"Transanal endoscopic surgery (TES) for T2N0 rectal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Transanal endoscopic surgery (TES) for T2N0 rectal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Series</td> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\">Platform</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Chemoradiation</td> <td class=\"subtitle1\">Recurrence<br /> (percent)</td> <td class=\"subtitle1\">Follow-up<br /> (months)</td> </tr> <tr> <td>Endreseth<sup>[1]</sup></td> <td class=\"centered\">2005</td> <td class=\"centered\">TEM</td> <td class=\"centered\">5</td> <td class=\"centered\">None</td> <td class=\"centered\">20</td> <td class=\"centered\">24</td> </tr> <tr> <td>Ganai<sup>[2]</sup></td> <td class=\"centered\">2006</td> <td class=\"centered\">TEM</td> <td class=\"centered\">4</td> <td class=\"centered\">Adjuvant</td> <td class=\"centered\">50</td> <td class=\"centered\">44</td> </tr> <tr> <td>Jeong<sup>[3]</sup></td> <td class=\"centered\">2009</td> <td class=\"centered\">TEM</td> <td class=\"centered\">6</td> <td class=\"centered\">Adjuvant</td> <td class=\"centered\">16.7</td> <td class=\"centered\">37</td> </tr> <tr> <td>Tsai<sup>[4]</sup></td> <td class=\"centered\">2010</td> <td class=\"centered\">TEM</td> <td class=\"centered\">17</td> <td class=\"centered\">Selective</td> <td class=\"centered\">23.5</td> <td class=\"centered\">42.8</td> </tr> <tr> <td>Lezoche<sup>[5]</sup></td> <td class=\"centered\">2011</td> <td class=\"centered\">TEM</td> <td class=\"centered\">84</td> <td class=\"centered\">Neoadjuvant</td> <td class=\"centered\">4.7</td> <td class=\"centered\">97</td> </tr> <tr> <td>Amann<sup>[6]</sup></td> <td class=\"centered\">2015</td> <td class=\"centered\">TEM</td> <td class=\"centered\">53</td> <td class=\"centered\">Variable</td> <td class=\"centered\">20.8</td> <td class=\"centered\">33.9</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Outcomes of transanal endoscopic surgery (TES) for T2N0 rectal cancer in various studies are presented in this table.</div><div class=\"graphic_footnotes\">TEM: transanal endoscopic microsurgery.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>â€‹Endreseth BH, Wibe A, Svinsas M, et al. Postoperative morbidity and recurrence after local excision of rectal adenomas and rectal cancer by transanal endoscopic microsurgery. Colorectal Dis 2005; 7:133.</li>&#xD;&#xA;    <li>Ganai S, Kanumuri P, Rao RS, Alexander AI. Local recurrence after transanal endoscopic microsurgery for rectal polyps and early cancers. Ann Surg Oncol 2006; 13:547.</li>&#xD;&#xA;    <li>Jeong WK, Park JW, Choi HS, et al. Transanal endoscopic microsurgery for rectal tumors: Experience at Korea's national cancer center. Surg Endosc 2009; 23:2575.</li>&#xD;&#xA;    <li>Tsai BM, Finne CO, Nordenstam JF, et al. Transanal endoscopic microsurgery resection of rectal tumors: Outcomes and recommendations. Dis Colon Rectum 2010; 53:16.</li>&#xD;&#xA;    <li>Lezoche G, Guerrieri M, Baldarelli M, et al. Transanal endoscopic microsurgery for 135 patients with small nonadvanced low rectal cancer (iT1-iT2, iN0): Short- and long-term results. Surg Endosc 2011; 25:1222.</li>&#xD;&#xA;    <li>Amann M, Burghardt J, Stratz C, et al. Transanal endoscopic microsurgery in treatment of small rectal T1 high-risk, T2 and T3 carcinomas combined with radiochemotherapy. Eur Surg 2015; 47:226.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Thompson EV, Bleier JI. Transanal minimally invasive surgery. Clin Colon Rectal Surg 2017; 30:112. Copyright &copy; Georg Thieme Verlag KG.</div><div id=\"graphicVersion\">Graphic 109878 Version 1.0</div></div></div>"},"109880":{"type":"graphic_picture","displayName":"Reactive perforating collagenosis","title":"Reactive perforating collagenosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Reactive perforating collagenosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109880_Reactive_perf_collagenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Umbilicated, keratotic papules.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109880 Version 1.0</div></div></div>"},"109882":{"type":"graphic_picture","displayName":"Reactive perforating collagenosis Koebner reaction","title":"Reactive perforating collagenosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Reactive perforating collagenosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109882_Perf_collagenosis_Koebner.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented papules of reactive perforating collagenosis demonstrating the Koebner phenomenon (occurrence in sites of trauma).</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109882 Version 1.0</div></div></div>"},"109884":{"type":"graphic_picture","displayName":"Dermatofibroma","title":"Dermatofibroma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Dermatofibroma</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/109884_Dermatofibroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratotic papule.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109884 Version 1.0</div></div></div>"},"109885":{"type":"graphic_picture","displayName":"Elastosis perforans serpiginosa","title":"Elastosis perforans serpiginosa","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Elastosis perforans serpiginosa</div><div class=\"cntnt\"><img style=\"width:496px; height:756px;\" src=\"images/DERM/109885_Elastosis_perforans_srpgns2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular, scaly plaques with satellite papules on the ear and preauricular area of a child.</div><div class=\"graphic_reference\">Reproduced from: Brooke Army Medical Center and Dirk Elston, MD.</div><div id=\"graphicVersion\">Graphic 109885 Version 1.0</div></div></div>"},"109886":{"type":"graphic_picture","displayName":"Elastosis perforans serpiginosa histopathology","title":"Elastosis perforans serpiginosa","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Elastosis perforans serpiginosa</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/109886_Elastosis_perforans_serpgns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verhoeff-Van Gieson staining showing dense clumps of altered elastic fibers in the papillary dermis.</div><div class=\"graphic_reference\">Reproduced from: Dirk Elston, MD.</div><div id=\"graphicVersion\">Graphic 109886 Version 1.0</div></div></div>"},"109887":{"type":"graphic_picture","displayName":"Granuloma annulare plaques","title":"Granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Granuloma annulare</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109887_Granuloma_annulare_plaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular, erythematous plaques with central clearing.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109887 Version 1.0</div></div></div>"},"109888":{"type":"graphic_picture","displayName":"Porokeratosis of Mibelli plaques","title":"Porokeratosis of Mibelli","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Porokeratosis of Mibelli</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109888_Porokeratosis_Mibelli_plqs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-defined plaque with fine scale at outer ridge.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109888 Version 1.0</div></div></div>"},"109889":{"type":"graphic_picture","displayName":"Discoid lupus erythematosus atrophic plaque","title":"Discoid lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Discoid lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/109889_Dscd_lps_erythmtss_atrphc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, atrophic, scarred plaque with hyperpigmented border.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109889 Version 1.0</div></div></div>"},"109890":{"type":"graphic_picture","displayName":"Perforating folliculitis","title":"Perforating folliculitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Perforating folliculitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109890_Perforating_folliculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratotic, pinpoint monomorphic papules on the leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109890 Version 1.0</div></div></div>"},"109891":{"type":"graphic_table","displayName":"LABA implications for pregnancy and lactation","title":"Long-acting bronchodilators: Implications for pregnancy and lactation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Long-acting bronchodilators: Implications for pregnancy and lactation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Human data</td> <td class=\"subtitle1\">Adverse events in animal studies</td> <td class=\"subtitle1\">Crosses placenta</td> <td class=\"subtitle1\">Excreted in human milk</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Long-acting beta agonists*</td> </tr> <tr> <td class=\"indent1\">Salmeterol</td> <td>Limited data suggest safety</td> <td>Observed in some studies</td> <td>&nbsp;</td> <td>Unknown</td> </tr> <tr> <td class=\"indent1\">Formoterol</td> <td>Limited data suggest safety</td> <td>Observed in some studies</td> <td>&nbsp;</td> <td>Unknown</td> </tr> <tr> <td class=\"indent1\">Indacaterol<sup>&#182;</sup></td> <td>&nbsp;</td> <td>No</td> <td>&nbsp;</td> <td>Unknown</td> </tr> <tr> <td class=\"indent1\">Olodaterol<sup>&#182;</sup></td> <td>&nbsp;</td> <td>Yes</td> <td>&nbsp;</td> <td>Unknown, but likely</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vilanterol<sup>&#916;</sup></td> <td>&nbsp;</td> <td>No</td> <td>&nbsp;</td> <td>Unknown</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Long-acting anticholinergic agents </td> </tr> <tr> <td class=\"indent1\">Aclidinium<sup>&#182;</sup></td> <td>&nbsp;</td> <td>Yes</td> <td>Not known</td> <td>Probable</td> </tr> <tr> <td class=\"indent1\">Glycopyrrolate<sup>&#182;</sup></td> <td>&nbsp;</td> <td>Yes</td> <td>Small amounts</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Tiotropium</td> <td>&nbsp;</td> <td>Yes</td> <td>Not known</td> <td>Not known</td> </tr> <tr> <td class=\"indent1\">Umeclidinium<sup>&#182;</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Negligible systemic absorption following oral inhalation</td> <td>Not known</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data obtained from package inserts. Refer to the UpToDate topic on the management of asthma in pregnancy for additional information.</div><div class=\"graphic_footnotes\">* Long-acting beta agonists (LABAs) should be used for asthma in combination with inhaled glucocorticoids, and not as monotherapy. LABAs have the potential to decrease uterine contractility, if administered during labor. LABAs are not considered a contraindication to breast feeding, when necessary to control asthma.<br />Â¶ Not approved by the US Food and Drug Administration for use in asthma.<br />Î” Approved for use in asthma in the combination preparation fluticasone-vilanterol. </div><div id=\"graphicVersion\">Graphic 109891 Version 1.0</div></div></div>"},"109892":{"type":"graphic_picture","displayName":"Perforating folliculitis 2","title":"Perforating folliculitis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Perforating folliculitis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/109892_Perforating_folliculitis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Umbilicated papules with central crusting.</div><div id=\"graphicVersion\">Graphic 109892 Version 1.0</div></div></div>"},"109893":{"type":"graphic_picture","displayName":"Acquired perforating dermatosis","title":"Acquired perforating dermatosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Acquired perforating dermatosis</div><div class=\"cntnt\"><img style=\"width:756px; height:473px;\" src=\"images/DERM/109893_Acq_perforating_dermatosis2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red-brown hyperpigmented papules with central umbilication in a patient with end-stage renal disease.</div><div class=\"graphic_reference\">Reproduced from: Dirk Elston, MD.</div><div id=\"graphicVersion\">Graphic 109893 Version 1.0</div></div></div>"},"109894":{"type":"graphic_picture","displayName":"Acquired perforating dermatosis 2","title":"Acquired perforating dermatosis","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Acquired perforating dermatosis</div><div class=\"cntnt\"><img style=\"width:628px; height:471px;\" src=\"images/DERM/109894_Acq_perf_dermatosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcerations with keratotic, protruding central keratinaceous cores on the arm of an end-stage renal dialysis patient.</div><div class=\"graphic_reference\">Courtesy of Laurence Bradley, MD.</div><div id=\"graphicVersion\">Graphic 109894 Version 1.0</div></div></div>"},"109895":{"type":"graphic_picture","displayName":"Acquired perforating dermatosis Koebner phenomenon","title":"Acquired perforating dermatosis","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Acquired perforating dermatosis</div><div class=\"cntnt\"><img style=\"width:640px; height:480px;\" src=\"images/DERM/109895_Acq_perf_dermatosis_Koebner.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Koebner phenomenon with linear arrangement of small, umbilicated papules in acquired perforating dermatosis.</div><div class=\"graphic_reference\">Courtesy of Mary Maiberger, MD. </div><div id=\"graphicVersion\">Graphic 109895 Version 1.0</div></div></div>"},"109896":{"type":"graphic_picture","displayName":"Acquired perforating dermatosis histopathology","title":"Acquired perforating dermatosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Acquired perforating dermatosis</div><div class=\"cntnt\"><img style=\"width:756px; height:426px;\" src=\"images/DERM/109896_Acq_perforating_dermatosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epidermal invagination with basophilic debris.</div><div class=\"graphic_reference\">Reproduced from: Dirk Elston, MD.</div><div id=\"graphicVersion\">Graphic 109896 Version 1.0</div></div></div>"},"109897":{"type":"graphic_picture","displayName":"Acquired perforating dermatosis histopathology 2","title":"Acquired perforating dermatosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Acquired perforating dermatosis</div><div class=\"cntnt\"><img style=\"width:756px; height:569px;\" src=\"images/DERM/109897_Acq_perf_dermatosis_histo2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology revealing an epidermal invagination filled with a keratin plug containing basophilic debris. Note the surrounding epidermal hyperplasia and dermal lymphocytic infiltrate.</div><div class=\"graphic_reference\">Courtesy of Wen Chen, MD.</div><div id=\"graphicVersion\">Graphic 109897 Version 1.0</div></div></div>"},"109898":{"type":"graphic_table","displayName":"Severity of hepatopulmonary syndrome","title":"Severity of hepatopulmonary syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Severity of hepatopulmonary syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">A-a gradient</td> <td class=\"subtitle1\">PaO<sub>2</sub> (on room air)</td> <td class=\"subtitle1\">Graded severity</td> </tr> <tr> <td>&#8805;15 mmHg (&#8805;2 kPa)</td> <td>&#8805;80 mmHg (&#8805;10.7 kPa)</td> <td>Mild</td> </tr> <tr> <td>&#8805;15 mmHg (&#8805;2 kPa)</td> <td>&#8805;60 mmHg and &#60;80 mmHg (&#8805;8 kPa and &#60;10.7 kPa)</td> <td>Moderate</td> </tr> <tr> <td>&#8805;15 mmHg (&#8805;2 kPa)</td> <td>&#8805;50 mmHg and &#60;60 mmHg (&#8805;6.7 kPa and &#60;8 kPa)</td> <td>Severe</td> </tr> <tr> <td>&#8805;15 mmHg (&#8805;2 kPa)</td> <td>&#60;50 mmHg (&#60;6.7 kPa)*</td> <td>Very severe</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">A-a gradient: Alveolar-arterial oxygen gradient; PaO<SUB>2</SUB>: arterial oxygen tension.<br />* Patients with a PaO<SUB>2</SUB> &lt;300 mmHg (40 kPa) while breathing 100% oxygen also have very severe hepatopulmonary syndrome.</div><div class=\"graphic_reference\">Reproduced with permission of the European Respiratory Society &copy;: European Respiratory Journal Nov 2004; 24(5): 861-880. DOI: 10.1183/09031936.04.00010904.</div><div id=\"graphicVersion\">Graphic 109898 Version 1.0</div></div></div>"},"109899":{"type":"graphic_picture","displayName":"D-penicillamine-induced elastosis perforans serpiginosa","title":"D-penicillamine-induced elastosis perforans serpiginosa","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">D-penicillamine-induced elastosis perforans serpiginosa</div><div class=\"cntnt\"><img style=\"width:562px; height:750px;\" src=\"images/DERM/109899_D_pnclmn_elsts_prfrn_srpgn1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows thickened elastic fibers in the process of transepidermal elimination. The papillary dermal elastic fibers otherwise appear normal on routine stained sections.</div><div class=\"graphic_reference\">Reproduced with permission from: Hughes MP, Pellowski DM, Hiatt KM. Cutaneous toxicities of drugs. In: Lever's Histopathology of the Skin, 11th ed, Elder DE, Elenitsas R, Rosenbach M, et al (Eds), Wolters Kluwer, Philadelphia 2015. Copyright &copy; 2015 Wolters Kluwer. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 109899 Version 1.0</div></div></div>"},"109900":{"type":"graphic_picture","displayName":"D-penicillamine-induced elastosis perforans serpiginosa 2","title":"D-penicillamine-induced elastosis perforans serpiginosa","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">D-penicillamine-induced elastosis perforans serpiginosa</div><div class=\"cntnt\"><img style=\"width:754px; height:565px;\" src=\"images/DERM/109900_D_pnclmn_elsts_prfrn_srpgn2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The elastic fibers in the mid-dermis show the lateral budding characteristic of penicillamine effect. Verhoeff-von Gieson elastic stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Hughes MP, Pellowski DM, Hiatt KM. Cutaneous toxicities of drugs. In: Lever's Histopathology of the Skin, 11th ed, Elder DE, Elenitsas R, Rosenbach M, et al (Eds), Wolters Kluwer, Philadelphia 2015. Copyright &copy; 2015 Wolters Kluwer. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 109900 Version 1.0</div></div></div>"},"109904":{"type":"graphic_table","displayName":"Duration of antibiotic therapy for B. pseudomallei infections","title":"Duration of antibiotic therapy for <EM>Burkholderia pseudomallei</EM> infections (melioidosis)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Duration of antibiotic therapy for <EM>Burkholderia pseudomallei</EM> infections (melioidosis)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical focus</td> <td class=\"subtitle1\">Minimum intensive intravenous phase*</td> <td class=\"subtitle1\">Eradication oral phase</td> </tr> <tr> <td>Skin abscess</td> <td class=\"centered\">2 weeks</td> <td class=\"centered\">3 months</td> </tr> <tr> <td>Bacteremia with no focus</td> <td class=\"centered\">2 weeks</td> <td class=\"centered\">3 months</td> </tr> <tr> <td>Pneumonia</td> <td class=\"centered\">2 to 4 weeks</td> <td class=\"centered\">3 months</td> </tr> <tr> <td>Prostatic abscess, septic arthritis, organ or deep-seated tissue collection<sup>&#182;</sup></td> <td class=\"centered\">4 weeks</td> <td class=\"centered\">3 months</td> </tr> <tr> <td>Osteomyelitis</td> <td class=\"centered\">6 weeks</td> <td class=\"centered\">6 months</td> </tr> <tr> <td>Central nervous system infection</td> <td class=\"centered\">8 weeks</td> <td class=\"centered\">6 months</td> </tr> <tr> <td>Mycotic aneurysms</td> <td class=\"centered\">8 weeks</td> <td class=\"centered\">Maybe lifelong</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Use clinical judgment to guide prolongation of intensive phase if improvement is slow or if blood cultures remain positive at seven days.<br />Â¶ Time the duration of the intensive phase from the date of the most recent collection drainage (eg, prostatic abscess or joint washout) that grew <EM>B. pseudomallei </EM>or&nbsp;the most recent collection drainage that was not&nbsp;sent for culture. The clock does not have to be reset if subsequent drainage specimens are culture negative.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Dance D. Treatment and prophylaxis of melioidosis. Int J Antimicrob Agents 2014; 43:310.</li>&#xD;&#xA;    <li>Pitman MC, Luck T, Marshall CS, et al. Intravenous therapy duration and outcomes in melioidosis: a new treatment paradigm. PloS Negl Trop Dis 2015; 9:e0003586.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109904 Version 1.0</div></div></div>"},"109906":{"type":"graphic_table","displayName":"Response to regimens for subtype 1a versus 1b HCV infection","title":"Response to sofosbuvir-containing regimens for subtype 1a versus 1b HCV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Response to sofosbuvir-containing regimens for subtype 1a versus 1b HCV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\"> <p>Simeprevir plus sofosbuvir</p> <p>(12 weeks)<sup>[1,2]</sup></p> </td> <td class=\"subtitle1\"> <p>Ledipasvir-sofosbuvir</p> <p>(TN: 12 weeks; TE: 24 weeks)<sup>[3,4]</sup></p> </td> <td class=\"subtitle1\"> <p>Sofosbuvir-velpatasvir</p> <p>(12 weeks)<sup>[5]</sup></p> </td> </tr> <tr> <td rowspan=\"2\">1a</td> <td>No cirrhosis: 97%</td> <td>TN: 99.3%</td> <td>98% (95 to &#62;99%)</td> </tr> <tr> <td>Cirrhosis: 83%</td> <td>TE: 98.8%</td> <td>98% (95 to &#62;99%)</td> </tr> <tr> <td rowspan=\"2\">1b</td> <td>No cirrhosis: 97%</td> <td>TN: 100%</td> <td>99% (95 to 100%)</td> </tr> <tr> <td>Cirrhosis: 84%</td> <td>TE: 100%</td> <td>99% (95 to 100%)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TE: treatment-experienced; TN: treatment-naÃ¯ve.&nbsp; </div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>â€‹Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 2016; 64:370.</li>&#xD;&#xA;    <li>Lawitz E, Matusow G, Dejesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 2016; 64:360.</li>&#xD;&#xA;    <li>Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889.</li>&#xD;&#xA;    <li>Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483.</li>&#xD;&#xA;    <li>Feld JJ, Jacobson IM, H&eacute;zode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015; 373:2599.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109906 Version 2.0</div></div></div>"},"109907":{"type":"graphic_table","displayName":"Common ototoxicity grading scales","title":"Commonly used ototoxicity grading scales","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used ototoxicity grading scales</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grading scale</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Target population</td> <td class=\"subtitle1\">Features</td> <td class=\"subtitle1\">Limitations</td> </tr> <tr class=\"divider_bottom\"> <td>Brock<br /> (Brock <span style=\"white-space: nowrap;\">1991)<sup>[1]</sup></span></td> <td>Designed to grade hearing loss progression from high to low frequencies in the configuration commonly associated with ototoxic cancer therapy; hearing loss is graded on 5-point scale</td> <td>Pediatric</td> <td>Widely used; baseline assessment not required</td> <td>Does not capture hearing loss &#60;40 dB, misses significant functional deficits</td> </tr> <tr class=\"divider_bottom\"> <td>ASHA<br /> <span style=\"white-space: nowrap;\">(1994)<sup>[2]</sup></span></td> <td>Hearing is compared with baseline in absolute terms (ie, presence/absence of hearing loss in comparison with baseline)</td> <td>Pediatric and adult</td> <td>Designed for early detection of hearing loss</td> <td>Does not classify severity of hearing loss; baseline assessment is required</td> </tr> <tr class=\"divider_bottom\"> <td>Muenster<br /> (Schmidt <span style=\"white-space: nowrap;\">2007)<sup>[3]</sup></span></td> <td>8-point scale accounts for minimal hearing loss (&#62;10 to 20 dB), subgroups within major classifications, and tinnitus</td> <td>Pediatric</td> <td>Designed for early detection of hearing loss</td> <td>Complexity of use</td> </tr> <tr class=\"divider_bottom\"> <td>Chang<br /> (Chang &#38; Chinosornvatana <span style=\"white-space: nowrap;\">2010)<sup>[4]</sup></span></td> <td>Modification of Brock scale with similar configuration and expansion to 7-point scale; grades hearing loss &#62;20 dB and measures interval frequencies (ie, 3000 and 6000 Hz)</td> <td>Pediatric</td> <td>Addresses functional deficits; baseline assessment not required</td> <td>Complexity of use</td> </tr> <tr class=\"divider_bottom\"> <td>NCI CTCAE, version 5<br /> <span style=\"white-space: nowrap;\">(2017)<sup>[5]</sup></span></td> <td>4-point scale includes both objective and subjective criteria; grades are assigned based on threshold shift from baseline and actual hearing loss</td> <td>Pediatric and adult</td> <td>Familiar to oncologists; widely used in NCI-sponsored clinical trials</td> <td>Baseline assessment required</td> </tr> <tr class=\"divider_bottom\"> <td>SIOP Boston<br /> (Brock <span style=\"white-space: nowrap;\">2012)<sup>[6]</sup></span></td> <td>5-point scale designed to grade hearing loss progression from high to low frequencies; grades hearing loss &#62;20 dB; uses absolute hearing levels</td> <td>Pediatric</td> <td>Proposed through consensus of international working group; potential application across clinical trials worldwide; baseline assessment not required</td> <td>Limited reliability and validity testing to date</td> </tr> <tr> <td>TUNE grading system<br /> (Theunissen <span style=\"white-space: nowrap;\">2014)<sup>[7]</sup></span></td> <td>7-point scale designed to provide insight into the effect of hearing loss on specific daily life situations (such as speech intelligibility and ability to appreciate ultrahigh sounds)</td> <td>Adults</td> <td>Includes subjective symptoms and threshold shifts at higher frequencies (up to 12.5 kHz); uses air conduction thresholds only; designed to represent the auditory system's real-world functionality</td> <td>Time-consuming to use; feasibility testing completed; needs external validation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">dB: decibels; ASHA: American Speech-Language-Hearing Association; Hz: Hertz; NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; SIOP: International Society of Pediatric Oncology Boston ototoxicity scale; kHz: kilo Hertz.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 1991; 19:295.</li>&#xD;&#xA;    <li>American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 1994; 36(suppl 12):11.</li>&#xD;&#xA;    <li>Schmidt CM, Bartholomaus E, Deuster D, et al. [The \"Muenster classification\" of high frequency hearing loss following cisplatin chemotherapy]. HNO 2007; 55:299.</li>&#xD;&#xA;    <li>Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 2010; 28:1788.</li>&#xD;&#xA;    <li>Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</li>&#xD;&#xA;    <li>Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 2012; 30:2408.</li>&#xD;&#xA;    <li>Theunissen EA, Dreschler WA, Latenstein MN, et al. A new grading system for ototoxicity in adults. Ann Otol Rhinol Laryngol 2014; 123:711.</li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted from: Landier W. Ototoxicity and cancer therapy. Cancer 2016; 122:1647. DOI: <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29779/abstract\" target=\"_blank\">10.1002/cncr.29779</a>. Copyright &copy; 2016 Wiley Periodicals, Inc. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" target=\"_true\">permissions@wiley.com</a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 109907 Version 3.0</div></div></div>"},"109908":{"type":"graphic_table","displayName":"Erythema nodosum associated conditions","title":"Conditions associated with erythema nodosum","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with erythema nodosum</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"indent1\">Bacterial</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Streptococcal infection (the most common infectious cause) </li> <li>Tuberculosis </li> <li>Leprosy </li> <li><em>Yersinia</em>, <em>Salmonella</em>, <em>Campylobacter</em> gastroenteritis </li> <li><em>Mycoplasma</em> pneumonia </li> <li>Tularemia </li> <li>Leptospirosis </li> <li>Brucellosis </li> <li><em>Chlamydia trachomatis</em> </li> <li>Psittacosis </li> <li>Lymphogranuloma venereum </li> <li>Cat-scratch disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fungal</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Coccidioidomycosis </li> <li>Histoplasmosis </li> <li>Blastomycosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Viral</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Infectious mononucleosis</li> <li>Hepatitis B</li> <li>Paravaccinia</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td class=\"indent1\">Oral contraceptives</td> </tr> <tr> <td class=\"indent1\">Penicillin</td> </tr> <tr> <td class=\"indent1\">Sulfonamides</td> </tr> <tr> <td class=\"indent1\">Bromides and iodides</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">TNF-alpha inhibitors (rare)</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"indent1\">Crohn's disease (more often than ulcerative colitis)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ulcerative colitis</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancy</td> </tr> <tr> <td class=\"indent1\">Lymphoma (Hodgkin, most often)</td> </tr> <tr> <td class=\"indent1\">Leukemia (acute myelogenous, most often)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Internal carcinomas</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Whipple disease</td> </tr> <tr> <td class=\"indent1\">Beh&#231;et disease</td> </tr> <tr> <td class=\"indent1\">Sweet syndrome</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNF: tumor necrosis factor.</div><div id=\"graphicVersion\">Graphic 109908 Version 2.0</div></div></div>"},"109909":{"type":"graphic_table","displayName":"Continuum of depth of sedation","title":"Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Minimal sedation anxiolysis</td> <td class=\"subtitle1\">Moderate sedation/analgesia<br /> (\"conscious sedation\")</td> <td class=\"subtitle1\">Deep sedation/analgesia</td> <td class=\"subtitle1\">General anesthesia</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Responsiveness</strong></td> <td>Normal response to verbal stimulation</td> <td>Purposeful<sup>&#182;</sup> response to verbal or tactile stimulation</td> <td>Purposeful<sup>&#182;</sup> response following repeated or painful stimulation</td> <td>Unarousable even with painful stimulus</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Airway</strong></td> <td>Unaffected</td> <td>No intervention required</td> <td>Intervention may be required</td> <td>Intervention often required</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Spontaneous ventilation</strong></td> <td>Unaffected</td> <td>Adequate</td> <td>May be inadequate</td> <td>Frequently inadequate</td> </tr> <tr> <td><strong>Cardiovascular function</strong></td> <td>Unaffected</td> <td>Usually maintained</td> <td>Usually maintained</td> <td>May be impaired</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li><strong>Minimal sedation (anxiolysis)</strong> is a drug-induced state during which patients respond normally to verbal commands. Although cognitive function and physical coordination may be impaired, airway reflexes, and ventilatory and cardiovascular functions are unaffected.</li>&#xD;&#xA;    <li><strong>Moderate sedation/analgesia (\"conscious sedation\")</strong> is a drug-induced depression of consciousness during which patients respond purposefully<sup>&para;</sup> to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway, and spontaneous ventilation is adequate. Cardiovascular function is usually maintained.</li>&#xD;&#xA;    <li><strong>Deep sedation/analgesia</strong> is a drug-induced depression of consciousness during which patients cannot be easily aroused but respond purposefully<sup>&para;</sup> following repeated or painful stimulation. The ability to independently maintain ventilatory function may be impaired. Patients may require assistance in maintaining a patent airway, and spontaneous ventilation may be inadequate. Cardiovascular function is usually maintained.</li>&#xD;&#xA;    <li><strong>General anesthesia</strong> is a drug-induced loss of consciousness during which patients are not arousable, even by painful stimulation. The ability to independently maintain ventilatory function is often impaired. Patients often require assistance in maintaining a patent airway, and positive pressure ventilation may be required because of depressed spontaneous ventilation or drug-induced depression of neuromuscular function. Cardiovascular function may be impaired.</li>&#xD;&#xA;    <li>Because sedation is a continuum, it is not always possible to predict how an individual patient will respond. Hence, practitioners intending to produce a given level of sedation should be able to rescue<sup>&Delta;</sup> patients whose level of sedation becomes deeper than initially intended. Individuals administering moderate sedation/analgesia (\"conscious sedation\") should be able to rescue<sup>&Delta;</sup> patients who enter a state of deep sedation/analgesia, while those administering deep sedation/analgesia should be able to rescue<sup>&Delta;</sup> patients who enter a state of general anesthesia.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">* Monitored anesthesia care (\"MAC\") does not describe the continuum of depth of sedation, rather it describes \"a specific anesthesia service in which an anesthesiologist has been requested to participate in the care of a patient undergoing a diagnostic or therapeutic procedure.\"<br />&para; Reflex withdrawal from a painful stimulus is NOT considered a purposeful response.<br />&Delta; Rescue of a patient from a deeper level of sedation than intended is an intervention by a practitioner proficient in airway management and advanced life support. The qualified practitioner corrects adverse physiologic consequences of the deeper-than intended level of sedation (such as hypoventilation, hypoxia, and hypotension) and returns the patient to the originally intended level of sedation. It is not appropriate to continue the procedure at an unintended level of sedation.</div><div class=\"graphic_reference\">Approved by the ASA House of Delegates on October 13, 1999, and last amended on October 15, 2014. Published in: American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 2002; 96:1004. Copyright &copy; 2002 &amp; 2014 American Society of Anesthesiologists, Inc. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 109909 Version 2.0</div></div></div>"},"109912":{"type":"graphic_table","displayName":"HIES scoring system","title":"Scoring system with clinical and laboratory tests for individuals in kindreds with HIES","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Scoring system with clinical and laboratory tests for individuals in kindreds with HIES</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"10\" width=\"7.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Clinical findings</td> <td class=\"subtitle1\" colspan=\"10\">Points*</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> <td class=\"subtitle2\">3</td> <td class=\"subtitle2\">4</td> <td class=\"subtitle2\">5</td> <td class=\"subtitle2\">6</td> <td class=\"subtitle2\">7</td> <td class=\"subtitle2\">8</td> <td class=\"subtitle2\">10</td> </tr> <tr> <td>Highest serum-IgE level (international units/mL)<sup>&#182;</sup></td> <td class=\"centered\">&#60;200</td> <td class=\"centered\">200 to 500</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">501 to 1000</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1001 to 2000</td> <td class=\"centered\">&#62;2000</td> </tr> <tr> <td>Skin abscesses</td> <td class=\"centered\">None</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1 to 2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">3 to 4</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#62;4</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Pneumonia (episodes over lifetime)</td> <td class=\"centered\">None</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">3</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#62;3</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Parenchymal lung anomalies</td> <td class=\"centered\">Absent</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Bronchiectasis</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Pneumatocele</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Retained primary teeth</td> <td class=\"centered\">None</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">3</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#62;3</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Scoliosis, maximum curvature</td> <td class=\"centered\">&#60;10&#176;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">10 to 14&#176;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">15 to 20&#176;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#62;20&#176;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Fractures with minor trauma</td> <td class=\"centered\">None</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1 to 2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#62;2</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Highest eosinophil count (cells/microL)<sup>&#916;</sup></td> <td class=\"centered\">&#60;700</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">700 to 800</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#62;800</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Characteristic face</td> <td class=\"centered\">Absent</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Mildly present</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Present</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Midline anomaly<sup>&#9674;</sup></td> <td class=\"centered\">Absent</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Present</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Newborn rash</td> <td class=\"centered\">Absent</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Present</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Eczema (worst stage)</td> <td class=\"centered\">Absent</td> <td class=\"centered\">Mild</td> <td class=\"centered\">Moderate</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Severe</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Upper respiratory infections per year</td> <td class=\"centered\">1 to 2</td> <td class=\"centered\">3</td> <td class=\"centered\">4 to 6</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#62;6</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Candidiasis</td> <td class=\"centered\">None</td> <td class=\"centered\">Oral</td> <td class=\"centered\">Fingernails</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Systemic</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Other serious infections</td> <td class=\"centered\">None</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Severe</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Fatal infection</td> <td class=\"centered\">Absent</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Present</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Hyperextensibility</td> <td class=\"centered\">Absent</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Present</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Lymphoma</td> <td class=\"centered\">Absent</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Present</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Increased nasal width<sup>&#167;</sup></td> <td class=\"centered\">&#60;1 SD</td> <td class=\"centered\">1 to 2 SD</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#62;2 SD</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>High palate</td> <td class=\"centered\">Absent</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Present</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Young-age correction</td> <td class=\"centered\">&#62;5 years</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">2 to 5 years</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1 to 2 years</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8804;1 year</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIES: hyperimmunoglobulin E syndrome; IgE: immunoglobulin E; SD: standard deviation.<br />* The entry in the furthest right column is assigned the maximum points allowed for each finding.<br />&para; Normal &lt;130 international units/mL.<br />&Delta; 700/microL = 1 SD, 800/microL = 2 SD above the mean value for normal individuals.<br /><span class=\"lozenge\">&loz;</span> For example, cleft palate, cleft tongue, hemivertebrae, other vertebral anomaly, etc.<sup>[1]</sup><br />&sect; Compared with age- and sex-matched controls.<sup>[2]</sup></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Grimbacher B, Holland SM, Gallin JI, et al. Hyper IgE syndrome with recurrent infections: An autosomal dominant multisystem disorder. New Engl J Med 1999; 340:692.</li>&#xD;&#xA;    <li>Farkas LG. Anthropometry of the Head and Face in Medicine, 2nd ed, Raven Press, New York, 1994.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Grimbacher B, Sch&auml;ffer AA, Holland SM, et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet 1999; 65:735. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109912 Version 1.0</div></div></div>"},"109916":{"type":"graphic_figure","displayName":"Malperfusion in aortic dissection from dynamic obstruction","title":"Malperfusion in aortic dissection from dynamic obstructionâ€‹","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Malperfusion in aortic dissection from dynamic obstructionâ€‹</div><div class=\"cntnt\"><img style=\"width:532px; height:242px;\" src=\"images/SURG/109916_Malperfusion_in_aortic_dissection_from_dynamic_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With dynamic obstruction, the intimal flap moves back and forth, intermittently reducing branch vessel perfusion.</div><div class=\"graphic_reference\">Modified from: Aortic Dissection: Type A vs. Type B. James H. Black, III, MD, Johns Hopkins University School of Medicine.</div><div id=\"graphicVersion\">Graphic 109916 Version 1.0</div></div></div>"},"109917":{"type":"graphic_figure","displayName":"Malperfusion in aortic dissection from static obstruction","title":"Malperfusion in aortic dissection from static obstruction","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Malperfusion in aortic dissection from static obstruction</div><div class=\"cntnt\"><img style=\"width:533px; height:352px;\" src=\"images/SURG/109917_Malperfusion_in_aortic_dissection_from_static_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Static obstruction of aortic branch vessels can occur as aortic dissection extends distally and compresses the origin of the vessel as shown. Depending upon the location of the intimal flap, dissection can extend directly into the branch vessel as well (not shown).</div><div class=\"graphic_reference\">Modified from: Aortic Dissection: Type A vs. Type B. James H. Black, III, MD, Johns Hopkins University School of Medicine.</div><div id=\"graphicVersion\">Graphic 109917 Version 1.0</div></div></div>"},"109918":{"type":"graphic_movie","displayName":"Dynamic aortic obstruction from type B aortic dissection","title":"Dynamic aortic obstruction from type B aortic dissection","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dynamic aortic obstruction from type B aortic dissection</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/109918_TypeBaortcdissctnMRvid.mp4\" style=\"width:398px;height:390px\"></div><img style=\"width:396px; height:181px;\" src=\"images/SURG/109918_TypeBaortcdissctnMRimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This dynamic magnetic resonance angiogram&nbsp;demonstrates the mobility of the&nbsp;aortic dissection flap throughout the cardiac cycle.&nbsp;During systole, the dissection flap moves into the aortic lumen, which can compromise the renal and visceral artery takeoffs as the dissection flap distally moves and covers their origins. </div><div id=\"graphicVersion\">Graphic 109918 Version 1.0</div></div></div>"},"109920":{"type":"graphic_diagnosticimage","displayName":"Normal three-vessel umbilical cord","title":"Normal three-vessel umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 752px\" class=\"figure\"><div class=\"ttl\">Normal three-vessel umbilical cord</div><div class=\"cntnt\"><img style=\"width:732px; height:756px;\" src=\"images/OBGYN/109920_Norm_3vessel_umblcl_cord.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cross-sectional ultrasound image of a normal three-vessel umbilical cord. The arrows point to the two umbilical arteries.</div><div class=\"graphic_footnotes\">v: single umbilical vein.</div><div id=\"graphicVersion\">Graphic 109920 Version 1.0</div></div></div>"},"109921":{"type":"graphic_table","displayName":"Resistance associated substitutions for HCV NS5A inhibitors","title":"Resistance associatedÂ substitutions for hepatitisÂ C virus (HCV)Â NS5A inhibitors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resistance associated&nbsp;substitutions for hepatitis&nbsp;C virus (HCV)&nbsp;NS5A inhibitors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">NS5A inhibitor</td> <td class=\"subtitle1\">Genotype 1a</td> <td class=\"subtitle1\">Genotype 3</td> </tr> <tr> <td>Daclatasvir</td> <td>M28, Q30, L31, Y93</td> <td>A30K, Y93H</td> </tr> <tr> <td>Elbasvir</td> <td>M28, Q30, L31, Y93</td> <td>N/A</td> </tr> <tr> <td>Ledipasvir</td> <td>K24, M28, Q30, L31, Y93</td> <td>N/A</td> </tr> <tr> <td>Ombitasvir</td> <td>M28, Q30, L31, (V only), Y93</td> <td>N/A</td> </tr> <tr> <td>Velpatasvir</td> <td>Y93</td> <td>Y93H</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection. Presented at the American Association for the Study of Liver Diseases Liver Meeting, San Francisco CA, November 13-17, 2015. Abstract #LB-22.</li>&#xD;&#xA;    <li>Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. Gastroenterology 2016; 151:501.</li>&#xD;&#xA;    <li>Lawitz EJ, Dvory-Sobol H, Doehle BP, et al. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother 2016; 60:5368.</li>&#xD;&#xA;    <li>Krishnan P, Tripathi R, Schnell G, et al. Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials. Hepatology 2014; 60:1134A.</li>&#xD;&#xA;    <li>Daklinza [package insert]. Princeton, NJ USA. Bristol Myers Squibb. April 2016.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109921 Version 2.0</div></div></div>"},"109922":{"type":"graphic_diagnosticimage","displayName":"First-trimester color Doppler of one vs two umbilical arteries","title":"First-trimester color Doppler image of one versus two (normal) umbilical arteries","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">First-trimester color Doppler image of one versus two (normal) umbilical arteries</div><div class=\"cntnt\"><img style=\"width:764px; height:373px;\" src=\"images/OBGYN/109922_First-tri_Dopp_1vs2_umblcl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">First-trimester color flow Doppler image showing (A) a single umbilical artery alongside the fetal bladder and (B) two umbilical arteries with the bladder between them.</div><div class=\"graphic_footnotes\">b: bladder.</div><div id=\"graphicVersion\">Graphic 109922 Version 1.0</div></div></div>"},"109925":{"type":"graphic_figure","displayName":"Pneumonitis with anti-PD-1/PD-L1 therapy","title":"Pneumonitis with anti-PD-1/PD-L1 therapy","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Pneumonitis with anti-PD-1/PD-L1 therapy</div><div class=\"cntnt\"><img style=\"width:644px; height:896px;\" src=\"images/ONC/109925_Pneumo_antiPD1_PDL1_therapy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiologic features of pneumonitis associated with anti-PD-1/PD-L1 therapy stratified into five distinct phenotypes.</div><div class=\"graphic_footnotes\">PD-1: programmed cell death protein 1; PD-L1: programmed cell death ligand 1.</div><div class=\"graphic_reference\">From: Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol 2016. Reprinted with permission. Copyright &copy; 2016 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109925 Version 1.0</div></div></div>"},"109927":{"type":"graphic_table","displayName":"Pediatric CVD risk factors","title":"Risk factors for development of atherosclerosis in childhood","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for development of atherosclerosis in childhood</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td>Obesity</td> </tr> <tr> <td>Hypertension</td> </tr> <tr> <td>Dyslipidemia</td> </tr> <tr> <td>Family history of premature coronary artery disease*</td> </tr> <tr> <td>Smoke exposure</td> </tr> <tr> <td>Special-risk conditions <ul class=\"decimal_heading\"> <li>High-risk conditions: <ul> <li>Diabetes mellitus </li> <li>Chronic kidney disease </li> <li>Cardiac transplantation </li> <li>Kawasaki disease with current coronary artery aneurysms </li> </ul> </li> <li>Moderate-risk conditions: <ul> <li>Chronic inflammatory diseases (eg, SLE) </li> <li>HIV infection </li> <li>Nephrotic syndrome </li> <li>Kawasaki disease with regressed coronary artery aneurysms </li> <li>Depressive and bipolar disorders<sup>&#182;</sup> </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SLE: systemic lupus erythematosus; HIV: human immunodeficiency virus.<br />* Family history of premature coronary artery disease is defined as heart attack, treated angina, interventions for coronary artery disease, stroke, or sudden cardiac disease in a male parent or sibling before 55 years of age, or a female parent or sibling before 65 years of age.<br />Â¶ Though not included in the 2011 National Heart, Lung, and Blood Institute (NHLBI) recommendations, a 2015 American Heart Association (AHA) statement advocates including major depressive disorder and bipolar disorder in adolescents as moderate-risk conditions for premature cardiovascular disease (CVD).</div><div id=\"graphicVersion\">Graphic 109927 Version 1.0</div></div></div>"},"109928":{"type":"graphic_picture","displayName":"Small plaque parapsoriasis histopathology","title":"Histopathologic features of small plaque parapsoriasisâ€‹","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of small plaque parapsoriasisâ€‹</div><div class=\"cntnt\"><img style=\"width:753px; height:600px;\" src=\"images/DERM/109928_Sm_plq_parapsrss_hstpthlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic elongated mound of parakeratosis with collections of plasma above a basket-weave cornified layer, preserved granular layer, and minimal acanthosis. There is a sparse superficial perivascular lymphocytic infiltrate.</div><div class=\"graphic_reference\">Reproduced with permission from: Mobini N, Toussaint Caire S, Hu S, Kamino H. Noninfectious erythematous, popular, and squamous diseases. In: Lever's Histopathology of the Skin, 11th ed, Elder DE, Elenitsas R, Rosenbach M, et al (Eds), Wolters Kluwer, Philadelphia 2015. Copyright &copy; 2015 Wolters Kluwer. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 109928 Version 1.0</div></div></div>"},"109929":{"type":"graphic_picture","displayName":"Digitate dermatosis 2","title":"Digitate dermatosis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Digitate dermatosis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/109929_Digitate_dermatosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-demarcated, round or oval, minimally scaly plaques less than 5 cm, or symmetric, narrow, typically elongated, digitate (finger-shaped) plaques located on the trunk along the skin lines in this patient with small plaque parapsoriasis (digitate dermatosis).</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109929 Version 1.0</div></div></div>"},"109931":{"type":"graphic_algorithm","displayName":"Proposal to integrate RT into Rx HCC","title":"Proposed role for radiotherapy in the management of hepatocellular carcinoma (HCC) within the current Barcelona Clinic Liver Classification (BCLC) system","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Proposed role for radiotherapy in the management of hepatocellular carcinoma (HCC) within the current Barcelona Clinic Liver Classification (BCLC) system</div><div class=\"cntnt\"><img style=\"width:720px; height:296px;\" src=\"images/ONC/109931_Proposl_integrate_RT_Rx_HCC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Current BCLC system and proposed roles for RT in the management of HCC.</div><div class=\"graphic_footnotes\">RT: radiotherapy; PS: performance status; RFA: radiofrequency ablation; TACE: transarterial chemoembolization; SBRT: stereotactic body radiotherapy.</div><div class=\"graphic_reference\">Reproduced From: Ohri N, Dawson LA, Krishnan S, et al. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst 2016; 108(9), by permission of Oxford University Press on behalf of the National Cancer Institute. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 109931 Version 2.0</div></div></div>"},"109933":{"type":"graphic_figure","displayName":"Distribution histologic tumor types in duodenum, jejunum, ileum","title":"Proportion of histologic tumor subtypes found in the three anatomical segments of the small bowel from a combined analysis of registry-based data from three published series","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proportion of histologic tumor subtypes found in the three anatomical segments of the small bowel from a combined analysis of registry-based data from three published series</div><div class=\"cntnt\"><img style=\"width:352px; height:490px;\" src=\"images/ONC/109933_Dstrbtn_histolgc_tumor_typs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epidemiology of small bowel tumors from the NCDB (1985 to 2005) and United States SEER (1973 to 2005) cohorts, and the Connecticut Tumor Registry 1980 to 2000. The proportion of histological tumor subtypes found in the small bowel varies depending on the anatomic location of the small bowel.</div><div class=\"graphic_footnotes\">NCDB: National Cancer Data Base; SEER: Surveillance, Epidemiology, and End Results.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Clinical Oncology. Raghav K, Overman MJ. Small bowel adenocarcinomas--existing evidence and evolving paradigms. Nat Rev Clin Oncol 2013; 10:534. Copyright Â© 2013. <A href=\"http://www.nature.com/nrclinonc\" target=_blank>www.nature.com/nrclinonc</A>.</div><div id=\"graphicVersion\">Graphic 109933 Version 1.0</div></div></div>"},"109934":{"type":"graphic_table","displayName":"Anesthetic goals for patients with hypertrophic cardiomyopathy","title":"Key points for anesthetic and hemodynamic management of patients with hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management of patients with hypertrophic cardiomyopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr class=\"divider_bottom\"> <td>Sinus rhythm</td> <td>Avoid atrial fibrillation or other SVT</td> <td>5-lead ECG</td> <td>Manage new-onset atrial fibrillation or other SVT: <ul class=\"decimal_heading\"> <li>Control HR </li> <li>Cardioversion of atrial fibrillation for hemodynamic compromise </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Slow to normal HR (60 to 80 bpm)</td> <td> <p>Avoid tachycardia</p> <p>Avoid severe bradycardia</p> Avoid junctional rhythm</td> <td> <p>5-lead ECG</p> Pulse oximetry with visible waveform</td> <td> <p>Prevent tachycardia by ensuring adequate depth of anesthesia and analgesia</p> <p>Manage tachycardia related to hypotension with a vasoconstrictor (eg, phenylephrine, norepinephrine) and fluid administration</p> Slow HR with beta blockers if necessary</td> </tr> <tr class=\"divider_bottom\"> <td>Maintain afterload</td> <td> <p>Avoid hypotension</p> Avoid sympathectomy (eg, spinal anesthesia)</td> <td>Intra-arterial blood pressure for major surgical procedures</td> <td>Administer a vasoconstrictor without inotropic properties (eg, phenylephrine or, if necessary, vasopressin) to manage hypotension</td> </tr> <tr class=\"divider_bottom\"> <td>Augment preload</td> <td>Avoid hypovolemia</td> <td>Assess clinical response to fluid boluses</td> <td> <p>Maintain intravascular volume status</p> Rapid resuscitation for hemorrhage</td> </tr> <tr> <td>Reduce contractility</td> <td>Avoid inotropic agents</td> <td>Hemodynamics</td> <td>Deepen anesthesia or, if necessary, administer beta blockers</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SVT: supraventricular tachycardia; ECG: electrocardiogram; HR: heart rate. </div><div id=\"graphicVersion\">Graphic 109934 Version 1.0</div></div></div>"},"109935":{"type":"graphic_table","displayName":"Intraoperative hemodynamics for aortic or mitral valve disease","title":"Key points for hemodynamic management in patients with aortic or mitral valve disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for hemodynamic management in patients with aortic or mitral valve disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Valvular lesion</td> <td class=\"subtitle1\">Heart rate</td> <td class=\"subtitle1\">Heart rhythm</td> <td class=\"subtitle1\">Preload</td> <td class=\"subtitle1\">Afterload</td> <td class=\"subtitle1\">Contractility</td> <td class=\"subtitle1\">PVR</td> </tr> <tr class=\"divider_bottom\"> <td>Aortic stenosis</td> <td> <p>Normal HR at 60 to 80 bpm</p> <p>Avoid tachycardia</p> Avoid bradycardia</td> <td> <p>Maintain sinus rhythm</p> Avoid SVT, avoid AV dissociation</td> <td> <p>Maintain intravascular volume</p> Avoid hypovolemia</td> <td> <p>Maintain systolic BP &#62;100 mmHg, MAP &#62;70 mmHg, or both within 20% of baseline</p> Avoid hypotension</td> <td>Avoid myocardial depression</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Mitral stenosis</td> <td> <p>Slow to normal HR at 50 to 70 bpm</p> Avoid tachycardia</td> <td>Control ventricular rate regardless of rhythm</td> <td> <p>Maintain intravascular volume</p> <p>Avoid hypovolemia</p> Avoid hypervolemia</td> <td> <p>Maintain systolic BP &#62;100 mmHg, MAP &#62;70 mmHg, or both within 20% of baseline</p> Avoid hypotension</td> <td>Avoid myocardial depression</td> <td>Avoid hypoxemia and hypercarbia</td> </tr> <tr class=\"divider_bottom\"> <td>Aortic regurgitation</td> <td> <p>Normal to fast HR at 80 to 100 bpm</p> Avoid bradycardia</td> <td>Maintain relatively fast HR regardless of rhythm</td> <td> <p>Maintain or reduce preload</p> Avoid hypervolemia</td> <td> <p>Maintain a low-normal systolic BP of approximately 100 to 120 mmHg or within 10% of baseline</p> Avoid hypertension</td> <td>Avoid myocardial depression</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Mitral regurgitation</td> <td> <p>Normal to fast HR at 80 to 100 bpm</p> <p>Avoid bradycardia</p> <p><em>(In patients with MR due to ischemic heart disease, maintain a slower HR at 60 to 80 bpm)</em></p> </td> <td>Maintain relatively fast HR regardless of rhythm</td> <td> <p>Maintain or reduce preload</p> Avoid hypervolemia</td> <td> <p>Maintain a low-normal systolic BP of approximately 100 to 120 mmHg or within 10% of baseline</p> <p>Avoid hypertension</p> <em>(In patients with MR due to ischemic heart disease, maintain a normal BP approximating preoperative values)</em></td> <td>Avoid myocardial depression</td> <td>Avoid hypoxemia and hypercarbia</td> </tr> <tr> <td>Mitral regurgitation due to hypertrophic cardiomyopathy with LVOT obstruction</td> <td> <p>Normal HR at 60 to 80 bpm</p> <p>Avoid tachycardia</p> Avoid bradycardia</td> <td> <p>Maintain sinus rhythm</p> <p>Avoid SVT</p> Avoid AV dissociation</td> <td> <p>Maintain intravascular volume</p> Avoid hypovolemia</td> <td> <p>Maintain systolic BP &#62;100 mmHg, MAP &#62;70 mmHg, or both within 20% of baseline</p> Treat hypotension with vasoconstrictors without inotropic properties (eg, phenylephrine, vasopressin)</td> <td> <p>Decrease contractility by deepening anesthesia or administering beta blockers</p> Avoid inotropic agents</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PVR: pulmonary vascular resistance; HR: heart rate; bpm: beats/minute; SVT: supraventricular tachycardia; BP: blood pressure; MAP: mean arterial pressure; MR: mitral regurgitation; LVOT: left ventricular outflow tract; AV: atrioventricular.</div><div id=\"graphicVersion\">Graphic 109935 Version 1.0</div></div></div>"},"109938":{"type":"graphic_algorithm","displayName":"Indications for treatment of subclinical hyperthyroidism","title":"Indications for treatment of endogenous subclinical hyperthyroidism in nonpregnant adults*","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Indications for treatment of endogenous subclinical hyperthyroidism in nonpregnant adults*</div><div class=\"cntnt\"><img style=\"width:616px; height:494px;\" src=\"images/ENDO/109938_Trtmnt_subclinical_hyprthyr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone.<br />* Subclinical hyperthyroidism is defined as a normal serum free thyroxine (T4) and triiodothyronine (T3) in the presence of a subnormal TSH, confirmed on repeated measurement over a three- to six-month period.<br />&para; Symptoms of hyperthyroidism include palpitations, tremulousness, heat intolerance, and insomnia (refer to UpToDate topics on hyperthyroidism).<br />&Delta; A radionuclide scan showing one or more focal areas of increased uptake is consistent with autonomy and is a risk factor for progression to overt hyperthyroidism.<br /><span class=\"lozenge\">&loz;</span> There are insufficient data for or against treatment of subclinical hyperthyroidism in patients with TSH between 0.1 and the lower limit of normal and in younger patients (&lt;65 years of age) with TSH &lt;0.1 mU/L. A decision for individual management is based upon patient characteristics and preferences (refer to UpToDate topics on subclinical hyperthyroidism).<br />&sect; Check TSH, free T4, and T3 every six months.</div><div id=\"graphicVersion\">Graphic 109938 Version 2.0</div></div></div>"},"109939":{"type":"graphic_waveform","displayName":"ECG seven-month-old with Ebstein","title":"Electrocardiogram of seven-month-old with Ebstein anomaly","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram of seven-month-old with Ebstein anomaly</div><div class=\"cntnt\"><img style=\"width:768px; height:428px;\" src=\"images/CARD/109939_ECG_seven-month-old_Ebstein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The electrocardiogram of a seven-month-old with Ebstein anomaly shows preexcitation with a right bundle branch block pattern and right atrial enlargement.</div><div id=\"graphicVersion\">Graphic 109939 Version 1.0</div></div></div>"},"109940":{"type":"graphic_diagnosticimage","displayName":"MRI of Ebstein anomaly","title":"Cardiac magnetic resonance imaging of a patient with Ebstein anomaly","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Cardiac magnetic resonance imaging of a patient with Ebstein anomaly</div><div class=\"cntnt\"><img style=\"width:628px; height:1249px;\" src=\"images/CARD/109940_MRI_Ebstein_anomaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cardiac magnetic resonance imaging of a patient with Ebstein anomaly in four chamber (A) and short axis (B) orientations, showing dilated right ventricle (RV). The tricuspid valve leaflets (arrowheads) are tethered to the underlying RV myocardium with severe apical displacement of the septal leaflet, creating \"atrialized\" right ventricle (aRV) from the portion of RV between the functional tricuspid valve orifice and the right atrioventricular junction.</div><div class=\"graphic_footnotes\">LV: left ventricle; RA: right atrium.</div><div id=\"graphicVersion\">Graphic 109940 Version 2.0</div></div></div>"},"109955":{"type":"graphic_algorithm","displayName":"VSD management in infancy","title":"Overview of our approach to the management of infants with isolated ventricular septal defects*","html":"<div class=\"graphic\"><div style=\"width: 1156px\" class=\"figure\"><div class=\"ttl\">Overview of our approach to the management of infants with isolated ventricular septal defects*</div><div class=\"cntnt\"><img style=\"width:1136px; height:754px;\" src=\"images/PEDS/109955_VSD_management_in_infancy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">VSD: ventricular septal defect; PH: pulmonary hypertension; LV: left ventricle; IV: intravenous; PVR: pulmonary vascular resistance.<br />* This algorithm is intended for use in conjunction with additional UpToDate content on VSDs in children. Refer to UpToDate topics on the management of patients with VSDs and the management of heart failure in children for additional details of our approach to treatment and the overall efficacy of these treatments.<br />&para; The timing of the initial follow-up with the pediatric cardiologist corresponds to the timing of the normal decline in PVR during the newborn period. Infants with moderate to large VSDs usually become symptomatic within the first months of life. The primary care provider should monitor the infant during the first weeks of life for manifestations of heart failure (eg, tachypnea, increased work of breathing, poor weight gain or failure to thrive, and diaphoresis, particularly with feeding). Infants who develop symptoms before the first follow-up with the pediatric cardiologist should be referred for urgent evaluation and management. For infants with trivial muscular VSDs (ie, initial imaging and Doppler demonstrate a very small, very restrictive defect), follow-up is not generally necessary until three to six months of age, by which time many will have closed.<br />&Delta; Symptoms of heart failure in infancy include poor feeding (eg, tiring during feeds), poor weight gain, tachypnea, increased work of breathing, and diaphoresis, particularly with feeding. \"Asymptomatic\" refers to infants who lack symptoms of heart failure, have normal growth, and do not have evidence (clinical or echocardiographic) of PH. Mild symptoms of heart failure may include mild tachypnea or diaphoresis while feeding; however, growth is typically adequate. Moderate heart failure in an infant is characterized by tachypnea or diaphoresis with feeding and signs of growth failure. Severe heart failure is characterized by respiratory distress (tachypnea, grunting, retractions, or diaphoresis) at rest and failure to thrive.<br /><span class=\"lozenge\">&loz;</span> Infants who develop symptoms of heart failure before their next scheduled follow-up with the pediatric cardiologist should be referred for more urgent evaluation.<br />&sect; Since heart failure is not expected in association with small VSDs, the development of new symptoms, particularly late, should prompt reassessment of the original diagnosis and evaluation for other causes of the symptoms.</div><div id=\"graphicVersion\">Graphic 109955 Version 3.0</div></div></div>"},"109956":{"type":"graphic_picture","displayName":"Hook test for distal biceps tendon","title":"Hook test for distal biceps tendon","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Hook test for distal biceps tendon</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/SM/109956_Hook_test_distl_biceps_tndn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hook test is used to assess the integrity of the distal biceps tendon. To perform the test, the clinician uses their index finger to catch the tendon.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 109956 Version 2.0</div></div></div>"},"109957":{"type":"graphic_movie","displayName":"Distal biceps tendon squeeze test","title":"Distal biceps tendon squeeze test","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Distal biceps tendon squeeze test</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/109957_Bicepstendonsquztestvid.mp4\" style=\"width:480px;height:736px\"></div><img style=\"width:398px; height:670px;\" src=\"images/SM/109957_Bicepstendonsquztestimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The squeeze test demonstrated in the video clip is used to assess the integrity of the distal biceps tendon.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 109957 Version 2.0</div></div></div>"},"109960":{"type":"graphic_table","displayName":"Distinguishing RCVS from PACNS","title":"Distinguishing reversible cerebral vasoconstriction syndrome (RCVS) from primary angiitis of the central nervous system (PACNS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing reversible cerebral vasoconstriction syndrome (RCVS) from primary angiitis of the central nervous system (PACNS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"4\" width=\"17.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Sensitivity<br /> (95% CI)</td> <td class=\"subtitle1\">Specificity<br /> (95% CI)</td> <td class=\"subtitle1\">PPV<br /> (95% CI)</td> <td class=\"subtitle1\">NPV<br /> (95% CI)</td> </tr> <tr class=\"divider_bottom\"> <td>Recurrent TCH*</td> <td class=\"centered\">74 (67-81)</td> <td class=\"centered\">98 (89-100)</td> <td class=\"centered\">99 (95-100)</td> <td class=\"centered\">53 (43-64)</td> </tr> <tr> <td>Single TCH*</td> <td class=\"centered\">15 (10-22)</td> <td class=\"centered\">96 (85-99)</td> <td class=\"centered\">92 (75-99)</td> <td class=\"centered\">25 (19-32)</td> </tr> <tr> <td class=\"indent1\">Plus normal brain MRI</td> <td class=\"centered\">2 (0-5)</td> <td class=\"centered\">100 (92-100)</td> <td class=\"centered\">100 (30-100)</td> <td class=\"centered\">23 (18-30)</td> </tr> <tr> <td class=\"indent1\">Plus FLAIR dot sign</td> <td class=\"centered\">10 (6-16)</td> <td class=\"centered\">100 (92-100)</td> <td class=\"centered\">100 (79-100)</td> <td class=\"centered\">25 (19-32)</td> </tr> <tr> <td class=\"indent1\">Plus border zone-only infarcts</td> <td class=\"centered\">3 (1-6)</td> <td class=\"centered\">100 (92-100)</td> <td class=\"centered\">100 (40-100)</td> <td class=\"centered\">23 (18-30)</td> </tr> <tr> <td class=\"indent1\">Plus vasogenic edema (PRES)</td> <td class=\"centered\">4 (1-8)</td> <td class=\"centered\">100 (92-100)</td> <td class=\"centered\">100 (54-100)</td> <td class=\"centered\">24 (18-30)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Plus ICH or cSAH</td> <td class=\"centered\">9 (5-15)</td> <td class=\"centered\">96 (85-99)</td> <td class=\"centered\">88 (64-98)</td> <td class=\"centered\">24 (18-31)</td> </tr> <tr> <td>No TCH; positive angiogram</td> <td class=\"centered\">11 (6-17)</td> <td class=\"centered\">49 (34-64)</td> <td class=\"centered\">42 (23-58)</td> <td class=\"centered\">14 (9-20)</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">For the diagnosis of RCVS:</td> </tr> <tr> <td class=\"indent2\">Plus normal brain MRI</td> <td class=\"centered\">1 (0-3)</td> <td class=\"centered\">100 (92-100)</td> <td class=\"centered\">100 (17-100)</td> <td class=\"centered\">23 (17-29)</td> </tr> <tr> <td class=\"indent2\">Plus border zone-only infarcts</td> <td class=\"centered\">5 (2-9)</td> <td class=\"centered\">98 (89-100)</td> <td class=\"centered\">88 (47-98)</td> <td class=\"centered\">23 (18-30)</td> </tr> <tr> <td class=\"indent2\">Plus ICH or cSAH</td> <td class=\"centered\">3 (1-6)</td> <td class=\"centered\">98 (89-100)</td> <td class=\"centered\">80 (29-97)</td> <td class=\"centered\">23 (17-29)</td> </tr> <tr> <td class=\"indent2\">Plus vasogenic edema (PRES)</td> <td class=\"centered\">3 (1-7)</td> <td class=\"centered\">100 (92-100)</td> <td class=\"centered\">100 (48-100)</td> <td class=\"centered\">23 (18-30)</td> </tr> <tr> <td class=\"indent2\">Plus FLAIR dot sign</td> <td class=\"centered\">6 (3-11)</td> <td class=\"centered\">94 (83-99)</td> <td class=\"centered\">75 (43-94)</td> <td class=\"centered\">23 (18-30)</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">For the diagnosis of PACNS:</td> </tr> <tr> <td class=\"indent2\">Plus deep/brainstem infarcts</td> <td class=\"centered\">38 (35-54)</td> <td class=\"centered\">100 (98-100)</td> <td class=\"centered\">100 (81-100)</td> <td class=\"centered\">85 (79-89)</td> </tr> <tr> <td class=\"indent2\">Plus CSF abnormal<sup>&#182;</sup></td> <td class=\"centered\">28 (16-43)</td> <td class=\"centered\">99 (95-100)</td> <td class=\"centered\">87 (60-98)</td> <td class=\"centered\">82 (76-88)</td> </tr> <tr> <td class=\"indent2\">Plus both of the above</td> <td class=\"centered\">28 (16-43)</td> <td class=\"centered\">100 (98-100)</td> <td class=\"centered\">100 (75-100)</td> <td class=\"centered\">83 (77-87)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CI: confidence intervals; PPV: positive predictive value; NPV: negative predictive value; TCH: thunderclap headache; MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery; ICH: intracerebral hemorrhage; cSAH: convexal subarachnoid hemorrhage; CSF: cerebrospinal fluid.<br />* Values shown are for the diagnosis of RCVS.<br />&para; Abnormal is &gt;5 cells and &gt;80 mg/dL.</div><div class=\"graphic_reference\">From: Singhal AB, Topcuoglu MA, Fok JW, et al. Reversible cerebral vasoconstriction syndromes and primary angiitis of the central nervous system: clinical, imaging, and angiographic comparison. Ann Neurol 2016; 79:882. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/ana.24652/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1002/ana.24652/abstract</A>. Copyright Â© 2016 American Neurological Association. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 109960 Version 1.0</div></div></div>"},"109962":{"type":"graphic_diagnosticimage","displayName":"Brain lesions in RCVS","title":"Brain lesions in reversible cerebral vasoconstriction syndrome (RCVS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain lesions in reversible cerebral vasoconstriction syndrome (RCVS)</div><div class=\"cntnt\"><img style=\"width:334px; height:665px;\" src=\"images/NEURO/109962_Brain_lesions_RCVS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative brain images from patients with RCVS are shown to highlight different lesion patterns. The numbers in parenthesis show the percentages of the lesion patterns; totals exceed 100% due to lesion combinations.<br />(A) No acute parenchymal lesion (24%). Normal axial DWI, GRE, and FLAIR images are shown. The hyperintense dot sign is present on FLAIR (far right, arrow).<br />(B) Border zone/watershed infarcts (25%). On the far left, DWI shows typical symmetric, posterior infarcts that spare the cortical ribbon. In the middle and on the far right, DWI shows widespread watershed infarcts.<br />(C) Vasogenic edema (28%). Subcortical crescent-shaped T2-hyperintense lesions consistent with the posterior reversible encephalopathy syndrome are seen on FLAIR.<br />(D) Hemorrhagic lesions (42%). The two images on the left (axial GRE) show simultaneous lobar and deep intraparenchymal hemorrhages. The two images on the right show convexal subarachnoid hemorrhages on CT and axial GRE.<br />(E) Lesion combinations (28%). The two images on the left show bilateral watershed infarcts on DWI and the two images on the right show lobar as well as convexal subarachnoid hemorrhages on axial FLAIR and CT, all in the same patient.</div><div class=\"graphic_footnotes\">RCVS: reversible cerebral vasoconstriction syndrome; DWI: diffusion-weighted images; GRE: gradient-echo; FLAIR: fluid-attenuated inversion recovery.</div><div class=\"graphic_reference\">From: Singhal AB, Topcuoglu MA, Fok JW, et al. Reversible cerebral vasoconstriction syndromes and primary angiitis of the central nervous system: clinical, imaging, and angiographic comparison. Ann Neurol 2016; 79:882. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/ana.24652/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1002/ana.24652/abstract</A>. Copyright Â© 2016 American Neurological Association. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 109962 Version 1.0</div></div></div>"},"109963":{"type":"graphic_figure","displayName":"TKI activity on BCR-ABL1 mutations in CML","title":"Tyrosine kinase inhibitor activity on BCR-ABL1 mutations in chronic myeloid leukemia","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Tyrosine kinase inhibitor activity on BCR-ABL1 mutations in chronic myeloid leukemia</div><div class=\"cntnt\"><img style=\"width:536px; height:640px;\" src=\"images/HEME/109963_TKIactBCRABL1mutatCML.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Activity of imatinib mesylate and the second generation tyrosine kinase inhibitors nilotinib and dasatinib against a selection of BCR-ABL1 mutants found in patients with CML. All concentrations are shown in nanomoles per milliliter and represent IC<SUB>50</SUB> values.</div><div class=\"graphic_footnotes\">CML: chronic myeloid leukemia; TKI: tyrosine kinase inhibitor; NA: not available.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from QuintÃ¡s-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113:1619. Copyright Â© 2009; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 109963 Version 2.0</div></div></div>"},"109964":{"type":"graphic_picture","displayName":"Location of trapezoid for palpation","title":"Location of trapezoid for palpation","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Location of trapezoid for palpation</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/SM/109964_Location_trapezoid_palpatio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows the location of the trapezoid bone, and can serve as a guide for palpation.</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD.</div><div id=\"graphicVersion\">Graphic 109964 Version 2.0</div></div></div>"},"109965":{"type":"graphic_diagnosticimage","displayName":"Representative images of CPI-induced AKI","title":"Representative images of checkpoint inhibitor-induced acute kidney injury","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Representative images of checkpoint inhibitor-induced acute kidney injury</div><div class=\"cntnt\"><img style=\"width:763px; height:927px;\" src=\"images/ONC/109965_Rep_imgs_CPI-induced_AKI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Core needle biopsy specimens (A-C) from patient 9 show \"typical\" features of acute tubulointerstitial nephritis; (D) from patient 2 show granulomatous acute tubulointerstitial nephritis; (E,F) from patient 8 show acute thrombotic microangiopathy.<br />(A) Periodic acid-Schiff stain shows diffuse interstitial inflammation and focal severe tubulitis with infiltrating lymphocytes (arrows, times 200; bar = 50 mcg).<br />(B) Hematoxylin and eosin stain shows diffuse interstitial infiltrates predominantly composed of lymphocytes, with several eosinophils (arrows, times 400; bar = 25 mcg).<br />(C) Immunohistochemistry reveals the lymphocytic infiltrates in the interstitium to be predominantly CD4b T cells (times 40; bar = 100 mcg).<br />(D) Periodic acid-Schiff stain shows a noncaseating granuloma with multinucleated giant cells (striped arrows), severe interstitial inflammation and tubulitis (arrows), and severe glomerulitis (dashed arrow, times 200; bar = 50 mcg).<br />(E) Silver stain shows diffusely wrinkled glomerular basement membranes and \"onion-skin\" lesion of small arteries (arrow, times 200; bar = 50 mcg).<br />(F) Electron microscopy shows swollen endothelium and subintimal widening filled with electron-lucent \"fluffy\" material (arrows, times 1400; bar = 4 mcg).</div><div class=\"graphic_reference\">Reproduced from: Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 2016; 90:638. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109965 Version 1.0</div></div></div>"},"109966":{"type":"graphic_picture","displayName":"Small keloid","title":"Small keloid on the ear lobe","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Small keloid on the ear lobe</div><div class=\"cntnt\"><img style=\"width:756px; height:565px;\" src=\"images/PEDS/109966_Small_keloid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lower lobe piercing resulting in a small keloid. Piercing hardware was removed one month after piercing and picture was taken approximately one year later.</div><div id=\"graphicVersion\">Graphic 109966 Version 1.0</div></div></div>"},"109970":{"type":"graphic_picture","displayName":"Fava beans","title":"Fava beans and fried fava bean snack","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Fava beans and fried fava bean snack</div><div class=\"cntnt\"><img style=\"width:764px; height:277px;\" src=\"images/HEME/109970_Fava_beans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Fava beans, also called \"broad beans.\"&nbsp;These may&nbsp;be eaten fresh or cooked in salads, soups, meat dishes, and some falafel recipes. (B) Fried fava beans, sold as a snack food. Refer to UpToDate for further information about glucose-6-phosphate dehydrogenase (G6PD) deficiency and favism.</div><div class=\"graphic_reference\">Courtesy of Bertil Glader, MD, PhD.</div><div id=\"graphicVersion\">Graphic 109970 Version 2.0</div></div></div>"},"109974":{"type":"graphic_table","displayName":"Acinetobacter spp: MDR, XDR, and PDR","title":"<em>Acinetobacter</em> species: Antimicrobial categories and agents used to define MDR, XDR, and PDR","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\"><em>Acinetobacter</em> species: Antimicrobial categories and agents used to define MDR, XDR, and PDR</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antimicrobial category</td> <td class=\"subtitle1\">Antimicrobial agent</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Aminoglycosides</td> <td>Gentamicin</td> </tr> <tr> <td>Tobramycin</td> </tr> <tr> <td>Amikacin</td> </tr> <tr class=\"divider_bottom\"> <td>Netilmicin</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Antipseudomonal carbapenems</td> <td>Imipenem</td> </tr> <tr> <td>Meropenem</td> </tr> <tr class=\"divider_bottom\"> <td>Doripenem</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Antipseudomonal fluoroquinolones</td> <td>Ciprofloxacin</td> </tr> <tr class=\"divider_bottom\"> <td>Levofloxacin</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Antipseudomonal penicillins + beta-lactamase inhibitors</td> <td>Piperacillin-tazobactam</td> </tr> <tr class=\"divider_bottom\"> <td>Ticarcillin-clavulanic acid</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Extended-spectrum cephalosporins</td> <td>Cefotaxime</td> </tr> <tr> <td>Ceftriaxone</td> </tr> <tr> <td>Ceftazidime</td> </tr> <tr class=\"divider_bottom\"> <td>Cefepime</td> </tr> <tr class=\"divider_bottom\"> <td>Folate pathway inhibitors</td> <td>Trimethoprim-sulphamethoxazole</td> </tr> <tr class=\"divider_bottom\"> <td>Penicillins + beta-lactamase inhibitors</td> <td>Ampicillin-sulbactam</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Polymyxins</td> <td>Colistin</td> </tr> <tr class=\"divider_bottom\"> <td>Polymyxin B</td> </tr> <tr> <td rowspan=\"3\">Tetracyclines</td> <td>Tetracycline</td> </tr> <tr> <td>Doxycycline</td> </tr> <tr> <td>Minocycline</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Criteria for defining MDR, XDR, and PDR in <em>Acinetobacter</em> spp:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>MDR: Non-susceptible to &ge;1 agent in &ge;3 antimicrobial categories.</li>&#xD;&#xA;    <li>XDR: Non-susceptible to &ge;1 agent in all but &le;2 categories.</li>&#xD;&#xA;    <li>PDR: Non-susceptible to all antimicrobial agents listed.</li>&#xD;&#xA;</ul>&#xD;&#xA;This terminology and these criteria were created by a group of international experts as part of a joint initiative by the European Centre for Disease Prevention and Control (ECDC) and the United States Centers for Disease Control and Prevention (CDC).</div><div class=\"graphic_footnotes\">MDR: multidrug-resistant; XDR: extensively drug-resistant; PDR: pandrug-resistant.</div><div class=\"graphic_reference\">Reproduced from: Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109974 Version 5.0</div></div></div>"},"109975":{"type":"graphic_table","displayName":"Pseudomonas aeruginosa: MDR, XDR, and PDR","title":"<em>Pseudomonas aeruginosa</em>: Antimicrobial categories and agents used to define MDR, XDR, and PDR","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\"><em>Pseudomonas aeruginosa</em>: Antimicrobial categories and agents used to define MDR, XDR, and PDR</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antimicrobial category</td> <td class=\"subtitle1\">Antimicrobial agent</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Aminoglycosides</td> <td>Gentamicin</td> </tr> <tr> <td>Tobramycin</td> </tr> <tr> <td>Amikacin</td> </tr> <tr class=\"divider_bottom\"> <td>Netilmicin</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Antipseudomonal carbapenems</td> <td>Imipenem</td> </tr> <tr> <td>Meropenem</td> </tr> <tr class=\"divider_bottom\"> <td>Doripenem</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Antipseudomonal cephalosporins</td> <td>Ceftazidime</td> </tr> <tr class=\"divider_bottom\"> <td>Cefepime</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Antipseudomonal fluoroquinolones</td> <td>Ciprofloxacin</td> </tr> <tr class=\"divider_bottom\"> <td>Levofloxacin</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Antipseudomonal penicillins + beta-lactamase inhibitors</td> <td>Ticarcillin-clavulanic acid</td> </tr> <tr class=\"divider_bottom\"> <td>Piperacillin-tazobactam</td> </tr> <tr class=\"divider_bottom\"> <td>Monobactams</td> <td>Aztreonam</td> </tr> <tr class=\"divider_bottom\"> <td>Phosphonic acids</td> <td>Fosfomycin</td> </tr> <tr> <td rowspan=\"2\">Polymyxins</td> <td>Colistin</td> </tr> <tr> <td>Polymyxin B</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Criteria for defining MDR, XDR, and PDR in <em>Pseudomonas aeruginosa</em>:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>MDR: Non-susceptible to &ge;1 agent in &ge;3 antimicrobial categories.</li>&#xD;&#xA;    <li>XDR: Non-susceptible to &ge;1 agent in all but &le;2 categories.</li>&#xD;&#xA;    <li>PDR: Non-susceptible to all antimicrobial agents listed.</li>&#xD;&#xA;</ul>&#xD;&#xA;This terminology and these criteria were created by a group of international experts as part of a joint initiative by the European Centre for Disease Prevention and Control (ECDC) and the United States Centers for Disease Control and Prevention (CDC).</div><div class=\"graphic_footnotes\">MDR: multidrug-resistant; XDR: extensively drug-resistant; PDR: pandrug-resistant.</div><div class=\"graphic_reference\">Reproduced from: Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109975 Version 2.0</div></div></div>"},"109977":{"type":"graphic_picture","displayName":"Poikiloderma vasculare atrophicans","title":"Poikiloderma vasculare atrophicans","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Poikiloderma vasculare atrophicans</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/109977_Poikiloderma_vsclr_atrphcns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrophic patches with telangiectasia and mottled pigmentation on the trunk of this patient with poikiloderma vasculare atrophicans, a variant of large plaque parapsoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109977 Version 1.0</div></div></div>"},"109978":{"type":"graphic_picture","displayName":"Poikiloderma vasculare atrophicans dark skin","title":"Poikiloderma vasculare atrophicans","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Poikiloderma vasculare atrophicans</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/109978_Poikiloderma_vsclr_dark_skn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mottled pigmentation, telangiectasia, and epidermal atrophy on the arm and shoulder of this patient with&nbsp;poikiloderma vasculare atrophicans, a variant of large plaque parapsoriasis or \"premycotic\" stage of mycosis fungoides.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 109978 Version 1.0</div></div></div>"},"109979":{"type":"graphic_picture","displayName":"Ultrasound probe position lateral elbow","title":"Ultrasound probe position lateral elbow","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Ultrasound probe position lateral elbow</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/SM/109979_US_probe_pos_lateral_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound&nbsp;examination of the lateral elbow can be performed while&nbsp;the patient rests their&nbsp;forearm on a table and&nbsp;flexes&nbsp;their elbow&nbsp;to 90 degrees, as pictured above. </div><div class=\"graphic_reference\">Courtesy of David J Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 109979 Version 1.0</div></div></div>"},"109980":{"type":"graphic_picture","displayName":"Large plaque parapsoriasis histology","title":"Histopathologic features of large plaque parapsoriasis","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of large plaque parapsoriasis</div><div class=\"cntnt\"><img style=\"width:768px; height:307px;\" src=\"images/DERM/109980_Lg_plaque_parapsrss_histlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The epidermis appears flattened and shows hydropic degeneration of basal cells.<br />(B) The upper dermis contains a band-like infiltrate, which in places extends into the epidermis.</div><div class=\"graphic_reference\">Reproduced with permission from: Winfield H, Jaworsky C. Connective Tissue Diseases. In: Lever's Histopathology of the Skin, 11th ed, Elder DE, Elenitsas R, Rosenbach M, et al (Eds), Wolters Kluwer, Philadelphia 2015. Copyright &copy; 2015 Wolters Kluwer. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 109980 Version 1.0</div></div></div>"},"109983":{"type":"graphic_figure","displayName":"Classification of mesenteric dissection","title":"Classification of mesenteric dissection","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Classification of mesenteric dissection</div><div class=\"cntnt\"><img style=\"width:763px; height:504px;\" src=\"images/SURG/109983_Clssfctn_mesenteric_dssctn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiographic categorization of spontaneous isolated superior mesenteric artery&nbsp;(SMA)&nbsp;dissection on cross-sectional and sagittal views of computed tomographic angiography.<br />(A) Type I&nbsp;â€“ Patent true and false lumen revealing entry and reentry sites.<br />Type II&nbsp;â€“ Patent true lumen but no reentry flow from the false lumen. <br />(B) Type IIa&nbsp;â€“ Visible false lumen but no visible reentry site (blind pouch of false lumen).<br />(C) Type IIb&nbsp;â€“ No visible false luminal flow (thrombosed false lumen), which usually causes true lumen narrowing.<br />(D) Type III&nbsp;â€“ SMA dissection with occlusion of SMA.</div><div class=\"graphic_reference\">Reproduced from: Yun WS, Kim YW, Park KB, et al. Clinical and angiographic follow-up of spontaneous isolated superior mesenteric artery dissection. Eur J Vasc Endovasc Surg 2009; 37:572. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 109983 Version 1.0</div></div></div>"},"109986":{"type":"graphic_picture","displayName":"Tympanic membrane vascular engorgement","title":"Tympanic membrane vascular engorgement before and after modified Valsalva maneuver","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Tympanic membrane vascular engorgement before and after modified Valsalva maneuver</div><div class=\"cntnt\"><img style=\"width:766px; height:391px;\" src=\"images/PEDS/109986_Tympnc_mmbrn_vsclr_engrgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Otoendoscopic view of a normal right tympanic membrane.<br />(B) The same tympanic membrane after modified Valsalva maneuver. Note vascular engorgement of canal and tympanic vessels. Vessels of the central drum are spared. The drum remains variegated in color and in normal position. A similar pattern of engorgement occurs during crying.</div><div class=\"graphic_reference\">From: Isaacson G. Acute Otitis Media and the Crying Child. Pediatr Infect Dis J 2016; 35:e399. DOI: <A href=\"http://journals.lww.com/pidj/pages/articleviewer.aspx?year=2016&amp;issue=12000&amp;article=00032&amp;type=abstract\" target=_blank>10.1097/INF.0000000000001335</A>. Copyright Â© 2016 European Society for Paediatric Infectious Diseases. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 109986 Version 1.0</div></div></div>"},"109988":{"type":"graphic_table","displayName":"Medical planning timeline for mass sporting event","title":"Medical planningÂ timeline forÂ mass participation endurance sporting event","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical planning&nbsp;timeline for&nbsp;mass participation endurance sporting event</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Race planning</td> <td class=\"subtitle1\">Timeline</td> <td class=\"subtitle1\">Functions</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Pre-race</strong></td> <td>3 to 12 months</td> <td> <ul> <li>Designate leaders of&nbsp;medical operations committee </li> <li>Develop or review and revise: <ul> <li>Medical protocols </li> <li>Supply and equipment lists </li> <li>Personnel needs </li> <li>Communication protocol </li> <li>Rapid response plan </li> <li>Disaster (crisis) plan </li> <li>Cancellation parameters </li> <li>Heat ramp up plan </li> <li>Participant and volunteer education plan&nbsp; </li> </ul> </li> <li>Send save the date announcement for volunteer pool </li> </ul> </td> </tr> <tr> <td>2 to 3 months</td> <td> <ul> <li>Place equipment and supply orders </li> <li>Finalize race day plan </li> <li>Recruit medical team </li> <li>Integrate area law enforcement and emergency departments </li> </ul> </td> </tr> <tr> <td>1 month</td> <td> <ul> <li>Pre-race volunteer education </li> <li>Notify area emergency facilities </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>10 days</td> <td> <ul> <li>Monitor race day weather forecasts </li> <li>Initiate heat or inclement weather ramp up protocol as necessary&nbsp; </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Race day</strong></td> <td>&nbsp;</td> <td> <ul> <li>Make start/no-start decision </li> <li>Revise and make start line announcements </li> <li>Check that all course personnel are present </li> <li>Finish line race day education </li> </ul> </td> </tr> <tr> <td><strong>Post-race</strong></td> <td>1 to 2 weeks</td> <td> <ul> <li>Make after-action reports and review medical records&nbsp; <ul> <li>What went right? </li> <li>What went wrong? </li> <li>Consider solutions for&nbsp;problem(s) </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of William O Roberts, MD, MS.</div><div id=\"graphicVersion\">Graphic 109988 Version 1.0</div></div></div>"},"109989":{"type":"graphic_table","displayName":"Issues for planning mass participation sporting event","title":"Medical and nonmedical issues to address when planning for mass participation sporting event","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical and nonmedical issues to address when planning for mass participation sporting event</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Athlete issues</td> <td class=\"subtitle1\">Race course and management</td> <td class=\"subtitle1\">Medical and safety planning</td> <td class=\"subtitle1\">Equipment and logistics</td> </tr> <tr> <td> <ul> <li>Competitor education </li> <li>Pre-race health evaluation </li> <li>Impaired competitor policy* </li> <li>Competitor safety </li> </ul> </td> <td> <ul> <li>Start time and possible adjustments </li> <li>Race schedule </li> <li>Race day communications </li> <li>Medical station preparations </li> <li>Transportation of care providers along race course </li> </ul> </td> <td> <ul> <li>Hazardous conditions (eg, lightning, hail storm) </li> <li>Disaster or adverse event protocol </li> <li>Delay and cancellation protocol </li> <li>Medical condition protocols (eg, exertional hyperthermia, cardiac arrest, severe asthma, exercise-associated collapse, etc) </li> <li>Medical pathogen precaution protocol </li> <li>On-course medical care, including medical stations and staffing </li> <li>Advance notification and race day coordination with local emergency departments </li> <li>Advance notification and race day coordination with local law enforcement and safety officials </li> <li>Ambulance access to course and transportation to area hospitals </li> </ul> </td> <td> <ul> <li>General supplies and equipment </li> <li>Medical supplies and equipment, including all necessary medications </li> <li>Fluid and food for competitors and staff </li> <li>Medical and race records </li> <li>Family waiting area and related preparations </li> <li>Disaster or adverse event counseling </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Impaired competitor policy refers to athletes who need medical evaluation of any type and the criteria for disqualification&nbsp;versus continued participation following the evaluation.</div><div class=\"graphic_reference\">Courtesy of William O Roberts, MD, MS.</div><div id=\"graphicVersion\">Graphic 109989 Version 2.0</div></div></div>"},"109990":{"type":"graphic_table","displayName":"Twin Cities Marathon medical volunteers","title":"Twin Cities Marathon medical volunteers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Twin Cities Marathon medical volunteers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"4\" width=\"17.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Staff</td> <td class=\"subtitle1\">Total number<br /> (2015 capacity)</td> <td class=\"subtitle1\">Course with 12 fixed medical stations<br /> (2015 capacity)</td> <td class=\"subtitle1\">Finish area with 1 medical tent<br /> (2015 capacity)</td> <td class=\"subtitle1\">Number/1000 participants</td> </tr> <tr> <td>MD/DO - licensed</td> <td>29 (50)</td> <td>14 (26)</td> <td>15 (23)</td> <td>5</td> </tr> <tr> <td>MD/DO fellow - licensed</td> <td>3 (4)</td> <td>3 (2)</td> <td>2 (2)</td> <td>&nbsp;</td> </tr> <tr> <td>MD/DO resident - licensed</td> <td>2 (40)</td> <td>(24)</td> <td>2 (16)</td> <td>5</td> </tr> <tr> <td>MD/DO resident - non-licensed</td> <td>7 (total above)</td> <td>(total above)</td> <td>7 (total above)</td> <td>&nbsp;</td> </tr> <tr> <td>RN - licensed</td> <td>10 (34)</td> <td>(24)</td> <td>10 (10)</td> <td>3</td> </tr> <tr> <td>RN - student</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Physical therapist - licensed</td> <td>12 (20)</td> <td>5 (12)</td> <td>7</td> <td>1</td> </tr> <tr> <td>Physical therapist - student</td> <td>7 (15)</td> <td>2 (12)</td> <td>5 (5)</td> <td>&nbsp;</td> </tr> <tr> <td>Nurse practitioner - licensed</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Nurse practitioner - student</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>National Ski Patrol - OEC</td> <td>41 (50)</td> <td>41 (50)</td> <td>&nbsp;</td> <td>5</td> </tr> <tr> <td>Podiatry</td> <td>(2)</td> <td>&nbsp;</td> <td>(2)</td> <td>&nbsp;</td> </tr> <tr> <td>Physician assistant - licensed</td> <td>1</td> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Physician assistant - student</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Medical student - year 1, 2</td> <td>2</td> <td>2</td> <td>&nbsp;</td> <td>1</td> </tr> <tr> <td>Medical student - year 3, 4</td> <td>8</td> <td>3</td> <td>5</td> <td>1</td> </tr> <tr> <td>MATA ATC - finish triage</td> <td>18 (30)</td> <td>(10)</td> <td>18 (20)</td> <td>3</td> </tr> <tr> <td>National Mountain Bike Patrol</td> <td>15 (16)</td> <td>15 (16)</td> <td>&nbsp;</td> <td>1-2</td> </tr> <tr> <td>EMT Osseo/SLP - high school program</td> <td>52</td> <td>&nbsp;</td> <td>52</td> <td>&nbsp;</td> </tr> <tr> <td>EMT - independent</td> <td>7</td> <td>&nbsp;</td> <td>7</td> <td>&nbsp;</td> </tr> <tr> <td>EMT Inver Hills - college program</td> <td>9</td> <td>&nbsp;</td> <td>9</td> <td>&nbsp;</td> </tr> <tr> <td>EMT - community ambulance</td> <td>24</td> <td>24</td> <td>&nbsp;</td> <td>3</td> </tr> <tr> <td>Paramedic</td> <td>27 (30)</td> <td>15 (18)</td> <td>12</td> <td>1</td> </tr> <tr> <td>Pre-med student</td> <td>2</td> <td>&nbsp;</td> <td>2</td> <td>&nbsp;</td> </tr> <tr> <td>Social worker</td> <td>4 (4)</td> <td>&nbsp;</td> <td>4 (4)</td> <td>&nbsp;</td> </tr> <tr> <td>Adult volunteer (includes communications team)</td> <td>71</td> <td>?</td> <td>71</td> <td>7</td> </tr> <tr> <td>High school volunteer</td> <td>10 (22)</td> <td>(12)</td> <td>10 (10)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table above summarizes the make-up&nbsp;and role of the medical volunteers who participated in the 2015 Twin Cities Marathon.&nbsp;The actual numbers for 2015 are listed; the numbers in parentheses represent&nbsp;full capacity. Note that the number of volunteers in&nbsp;2015&nbsp;was relatively low,&nbsp;but fortunately race day conditions were ideal and&nbsp;medical encounters were relatively few.</div><div class=\"graphic_footnotes\">RN: registered nurse; OEC: outdoor emergency care; MATA: Maryland Athletic Trainers Association; ATC: certified athletic trainer; EMT: emergency medical technician; SLP: Spring Lake Park.</div><div class=\"graphic_reference\">Courtesy of William O Roberts, MD, MS.</div><div id=\"graphicVersion\">Graphic 109990 Version 1.0</div></div></div>"},"109991":{"type":"graphic_table","displayName":"Non-medical equipment for medical tent at mass sporting event","title":"Non-medicalÂ equipment needed for medical tent at mass participation endurance sporting event","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Non-medical&nbsp;equipment needed for medical tent at mass participation endurance sporting event</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td>Shelter (eg, tents with flooring, buildings) - 340 sq ft [100 sq m] for 44 cots and administrative space</td> <td>Portable sink(s) (2/tent)</td> <td> <p>Salty crackers</p> <p>Salty bouillon cubes</p> </td> </tr> <tr> <td>Security fencing for medical tent</td> <td>Fans (2/tent)</td> <td>Microwave oven (1 to 2)</td> </tr> <tr> <td>Tables (1)</td> <td>Lights (70 lumens/sq ft, or /0.3 sq m)</td> <td>Rope; 550 Paracord&nbsp;</td> </tr> <tr> <td>Chairs (2)</td> <td>Divider drapes</td> <td>Contaminated waste bin(s) (1)</td> </tr> <tr> <td>Cots (chaise loungers) (5)</td> <td>Ladder (1/tent)</td> <td>Trash bin(s) (1)</td> </tr> <tr> <td>Heating unit(s) (1/tent)</td> <td>Sound system (1/tent)</td> <td>Paper elastic bandage</td> </tr> <tr> <td>Blankets (10)</td> <td>Toilet(s) for medical area (3)</td> <td>&nbsp;</td> </tr> <tr> <td>Generator (1/tent)</td> <td>Signs</td> <td>&nbsp;</td> </tr> <tr> <td>Cooling unit(s) (1/tent)</td> <td>Shrink wrap 4 to 6 inch</td> <td>&nbsp;</td> </tr> <tr> <td>Towels (10)</td> <td>Cups (for cold and hot fluids)</td> <td>&nbsp;</td> </tr> <tr> <td>Plastic bags for ice</td> <td>Soup urn (10)</td> <td>&nbsp;</td> </tr> <tr> <td>Ice (six 50 lb (23 kg) bags for cool conditions; more for warmer temperatures)</td> <td> <p>Coffee urn (1/tent)</p> <p>Coffee</p> </td> <td>&nbsp;</td> </tr> <tr> <td>Ice chests (1)</td> <td>Sports drinks/fruit juice&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <p>Large tubs for immersion cooling (2)</p> <p>(or may use two&nbsp;child wading&nbsp;pools)</p> </td> <td>Salt packets</td> <td>&nbsp;</td> </tr> <tr> <td>Back board(s)&nbsp;</td> <td>Potable water&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The equipment list above is what would be needed&nbsp;at the primary medical station to care for the participants at a mass participation endurance sporting event. The equipment&nbsp;estimates above are just that, and more or less of any item may be needed depending on&nbsp;the race environment. The list above is&nbsp;calculated per&nbsp;1000 participants. It is drawn from&nbsp;the author's experience supervising marathons with approximately 10,000 entrants.</div><div class=\"graphic_reference\">William O Roberts, MD, MS.</div><div id=\"graphicVersion\">Graphic 109991 Version 1.0</div></div></div>"},"109992":{"type":"graphic_figure","displayName":"Fitting breast flange for pumping PI","title":"CorrectÂ fit of a breast flange for pumping breast milk","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Correct&nbsp;fit of a breast flange for pumping breast milk</div><div class=\"cntnt\"><img style=\"width:445px; height:634px;\" src=\"images/PEDS/109992_Fttng_breast_flange_pmpngPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the proper fit of a flange for pumping breast milk. (The flange is the cone-shaped piece that fits over the breast and connects to the pump.) The nipple should be centered and move easily within the tunnel. If the flange is too small, the nipple will rub against the sides of the tunnel. This can cause pain and even injury to the nipple. If the flange is too large, air can leak out the sides, and&nbsp;milk won't flow&nbsp;as well.</div><div id=\"graphicVersion\">Graphic 109992 Version 2.0</div></div></div>"},"109993":{"type":"graphic_table","displayName":"Drugs and equipment main medical station mass sporting event","title":"Medications andÂ equipment needed for primary medical station at mass participation sporting event","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications and&nbsp;equipment needed for primary medical station at mass participation sporting event</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Airway management&nbsp;equipment*</td> <td class=\"subtitle1\">Airway medications*</td> <td class=\"subtitle1\">Cardiac medications</td> <td class=\"subtitle1\">IV solutions</td> <td class=\"subtitle1\">Other drugs</td> <td class=\"subtitle1\">Other&nbsp;medical equipment&nbsp;</td> </tr> <tr> <td> <ul> <li>Laryngoscope handles and blades - Macintosh sizes 3&nbsp;and 4; Miller&nbsp;sizes 3&nbsp;and 4 </li> <li>Video laryngoscope </li> <li>Endotracheal tubes - Sizes 7, 7.5,&nbsp;and 8 </li> <li>Intubating stylet (1 in each airway kit) </li> <li>Nasal airways - Sizes 6 and 7 </li> <li>Oral airways - Sizes 6 and 7 </li> <li>Intubation introducer (gum elastic \"bougie\") </li> <li>ETCO<sub>2</sub> detector </li> <li>Esophageal detector device </li> <li>Bag mask ventilation kit </li> <li>LMA - Sizes 4 and 5 </li> </ul> </td> <td> <ul> <li>Rocuronium </li> <li>Succinylcholine </li> <li>Etomidate </li> <li>Ketamine </li> </ul> </td> <td> <ul> <li>Epinephrine -minimum of 4 pre-filled syringes </li> <li>Sodium bicarbonate -minimum of 2 pre-filled syringes </li> <li>Amiodarone -minimum of 2 vials </li> </ul> </td> <td> <ul> <li>D5NS (50 1 L bags) (1/tent) </li> <li>NS (50 1 L bags) </li> <li>Hypertonic (3%) saline 250 mL bags (3 to 5 bags) (separate from other IV solutions) </li> </ul> </td> <td> <ul> <li>EpiPens or 1 mL vials&nbsp;with 1 mL syringes&nbsp;(3) </li> <li>Nebulizer mask (3) </li> <li>Albuterol nebulization solution canisters (1 box) </li> <li>Atrovent nebulization solution canisters (1 box) </li> <li>Benadryl 50 mg (minimum of 5) </li> <li>Ondansetron 4 mg (25 tablets) </li> <li>D50W 50 mL (minimum of&nbsp;10 to 12 vials) </li> <li>Midazolam 2 mg vials (1 box) </li> <li>Glucagon </li> </ul> </td> <td> <ul> <li>Defibrillators (5) </li> <li>Blood glucose analyzer (1/tent or station) </li> <li>Blood glucose strips (1 pack) </li> <li>100 mL syringes (3/tent) </li> <li>3 mL syringes </li> <li>IV tubing sets (5)&nbsp; </li> <li>22 gauge needles </li> <li>25 gauge needles </li> <li>18 and 20 gauge IV cannulas (blunt) </li> <li>Point-of-care chemistry analyzer (iStat) (2/tent) </li> <li>Serum chips for analyzer (10) </li> <li>Rectal thermometers; rectal thermistors </li> <li>Ice </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table above lists the medications, airway management equipment, and other medical supplies that should be available in the primary medical station of a mass participation endurance sporting event. The numbers provided are for a combined marathon-10 mile race with approximately 20,000 entrants.</div><div class=\"graphic_footnotes\">*Airway medications and equipment&nbsp;should be available in sufficient amounts to perform at least four tracheal intubations per 1000 racers.<br />D5NS: Isotonic saline solution with 5 percent dextrose; D5W: 5 percent dextrose in water; D50W: 50 g dextrose solution;&nbsp;ETCO2: end tidal carbon dioxide; ET: endotracheal; IV: intravenous; LMA: laryngeal mask airway; NS: normal (isotonic)&nbsp;saline.</div><div class=\"graphic_reference\">Courtesy of William O Roberts, MD, MS.</div><div id=\"graphicVersion\">Graphic 109993 Version 3.0</div></div></div>"},"109995":{"type":"graphic_table","displayName":"Antibiotic options and doses for treatment of typhoid fever","title":"Antibiotic options and doses for treatment of typhoid fever","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic options and doses for treatment of typhoid fever</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Adults</td> <td class=\"subtitle1\">Children</td> <td class=\"subtitle1\">Duration</td> </tr> <tr> <td rowspan=\"2\"><strong>Ciprofloxacin</strong></td> <td>Oral: 500 mg twice daily</td> <td>Oral: 30 mg/kg per day in two divided doses (maximum 1000 mg per day)*</td> <td rowspan=\"2\">7 to 10 days</td> </tr> <tr> <td>IV: 400 mg twice daily</td> <td>IV: 20 mg/kg per day in two divided doses (maximum 800 mg per day)*</td> </tr> <tr> <td><strong>Ofloxacin</strong><sup>&#182;</sup></td> <td>400 mg orally or IV twice daily</td> <td>15 to 30 mg/kg per day orally in two divided doses (maximum 800 mg per day)*<sup>&#182;</sup> based upon limited experience; optimal pediatric dose is not known</td> <td>7 to 10 days</td> </tr> <tr> <td><strong>Ceftriaxone</strong></td> <td>2 g IV once or twice daily</td> <td>50 to 100 mg/kg IV in one or two divided doses (maximum 2 g per day)</td> <td>10 to 14 days</td> </tr> <tr> <td><strong>Cefotaxime</strong></td> <td>1 to 2 g IV every six or eight hours</td> <td>150 to 200 mg/kg IV per day in three to four divided doses (maximum 8 g per day)</td> <td>10 to 14 days</td> </tr> <tr> <td><strong>Cefixime</strong></td> <td>200 mg orally twice daily</td> <td>20 mg/kg orally in two divided doses (maximum 400 mg per day)</td> <td>10 to 14 days</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Azithromycin</strong></td> <td>1 g orally once then 500 mg orally daily OR 1 g orally once daily</td> <td>20 mg/kg orally once then 10 to 20 mg/kg orally once per day (maximum 1000 mg per day)</td> <td>5 to 7 days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Agents of limited usefulness due to the high prevalence of multidrug resistance</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Chloramphenicol<sup>&#916;</sup></td> <td>Oral: 500 to 750 mg four times per day</td> <td rowspan=\"2\">50 to 100 mg/kg per day orally or IV in four divided doses (maximum 3 g per day)</td> <td rowspan=\"2\">14 to 21 days</td> </tr> <tr> <td>IV: 50 to 100 mg/kg per day in four divided doses (maximum 3 g per day)</td> </tr> <tr> <td class=\"indent1\">Amoxicillin</td> <td>1 g orally three times daily</td> <td>100 mg/kg per day orally in three divided doses (maximum 3 g per day)</td> <td>10 to 14 days</td> </tr> <tr> <td class=\"indent1\">TMP-SMX</td> <td>1 double strength tablet (160/800 mg) orally twice daily</td> <td>8 mg/kg TMP and 40 mg/kg SMX orally in two or four divided doses (maximum 320 mg TMP/1600 mg SMX per day)</td> <td>10 to 14 days</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Antibiotic selection depends upon the severity of illness, local resistance patterns, whether oral medications are feasible, the clinical setting, and available resources. Refer to the topic on treatment of typhoid fever for detailed discussion. The doses listed above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.</div><div class=\"graphic_footnotes\">TMP-SMX: trimethoprim-sulfamethoxazole (co-trimoxazole).<br />* Although fluoroquinolones are not routinely used as first-line therapy for children &lt;18 years old, their use in children is justified in severe infections such as typhoid fever when alternatives are not appropriate or available.<br />&para; IV ofloxacin formulation is not available in North America but may be available elsewhere.<br />&Delta; Chloramphenicol use is restricted in many countries due to a low risk of fatal aplastic anemia. Oral chloramphenicol formulation is not available in North America but may be available elsewhere.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Bhutta ZA. Current concepts in the diagnosis and treatment of typhoid fever. BMJ 2006; 333:78.</li>&#xD;&#xA;    <li>Harris JB and Brooks WA. Typhoid and paratyphoid fever. In: Hunter's Tropical Medicine and Emerging Infectious Disease, 9th edition, Magill AJ, Ryan ET, Hill DR, and Solomon T (Eds), Saunders Elsevier, 2013.</li>&#xD;&#xA;    <li>Levine M, Tapia MD, and Zaidi AKM. Typhoid and paratyphoid (enteric) fever. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd edition, Guerrant RL, Walker DH, and Weller PF (Eds), Saunders Elsevier, 2011.</li>&#xD;&#xA;    <li>World Health Organization Department of Vaccines and Biologicals. Background document: the diagnosis, prevention and treatment of typhoid fever. Geneva, 2003; 1:19.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 109995 Version 2.0</div></div></div>"},"109997":{"type":"graphic_picture","displayName":"Cutaneous polyarteritis nodosa with livedo","title":"Cutaneous polyarteritis nodosa","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Cutaneous polyarteritis nodosa</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/DERM/109997_Ctns_polyartrts_ndsa_livedo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patchy \"starburst\" livedo reticularis and subcutaneous nodules on the legs of a patient with cutaneous polyarteritis nodosa.</div><div class=\"graphic_reference\">Courtesy of Robert G. Micheletti, MD.</div><div id=\"graphicVersion\">Graphic 109997 Version 1.0</div></div></div>"}};